

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/30465 A2

- (51) International Patent Classification⁷: **A61K 45/00**
- (21) International Application Number: **PCT/US01/32127**
- (22) International Filing Date: 12 October 2001 (12.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/239,705 12 October 2000 (12.10.2000) US
60/242,812 24 October 2000 (24.10.2000) US
- (71) Applicant (for all designated States except US): **UNIVERSITY OF ROCHESTER** [US/US]; 601 Elmwood Avenue, Box 706, Rochester, NY 14642 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LAND, Hartmut** [US/US]; 195 Hollywood Avenue, Rochester, NY 14618 (US). **DELEU, Laurent** [US/US]; 104 Westland Avenue, Rochester, NY 14618 (US).
- (74) Agents: **SPRATT, Gwendolyn, D.** et al.; Needle & Rosenberg, P.C., Suite 1200, The Candler Building, 127 Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/30465 A2

(54) Title: COMPOSITIONS THAT INHIBIT PROLIFERATION OF CANCER CELLS

(57) Abstract: Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.

COMPOSITIONS THAT INHIBIT PROLIFERATION OF CANCER CELLS

This application claims priority to United States Provisional Application No. 60/239,705 filed on October 12, 2000, entitled "Agents promoting apoptosis in cancer cells via interruption of oncogene-induced integrin signaling," which application is herein incorporated by reference in its entirety and to United States Provisional Application No. 60/242,812 filed on October 24, 2000 entitled, "Agents promoting apoptosis in cancer cells via interruption of oncogene-induced integrin signaling", and which application is herein incorporated by reference in its entirety.

I. BACKGROUND OF THE INVENTION

10 In cancer cells multiple oncogenic lesions cooperate in malignant transformation. Such cooperation permits survival and proliferation of tumor cells in absence of contact with extra-cellular matrix (ECM), suggesting that tumor cell survival and proliferation have become independent of the engagement of integrin signaling by ECM.

Carcinogenesis is caused by multiple cooperating genetic lesions leading to a progressive 15 deregulation of cellular signaling and cell cycle restriction point control. The mutations involved result in oncogene activation or loss of tumor-suppressor gene function. Typically, single oncogenes are insufficient to cause malignant transformation because they simultaneously induce signals stimulating and inhibiting cell growth. As a result cell proliferation remains restricted. In contrast, cooperating oncogenic lesions act in concert to disable such inhibitory signals while 20 reinforcing the growth-promoting stimuli. The co-operation of oncogenic lesions involves integration of multiple signals converging on the regulation of cell cycle-dependent kinase complexes (Lloyd *et al.*, 1997; Perez-Roger *et al.*, 1999; Roper *et al.*, 2001; Sewing *et al.*, 1997).

Disclosed herein are compositions and methods that show survival of various transformed cell types requires cell-autonomous (autocrine) integrin signaling activity. This activity is induced 25 by cooperating oncogenic lesions and involves induction of integrin receptor and ligand components such as integrin alpha6 and integrin beta4, and laminin5-gamma2 chains. Blocking of integrin or the laminin ligand function induces rapid apoptosis of the transformed cells, even when growing in presence of ECM. In contrast, normal cells remain viable when exposed to the same treatment.

30 The disclosed compositions and methods are related to the cooperation of oncogenic lesions controlling the ability of transformed cells to proliferate in the absence of contact with the extra-cellular matrix (ECM). As taught herein, oncogenes cooperate to promote a cell-autonomous (autocrine) integrin signaling loop that proves essential for the survival of various transformed cell

types. As this signaling loop is not established in corresponding normal cells, the signaling components of this loop constitute attractive targets for cancer therapy.

II. SUMMARY OF THE INVENTION

In accordance with the purposes of this invention, as embodied and broadly described herein, this invention, in one aspect, relates to compositions and methods related to integrin mediated cancer cell growth.

Additional advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

III. BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.

Figure 1 shows a series of schematics representative of the disclosed relationships and compositions. In normal cells integrin receptors signal to suppress programmed cell death (apoptosis) when engaged by appropriate extra-cellular matrix (ECM) ligands. When receptor-ligand interaction is lost, the cells undergo apoptosis due to the lack of survival signals (Figure 1- Panel 1). In cancer cells multiple oncogenic lesions cooperate to cause malignant transformation. Such cooperation permits survival and proliferation of tumor cells independent of integrin receptor-ECM interactions. This property has been termed anchorage-independence (Panel 2). We have discovered the mechanistic basis of anchorage-independence. The transformed cells replace the requirement for ECM-dependent signaling with a surrogate integrin signaling loop on which they rely for survival. In colonic epithelial cells, activation of Ras in combination with APC (adenomatous polyposis coli) or p53 mutations leads to induction of integrin receptor and ligand components such as integrin alpha6 and laminin gamma2 chains. As a consequence, laminin-dependent activation of alpha6/beta4 integrin receptors signals to inhibit caspase activity and thus to suppress apoptosis (Panel 3). Ablation of integrin alpha6, laminin ligand function or alpha6/beta4 integrin receptor function induces apoptosis of the transformed cells, even when growing in the presence of ECM. In contrast, non-transformed control cells remain viable when exposed to the same treatment, indicating that the dependence of the transformed cells on autocrine integrin signaling may be a particular feature of the cancer cell phenotype. The essential role of alpha6 integrin extends to various transformed cell types including mesenchymal and

SW480 human colon carcinoma cells. Thus inhibition of laminin/alpha6 integrin-mediated signaling is an important method to induce cancer cell-specific death in a variety of cell types (Panel 4).

Figure 2 shows that oncogene cooperation protects cells from apoptosis. Figure 2A shows control, APCm, Ras, APCm+Ras cells that were detached from collagen IV substrates with Trypsin/EDTA and kept in suspension at 2×10^5 cells/ml in RPMI 10%FCS for 12 h at 39°C. Subsequently TUNEL analysis was performed on poly-lysine treated slides. The percentage of tunel-positive cells was determined by immunofluorescence microscopy. Figure 2B shows control, APCm, Ras, APCm Ras, SW480 cells were detached and maintained in suspension as described in (A). SW480 beta4 dn/Gal4VPER cells, express a 4OH-tamoxifen-inducible dominant-negative form of the beta4 integrin. Cells were pelleted and protein extracts were prepared in 300 μ l of 50 mM Tris-HCl, pH 7.4; 1% NP40 ; 0.25% sodium deoxycholate; 150 mM NaCl ; 1 mM EGTA. 200 μ l of extracts were incubated for 10 min with 2 μ l of Caspase 3 fluorometric Substrate (Upstate Biotechnology). Vmax of caspase activity was determined by measuring the fluorescence at 460 nm after excitation at 380 nm for 1 h. Figure 2C shows laminin gamma1 and gamma2-specific peptides were added to APCmin+Ras cells at the concentration of 100 μ g/ml. Caspase activity was measured as in (B). Figure 2D shows caspase 8 and caspase 9 activities were measured as in (B) using caspase 8 and caspase 9-specific fluorimetric substrates (Upstate Biotechnologies).

Figure 3 shows alterations of integrin and laminin expression profiles in malignant cell transformation. Figure 3A shows integrin expression and figure 3B shows laminin expression. The indicated cell populations were cultured on collagen IV-coated dishes at 39°C in RPMI 10% FCS. Total RNA was extracted from 10^6 cells for each sample and used for RT-PCR (laminins, alpha4, gamma2 and GAPDH) or RNase protection. For RT-PCR, cDNA was subjected to 28 cycles (linear range) of PCR amplification. PCR products were analyzed on a 2% agarose gel. For RNase protection, 10 μ g of total RNA was used per reaction. Products were resolved on a 4.5% polyacrylamide/10M urea gel.

Figure 4 shows alpha6/beta4 integrin is engaged by the laminin gamma2 chain to activate Shc (a src homology domain containing protein). Figure 4A shows cells detached from collagen IV coated dishes with 3mM EDTA (in PBS) were incubated on ice with the indicated antibodies for 1 h. Cells were then plated on 96well dishes coated with gamma1 or gamma2-specific peptides and were permitted to attach for 30 min in RPMI medium at 39°C. After incubation, wells were washed with RPMI. The percentage of attached cells per well was measured by hexoaminidase activity after lysis of the cells in the well and incubation with the substrate p-nitrophenol-N-acetyl- β -D-glucosaminide for 5 h at 37°C. Figure 4B shows cells indicated were detached as in (A) and

resuspended at 10^7 cells/ml in PBS. After 1 h of incubation on ice, cells were pelleted by centrifugation 5 min at 900 rpm and resuspended in RPMI containing the phosphatase inhibitor pervanadate at $10\mu\text{M}$. The cells were incubated with beta1 and beta4 integrin antibodies as well as the laminin gamma2-specific peptide for 40 min. Protein extracts were prepared and subjected to an immuno-precipitation with an anti-Shc antibody. Phospho-tyrosine was detected with a phospho-tyrosine-specific antibody in IP-western-blots (upper panels). The levels of Shc protein were monitored with a Shc-specific antibody reusing the same membrane (lower panels).

Figure 5 shows integrin alpha6/beta4 and Laminin gamma2 chain expression is essential for survival of transformed cells. Figure 5A1 shows the indicated cell populations were infected at an MOI of 2 with recombinant retroviruses expressing anti-sense RNA for alpha6 integrin, the gamma2 laminin chain or a beta4 integrin dominant-negative mutant together with a puromycin resistance gene. After 2 weeks of selection with puromycin, colonies were stained with Giemsa and counted. APCm+Ras alpha6 and APCm+Ras p35 cells express the alpha6 integrin chain and the anti-apoptotic baculovirus p35, respectively. APCm+Ras cells were also plated on dishes pre-coated with a laminin gamma2-specific peptide. Figure 5A2 shows APCm+Ras hygro, APCm+Ras Bcl2 and APCm+Ras p35 cells express the hygromycin resistance marker, and the anti-apoptotic proteins Bcl2 or p35, respectively. The cells were infected at an MOI of 2 with retroviruses carrying the beta4 integrin dominant-negative mutant and a puromycin resistance gene, or the puromycin resistance gene alone. Cells (10^5) were maintained in soft agar at 39°C for two weeks after which macroscopically visible colonies were counted. Figure 5A3 shows the indicated cell populations were infected at an MOI of 2 with recombinant retroviruses, drug-selected and maintained as described in A1. Figure 5A4 shows the indicated cell populations were infected at an MOI of 2 with recombinant retroviruses expressing anti-sense RNA for alpha6 integrin, the beta4 integrin dominant-negative mutant or the puromycin resistance marker. Cells (10^5) were maintained in soft agar and evaluated as described in A2. Figure 5B shows the effect of the alpha6 anti-sense RNA expression on the cell surface expression of alpha6 integrin was monitored by FACS analysis using an anti-alpha6 rat monoclonal antibody and a FITC conjugated goat anti-rat antiserum as the secondary antibody (upper panel). Expression of the beta4 dominant-negative mutant was confirmed by RNase protection. A probe overlapping the c-terminal end of the beta4 dominant negative mRNA was used to measure beta4 integrin and beta4 dn expression in the same sample (lower panel). Figure 5C shows arf null mouse embryo fibroblasts (MEFs) that were infected with retroviruses expressing the oncogenes Myc and Ras. Cells were then additionally infected with a retroviruses expressing anti-sense RNA for alpha6 integrin or the beta4 integrin dominant-negative mutant as shown in (A). MEFs Ras/Myc/Arfnull+alpha6 sense express the alpha6 integrin chain. Figure 4D shows SW480 human

colon carcinoma cells that were infected as described in (A) using VSV pseudo-typed viruses. Infected cells were selected with puromycin in soft agar. Clones were counted 2 weeks after selection. SW480 beta4 dn/Gal4VPER cells, express a 4OH-tamoxifen-inducible dominant-negative form of the beta4 integrin. The cells (10⁵) were maintained in soft agar for 2 weeks in presence or absence of 4OH-tamoxifen.

IV. DETAILED DESCRIPTION

The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the Examples included therein and to the Figures and their previous and following description.

Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that this invention is not limited to specific synthetic methods, specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

A. Definitions

As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

Ranges may be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

"Primers" are a subset of probes which are capable of supporting some type of enzymatic manipulation and which can hybridize with a target nucleic acid such that the enzymatic manipulation can occur. A primer can be made from any combination of nucleotides or nucleotide

derivatives or analogs available in the art which do not interfere with the enzymatic manipulation.

"Probes" are molecules capable of interacting with a target nucleic acid, typically in a sequence specific manner, for example through hybridization. The hybridization of nucleic acids is well understood in the art and discussed herein. Typically a probe can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art.

B. Compositions and methods

Disclosed are compositions and methods related to integrins and integrin signaling. It is shown herein that integrin alpha6, integrin beta4, and laminin5, through at least up regulation of the beta and gamma chains of laminin5, are upregulated in cancer cells. Integrin alpha6 and integrin beta4 interact to form the integrin receptor, A6B4. The integrin receptor A6B4 specifically interacts with laminin5 and laminin5 specifically interacts with A6B4. Furthermore, it is shown that interference with the production or function of alpha6, beta4, or the laminin gamma2 chain not only prevents proliferation of the cancer cells, dependent on the upregulation of alpha6, beta4, and the laminin gamma2 chain, but that this kills the cancer cells as well. Alpha6 and beta4 signaling occur through the integrin receptor A6B4. Thus, interference with the formation of A6B4, will interfere with the function of A6B4, for example, the signaling of A6B4. Thus, disclosed are compositions and methods that interfere with the function of alpha6, beta4, laminin5, the laminin gamma2 chain, or A6B4. Also disclosed are compositions and methods that interfere with the function of molecules involved with the signal transduction that is connected to either alpha6, beta4, laminin5, the laminin gamma2 chain, or A6B4. Also disclosed are methods for reducing the proliferation of cancer cells, as well as methods of killing cancer cells that involve using the compositions disclosed herein that interfere, reduce, or eliminate the function or the alpha6, beta4, laminin5, the laminin gamma2 chain, or A6B4 function.

Disclosed herein is a relationship between two types of molecules in a cancer cell. The first type of molecule is an integrin receptor, composed of integrins, and the second type of molecule is a ligand that interacts with the integrin receptor, through the integrins. There are specificities that exist between the integrin receptors and their ligands. One aspect, disclosed herein is that when a cell goes from a non-cancerous state to a cancerous state, there is a co-upregulation of both the ligand (or parts of the ligand, such as subunits) and the cognate integrin receptor. The co-upregulation of both types of molecules creates an autocrine loop situation, wherein the signaling pathways controlled by the integrin receptor become autonomously activated, rather than exogenously activated, as would normally occur. The upregulation of both types of molecules creates a more fully transformed cellular phenotype in which cancer cell survival depends on the autocrine loop. Now therapeutic activities can target both points in the autocrine loop. Specific examples, of this co-upregulation in cancer cells are disclosed herein. For

example, laminin 5 (both the beta and gamma2 chains are upregulated) and integrin receptor alpha6beta4; laminin 10/11 and the integrin receptors alpha6beta1 and alpha3beta1.

As the Examples herein indicate which integrins, which integrin receptor, and which integrin ligand are involved in conferring cancer cells ability to grow in the absence of extra cellular matrix (ECM), also disclosed are methods using these integrins, integrin receptors and ligands to identify molecules that interact with them and/or interfere with their function.

1. Compositions

Disclosed are the components to be used to prepare the disclosed compositions as well as the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed, while specific reference of each various individual and collective permutation of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular beta4 or alpha6 is disclosed and discussed and a number of modifications that can be made to a number of molecules including the modifications to beta4 or alpha6 are discussed, specifically contemplated is each and every combination and permutation of these modifications and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively contemplated. Thus, combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods.

a) Integrins and their ligands

For proper embryonic development, tissue homeostasis, and wound healing, cell proliferation must be tightly regulated, both in space and over time. In particular, a cell must be able to sense its relationship to other cells and the extra-cellular matrix (ECM) and convert these positional cues into biochemical signals affecting the regulation of proliferation. Because of their ability to couple the recognition of positional cues to the activation of intracellular signaling pathways, adhesion receptors, such as integrins and cadherins, are likely to be necessary to achieve this goal.

The integrins mediate cell adhesion primarily by binding to distinct, although overlapping,

subsets of ECM proteins. Normal cells require contact with serum-derived ECM components for proliferation, differentiation and survival (e.g. Clark and Brugge, 1995; Lin and Bissell, 1993; Parise *et al.*, 2000), a phenomenon called anchorage-dependence. This involves signaling through integrin receptors (Hynes, 1992). Fibronectin and laminin as well as other ECM proteins are
5 known to act as ligands for integrin receptors (Akiyama *et al.*, 1990). Integrins are transmembrane proteins forming alpha-beta chain heterodimers. Alpha and beta chain integrins are members of distinct gene families. The ligand binding specificity of the hetero dimers is determined by specific combinations of alpha and beta chain gene family members (Hynes, 1992). Ligand binding triggers signaling of integrin receptors through the cytoplasmic tail of the beta chain via
10 interaction with various signaling components.

Integrins activate common as well as subgroup-specific signaling pathways (Clark and Brugge, 1995; Giancotti and Ruoslahti, 1999). In particular, while most integrins activate focal adhesion kinase (FAK), the $\alpha 1\beta 1$, $\alpha 5\beta 1$, $\alpha v\beta 3$ and $\alpha 6\beta 4$ integrins are coupled to the Ras-extracellular signal-regulated kinase (ERK) signaling pathway by Shc (Mainiero *et al.*, 1997;
15 Mainiero *et al.*, 1995; Wary *et al.*, 1996). Shc is an SH2-PTB domain adapter protein expressed in three forms, p46, p52 and p66, two of which (p46 and p52) link various tyrosine kinases to Ras by recruiting the Grb2/SOS complex to the plasma membrane (Pawson and Scott, 1997). Upon activation by SOS, Ras stimulates a kinase cascade culminating in the activation of the mitogen-activated protein kinase (MAPK) ERK (Marshall, 1995). ERK phosphorylates ternary complex
20 transcription factors, such as Elk-1 and Sap-1/2, and promotes transcription of the immediate-early gene Fos (Treisman, 1996). In primary endothelial cells and keratinocytes, mitogens and Shc-linked integrins cooperate, in a synergic fashion, to promote transcription from the Fos promoter. Accordingly, ligation of integrins linked to Shc enables these cells to progress through G1 in response to mitogens, whereas ligation of other integrins results in growth arrest, even in the
25 presence of mitogens (Mainiero *et al.*, 1997; Wary *et al.*, 1996). Shc is like a binary switch controlling cell cycle progression in response to the ECM. Moreover, integrin receptors have been shown to induce intracellular signaling leading to AKT activation supporting cell survival (Lee and Juliano, 2000).

In contrast with normal cells, cancer cells generally are able to survive and proliferate in
30 the absence of anchorage to ECM (Giancotti and Mainiero, 1994), suggesting that tumor cell survival and proliferation have become independent of the engagement of integrin signaling through ECM.

Proliferation in the absence of anchorage to ECM of secondary rat embryo fibroblasts requires the cooperation of Ras and Myc or Ras and adenovirus E1a oncogenes (Land *et al.*, 1983;
35 Ruley, 1983). Similarly, murine colonic epithelial cells require both activated Ras and mutation of

the adenomous polyposis coli gene (APCmin) (D'Abaco et al., 1996) in order to proliferate in suspension.

Integrins are a large family of cell surface receptor molecules that function to mediate interactions between cells and between cells and the extracellular matrix. Integrin receptors are heterodimers composed of two subunits, an alpha integrin and a beta integrin. The heterodimer forms, is expressed on the cell surface, and acts to transmit signals obtained from interactions with the extracellular matrix or other cells, through the cellular membrane and into the cytosol of the cell. The signal transduction that takes place occurs because of ligand interactions with the receptor. Integrin receptors can have a number of ligands, including collagens, fibronectins, and laminins.

There are currently at least 18 different alpha integrins and at least 8 different beta integrins that have been shown to form at least 24 different alphabeta heterodimers. Certain integrins, such as beta1, interact in a number of different heterodimers, but many subunits only form a single heterodimer, either because of structural constraints on their interactions, or cellular expression patterns that provide only a limited number of potential dimer partners. Disclosed herein are specific relationships that occur between a subset of integrins, integrin receptors, and their ligands. The disclosed relationships, revolve around the alpha6beta4 receptor, formed by the alpha6 and beta4 integrins. Of particular interest is the relationship between the ligand for the alpha6beta4 receptor, laminin5. The laminins are made up of 3 chains, an alpha chain, a beta chain, and a gamma chain. The specificity of the interaction between laminin5 and alpha6beta4 receptor is controlled by the gamma chain. Laminin5 contains a gamma2 chain which only interacts with the alpha6beta4 integrin receptor.

Integrin alpha6 has seven amino-terminal repeating segments that may fold into a seven unit beta-propeller, five n-terminal FG-GAP domains and three divalent cation sites. The transmembrane domain is followed by a short cytoplasmic tail, that is alternatively spliced in A and B forms. The alpha6 integrin chain also shows alternative splicing between repeat units III and IV, resulting in the presence or absence of Exon X2. Integrin alpha6 is processed into a heavy and a light chain that are disulphide linked. A representative allele of the human alpha6 cDNA is set forth in SEQ ID NO:1. It is understood that the disclosed functional domains as well as the others contained within alpha6 are considered separately disclosed as discreet fragments of the alpha6 protein as well as the nucleic acid that encodes them.

Integrin beta4 contains a MIDAS-like motif and four cysteine-rich repeats, three EGF-like domains in the N-terminal extracellular domain, a trans-membrane region and a long cytoplasmic tail containing two pairs of fibronectin Type III repeats. The latter are connected by a variable segment that may undergo alternative splicing. Integrin beta4 also undergoes proteolytic

processing in its cytoplasmic tail, causing the 200kD mature form to be converted to 165 and 130kD fragments. A representative allele of the human beta4 cDNA is set forth in SEQ ID NO:5. It is understood that the disclosed functional domains as well as the others contained within beta4 are considered separately disclosed as discrete fragments of the beta4 protein as well as the nucleic acid that encodes them.

Laminin5 is composed of the laminin chains alpha3, beta3 and gamma2. Laminin5 can may contain either the shorter laminin alpha3A chain or the longer alpha3B chain. Laminin5 can also be trimmed by proteolytic processing of the N-terminal portion of its alpha3A chain and the N-terminal portion of the gamma2 chain. The Laminin gamma2 chain contains at least six laminin EGF-like domains (Domains III and V) with an embedded laminin B domain (Domain IV) within the N-terminal half. The c-terminal tail contains a coiled-coil domain. The N-terminal processed portion of the gamma2 chain is sufficient to bind to and activate the integrin alpha6/beta4 receptor. A representative allele of the human laminin5-gamma2 cDNA is set forth in SEQ ID NO:13. It is understood that the disclosed functional domains as well as the others contained within the laminin5 protein and laminin5-gamma2 protein are considered separately disclosed as discrete fragments of the laminin5 protein and laminin5-gamma2 protein as well as and the nucleic acid that encodes them.

Disclosed are compositions and methods for inhibiting integrin signaling, for example, integrin signaling dependent on alpha6 and beta4 integrins. For example, compositions and methods that inhibit integrin receptor signaling from, for example, the alpha6beta4 integrin receptor are disclosed. It is also understood that the integrin receptor signaling can be affected by, for example, interfering with a molecule, such as a ligand for the integrin receptor, or a downstream signaling molecule of the integrin receptor in a way that prevents the integrin receptor signal from being fully propagated. It is understood that the compositions and methods for inhibition of integrin signaling and function can be any composition or method that ultimately inhibits the cell proliferation in which the integrin is expressed, by for example killing the cell. It is understood that the compositions and methods typically can fall into three basic non-limiting classes of function regulators, which are discussed herein.

(1) Classes

(a) Production regulators

Production regulators is a broad class of integrin function regulators that are directed at the production of the target integrin, by for example, preventing mRNA synthesis or expression of the target integrin, or by causing mRNA degradation of the target integrin which inhibits the translation of the target integrin. While production regulators, can be any type of molecule targeting any point in the integrin production pathway, typically these types of compositions will

target either the mRNA expression or the protein expression of the integrin. For example, if beta4 integrin, alpha6 integrin, or the gamma2 subunit of laminin5, which has been shown herein to be upregulated in cancer cells and which causes the cancer cell to be able to live in the absence of the ECM, was the target integrin, a typical production regulator of beta4 integrin, alpha6 integrin, or the gamma2 subunit of laminin5 would be for example, an antisense molecule that targeted the mRNA of beta4 integrin, alpha6 integrin, or the gamma2 subunit of laminin5. It is also understood that a production regulator could also target any molecule that is disclosed herein, or is within the signaling chain associated with a target integrin or integrin receptor. For example, the inhibition of the production of the ligand for a target integrin receptor is one way of inhibiting integrin function of that receptor. Thus, production regulators can either inhibit or enhance integrin production.

(b) Integrin to integrin regulators

Another type of integrin function regulator is an integrin-integrin regulator. This type of function regulator, typically prevents integrins from interacting to form a functional integrin receptor. For example, an integrin to integrin regulator could be a composition that would interact with beta4 in a way that would prevent beta4 from interacting with alpha6 to form the alpha6beta4 integrin receptor or it could be a composition that would interact with alpha6 in a way that would prevent alpha6 from interacting with beta4 to form the alpha6beta4 integrin receptor. It is also contemplated that the function regulators of the integrin to integrin interaction can affect the signaling pathways dependent on integrin receptors containing alpha6 or beta4 integrins. It is not required that an integrin to integrin regulator prevent an integrin from interacting with all of the possible integrin partners it could interact with, just that it prevent the interaction of the target integrin with another specific integrin. For example, the integrin alpha6 interacts with beta1 integrin and beta4 integrin. In certain embodiments, the compositions interfere with alpha6-beta4 interactions but do not interfere with alpha6-beta1 interactions.

(c) Integrin to other molecule regulators

The third class of function regulators are the integrin to other molecule regulators. These compositions are designed to specifically interfere with molecules such as small molecule ligands or other proteins that interact with the integrin or integrin receptor. For example, an integrin to other molecule regulator might target a ligand for a particular integrin receptor, such as the alpha6beta4 receptor. The ligand for the alpha6beta4 receptor is laminin5 or the laminin gamma2 chain. Compositions that interact with laminin5 such that laminin5 or the laminin gamma2 chain interactions with alpha6beta4 are inhibited or reduced are specifically contemplated herein. Likewise, there are other molecules, such as Shc molecules, that also interact with integrins, such as the alpha6beta4 receptor. Compositions that specifically interact with the Shc molecules such that they prevent the appropriate interactions between the Shc molecule and the alpha6beta4

receptor are disclosed.

(2) Types

Just as there are different general classes of molecules that can regulate (such as by inhibition) the function of the disclosed integrins and integrin receptors, so to there are many different types of molecules that perform that regulation. For example, any molecule that can perform the regulation of for example, the disclosed integrins, integrin receptors, or signaling pathways produced by the disclosed integrins and integrin receptors are contemplated. For example, antibodies or small molecules which inhibit the disclosed compositions are herein disclosed. Also disclosed are, for example, functional nucleic acids, such as ribozymes or antisense molecules that can inhibit the disclosed integrin function in a variety of ways. A non-limiting list of exemplary molecules is discussed herein.

(a) Antibodies

Antibodies can be used to regulate, for example, the function of the disclosed integrins and integrin receptors, molecules that interact with the disclosed integrin receptors, and molecules in the signaling pathways of the disclosed integrin receptors.

As used herein, the term "antibody" encompasses, but is not limited to, whole immunoglobulin (i.e., an intact antibody) of any class. Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V(H)) followed by a number of constant domains. Each light chain has a variable domain at one end (V(L)) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (l), based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. One skilled in the art would recognize the comparable classes for mouse. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.

Antibodies can be either polyclonal or monoclonal. Polyclonal antibodies, typically are derived from the serum of an animal that has been immunogenically challenged, and monoclonal antibodies are derived as discussed herein.

The term "variable" is used herein to describe certain portions of the variable domains that differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies (see Kabat E. A. et al., "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1987)). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

As used herein, the term "antibody or fragments thereof" encompasses chimeric antibodies and hybrid antibodies, with dual or multiple antigen or epitope specificities, and fragments, such as F(ab')₂, Fab', Fab and the like, including hybrid fragments. Thus, fragments of the antibodies that retain the ability to bind their specific antigens are provided. For example, fragments of antibodies which maintain EphA2 binding activity are included within the meaning of the term "antibody or fragment thereof." Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).

Also included within the meaning of "antibody or fragments thereof" are conjugates of antibody fragments and antigen binding proteins (single chain antibodies) as described, for example, in U.S. Pat. No. 4,704,692, the contents of which are hereby incorporated by reference. Single chain divalent antibodies are also provided.

Optionally, the antibodies are generated in other species and "humanized" for administration in humans. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂, or

other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or
5 rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or
10 substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-
15 596 (1992)).

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially
20 performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeven et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been
25 substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity. According to the "best-fit"
30 method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., *J. Immunol.*, 151:2296 (1993) and Chothia et al., *J. Mol. Biol.*, 196:901 (1987)). Another method uses a particular framework derived from the consensus sequence of all human antibodies
35 of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (Carter et al., *Proc. Natl. Acad. Sci. USA*, 89:4285 (1992);

Presta et al., J. Immunol., 151:2623 (1993)).

It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, according to a preferred method, humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding (see, WO 94/04679, published 3 March 1994).

Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Year in Immuno., 7:33 (1993)). Human antibodies can also be produced in phage display libraries (Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). The techniques of Cote et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1):86-95 (1991)).

The present invention further provides a hybridoma cell that produces the monoclonal antibody of the invention. The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a

particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

Monoclonal antibodies of the invention may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975) or Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988). In a hybridoma method, a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. Preferably, the immunizing agent comprises EphA2. Traditionally, the generation of monoclonal antibodies has depended on the availability of purified protein or peptides for use as the immunogen. More recently DNA based immunizations have shown promise as a way to elicit strong immune responses and generate monoclonal antibodies. In this approach, DNA-based immunization can be used, wherein DNA encoding a portion of EphA2 expressed as a fusion protein with human IgG1 is injected into the host animal according to methods known in the art (e.g., Kilpatrick KE, et al. Gene gun delivered DNA-based immunizations mediate rapid production of murine monoclonal antibodies to the Flt-3 receptor. Hybridoma. 1998 Dec;17(6):569-76; Kilpatrick KE et al. High-affinity monoclonal antibodies to PED/PEA-15 generated using 5 microg of DNA. Hybridoma. 2000 Aug;19(4):297-302, which are incorporated herein by referenced in full for the methods of antibody production).

An alternate approach to immunizations with either purified protein or DNA is to use antigen expressed in baculovirus. The advantages to this system include ease of generation, high levels of expression, and post-translational modifications that are highly similar to those seen in mammalian systems. Use of this system involves expressing domains of EphA2 antibody as fusion proteins. The antigen is produced by inserting a gene fragment in-frame between the signal sequence and the mature protein domain of the EphA2 antibody nucleotide sequence. This results in the display of the foreign proteins on the surface of the virion. This method allows immunization with whole virus, eliminating the need for purification of target antigens.

Generally, peripheral blood lymphocytes ("PBLs") are used in methods of producing monoclonal antibodies if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, "Monoclonal Antibodies: Principles and Practice" Academic Press,

(1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, including myeloma cells of rodent, bovine, equine, and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, 5 immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells. Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing 10 cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Rockville, Md. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., "Monoclonal Antibody Production Techniques and Applications" Marcel Dekker, Inc., New 15 York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against EphA2. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or 20 by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art, and are described further in the Examples below or in Harlow and Lane "Antibodies, A Laboratory Manual" Cold Spring Harbor Publications, New York, (1988).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting 25 dilution or FACS sorting procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown in vivo as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, 30 for example, protein A-Sepharose, protein G, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using 35 oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and

light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, plasmacytoma cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to
5 obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Optionally, such a non-immunoglobulin polypeptide is
10 substituted for the constant domains of an antibody of the invention or substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for EphA2 and another antigen-combining site having specificity for a different antigen.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of
15 antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994, U.S. Pat. No. 4,342,566, and Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, (1988). Papain digestion of antibodies typically produces two identical
20 antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment, called the F(ab')₂ fragment, that has two antigen combining sites and is still capable of cross-linking antigen.

The Fab fragments produced in the antibody digestion also contain the constant domains of the light chain and the first constant domain of the heavy chain. Fab' fragments differ from Fab
25 fragments by the addition of a few residues at the carboxy terminus of the heavy chain domain including one or more cysteines from the antibody hinge region. The F(ab')₂ fragment is a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. Antibody fragments originally were produced as pairs of Fab' fragments
30 which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

An isolated immunogenically specific paratope or fragment of the antibody is also provided. A specific immunogenic epitope of the antibody can be isolated from the whole antibody by chemical or mechanical disruption of the molecule. The purified fragments thus
35 obtained are tested to determine their immunogenicity and specificity by the methods taught

herein. Immunoreactive paratopes of the antibody, optionally, are synthesized directly. An immunoreactive fragment is defined as an amino acid sequence of at least about two to five consecutive amino acids derived from the antibody amino acid sequence.

One method of producing proteins comprising the antibodies of the present invention is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butylloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the antibody of the present invention, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of an antibody can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. (Grant GA (1992) *Synthetic Peptides: A User Guide*. W.H. Freeman and Co., N.Y. (1992); Bodansky M and Trost B., Ed. (1993) *Principles of Peptide Synthesis*. Springer-Verlag Inc., NY. Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described above. Once isolated, these independent peptides or polypeptides may be linked to form an antibody or fragment thereof via similar peptide condensation reactions.

For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., *Biochemistry*, 30:4151 (1991)). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al. *Synthesis of Proteins by Native Chemical Ligation*. *Science*, 266:776-779 (1994)). The first step is the chemoselective reaction of an unprotected synthetic peptide- α -thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site. Application of this native chemical ligation method to the total synthesis of a protein molecule is illustrated by the preparation of human interleukin 8 (IL-8) (Baggiolini M et al. (1992) *FEBS Lett.* 307:97-101; Clark-Lewis I et al., *J.Biol.Chem.*, 269:16075 (1994); Clark-Lewis I et al., *Biochemistry*, 30:3128 (1991); Rajarathnam K et al., *Biochemistry* 33:6623-30 (1994)).

Alternatively, unprotected peptide segments are chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, M et al. Science, 256:221 (1992)). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton RC et al., Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267 (1992)).

The invention also provides fragments of antibodies which have bioactivity. The polypeptide fragments of the present invention can be recombinant proteins obtained by cloning nucleic acids encoding the polypeptide in an expression system capable of producing the polypeptide fragments thereof, such as an adenovirus or baculovirus expression system. For example, one can determine the active domain of an antibody from a specific hybridoma that can cause a biological effect associated with the interaction of the antibody with EphA2. For example, amino acids found to not contribute to either the activity or the binding specificity or affinity of the antibody can be deleted without a loss in the respective activity. For example, in various embodiments, amino or carboxy-terminal amino acids are sequentially removed from either the native or the modified non-immunoglobulin molecule or the immunoglobulin molecule and the respective activity assayed in one of many available assays. In another example, a fragment of an antibody comprises a modified antibody wherein at least one amino acid has been substituted for the naturally occurring amino acid at a specific position, and a portion of either amino terminal or carboxy terminal amino acids, or even an internal region of the antibody, has been replaced with a polypeptide fragment or other moiety, such as biotin, which can facilitate in the purification of the modified antibody. For example, a modified antibody can be fused to a maltose binding protein, through either peptide chemistry or cloning the respective nucleic acids encoding the two polypeptide fragments into an expression vector such that the expression of the coding region results in a hybrid polypeptide. The hybrid polypeptide can be affinity purified by passing it over an amylose affinity solid support, and the modified antibody receptor can then be separated from the maltose binding region by cleaving the hybrid polypeptide with the specific protease factor Xa. (See, for example, New England Biolabs Product Catalog, 1996, pg. 164.). Similar purification procedures are available for isolating hybrid proteins from eukaryotic cells as well.

The fragments, whether attached to other sequences or not, include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove or add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc.

Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antigen. (Zoller MJ et al. Nucl. Acids Res. 10:6487-500 (1982).

5 A variety of immunoassay formats may be used to select antibodies that selectively bind with a particular protein, variant, or fragment. For example, solid-phase ELISA immunoassays are routinely used to select antibodies selectively immunoreactive with a protein, protein variant, or fragment thereof. See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988), for a description of immunoassay formats and conditions that
10 could be used to determine selective binding. The binding affinity of a monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al., Anal. Biochem., 107:220 (1980).

Also provided is an antibody reagent kit comprising containers of the monoclonal antibody or fragment thereof of the invention and one or more reagents for detecting binding of the antibody
15 or fragment thereof to the EphA2 receptor molecule. The reagents can include, for example, fluorescent tags, enzymatic tags, or other tags. The reagents can also include secondary or tertiary antibodies or reagents for enzymatic reactions, wherein the enzymatic reactions produce a product that can be visualized.

(b) Functional Nucleic Acids

20 Functional nucleic acids can also be used to regulate the , for example, the function of the disclosed integrins, integrin receptors, molecules that interact with the disclosed integrin receptors, and molecules in the signaling pathways of the disclosed integrin receptors.

Functional nucleic acids are nucleic acid molecules that have a specific function, such as binding a target molecule or catalyzing a specific reaction. Functional nucleic acid molecules can
25 be divided into the following categories, which are not meant to be limiting. For example, functional nucleic acids include antisense molecules, aptamers, ribozymes, triplex forming molecules, and external guide sequences. The functional nucleic acid molecules can act as effectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or the functional nucleic acid molecules can possess a de novo activity independent of
30 any other molecules.

Functional nucleic acid molecules can interact with any macromolecule, such as DNA, RNA, polypeptides, or carbohydrate chains. Thus, functional nucleic acids can interact with the mRNA of beta4 integrin for example, or the genomic DNA of alpha6 integrin for example, or they can interact with the polypeptide laminin5, or the gamma2 subunit of laminin5. Often functional
35 nucleic acids are designed to interact with other nucleic acids based on sequence homology

between the target molecule and the functional nucleic acid molecule. In other situations, the specific recognition between the functional nucleic acid molecule and the target molecule is not based on sequence homology between the functional nucleic acid molecule and the target molecule, but rather is based on the formation of tertiary structure that allows specific recognition to take place. Antisense molecules are designed to interact with a target nucleic acid molecule through either canonical or non-canonical base pairing. The interaction of the antisense molecule and the target molecule is designed to promote the destruction of the target molecule through, for example, RNaseH mediated RNA-DNA hybrid degradation. Alternatively the antisense molecule is designed to interrupt a processing function that normally would take place on the target molecule, such as transcription or replication. Antisense molecules can be designed based on the sequence of the target molecule. Numerous methods for optimization of antisense efficiency by finding the most accessible regions of the target molecule exist. Exemplary methods would be in vitro selection experiments and DNA modification studies using DMS and DEPC. It is preferred that antisense molecules bind the target molecule with a dissociation constant (k_d) less than 10^{-6} . It is more preferred that antisense molecules bind with a k_d less than 10^{-8} . It is also more preferred that the antisense molecules bind the target molecule with a k_d less than 10^{-10} . It is also preferred that the antisense molecules bind the target molecule with a k_d less than 10^{-12} . A representative sample of methods and techniques which aid in the design and use of antisense molecules can be found in the following non-limiting list of United States patents: 5,135,917, 5,294,533, 5,627,158, 5,641,754, 5,691,317, 5,780,607, 5,786,138, 5,849,903, 5,856,103, 5,919,772, 5,955,590, 5,990,088, 5,994,320, 5,998,602, 6,005,095, 6,007,995, 6,013,522, 6,017,898, 6,018,042, 6,025,198, 6,033,910, 6,040,296, 6,046,004, 6,046,319, and 6,057,437.

Aptamers are molecules that interact with a target molecule, preferably in a specific way. Typically aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-quartets. Aptamers can bind small molecules, such as ATP (United States patent 5,631,146) and theophiline (United States patent 5,580,737), as well as large molecules, such as reverse transcriptase (United States patent 5,786,462) and thrombin (United States patent 5,543,293). Aptamers can bind very tightly with k_d s from the target molecule of less than 10^{-12} M. It is preferred that the aptamers bind the target molecule with a k_d less than 10^{-6} . It is more preferred that the aptamers bind the target molecule with a k_d less than 10^{-8} . It is also more preferred that the aptamers bind the target molecule with a k_d less than 10^{-10} . It is also preferred that the aptamers bind the target molecule with a k_d less than 10^{-12} . Aptamers can bind the target molecule with a very high degree of specificity. For example, aptamers have been isolated that have greater than a 10000 fold difference in binding affinities between the target molecule and another molecule that differ at only a single position on the molecule (United States patent 5,543,293). It is preferred that the aptamer have a k_d with the target

molecule at least 10 fold lower than the k_d with a background binding molecule. It is more preferred that the aptamer have a k_d with the target molecule at least 100 fold lower than the k_d with a background binding molecule. It is more preferred that the aptamer have a k_d with the target molecule at least 1000 fold lower than the k_d with a background binding molecule. It is preferred that the aptamer have a k_d with the target molecule at least 10000 fold lower than the k_d with a background binding molecule. It is preferred when doing the comparison for a polypeptide for example, that the background molecule be a different polypeptide. For example, when determining the specificity of beta4 integrin aptamers, the background protein could be bovine serum albumin. Representative examples of how to make and use aptamers to bind a variety of different target molecules can be found in the following non-limiting list of United States patents: 5,476,766, 5,503,978, 5,631,146, 5,731,424, 5,780,228, 5,792,613, 5,795,721, 5,846,713, 5,858,660, 5,861,254, 5,864,026, 5,869,641, 5,958,691, 6,001,988, 6,011,020, 6,013,443, 6,020,130, 6,028,186, 6,030,776, and 6,051,698.

Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction, either intramolecularly or intermolecularly. Ribozymes are thus catalytic nucleic acid. It is preferred that the ribozymes catalyze intermolecular reactions. There are a number of different types of ribozymes that catalyze nuclease or nucleic acid polymerase type reactions which are based on ribozymes found in natural systems, such as hammerhead ribozymes, (for example, but not limited to the following United States patents: 5,334,711, 5,436,330, 5,616,466, 5,633,133, 5,646,020, 5,652,094, 5,712,384, 5,770,715, 5,856,463, 5,861,288, 5,891,683, 5,891,684, 5,985,621, 5,989,908, 5,998,193, 5,998,203, WO 9858058 by Ludwig and Sproat, WO 9858057 by Ludwig and Sproat, and WO 9718312 by Ludwig and Sproat) hairpin ribozymes (for example, but not limited to the following United States patents: 5,631,115, 5,646,031, 5,683,902, 5,712,384, 5,856,188, 5,866,701, 5,869,339, and 6,022,962), and tetrahymena ribozymes (for example, but not limited to the following United States patents: 5,595,873 and 5,652,107). There are also a number of ribozymes that are not found in natural systems, but which have been engineered to catalyze specific reactions de novo (for example, but not limited to the following United States patents: 5,580,967, 5,688,670, 5,807,718, and 5,910,408). Preferred ribozymes cleave RNA or DNA substrates, and more preferably cleave RNA substrates. Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage. This recognition is often based mostly on canonical or non-canonical base pair interactions. This property makes ribozymes particularly good candidates for target specific cleavage of nucleic acids because recognition of the target substrate is based on the target substrates sequence. Representative examples of how to make and use ribozymes to catalyze a variety of different reactions can be found in the following non-limiting list of United States patents: 5,646,042, 5,693,535, 5,731,295, 5,811,300, 5,837,855, 5,869,253, 5,877,021, 5,877,022, 5,972,699,

5,972,704, 5,989,906, and 6,017,756.

Triplex forming functional nucleic acid molecules are molecules that can interact with either double-stranded or single-stranded nucleic acid. When triplex molecules interact with a target region, a structure called a triplex is formed, in which there are three strands of DNA forming a complex dependant on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are preferred because they can bind target regions with high affinity and specificity. It is preferred that the triplex forming molecules bind the target molecule with a k_d less than 10^{-9} . It is more preferred that the triplex forming molecules bind with a k_d less than 10^{-8} . It is also more preferred that the triplex forming molecules bind the target molecule with a k_d less than 10^{-10} . It is also preferred that the triplex forming molecules bind the target molecule with a k_d less than 10^{-12} . Representative examples of how to make and use triplex forming molecules to bind a variety of different target molecules can be found in the following non-limiting list of United States patents: 5,176,996, 5,645,985, 5,650,316, 5,683,874, 5,693,773, 5,834,185, 5,869,246, 5,874,566, and 5,962,426.

External guide sequences (EGSs) are molecules that bind a target nucleic acid molecule forming a complex, and this complex is recognized by RNase P, which cleaves the target molecule. EGSs can be designed to specifically target a RNA molecule of choice. RNase P aids in processing transfer RNA (tRNA) within a cell. Bacterial RNase P can be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS complex to mimic the natural tRNA substrate. (WO 92/03566 by Yale, and Forster and Altman, *Science* 238:407-409 (1990)).

Similarly, eukaryotic EGS/RNase P-directed cleavage of RNA can be utilized to cleave desired targets within eukaryotic cells. (Yuan et al., *Proc. Natl. Acad. Sci. USA* 89:8006-8010 (1992); WO 93/22434 by Yale; WO 95/24489 by Yale; Yuan and Altman, *EMBO J* 14:159-168 (1995), and Carrara et al., *Proc. Natl. Acad. Sci. (USA)* 92:2627-2631 (1995)). Representative examples of how to make and use EGS molecules to facilitate cleavage of a variety of different target molecules be found in the following non-limiting list of United States patents: 5,168,053, 5,624,824, 5,683,873, 5,728,521, 5,869,248, and 5,877,162

(c) Small molecules

Small molecules can also be used to regulate, for example, the function of the disclosed integrins, integrin receptors, molecules that interact with the disclosed integrin receptors, and molecules in the signaling pathways of the disclosed integrin receptors. Those of skill in the art understand how to generate small molecules of this type, and exemplary libraries and methods for isolating small molecule regulators are disclosed herein.

b) Compositions identified by screening with disclosed compositions / combinatorial chemistry

(1) Combinatorial chemistry

The disclosed compositions can be used as targets for any combinatorial technique to
5 identify molecules or macromolecular molecules that interact with the disclosed compositions,
such as beta4 integrin, alpha6 integrin, or the gamma2 subunit of laminin5, in a desired way. The
nucleic acids, peptides, and related molecules disclosed herein can be used as targets for the
combinatorial approaches. Also disclosed are the compositions that are identified through
combinatorial techniques or screening techniques in which the herein disclosed compositions, for
10 example set forth in SEQ ID NOS:1-19 or portions thereof, are used as the target or reagent in a
combinatorial or screening protocol.

It is understood that when using the disclosed compositions in combinatorial techniques or
screening methods, molecules, such as macromolecular molecules, will be identified that have
particular desired properties such as inhibition or stimulation or the target molecule's function.
15 The molecules identified and isolated when using the disclosed compositions, such as, beta4
integrin, alpha6 integrin, or the gamma2 subunit of laminin5, are also disclosed. Thus, the products
produced using the combinatorial or screening approaches that involve the disclosed compositions,
such as, beta4 integrin, alpha6 integrin, or the gamma2 subunit of laminin5, are also considered
herein disclosed.

20 Combinatorial chemistry includes but is not limited to all methods for isolating small
molecules or macromolecules that are capable of binding either a small molecule or another
macromolecule, typically in an iterative process. Proteins, oligonucleotides, and sugars are
examples of macromolecules. For example, oligonucleotide molecules with a given function,
catalytic or ligand-binding, can be isolated from a complex mixture of random oligonucleotides in
25 what has been referred to as "in vitro genetics" (Szostak, TIBS 19:89, 1992). One synthesizes a
large pool of molecules bearing random and defined sequences and subjects that complex mixture,
for example, approximately 10^{15} individual sequences in 100 μg of a 100 nucleotide RNA, to some
selection and enrichment process. Through repeated cycles of affinity chromatography and PCR
amplification of the molecules bound to the ligand on the solid support, Ellington and Szostak
30 (1990) estimated that 1 in 10^{10} RNA molecules folded in such a way as to bind a small molecule
dyes. DNA molecules with such ligand-binding behavior have been isolated as well (Ellington and
Szostak, 1992; Bock et al. 1992). Techniques aimed at similar goals exist for small organic
molecules, proteins, antibodies and other macromolecules known to those of skill in the art.
Screening sets of molecules for a desired activity whether based on small organic libraries,
35 oligonucleotides, or antibodies is broadly referred to as combinatorial chemistry. Combinatorial
techniques are particularly suited for defining binding interactions between molecules and for

isolating molecules that have a specific binding activity, often called aptamers when the macromolecules are nucleic acids.

There are a number of methods for isolating proteins which either have de novo activity or a modified activity. For example, phage display libraries have been used to isolate numerous
5 peptides that interact with a specific target. (See for example, United States Patent No. 6,031,071; 5,824,520; 5,596,079; and 5,565,332 which are herein incorporated by reference at least for their material related to phage display and methods relate to combinatorial chemistry)

A preferred method for isolating proteins that have a given function is described by Roberts and Szostak (Roberts R.W. and Szostak J.W. Proc. Natl. Acad. Sci. USA,
10 94(23)12997-302 (1997)). This combinatorial chemistry method couples the functional power of proteins and the genetic power of nucleic acids. An RNA molecule is generated in which a puromycin molecule is covalently attached to the 3'-end of the RNA molecule. An *in vitro* translation of this modified RNA molecule causes the correct protein, encoded by the RNA to be translated. In addition, because of the attachment of the puromycin, a peptidyl acceptor which
15 cannot be extended, the growing peptide chain is attached to the puromycin which is attached to the RNA. Thus, the protein molecule is attached to the genetic material that encodes it. Normal *in vitro* selection procedures can now be done to isolate functional peptides. Once the selection procedure for peptide function is complete traditional nucleic acid manipulation procedures are performed to amplify the nucleic acid that codes for the selected functional peptides. After
20 amplification of the genetic material, new RNA is transcribed with puromycin at the 3'-end, new peptide is translated and another functional round of selection is performed. Thus, protein selection can be performed in an iterative manner just like nucleic acid selection techniques. The peptide which is translated is controlled by the sequence of the RNA attached to the puromycin. This sequence can be anything from a random sequence engineered for optimum translation (i.e.
25 no stop codons etc.) or it can be a degenerate sequence of a known RNA molecule to look for improved or altered function of a known peptide. The conditions for nucleic acid amplification and *in vitro* translation are well known to those of ordinary skill in the art and are preferably performed as in Roberts and Szostak (Roberts R.W. and Szostak J.W. Proc. Natl. Acad. Sci. USA, 94(23)12997-302 (1997)).

30 Another preferred method for combinatorial methods designed to isolate peptides is described in Cohen et al. (Cohen B.A., et al., Proc. Natl. Acad. Sci. USA 95(24):14272-7 (1998)). This method utilizes and modifies two-hybrid technology. Yeast two-hybrid systems are useful for the detection and analysis of protein:protein interactions. The two-hybrid system, initially described in the yeast *Saccharomyces cerevisiae*, is a powerful molecular genetic
35 technique for identifying new regulatory molecules, specific to the protein of interest (Fields and

Song, *Nature* 340:245-6 (1989)). Cohen et al., modified this technology so that novel interactions between synthetic or engineered peptide sequences could be identified which bind a molecule of choice. The benefit of this type of technology is that the selection is done in an intracellular environment. The method utilizes a library of peptide molecules that attached to an acidic
 5 activation domain. A peptide of choice, for example a portion of beta4 or alpha6 or gamma2 or laminin5 is attached to a DNA binding domain of a transcriptional activation protein, such as Gal
 4. By performing the Two-hybrid technique on this type of system, molecules that bind the portion of beta4 or alpha6 or gamma2 or laminin5 can be identified.

There are molecules that can act like antibodies, in that they can having varying binding
 10 specificities, that are based on a fibronectin motif. The fibronectin type III domain (FN3) is a small autonomous folding unit. This FN3 domain can be found in numerous proteins that bind ligand, such as animal proteins. The beta-sandwich structure of FN3 closely resembles that of immunoglobulin domains. FN3 mutants can be isolated using combinatorial approaches disclosed herein, for example phage display, that bind desired targets. Typically the libraries of FN3
 15 molecules have been randomized in the two surface loops. Thus, FN3 can be used at least as a scaffold for engineering novel binding proteins. (Koide A, Bailey CW, Huang X, Koide S., "The fibronectin type III domain as a scaffold for novel binding proteins." *J Mol Biol* 1998: 284,1141-1151 which is herein incorporated by reference at least for material related to the fibronectin based novel binding proteins).

20 Using methodology well known to those of skill in the art, in combination with various combinatorial libraries, one can isolate and characterize those small molecules or macromolecules, which bind to or interact with the desired target. The relative binding affinity of these compounds can be compared and optimum compounds identified using competitive binding studies, which are well known to those of skill in the art.

25 Techniques for making combinatorial libraries and screening combinatorial libraries to isolate molecules which bind a desired target are well known to those of skill in the art. Representative techniques and methods can be found in but are not limited to United States patents
 5,084,824, 5,288,514, 5,449,754, 5,506,337, 5,539,083, 5,545,568, 5,556,762, 5,565,324,
 5,565,332, 5,573,905, 5,618,825, 5,619,680, 5,627,210, 5,646,285, 5,663,046, 5,670,326,
 30 5,677,195, 5,683,899, 5,688,696, 5,688,997, 5,698,685, 5,712,146, 5,721,099, 5,723,598,
 5,741,713, 5,792,431, 5,807,683, 5,807,754, 5,821,130, 5,831,014, 5,834,195, 5,834,318,
 5,834,588, 5,840,500, 5,847,150, 5,856,107, 5,856,496, 5,859,190, 5,864,010, 5,874,443,
 5,877,214, 5,880,972, 5,886,126, 5,886,127, 5,891,737, 5,916,899, 5,919,955, 5,925,527,
 5,939,268, 5,942,387, 5,945,070, 5,948,696, 5,958,702, 5,958,792, 5,962,337, 5,965,719,
 35 5,972,719, 5,976,894, 5,980,704, 5,985,356, 5,999,086, 6,001,579, 6,004,617, 6,008,321,

6,017,768, 6,025,371, 6,030,917, 6,040,193, 6,045,671, 6,045,755, 6,060,596, and 6,061,636.

Combinatorial libraries can be made from a wide array of molecules using a number of different synthetic techniques. For example, libraries containing fused 2,4-pyrimidinediones (United States patent 6,025,371) dihydrobenzopyrans (United States Patent 6,017,768 and 5,821,130), amide alcohols (United States Patent 5,976,894), hydroxy-amino acid amides (United States Patent 5,972,719) carbohydrates (United States patent 5,965,719), 1,4-benzodiazepin-2,5-diones (United States patent 5,962,337), cyclics (United States patent 5,958,792), biaryl amino acid amides (United States patent 5,948,696), thiophenes (United States patent 5,942,387), tricyclic Tetrahydroquinolines (United States patent 5,925,527), benzofurans (United States patent 5,919,955), isoquinolines (United States patent 5,916,899), hydantoin and thiohydantoin (United States patent 5,859,190), indoles (United States patent 5,856,496), imidazol-pyrido-indole and imidazol-pyrido-benzothiophenes (United States patent 5,856,107) substituted 2-methylene-2, 3-dihydrothiazoles (United States patent 5,847,150), quinolines (United States patent 5,840,500), PNA (United States patent 5,831,014), containing tags (United States patent 5,721,099), polyketides (United States patent 5,712,146), morpholino-subunits (United States patent 5,698,685 and 5,506,337), sulfamides (United States patent 5,618,825), and benzodiazepines (United States patent 5,288,514).

Screening molecules similar to alpha6 for inhibition of alpha6beta4 formation is a method of identifying and isolating desired compounds that can inhibit the formation of A6B4 receptor.

For example, the disclosed compositions, such as alpha6 integrin or beta4 integrin can be used as targets in a selection scheme disclosed herein, and then the counter part integrin could be used as a competitive inhibitor to isolate the desired molecules. For example, a library of molecules could be incubated with beta4 integrin, which is bound to a solid support. The solid support can be washed to remove the unbound molecules and then the solid support can be incubated with, for example, alpha6 integrin at a concentration that will saturate all beta4 binding sites. The molecules which are collected in the flowthrough after washing the solid support will be enriched for molecules that interact with beta4 integrin in a way that is competitive to the alpha6-beta4 interaction. Likewise, the solid support, bound with a target integrin, or more preferably a target integrin receptor, such as alpha6beta4 receptor, could also be washed, with for example, laminin5 or the gamma2 subunit of laminin5 at a concentration that will saturate all of the gamma2 binding sites on the beta4 integrin. Collection of the wash under these conditions will yield a population of molecules enriched for molecules that competitively interact with beta4 integrin at the beta4-gamma2 site. Another example, is the following: bind target to solid support on microtiter plate. Incubate with ligand in presence of gridded subset of library members (or single compounds), wash, identify competitor by reduction of ligand binding. It is understood that the exemplary discussions of alpha6beta4 and/or beta4 are equally applicable to alpha6, as well as other

alpha6betax receptors, such alpha6beta1.

Also disclosed are methods of isolating molecules that bind with a target molecule selected from the group consisting, B4 integrin, alpha6 integrin, and the gamma2 subunit of laminin5 comprising 1) contacting a library of molecules with the target molecule and 2)
5 collecting molecules that bind the target molecule producing an enriched population of molecules.

Disclosed are methods, further comprising the step of repeating steps 1 and 2 with the enriched population of molecules, and/or wherein the library comprises a small molecule, peptide, peptide mimetic, or oligonucleotide.

As used herein combinatorial methods and libraries included traditional screening methods
10 and libraries as well as methods and libraries used in iterative processes.

(2) Computer assisted design

The disclosed compositions can be used as targets for any molecular modeling technique to identify either the structure of the disclosed compositions or to identify potential or actual molecules, such as small molecules, which interact in a desired way with the disclosed
15 compositions. The nucleic acids, peptides, and related molecules disclosed herein can be used as targets in any molecular modeling program or approach.

It is understood that when using the disclosed compositions in modeling techniques, molecules, such as macromolecular molecules, will be identified that have particular desired properties such as inhibition or stimulation or the target molecule's function. The molecules
20 identified and isolated when using the disclosed compositions, such as, beta4, are also disclosed. Thus, the products produced using the molecular modeling approaches that involve the disclosed compositions, such as, beta4 integrin, alpha6 integrin, or laminin5, are also considered herein disclosed.

Thus, one way to isolate molecules that bind a molecule of choice is through rational
25 design. This is achieved through structural information and computer modeling. Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule. The molecular dynamics require force field data. The
30 computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity. Prediction of what the molecule-compound interaction will be when small changes are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly, menu-driven interfaces

between the molecular design program and the user.

Examples of molecular modeling systems are the CHARMM and QUANTA programs, Polygen Corporation, Waltham, MA. CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen, et al., 1988 *Acta Pharmaceutica Fennica* 97, 159-166; Ripka, *New Scientist* 54-57 (June 16, 1988); McKinally and Rossmann, 1989 *Annu. Rev. Pharmacol. Toxicol.* 29, 111-122; Perry and Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, 1989 *Proc. R. Soc. Lond.* 236, 125-140 and 141-162; and, with respect to a model enzyme for nucleic acid components, Askew, et al., 1989 *J. Am. Chem. Soc.* 111, 1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, CA., Allelix, Inc, Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario. Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of molecules specifically interacting with specific regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which alter substrate binding or enzymatic activity.

c) Nucleic acids

There are a variety of molecules disclosed herein that are nucleic acid based, including for example the nucleic acids that encode, for example beta4 and the gamma2 subunit of laminin5, as well as various functional nucleic acids. The disclosed nucleic acids are made up of for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and other molecules are discussed herein. It is understood that for example, when a vector is expressed in a cell, that the expressed mRNA will typically be made up of A, C, G, and U. Likewise, it is understood that if, for example, an antisense molecule is introduced into a cell or cell environment through for example exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.

(1) Nucleotides and related molecules

A nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate

moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an internucleoside linkage. The base moiety of a nucleotide can be adenin-9-yl (A), cytosin-1-yl (C), guanin-9-yl (G), uracil-1-yl (U), and thymine-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent
 5 phosphate. An non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).

A nucleotide analog is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to the base moiety would include natural and synthetic modifications of A, C, G, and T/U as well as different purine or pyrimidine bases, such
 10 as uracil-5-yl (.psi.), hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl. A modified base includes but is not limited to 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-
 15 uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Additional base modifications can be found for example in U.S. Pat. No. 3,687,808, Englisch et
 20 al., *Angewandte Chemie, International Edition*, 1991, 30, 613, and Sanghvi, Y. S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain nucleotide analogs, such as 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine can increase the stability of duplex formation. Base
 25 modifications can be combined, for example, with a sugar modification, such as 2'-O-methoxyethyl, to achieve unique properties such as increased duplex stability. There are numerous United States patents such as 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, which detail and describe a range of base
 30 modifications. Each of these patents is herein incorporated by reference.

Nucleotide analogs can also include modifications of the sugar moiety. Modifications to the sugar moiety would include natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include but are not limited to the following modifications at the 2' position: OH-; F-; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-
 35 alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀, alkyl or C₂ to C₁₀ alkenyl and alkynyl. 2' sugar modifications also include

but are not limited to $-O[(CH_2)_n O]_m CH_3$, $-O(CH_2)_n OCH_3$, $-O(CH_2)_n NH_2$, $-O(CH_2)_n CH_3$, $-O(CH_2)_n -ONH_2$, and $-O(CH_2)_n ON[(CH_2)_n CH_3]_2$, where n and m are from 1 to about 10.

Other modifications at the 2' position include but are not limited to: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 , $SOCH_3$, $SO_2 CH_3$, ONO_2 , NO_2 , N_3 , NH_2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Similar modifications may also be made at other positions on the sugar, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Modified sugars would also include those that contain modifications at the bridging ring oxygen, such as CH_2 and S. Nucleotide sugar analogs may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. There are numerous United States patents that teach the preparation of such modified sugar structures such as 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein incorporated by reference in its entirety.

Nucleotide analogs can also be modified at the phosphate moiety. Modified phosphate moieties include but are not limited to those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3'-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates. It is understood that these phosphate or modified phosphate linkage between two nucleotides can be through a 3'-5' linkage or a 2'-5' linkage, and the linkage can contain inverted polarity such as 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included. Numerous United States patents teach how to make and use nucleotides containing modified phosphates and include but are not limited to, 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference.

It is understood that nucleotide analogs need only contain a single modification, but may also contain multiple modifications within one of the moieties or between different moieties.

Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety.

- 5 Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.

Nucleotide substitutes are nucleotides or nucleotide analogs that have had the phosphate moiety and/or sugar moieties replaced. Nucleotide substitutes do not contain a standard phosphorus atom. Substitutes for the phosphate can be for example, short chain alkyl or
 10 cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones;
 15 sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts. Numerous United States patents disclose how to make and use these types of phosphate replacements and include but are not limited to 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;
 20 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

It is also understood in a nucleotide substitute that both the sugar and the phosphate moieties of the nucleotide can be replaced, by for example an amide type linkage
 25 (aminoethylglycine) (PNA). United States patents 5,539,082; 5,714,331; and 5,719,262 teach how to make and use PNA molecules, each of which is herein incorporated by reference. (See also Nielsen et al., Science, 1991, 254, 1497-1500).

It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the
 30 nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989,

86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol
 35 (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or

undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmitoyl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937. Numerous United States patents teach the preparation of such conjugates and include, but are not limited to U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.

It is understood that an oligonucleotide can be made from any combination of nucleotides, nucleotide analogs, or nucleotide substitutes disclosed herein or related molecules not specifically recited herein.

A Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute. The Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, N1, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.

A Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA. The Hoogsteen face includes the N7 position and reactive groups (NH₂ or O) at the C6 position of purine nucleotides.

(2) Sequences

There are a variety of sequences related to the beta4 integrin or the laminin5-gamma2 gene or the alpha6 integrin gene having the following Genbank Accession Numbers 6453379, 4557674, and AH006634, respectively. These sequences and others are herein incorporated by reference in their entireties as well as for individual subsequences contained therein.

One particular sequence set forth in SEQ ID NO:1 (beta4 integrin) and having Genbank accession number 6453379 is used herein, at various points, as an example, to exemplify the disclosed compositions and methods (or when another particular sequence is used as an example). It is understood that the description related to this sequence is applicable to any sequence related to
5 beta4 integrin or any of the other molecules disclosed herein, such as alpha6 integrin, or the subunits of laminin5, such as gamma2, unless specifically indicated otherwise. Those of skill in the art understand how to resolve sequence discrepancies and differences and to adjust the compositions and methods relating to a particular sequence to other related sequences (i.e. sequences of beta4 integrin). Primers and/or probes can be designed for any beta4 integrin
10 sequence given the information disclosed herein and known in the art.

(3) Primers and probes

Disclosed are compositions including primers and probes, which are capable of interacting with the for example, the alpha6 gene or mRNA, beta4 gene or mRNA, or gamma2 subunit of the laminin5 ligand gene as disclosed herein or mRNA as wells as primers or probes for any of the
15 sequences or fragments of the sequences, set forth in SEQ ID NOs:1,3,5,7,9,11, and 13. In certain embodiments the primers are used to support DNA amplification reactions. Typically the primers will be capable of being extended in a sequence specific manner. Extension of a primer in a sequence specific manner includes any methods wherein the sequence and/or composition of the nucleic acid molecule to which the primer is hybridized or otherwise associated directs or
20 influences the composition or sequence of the product produced by the extension of the primer. Extension of the primer in a sequence specific manner therefore includes, but is not limited to, PCR, DNA sequencing, DNA extension, DNA polymerization, RNA transcription, or reverse transcription. Techniques and conditions that amplify the primer in a sequence specific manner are preferred. In certain embodiments the primers are used for the DNA amplification reactions,
25 such as PCR or direct sequencing. It is understood that in certain embodiments the primers can also be extended using non-enzymatic techniques, where for example, the nucleotides or oligonucleotides used to extend the primer are modified such that they will chemically react to extend the primer in a sequence specific manner. Typically the disclosed primers hybridize with the beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, or region of the
30 beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, or they hybridize with the complement of the beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, or complement of a region of the beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, or any of the sequences or fragments of the sequences, set forth in SEQ ID NOs:1,3,5,7,9,11, and 13, for example.

35 The size of the primers or probes for interaction with the beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, in certain embodiments can be any size that supports

the desired enzymatic manipulation of the primer, such as DNA amplification or the simple hybridization of the probe or primer. A typical primer or probe for beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, or primer or probe for any of the sequences or fragments of the sequences, set forth in SEQ ID NOs:1,3,5,7,9,11, and 13 would be at least about
 5 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3500, or 4000 nucleotides long.

In other embodiments a primer or probe for beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, for example, primer or probe or a primer or probe for any of the sequences or fragments of the sequences, set forth in SEQ ID NOs:1,3,5,7,9,11, and 13 can be less than or equal to about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
 15 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3500, or 4000 nucleotides long.

20 The primers for the beta4 gene, alpha6 gene, or laminin5-gamma2 subunit gene, or any of the sequences or fragments of the sequences, set forth in SEQ ID NOs:1,3,5,7,9,11, and 13, for example, typically will be used to produce an amplified DNA product that contains a desired region. In general, typically the size of the product will be such that the size can be accurately determined to within 3, or 2 or 1 nucleotides.

25 In certain embodiments this product is at least about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3500, or 4000 nucleotides long.

In other embodiments the product is less than or equal to about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175,
 35 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850,

900, 950, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3500, or 4000 nucleotides long.

d) Sequence similarities

It is understood that as discussed herein the use of the terms homology and identity mean the same thing as similarity. Thus, for example, if the word homology is used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether or not they are evolutionarily related.

In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed genes and proteins herein, is through defining the variants and derivatives in terms of homology to specific known sequences. This identity of particular sequences disclosed herein is also discussed elsewhere herein. In general, variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids, such as genes. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. Mol Biol. 48: 443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment. It is understood that any of the methods typically can be used and that in certain instances the results of these various methods may differ, but the skilled artisan understands if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

For example, as used herein, a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

It is also understood that functional fragments as well as antigenic fragments as well as fragments that can be used in selection protocols of the disclosed compositions are also disclosed. For example, integrins have domains that interact with the other integrins. It may be advantageous in certain embodiments to utilize just the integrin binding domain fragment of, for example, the beta4 integrin, in a selection protocol disclosed herein. By using this domain of the beta4 integrin as the selection target, for example, the selection protocol will be biased for molecules binding this domain of beta4 integrin.

e) Hybridization/selective hybridization

The term hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene. Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide. The hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.

Parameters for selective hybridization between two nucleic acid molecules are well known to those of skill in the art. For example, in some embodiments selective hybridization conditions

can be defined as stringent hybridization conditions. For example, stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps. For example, the conditions of hybridization to achieve selective hybridization may involve hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature
5 that is about 12-25°C below the T_m (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the T_m . The temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled
10 nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA-RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as is known in the art. (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. *Methods Enzymol.* 1987:154:367, 1987 which is herein
15 incorporated by reference for material at least related to hybridization of nucleic acids). A preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C. Stringency of hybridization and washing, if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any
20 area wherein variability is searched for. Likewise, stringency of hybridization and washing, if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.

Another way to define selective hybridization is by looking at the amount (percentage) of
25 one of the nucleic acids bound to the other nucleic acid. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid. Typically, the non-limiting primer is in for example, 10 or 100 or 1000 fold excess. This type of assay can be performed at
30 under conditions where both the limiting and non-limiting primer are for example, 10 fold or 100 fold or 1000 fold below their k_d , or where only one of the nucleic acid molecules is 10 fold or 100 fold or 1000 fold or where one or both nucleic acid molecules are above their k_d .

Another way to define selective hybridization is by looking at the percentage of primer
that gets enzymatically manipulated under conditions where hybridization is required to promote
35 the desired enzymatic manipulation. For example, in some embodiments selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,

83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is DNA extension, then selective hybridization conditions would be when at least about 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 5 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer molecules are extended. Preferred conditions also include those suggested by the manufacturer or indicated in the art as being appropriate for the enzyme performing the manipulation.

Just as with homology, it is understood that there are a variety of methods herein disclosed for determining the level of hybridization between two nucleic acid molecules. It is understood 10 that these methods and conditions may provide different percentages of hybridization between two nucleic acid molecules, but unless otherwise indicated meeting the parameters of any of the methods would be sufficient. For example if 80% hybridization was required and as long as hybridization occurs within the required parameters in any one of these methods it is considered disclosed herein.

15 It is understood that those of skill in the art understand that if a composition or method meets any one of these criteria for determining hybridization either collectively or singly it is a composition or method that is disclosed herein.

f) Delivery of the compositions to cells

The disclosed compositions and methods often entail delivery of the compositions to cells. 20 For example, antisense molecules directed to alpha6 mRNA or gamma2 mRNA can be delivered to cells via any method. A number of exemplary methods are disclosed herein. It is also understood that in certain embodiments, non-nucleic acid molecules will be and can be delivered to cells, for example an antibody to beta4 integrin, alpha6 integrin or, gamma2, or a small molecule, or a peptide. Delivery of these molecules can occur by any means, and exemplary 25 compositions and methods for such delivery are disclosed herein.

There are a number of compositions and methods which can be used to deliver nucleic acids to cells, either in vitro or in vivo. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems. For example, the nucleic acids can be delivered through a number of direct delivery systems such as, 30 electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes. Appropriate means for transfection, including viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA, are described by, for example, Wolff, J. A., et al., Science, 247, 1465-1468, (1990); and Wolff, J. 35 A. Nature, 352, 815-818, (1991). Such methods are well known in the art and readily adaptable for

use with the compositions and methods described herein. In certain cases, the methods will be modified to specifically function with large DNA molecules. Further, these methods can be used to target certain diseases and cell populations by using the targeting characteristics of the carrier.

(1) Nucleic acid based delivery systems

5 Transfer vectors can be any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenovirus (Ram et al. Cancer Res. 53:83-88, (1993)).

As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as gamma2 antisense producing molecules into the cell without degradation and
10 include a promoter yielding expression of the gene in the cells into which it is delivered. In some embodiments the delivery vectors are derived from either a virus or a retrovirus. Viral vectors are, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families which share the properties of these viruses which
15 make them suitable for use as vectors. Retroviruses include Murine Moloney Leukemia virus, MMLV, and retroviruses that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, other than Lentivirus vectors, they are typically not as useful in non-proliferating cells. Adenovirus vectors are relatively stable
20 and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. A preferred embodiment is a viral vector which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens. Preferred vectors of this type will carry coding regions for
25 Interleukin 8 or 10.

Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstructural early genes, structural late genes, an RNA polymerase III transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the
30 transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promoter cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines which have been engineered to express the gene products of the early genes
35 in trans.

(a) Retroviral Vectors

A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, I.M., Retroviral vectors for gene transfer. In Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incorporated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Patent Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incorporated herein by reference.

A retrovirus is essentially a package which has packed into it nucleic acid cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5' to the 3' LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert.

Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.

(b) Adenoviral Vectors

- The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol. 6:2872-2883 (1986); Haj-Ahmad et al., J. Virology 57:267-274 (1986); Davidson et al., J. Virology 61:1226-1239 (1987);
- 5 Zhang "Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis" BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene
- 10 transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993); Roessler, J. Clin. Invest. 92:1085-1092 (1993); Moullier, Nature Genetics 4:154-159 (1993); La Salle, Science 259:988-990 (1993); Gomez-Foix, J. Biol. Chem. 267:25129-25134 (1992); Rich, Human Gene Therapy 4:461-476
- 15 (1993); Zabner, Nature Genetics 6:75-83 (1994); Guzman, Circulation Research 73:1201-1207 (1993); Bout, Human Gene Therapy 5:3-10 (1994); Zabner, Cell 75:207-216 (1993); Caillaud, Eur. J. Neuroscience 5:1287-1291 (1993); and Ragot, J. Gen. Virology 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild
- 20 type or replication-defective adenovirus (Chardonnet and Dales, Virology 40:462-477 (1970); Brown and Burlingham, J. Virology 12:386-396 (1973); Svensson and Persson, J. Virology 55:442-449 (1985); Seth, et al., J. Virol. 51:650-655 (1984); Seth, et al., Mol. Cell. Biol. 4:1528-1533 (1984); Varga et al., J. Virology 65:6061-6070 (1991); Wickham et al., Cell 73:309-319 (1993)).
- 25 A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virons are generated in a cell line such as the human 293 cell line. In another preferred embodiment both the E1 and E3 genes are removed from the adenovirus genome.

(c) Adeno-associated viral vectors

- Another type of viral vector is based on an adeno-associated virus (AAV). This defective
- 30 parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, CA, which can contain the herpes simplex virus thymidine kinase gene,
- 35 HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.

In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus.

5 Typically the AAV and B19 coding regions have been deleted, resulting in a safe, noncytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. United states Patent No. 6,261,834 is herein incorporated by reference for material related to the AAV vector.

The vectors of the present invention thus provide DNA molecules which are capable of
10 integration into a mammalian chromosome without substantial toxicity.

The inserted genes in viral and retroviral usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase
15 and transcription factors, and may contain upstream elements and response elements.

(d) Large payload viral vectors

Molecular genetic experiments with large human herpesviruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpesviruses (Sun et al., Nature genetics 8: 33-41, 1994; Cotter and
20 Robertson, Curr Opin Mol Ther 5: 633-644, 1999). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA > 150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable. The maintenance of these episomes requires a specific
25 EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro. Herpesvirus amplicon systems are also being used to package pieces of DNA > 220 kb and to infect cells that can stably maintain DNA as episomes.

Other useful systems include, for example, replicating and host-restricted non-replicating
30 vaccinia virus vectors.

(2) Non-nucleic acid based systems

The disclosed compositions can be delivered to the target cells in a variety of ways. For example, the compositions can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend in part on

the type of cell targeted and whether the delivery is occurring for example *in vivo* or *in vitro*.

Thus, the compositions can comprise, in addition to the disclosed nucleic acids and proteins or vectors for example, lipids such as liposomes, such as cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes. Liposomes can further comprise proteins
5 to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. *Am. J. Resp. Cell. Mol. Biol.* 1:95-100 (1989); Felgner et al. *Proc. Natl. Acad. Sci USA* 84:7413-7417 (1987); U.S. Pat. No.4,897,355. Furthermore, the compound can
10 be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), delivery of the
15 compositions to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the nucleic acid or vector of
20 this invention can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

The materials may be in solution or suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies,
25 receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K.D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80,
30 (1992); and Roffler, et al., Biochem. Pharmacol., 42:2062-2065, (1991)). These techniques can be used for a variety of other specific cell types. Vehicles, among others, include "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The
35 following references are examples of the use of this technology to target specific proteins to tumor

tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which
5 the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor
10 concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

Nucleic acids that are delivered to cells which are to be integrated into the host cell genome, typically contain integration sequences. These sequences are often viral related
15 sequences, particularly when viral based systems are used. These viral integration systems can also be incorporated into nucleic acids which are to be delivered using a non-nucleic acid based system of deliver, such as a liposome, so that the nucleic acid contained in the delivery system can be come integrated into the host genome.

Other general techniques for integration into the host genome include, for example,
20 systems designed to promote homologous recombination with the host genome. These systems typically rely on sequence flanking the nucleic acid to be expressed that has enough homology with a target sequence within the host cell genome that recombination between the vector nucleic acid and the target nucleic acid takes place, causing the delivered nucleic acid to be integrated into the host genome. These systems and the methods necessary to promote homologous
25 recombination are known to those of skill in the art.

(3) In vivo/ex vivo

As described above, the compositions can be administered in a pharmaceutically acceptable carrier and can be delivered to the subject's cells *in vivo* and/or *ex vivo* by a variety of mechanisms well known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular
30 injection of DNA via a gene gun, endocytosis and the like).

If *ex vivo* methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art. The compositions can be introduced into the cells via any gene transfer mechanism, such as, for example, calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes. The
35 transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or

homotopically transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.

It is understood that in certain embodiments, constructs which produce an integrin signal transduction inhibitor are driven by inducible promoters, rather than constitutive promoters.

- 5 inducible systems provide certain advantages, to the expression of the disclosed constructs. Any inducible system can be used. Also disclosed are cells containing the inducible systems, described herein, and in the Examples. These cells, can be used as model systems in a wide variety of assays, as well as in vivo settings.

g) Expression systems

- 10 The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic
15 interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

(1) Viral Promoters and Enhancers

- Preferred promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian
20 Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al., Nature, 273: 113 (1978)). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HindIII E
25 restriction fragment (Greenway, P.J. et al., Gene 18: 355-360 (1982)). Of course, promoters from the host cell or related species also are useful herein.

- Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al., Proc. Natl. Acad. Sci. 78: 993 (1981)) or 3' (Lusky, M.L., et al., Mol. Cell Bio. 3: 1108 (1983)) to the transcription unit.
30 Furthermore, enhancers can be within an intron (Banerji, J.L. et al., Cell 33: 729 (1983)) as well as within the coding sequence itself (Osborne, T.F., et al., Mol. Cell Bio. 4: 1293 (1984)). They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate
• 35 the regulation of transcription. Enhancers often determine the regulation of expression of a gene.

While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression. Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma
5 enhancer on the late side of the replication origin, and adenovirus enhancers.

The promoter and/or enhancer may be specifically activated either by light or specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

10 In certain embodiments the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed. In certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is the CMV promoter (650 bases). Other preferred promoters are SV40
15 promoters, cytomegalovirus (full length promoter), and retroviral vector LTR.

It has been shown that all specific regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types such as melanoma cells. The glial fibrillary acetic protein (GFAP) promoter has been used to selectively express genes in cells of glial origin.

20 Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contain a
25 polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs. In certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and
30 consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

(2) Markers

The viral vectors can include nucleic acid sequence encoding a marker product. This
35 marker product is used to determine if the gene has been delivered to the cell and once delivered is

being expressed. Preferred marker genes are the *E. Coli* lacZ gene, which encodes β -galactosidase, and green fluorescent protein.

In some embodiments the marker may be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, 5 neomycin, neomycin analog G418, hydromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: 10 CHO DHFR- cells and mouse LTK- cells. These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their 15 growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media.

The second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein 20 conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin, (Southern P. and Berg, P., *J. Molec. Appl. Genet.* 1: 327 (1982)), mycophenolic acid, (Mulligan, R.C. and Berg, P. *Science* 209: 1422 (1980)) or hygromycin, (Sugden, B. et al., *Mol. Cell. Biol.* 5: 410-413 (1985)). The three examples employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin 25 (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include the neomycin analog G418 and puromycin.

h) Peptides

(1) Protein variants

As discussed herein there are numerous variants of the beta4 integrin protein, alpha6 30 integrin protein, and gamma2 laminin5 protein, for example, that are known and herein contemplated. In addition, to the known functional homologue variants there are derivatives of the beta4, alpha6, and gamma2, and other disclosed proteins which also function in the disclosed methods and compositions. Protein variants and derivatives are well understood to those of skill in the art and in can involve amino acid sequence modifications. For example, amino acid sequence 35 modifications typically fall into one or more of three classes: substitutional, insertional or

deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues. Immunogenic fusion protein derivatives are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M13 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. The mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Tables 1 and 2 and are referred to as conservative substitutions.

TABLE 1: Amino Acid Abbreviations

Amino Acid	Abbreviations	
alanine	Ala	A
alloseleucine	Alle	
arginine	Arg	R
asparagine	Asn	N
aspartic acid	Asp	D
cysteine	Cys	C
glutamic acid	Glu	E
glutamine	Gln	K
glycine	Gly	G
histidine	His	H
isoleucine	Ile	I
leucine	Leu	L
lysine	Lys	K
phenylalanine	Phe	F
proline	Pro	P
pyroglutamic acid	pGlu	
serine	Ser	S
threonine	Thr	T

tyrosine	Tyr	Y	
tryptophan		Trp	W
valine		Val	V

5 TABLE 2: Amino Acid Substitutions

Original Residue	Exemplary Conservative Substitutions, others are known in the art.
Ala	ser
Arg	lys, gln
Asn	gln; his
10 Asp	glu
Cys	ser
Gln	asn, lys
Glu	asp
Gly	pro
15 His	asn;gln
Ile	leu; val
Leu	ile; val
Lys	arg; gln;
Met	Leu; ile
20 Phe	met; leu; tyr
Ser	thr
Thr	ser
Trp	tyr
Tyr	trp; phe
25 Val	ile; leu

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine, in this case, (e) by increasing the number of sites for sulfation and/or glycosylation.

For example, the replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. For example, a conservative substitution would be replacing one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the mosaic

polypeptides provided herein.

Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.

Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, *Proteins: Structure and Molecular Properties*, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. For example, SEQ ID NO:5 sets forth a particular sequence of beta4 integrin cDNA and SEQ ID NO:6 sets forth a particular sequence of a beta4 integrin protein. Specifically disclosed are variants of these and other proteins herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection.

The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein

incorporated by reference for at least material related to nucleic acid alignment.

It is understood that the description of conservative mutations and homology can be combined together in any combination, such as embodiments that have at least 70% homology to a particular sequence wherein the variants are conservative mutations.

- 5 As this specification discusses various proteins and protein sequences it is understood that the nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences.
- 10 Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence. For example, one of the many nucleic acid sequences that can encode the protein sequence set forth in SEQ ID NO:6 is set forth in SEQ ID NO:5. Another nucleic acid sequence that encodes the same protein sequence set forth in SEQ ID NO:6 is set forth in SEQ ID
- 15 NO:16. In addition, for example, a disclosed conservative derivative of SEQ ID NO:2 is shown in SEQ ID NO: 17, where the valine (V) at position 34 is changed to a isoleucine (I). It is understood that for this mutation all of the nucleic acid sequences that encode this particular derivative of the beta4 integrin are also disclosed including for example SEQ ID NO:18 and SEQ ID NO:19 which set forth two of the degenerate nucleic acid sequences that encode the particular polypeptide set
- 20 forth in SEQ ID NO:17. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where particular variants of a disclosed protein are disclosed herein, the known nucleic acid sequence that encodes that protein in the particular organism from which that protein arises is also known and herein disclosed and described.

25 i) Pharmaceutical carriers/Delivery of pharmaceutical products

- As described above, the compositions, for example, compositions that inhibit alpha6 function, beta4 function, or gamma2 function can also be administered *in vivo* in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along
- 30 with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

- 35 The compositions may be administered orally, parenterally (e.g., intravenously), by

intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like, although topical intranasal administration or administration by inhalant is typically preferred. As used herein, "topical intranasal administration" means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. The latter may be effective when a large number of animals is to be treated simultaneously. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein.

The materials may be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K.D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem. Pharmacol., 42:2062-2065, (1991)). Vehicles such as "stealth" and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells *in vivo*. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome

in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level
5 regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis has been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

(1) Pharmaceutically Acceptable Carriers

10 The compositions, including antibodies, can be used therapeutically in combination with a pharmaceutically acceptable carrier.

Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered
15 intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

Pharmaceutical compositions may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.

Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial
20 agents, anti-inflammatory agents, anesthetics, and the like.

The pharmaceutical composition may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular
25 injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl
30 oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for

example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

- 5 Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.

- Some of the compositions may potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as
- 10 hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted
- 15 ethanolamines.

(2) Therapeutic Uses

- The dosage ranges for the administration of the compositions are those large enough to produce the desired effect in which the symptoms disorder are effected. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions,
- 20 and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counterindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days.

- Other compositions which do not have a specific pharmaceutical function, but which may
- 25 be used for tracking changes within cellular chromosomes or for the delivery of diagnostic tools for example can be delivered in ways similar to those described for the pharmaceutical products.

i) Chips and micro arrays

- Disclosed are chips where at least one address is the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least
- 30 one address is the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein.

Also disclosed are chips where at least one address is a variant of the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least one address is a variant of the sequences or portion of sequences set forth in

any of the peptide sequences disclosed herein.

k) Computer readable mediums

It is understood that the disclosed nucleic acids and proteins can be represented as a sequence consisting of the nucleotides of amino acids. There are a variety of ways to display these sequences, for example the nucleotide guanosine can be represented by G or g. Likewise the amino acid valine can be represented by Val or V. Those of skill in the art understand how to display and express any nucleic acid or protein sequence in any of the variety of ways that exist, each of which is considered herein disclosed. Specifically contemplated herein is the display of these sequences on computer readable mediums, such as, commercially available floppy disks, tapes, chips, hard drives, compact disks, and video disks, or other computer readable mediums. Also disclosed are the binary code representations of the disclosed sequences. Those of skill in the art understand what computer readable mediums. Thus, computer readable mediums on which the nucleic acids or protein sequences are recorded, stored, or saved.

Disclosed are computer readable mediums comprising the sequences and information regarding the sequences set forth herein. Also disclosed are computer readable mediums comprising the sequences and information regarding the sequences set forth herein wherein the sequences do not include SEQ ID NOs: 1-19.

l) Kits

Disclosed herein are kits that are drawn to reagents that can be used in practicing the methods disclosed herein. The kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods. For example, the kits could include primers to perform the amplification reactions discussed in certain embodiments of the methods, as well as the buffers and enzymes required to use the primers as intended. For example, disclosed is a kit for assessing a subject's risk for acquiring cancer, such as colon cancer, comprising the primers or probes that hybridize to the sequences set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11, and 13, for example.

m) Compositions with similar functions

It is understood that the compositions disclosed herein have certain functions, such as inhibiting gamma2 function or binding alpha6 integrin or inhibiting beta4 function. Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures which can perform the same function which are related to the disclosed structures, and that these structures will ultimately achieve the same result, for example stimulation or inhibition alpha6beta4 signaling or interruption of the alpha6beta4 signaling pathway.

2. Methods of making the compositions

The compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted.

a) Nucleic acid synthesis

For example, the nucleic acids, such as, the oligonucleotides to be used as primers can be made using standard chemical synthesis methods or can be produced using enzymatic methods or any other known method. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System I Plus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). Synthetic methods useful for making oligonucleotides are also described by Ikuta *et al.*, *Ann. Rev. Biochem.* 53:323-356 (1984), (phosphotriester and phosphite-triester methods), and Narang *et al.*, *Methods Enzymol.*, 65:610-620 (1980), (phosphotriester method). Protein nucleic acid molecules can be made using known methods such as those described by Nielsen *et al.*, *Bioconjug. Chem.* 5:3-7 (1994).

b) Peptide synthesis

One method of producing the disclosed proteins, or fragments of the disclosed proteins, such as a fragment of SEQ ID NO:6, is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (*tert*-butoyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the disclosed proteins, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a peptide or protein can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. (Grant GA (1992) *Synthetic Peptides: A User Guide*. W.H. Freeman and Co., N.Y. (1992); Bodansky M and Trost B., Ed. (1993) *Principles of Peptide Synthesis*. Springer-Verlag Inc., NY (which is herein incorporated by reference at least for material related to peptide synthesis). Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described herein. Once isolated, these independent peptides or polypeptides

may be linked to form a peptide or fragment thereof via similar peptide condensation reactions.

For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., *Biochemistry*, 30:4151 (1991)). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al. *Synthesis of Proteins by Native Chemical Ligation*. *Science*, 266:776-779 (1994)).

The first step is the chemoselective reaction of an unprotected synthetic peptide--thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site (Baggiolini M et al. (1992) *FEBS Lett.* 307:97-101; Clark-Lewis I et al., *J.Biol.Chem.*, 269:16075 (1994); Clark-Lewis I et al., *Biochemistry*, 30:3128 (1991); Rajarathnam K et al., *Biochemistry* 33:6623-30 (1994)).

Alternatively, unprotected peptide segments are chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (non-peptide) bond (Schnolzer, M et al. *Science*, 256:221 (1992)). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton RC et al., *Techniques in Protein Chemistry IV*. Academic Press, New York, pp. 257-267 (1992)).

The disclosed proteins and polypeptides such as that for SEQ ID NO:6, beta4 integrin, can be made using any traditional recombinant biotechnology method. Examples of such methods can be found in Sambrook et al. which is herein incorporated by reference at least for material related to production of proteins and antibodies.

25 c) Processes for making the compositions

Disclosed are processes for making the compositions as well as making the intermediates leading to the compositions. For example, disclosed are nucleic acids in SEQ ID NOs:1, 3, 5, 7, 9, 11, and 13. There are a variety of methods that can be used for making these compositions, such as synthetic chemical methods and standard molecular biology methods. It is understood that the methods of making these and the other disclosed compositions are specifically disclosed.

Disclosed are nucleic acid molecules produced by the process comprising linking in an operative way a nucleic acid molecule comprising the sequence set forth in SEQ ID Nos:1, 3, 5, 7, 9, 11, or 13 or a fragment thereof, and a sequence controlling the expression of the nucleic acid.

Also disclosed are nucleic acid molecules produced by the process comprising linking in

an operative way a nucleic acid molecule comprising a sequence having at least 80% identity to a sequence set forth in SEQ ID Nos:1, 3, 5, 7, 9, 11, or 13 or a fragment thereof, and a sequence controlling the expression of the nucleic acid.

Disclosed are nucleic acid molecules produced by the process comprising linking in an
5 operative way a nucleic acid molecule comprising a sequence that hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the sequence set forth in SEQ ID Nos:1, 3, 5, 7, 9, 11, or 13 or a fragment thereof, and a sequence controlling the expression of the nucleic acid.

Disclosed are nucleic acid molecules produced by the process comprising linking in an
10 operative way a nucleic acid molecule comprising a sequence encoding a peptide set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof, and a sequence controlling an expression of the nucleic acid molecule.

Disclosed are nucleic acid molecules produced by the process comprising linking in an
operative way a nucleic acid molecule comprising a sequence encoding a peptide having 80%
15 identity to a peptide set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof and a sequence controlling an expression of the nucleic acid molecule.

Disclosed are nucleic acids produced by the process comprising linking in an operative way a nucleic acid molecule comprising a sequence encoding a peptide having 80% identity to a peptide set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof, wherein any change
20 from the sequences set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof are conservative changes and a sequence controlling an expression of the nucleic acid molecule.

Disclosed are cells produced by the process of transforming the cell with any of the disclosed nucleic acids. Disclosed are cells produced by the process of transforming the cell with any of the non-naturally occurring disclosed nucleic acids.

25 Disclosed are any of the disclosed peptides produced by the process of expressing any of the disclosed nucleic acids. Disclosed are any of the non-naturally occurring disclosed peptides produced by the process of expressing any of the disclosed nucleic acids. Disclosed are any of the disclosed peptides produced by the process of expressing any of the non-naturally disclosed nucleic acids.

30 Disclosed are animals produced by the process of transfecting a cell within the animal with any of the nucleic acid molecules disclosed herein. Disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the animal is a mammal. Also disclosed are animals produced by the process of transfecting a cell within the animal any of the nucleic acid molecules disclosed herein, wherein the mammal is

mouse, rat, rabbit, cow, sheep, pig, or primate.

Also disclosed are animals produced by the process of adding to the animal any of the cells disclosed herein.

d) Products produced from selection protocols

5 Also disclosed are methods of obtaining molecules that act as functional regulators of integrin function, integrin receptor function, and functional regulators of signaling pathways related to integrin receptors, in particular integrin alpha6beta4.

Disclosed are methods for isolating molecules that interact with the proteins set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof comprising, interacting a library of
10 molecules with the proteins set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof, removing the unbound molecules, and collecting the molecules that are bound to at least one of the proteins set forth in SEQ ID Nos:2, 4, 6, 8, 10, 12, or 14 or a fragment thereof.

3. Methods of using the compositions

a) Methods of using the compositions as research tools

15 The compositions can be used for example as targets in combinatorial chemistry protocols or other screening protocols to isolate molecules that possess desired functional properties related to A6B4 and A6B1 signaling pathways.

The disclosed compositions can also be used diagnostic tools related to diseases such as cancer, such as colon cancer.

20 The disclosed compositions can be used as discussed herein as either reagents in micro arrays or as reagents to probe or analyze existing microarrays. The disclosed compositions can be used in any known method for isolating or identifying single nucleotide polymorphisms. The compositions can also be used in any method for determining allelic analysis of for example, beta4 alleles having varying function, particularly allelic analysis as it relates to beta4 signaling and
25 functions. The compositions can also be used in any known method of screening assays, related to chip/micro arrays. The compositions can also be used in any known way of using the computer readable embodiments of the disclosed compositions, for example, to study relatedness or to perform molecular modeling analysis related to the disclosed compositions.

b) Methods for affecting cancer

30 The disclosed compositions can be used to affect the growth of cancer cells because as disclosed herein, the disclosed relationships are fundamental to the ability of cancer cells to continue growing. The disclosed compositions, such as antisense constructs that will inhibit the production of either alpha6, beta4, or the gamma2 chain of laminin5 reduce the proliferation of cancer cells. In fact, the compositions cannot only reduce the proliferation of the cancer cells, but

the compositions can kill the cancer cells, as shown herein.

It is understood that cancer is caused by a variety of cellular events, of which certain events related to alpha6 integrin (up regulated), beta4 integrin (upregulated) and gamma2 (upregulated) allow the continued viability of cancer cells, and that interference of these upregulated molecules inhibits the growth and kills the cancer cells. However, there are other known events that can cause non-cancerous cells to become oncogenic. For example, Abl, Ras, EGF receptor, Erb-2, APC, beta-catenin, Arf, Mdm2, p53, Rb, Myc are known to be involved in oncogenesis, and some of these molecules (For example, Ras, APC loss, p53 loss) are directly related to the disclosed target signal transduction pathways mediated by the alpha6beta4 receptor. Just as the presently disclosed compositions can be used as therapeutics targeting the disclosed relationships, so to there are other targets (For example, Abl, Erb-2) for which pharmaceutical compositions have been developed (For example, Glivec, Herceptin, respectively).

It is understood that the disclosed anti-cancer compositions can be used in combination with other anti-cancer compositions. Great benefits can be obtained from using anti-cancer compositions that target different molecules, in the same signal transduction pathway as well as, or in addition to, targeting molecules in different signal transduction pathways than those disclosed herein. Thus, the disclosed compositions which can affect the growth of cancer cells, indeed kill cancer cells, can be used in conjunction with any other chemotherapy, radiation, or any other anti-cancer therapy.

Disclosed are methods of reducing the proliferation of a cancer cell which comprises inhibiting ligand binding to an integrin receptor on the cancer cell, wherein the integrin receptor comprises an integrin.

Also disclosed are methods of reducing the proliferation of a cancer cell which comprises reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction.

Also disclosed are methods of selectively reducing the proliferation of cancer cells which comprises reducing integrins from interacting with one another, integrins from clustering, or integrins from interacting with other proteins associated with cancer cells.

Disclosed are methods of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin by the cancer cell.

Also disclosed are methods of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin receptor ligand by the cancer cell.

Disclosed are methods of reducing the proliferation of a cancer cell which comprises

interfering with an integrin signaling pathway.

Also disclosed are methods of selectively killing or reducing the proliferation of cancer cells which comprises inhibiting ligand binding to integrin receptors on the cancer cells, wherein the integrin receptor comprises a B4 integrin.

5 Disclosed are methods of selectively killing or reducing the proliferation of cancer cells which comprises inhibiting ligand binding to integrin receptors on the cancer cells, wherein the ligand comprises a laminin5.

Also disclosed are methods of selectively killing or reducing the proliferation of cancer cells which comprises inhibiting ligand binding to integrin receptors on the cancer cells, wherein
10 the ligand comprises the gamma2 subunit of the laminin L5.

Disclosed are methods of selectively killing or reducing the proliferation of cancer cells which comprises inhibiting ligand binding to integrin receptors on the cancer cells, wherein the integrin receptor comprises an alpha6 integrin.

Further disclosed are methods of selectively killing or reducing the proliferation of cancer
15 cells which comprises preventing integrin receptor subunits from interacting with one another, preventing integrin clustering, or preventing integrin receptor subunits from interacting with other proteins on cancer cells, wherein the integrin receptor comprises a B4 integrin.

Disclosed are methods of selectively killing or reducing the proliferation of cancer cells which comprises reducing the production of laminin by the cancer cells, wherein the laminin
20 comprises laminin5, and/or any of the subunits of laminin5, such as gamma2.

Also disclosed is a method of selectively killing or reducing the proliferation of cancer cells which comprises interfering with an integrin signaling pathway, wherein the integrin signaling pathway comprises a B4 integrin or an alpha6 integrin or a beta1 integrin or a laminin or a laminin5 or the gamma2 subunit of laminin5.

25 Also disclosed are methods, wherein the integrin receptor comprises integrin B4 and/or wherein the integrin receptor comprises integrin A6, and/or wherein the ligand that binds to the integrin receptor is laminin5, and/or wherein the integrin receptor is A6B4, and/or wherein the ligand comprises laminin5, and/or wherein the ligand comprises the gamma-2 subunit of laminin5, and/or wherein inhibiting ligand binding to an integrin receptor does not occur by using an
30 antisense molecule to A6, and/or wherein inhibiting ligand binding to an integrin receptor comprises contacting a A6 integrin with a composition that inhibits ligand binding, and/or wherein inhibiting ligand binding to an integrin receptor comprises contacting a B4 integrin with a composition that inhibits ligand binding, and/or wherein inhibiting ligand binding to an integrin receptor comprises contacting a laminin5 with a composition that inhibits ligand binding, and/or

- wherein inhibiting ligand binding to an integrin receptor comprises contacting a gamma-2 subunit with a composition that inhibits ligand binding, and/or wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction does not occur by using a B4-delta-cyt, and/or wherein reducing integrin-integrin interaction,
- 5 integrin receptor clustering interaction, or integrin-non-integrin protein interaction does not occur by using an antisense molecule to A6, and/or wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a A6 integrin with a composition that inhibits an interaction between the B4 integrin and another integrin or protein molecule, and/or wherein reducing integrin-integrin interaction,
- 10 integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a B4 integrin with a composition that inhibits the interaction between the B4 integrin and another integrin or protein molecule, and/or wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a laminin5 with a composition that inhibits ligand binding, and/or wherein reducing
- 15 integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a gamma2 subunit with a composition that inhibits ligand binding, and/or wherein the non-integrin protein comprises a growth factor receptor, and/or wherein the non-integrin protein comprises a hemi-desmosome junction, and/or wherein the non-integrin protein comprises a SH2 domain, and/or wherein the non-integrin protein comprises a Shc
- 20 protein, and/or wherein the non-integrin protein comprises a IRS-1 protein, and/or wherein the non-integrin protein comprises a IRS-2 protein, and/or wherein reducing the production of an integrin does not occur by using an antisense molecule to A6, and/or wherein the production of an integrin is reduced by inhibiting signaling leading to induction of expression of an integrin, and/or wherein reducing the production of an integrin comprises inhibiting alpha6 production, and/or
- 25 wherein inhibiting alpha6 production further comprises using antisense molecules to alpha6 mRNA, and/or wherein reducing the production of an integrin comprises inhibiting beta4 production, and/or wherein inhibiting beta4 production further comprises using antisense molecules to beta4 mRNA, and/or wherein reducing the production of an integrin receptor ligand comprises inhibiting gamma2 production, and/or wherein reducing the production of an integrin
- 30 receptor ligand comprises inhibiting laminin production, and/or wherein reducing the production of an integrin receptor ligand comprises inhibiting laminin5 production, and/or wherein interfering with an integrin signaling pathway does not occur by using a B4-delta-cyt, and/or wherein interfering with an integrin signaling pathway does not occur by using an antisense molecule to A6, and/or wherein interfering with an integrin signaling pathway comprises contacting an A6
- 35 integrin in the cell with a composition that inhibits ligand binding, and/or wherein interfering with an integrin signaling pathway comprises contacting a B4 integrin with a composition that inhibits

ligand binding, and/or wherein interfering with an integrin signaling pathway comprises contacting a laminin5 with a composition that inhibits ligand binding, and/or wherein interfering with an integrin signaling pathway comprises contacting a gamma2 subunit with a composition that inhibits ligand binding, and/or wherein interfering with an integrin signaling pathway comprises
5 contacting the cancer cell with a molecule that interferes with at least one of talin, paxillin, vinculin, a CAS family protein, CRX, NCK, FAK, ILK, Src, Fyn, Shc, Grb-2, Guanine nucleotide exchange factors, SOS, DOCK 180, Vav, Syk, P-1-3 kinase, AKT, Bad, Bid, Caspase 9, Cdc42, PAK, Rac, Rho, Rho kinase, Ras, Caveolin, Tetraspan, Receptor-type protein tyrosine phosphatase, SHP-2, Alpha-actinin, Filamin, Cytohesin, Beta3-endonexin, ICAP-1, RACK-1, CIB,
10 actin, receptor tyrosine kinase, IRS-1 or IRS-2, and/or wherein interfering with an integrin signaling pathway comprises contacting the cancer cell with an agent that interferes with post-translational modification of integrins, and/or wherein the post translational modification is glycosylation or phosphorylation.

Also disclosed are methods, wherein the integrin comprises an A6 integrin, and/or wherein
15 the integrin comprises a B4 integrin, and/or further comprising reducing a laminin5-integrin interaction, and/or further comprising reducing a laminin5 gamma2 integrin interaction, and/or wherein the cancer cell comprises normal p53, and/or wherein the proliferation of the cancer cells is not dependent on AKT/PKB, and/or wherein reducing the proliferation of the cancer cells is selective, and/or wherein the cancer cell is not an MDA-MB-435 cell, and/or wherein the cancer
20 cell is not an HMT-3522 cell, and/or wherein the cancer cell is not an RKO colon carcinoma line, and/or wherein the cancer cell does not express exogenous B4 integrin, and/or further comprising contacting the cancer cells with a small molecule, peptide, peptide mimetic, or oligonucleotide or synthetic analog thereof, and/or wherein the cancer cells are contacted with dominant-negative beta 4 integrin, and/or wherein the cancer cell is contacted with an antisense molecule, and/or
25 wherein the antisense molecule is linked to a leader sequence which enables translocation across a cell membrane, and/or wherein the leader sequence binds to a cell surface protein which facilitates internalization, and/or wherein the leader sequence is TAT or antennapedia, or fragment thereof, and/or wherein the antisense molecule is an alpha6 RNA antisense molecule, and/or wherein the small molecule peptide, peptide mimetic, or oligonucleotide or synthetic analog thereof is linked
30 to a carrier, and/or wherein the carrier is at least one of a lipidic carrier, charged carrier, retroviral carrier, TAT or fragment thereof, antennapedia or fragment thereof, or polyethylene glycol, and/or further comprising contacting the cancer cell with another agent which modulates cell signaling, a chemotherapeutic drug, or treated with radiation or angiogenesis inhibitor, and/or wherein reducing the proliferation of cancer cell is *in vitro*, and/or wherein reducing the proliferation of the
35 cancer cell is *in vivo*, and/or wherein the cancer cell is selected from the group consisting of melanoma, adenoma, lymphoma, myeloma, carcinoma, plasmacytoma, sarcoma, glioma, thymoma,

leukemia, skin cancer, retinal cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, stomach cancer, pancreas cancer, brain tumors, lung cancer, ovarian cancer, cervical cancer, hepatic cancer, gastrointestinal cancer, and head and neck cancer cells, and/or wherein the cancer cell is killed, and/or wherein the cancer cell expresses a mutated Ras, and/or wherein the cancer
5 cell expresses a mutated Ras and a mutated p53, and/or wherein the cancer cell expresses a mutated Ras and activates the AKT/PKB protein, and/or wherein the cancer cell expresses a mutated Ras, a mutated p53, and activates the AKT/PKB protein, and/or wherein the cancer cell expresses a mutated APC, and/or wherein the cancer cell expresses a mutated Ras and mutated APC.

10 Disclosed are methods of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which inhibits ligand binding to an integrin receptor on the cancer cell, wherein the integrin receptor comprises an integrin.

Also disclosed are methods of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces integrin-integrin interaction,
15 integrin receptor clustering interaction, or integrin-non-integrin protein interaction.

Also disclosed are methods of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces the production of an integrin or laminin by the cancer cell.

Further disclosed are methods of reducing the proliferation of a cancer cell in a patient
20 which comprises administering to the patient a composition which interferes with an integrin signaling pathway.

Also disclosed are methods, wherein the reduction in cancer cell proliferation is selective, and/or wherein the administering is local or systemic, and/or wherein the patient is additionally administered an agent which modulates cell signaling, a chemotherapeutic drug, or treated with
25 radiation or angiogenesis inhibitor, and/or wherein the additional agent is administered serially or in combination, and/or wherein the local administering is direct application to cancer cells, and/or wherein the direct application to cancer cells is performed during surgery, and/or wherein the direct application to cancer cells is performed topically to cancerous tissue, and/or wherein the systemic administration is by subcutaneous, intraperitoneal, intra-arterial, intravenous, or bolus
30 administration, or by application through a catheter or similar apparatus, and/or wherein the systemic administration comprises a long-term release formulation, and/or wherein the systemic administration is by oral administration, and/or wherein the oral administration comprises administering a pill, capsule, tablet, liquid or suspension.

Disclosed are methods of reducing the proliferation of a cancer cell in a patient which

comprises administering to a patient a vector comprising coding sequence for a protein or peptide which inhibits ligand binding to integrin receptors on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

Also disclosed are methods of reducing the proliferation of a cancer cell in a patient which
5 comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents integrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

10 Further disclosed are methods of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents integrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins in cancer cells wherein the coding sequence is under the control of a promoter which
15 functions in mammalian cells.

Also disclosed are method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with integrin subunit or laminin production wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

20 Further disclosed are methods of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with an integrin signaling pathway of cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

Also disclosed are methods, wherein the reduction in cancer cell proliferation is selective,
25 and/or wherein the vector is administered directly to a cancer cell, and/or wherein the vector is administered directly to a normal cell, and/or wherein the vector is packaged in a viral vector or liposome, and/or wherein the vector is a retroviral vector, and/or wherein the vector is administered systemically, and/or wherein the direct administration is by topical application, and/or wherein the direct administration is by topical application, and/or wherein the direct
30 administration is performed during surgery, and/or wherein the direct administration is performed during surgery, and/or wherein the patient is an animal, such as a mammal, mouse, rabbit, primate, chimp, ape, goriilla, and human, and/or wherein the cancer cells are selected from the group consisting of melanoma, adenoma, lymphoma, myeloma, carcinoma, plasmocytoma, sarcoma, glioma, thyoma, leukemia, skin cancer, retinal cancer, breast cancer, prostate cancer, colon cancer,
35 esophageal cancer, stomach cancer, pancreas cancer, brain tumors, lung cancer, ovarian cancer,

cervical cancer, hepatic cancer, gastrointestinal cancer, and head and neck cancer cells, and/or wherein the patient is additionally administered at least one of another agent which modulates cell signaling, a chemotherapeutic drug, an angiogenesis inhibitor or treated with radiation, and/or wherein the other agent which modifies cell signaling, chemotherapeutic drug, angiogenesis inhibitor or radiation treatment is administered serially or in combination.

c) Methods of gene modification and gene disruption

The disclosed compositions and methods can be used in targeted gene disruption and modification in any animal that can undergo these events. Gene modification and gene disruption refer to the methods, techniques, and compositions that surround the selective removal or alteration of a gene or stretch of chromosome in an animal, such as a mammal, in a way that propagates the modification through the germ line of the mammal. In general, a cell is transformed with a vector which is designed to homologously recombine with a region of a particular chromosome contained within the cell, as for example, described herein. This homologous recombination event can produce a chromosome which has exogenous DNA introduced, for example in frame, with the surrounding DNA. This type of protocol allows for very specific mutations, such as point mutations, to be introduced into the genome contained within the cell. Methods for performing this type of homologous recombination are disclosed herein.

One of the preferred characteristics of performing homologous recombination in mammalian cells is that the cells should be able to be cultured, because the desired recombination event occur at a low frequency.

Once the cell is produced through the methods described herein, an animal can be produced from this cell through either stem cell technology or cloning technology. For example, if the cell into which the nucleic acid was transfected was a stem cell for the organism, then this cell, after transfection and culturing, can be used to produce an organism which will contain the gene modification or disruption in germ line cells, which can then in turn be used to produce another animal that possesses the gene modification or disruption in all of its cells. In other methods for production of an animal containing the gene modification or disruption in all of its cells, cloning technologies can be used. These technologies generally take the nucleus of the transfected cell and either through fusion or replacement fuse the transfected nucleus with an oocyte which can then be manipulated to produce an animal. The advantage of procedures that use cloning instead of ES technology is that cells other than ES cells can be transfected. For example, a fibroblast cell, which is very easy to culture can be used as the cell which is transfected and has a gene modification or disruption event take place, and then cells derived from this cell can be used to clone a whole animal. Conditional knockouts can also be made which will conditionally delete

expression of the desired molecule, for example, an A6 or integrin or the gamma2 chain of laminin5.

d) Methods of diagnosing cancer

Methods of diagnosing cancer using the disclosed information and the disclosed
5 molecules. In particular disclosed are methods of diagnoses that rely on the combined upregulation of both the ligand and the cognate integrin receptor or cognate integrins. It is understood that all of the methods of diagnosis disclosed herein, can be used with any of the disclosed compositions, but they also can be used in conjunction, where for example, both the ligand and the integrin receptor are monitored and correlated with cancer developing.

10 Disclosed are methods of assessing a subject's risk of developing cancer comprising determining the amount of A6 present in a target cell obtained from the subject, wherein a determination of increased levels of A6 correlates with an increased risk of cancer.

Disclosed are methods of assessing a subject's risk of acquiring cancer comprising determining the amount of B4 present in a target cell obtained from the subject, wherein a
15 determination of increased levels of B4 correlates with an increased risk of cancer.

Disclosed are methods of assessing a subject's risk of acquiring cancer comprising determining the amount of laminin5 present in a target cell obtained from the subject, wherein a determination of increased levels of laminin5 correlates with an increased risk of cancer.

Disclosed are methods of assessing a subject's risk of acquiring cancer comprising
20 determining the amount of gamma2 subunit present in a target cell obtained from the subject, wherein a determination of increased levels of gamma2 subunit correlates with an increased risk of cancer.

Also disclosed are methods, further comprising comparing the amount A6 present to the amount in a control cell, and wherein determining the amount of A6 present in the target cell
25 comprises assaying the amount of A6 mRNA in the cell, and/or wherein the assaying the amount of mRNA in the cell comprises hybridizing a A6 probe to a sample of the subject's mRNA, and/or wherein the assaying the amount of mRNA in the cell comprises hybridizing a A6 primer to a sample of the subject's mRNA, and/or wherein the assaying the amount of mRNA further comprises performing a nucleic acid amplification reaction involving the primer, and/or wherein
30 the nucleic acid amplification reaction comprises reverse transcription, producing a cDNA, and/or wherein the nucleic acid amplification reaction further comprises performing a polymerase chain reaction on the cDNA, and/or wherein determining the amount of A6 present in the target cell comprises assaying the amount of A6 protein in the cell, and/or further comprising comparing the amount B4 present to the amount in a control cell, and/or further comprising comparing the

amount laminin5 present to the amount in a control cell, and/or further comprising comparing the amount gamma2 subunit present to the amount in a control cell.

C. Examples

Throughout this application, various publications are referenced. The disclosures of these 5 publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

It will be apparent to those skilled in the art that various modifications and variations can 10 be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

15 The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, 20 temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric.

1. Example 1 Colonic epithelial cells dependent on alpha6beta4 receptor signal transduction for growth in the absence of ECM

25 Integrin alpha6 and integrin beta4 and laminin gamma2 chains are essential for tumor cell survival in vivo. The data disclosed herein indicate that interfering with integrin alpha6-mediated signaling, integrin beta 4signaling, and laminin gamma2 signaling can constitute an effective approach to induce programmed cell death in cancer cells without damaging normal cells. Ablation of integrin alpha6-dependent signaling, integrin beta4-dependent signaling, and laminin 30 gamma2- dependent signaling in human cancer cell lines supports this.

The murine colonic epithelial transformation system introduced by D'Abaco et al. (1996) was used. In this system, control cells (control), cells containing an activated ras oncogene (Ras), a deletion in the APC gene (APCmin) or both alterations together (Ras+APCmin) can be compared with regard to their proliferation characteristics in tissue culture. The cells were derived from 35 transgenic mice containing a temperature-sensitive allele of SV40 large T under the control of a

gamma interferon-inducible promoter permitting conditional immortalization (Jat *et al.*, 1991). All experiments were carried out with the cells being kept at non-permissive temperature in the absence of gamma interferon. As shown previously (D'Abaco *et al.*, 1996), only the cells carrying activated Ras and the APCmin mutation were able to form colonies in soft agar in the absence of anchorage to a substratum. All other cell populations did not give rise to colonies under these conditions.

The frequency of tunel-staining cells (Fig.2A) and caspase 3 activity (Fig. 2B) in control, Ras, APCmin and Ras+APCmin colonic epithelial cells (D'Abaco *et al.*, 1996) in suspension was measured. Both assays show a strong suppression of apoptosis in Ras-APCmin cells, indicating that Ras and APCmin co-operate in preventing cell death in the absence of apparent ECM contacts. Activated Ras can protect cells from apoptosis via activation of the serine-threonine kinase AKT (Kauffmann-Zeh *et al.*, 1997; Khwaja *et al.*, 1997). However, both Ras and Ras+APCmin cells show equivalent levels of AKT phosphorylation (not shown), eliminating AKT as the relevant target of Ras+APCmin cooperation.

Although cancer cells have been thought to survive independently of integrin signaling, they frequently express high levels of alpha3 or alpha6 integrin receptors and/or their ligands (Dedhar *et al.*, 1993; Kennel *et al.*, 1989; Koshikawa *et al.*, 1999; Lohi *et al.*, 2000; Nejjari *et al.*, 1999; Van Waes and Carey, 1992). These integrins are suspected to play a role in invasion and metastasis (Mukhopadhyay *et al.*, 1999; Shaw *et al.*, 1997). Ras and APCmin mutations would induce alterations in the mRNA expression patterns of integrin and ECM components. Induction of alpha6 integrin alone, was specific to Ras+APCmin cells (Fig. 3A). In addition, we found elevated expression of the laminin alpha5, gamma2 and beta2 chains induced in Ras and Ras+APCmin cells (Fig. 3B). These chains are components of laminins 5, 10 and 11 (Malinda and Kleinman, 1996), which are ligands of integrin receptors alpha6/beta4 and alpha3/beta1 (Kikkawa *et al.*, 2000; Niessen *et al.*, 1994). These results indicate that Ras and APCmin mutations can cooperate to induce autocrine activation of integrin receptors.

Alpha6 integrin can form functional receptors together with either beta1 or beta4 integrins (Clark and Brugge, 1995), leading to signaling through downstream effectors such as focal adhesion kinase (FAK) or the SH2 domain adapter Shc (Giancotti and Ruoslahti, 1999). Conversely, beta4 integrin only binds to alpha6 integrin (Clark and Brugge, 1995). In transformed colonic epithelial cells alpha6 integrin functions in conjunction with integrin beta4 and is engaged by the laminin gamma2 chain to activate Shc (see Fig. 4). Consistent with alpha6 integrin induction, only Ras+APCmin cells can bind a laminin gamma2-specific peptide in an alpha6 and beta4 integrin-specific manner. In contrast, an alpha3/beta1 and alpha6/beta1-specific peptide derived from the laminin gamma1 chain, only binds to control cells (Fig. 4A). In addition, only in

Ras+APCmin cells is Shc phosphorylated in response to clustering of the integrin alpha6/beta4 receptor by beta4-specific antibodies (Mainiero *et al.*, 1995) and by the laminin gamma2-specific peptide (Fig. 4B). In both cases p52^{Shc} is the major phosphorylated form. Moreover, alpha6 integrin is required for Shc activation, as Shc phosphorylation is inhibited in response to
5 expression of a dominant-negative beta4 integrin mutant. This mutant lacks the cytoplasmic signaling domain but selectively binds to alpha6 integrin to form a ligand binding, yet signaling-defective alpha6/beta4 integrin (Spinardi *et al.*, 1993) (Fig. 4B)

Anti-sense RNAs specific for alpha6 integrin and gamma2 laminin, as well as dominant-negative beta4 integrin, were expressed and results indicated that integrin alpha6, integrin beta4,
10 and laminin gamma2 expression are relevant for the survival of Ras+APCmin cells in Ras+APCmin, Ras, APC and control cells. All three constructs efficiently inhibit the growth of Ras+APCmin cells in soft agar (not shown) and when attached to plastic (Fig. 5A1). In contrast, the proliferation of wt, Ras and APCmin cells is not affected by this treatment (Fig. 5A1). Importantly, the colony formation of Ras+APC cells exposed to any of the three inhibitory
15 constructs can be rescued by co-expression of baculovirus p35, a potent inhibitor of caspase activity and of apoptosis (Resnicoff *et al.*, 1998) (Fig. 5A1). Similarly, co-expression of exogenous integrin alpha6 mRNA efficiently rescues Ras-APCmin cell proliferation inhibited by alpha6 anti-sense RNA (Fig. 5A1). This is mirrored by a rescue of alpha6 integrin expression on the cell surface of alpha6 anti-sense RNA expressing cells (Fig. 5B). Moreover, ectopic alpha6
20 integrin expression also rescues apoptosis induced by dominant-negative beta4 integrin (Fig. 5A1). The latter is expressed at constant levels (Fig. 5B). As one would expect, the cells expressing laminin gamma2 antisense RNA could not be rescued by integrin alpha6 over-expression, but showed significant rescue when plated on dishes coated with laminin gamma2 peptide (Fig. 5A1). Similarly, this peptide increases the survival of Ras+APCmin cells in
25 suspension, as indicated by lower caspase 3 activity (Fig. 2C). In summary, the survival of Ras-APCmin cells depends on the expression of alpha6/beta4 integrin and the laminin gamma2 chain. Conversely, the inhibition of these gene activities leads to selective killing of transformed cells.

Data also indicate that cell death due to lack of alpha6/beta4 integrin receptor signaling in Ras-APCmin cells is independent of the death signaling pathway involving the induction of
30 mitochondrial damage and caspase 9 activity. Instead, the data indicate an involvement of the Fas/TNF receptor/death domain protein/caspase8 pathway (Kruidering and Evan, 2000) in the control of tumor cell survival by alpha6 integrin-containing integrin receptors.

Control, APCmin and Ras cells, which lack alpha6/beta4 integrin receptor signaling activity, show high levels of caspase 8 activity when kept in suspension, while at the same time
35 caspase 9 activity cannot be detected (Fig. 2D).

Although Ras-APCmin cells can be rescued from apoptosis by caspase inhibitor baculovirus p35 (Fig. 5 A1, A2 and text above), cell death induced by expression of dominant-negative beta4 integrin cannot be prevented by expression of the survival factor Bcl2 (see Fig. 5 A2). Bcl2 binds to and neutralizes BH3-domain killer proteins that cause mitochondrial damage, cytochrome C release and caspase 9 activation (Luo *et al.*, 1998).

Ras cells which lack alpha6/beta4 integrin receptor signaling activity and cannot survive in the absence of ECM contacts, and Ras+APCmin cells which depend on alpha6/beta4 integrin receptor signaling for survival, show equivalent levels of AKT phosphorylation (data not shown). This indicates that AKT does not serve as the key target for alpha6/beta4 integrin receptor signaling. AKT has been described to promote cell survival via phosphorylation and inactivation of Bad, a BH3-domain killer protein (Datta *et al.*, 1999).

2. Example 2 Other cancer cells dependent on alpha6beta4 receptor signal transduction for growth in the absence of ECM

The survival of highly transformed primary mouse embryo fibroblasts expressing Ras and Myc oncoproteins in conjunction with a homozygous ARF null mutation (Kamijo *et al.*, 1997) depends on expression and function of alpha6 integrin (Fig. 5C), thus demonstrating that this principle also may apply to transformed mesenchymal cells. Moreover, the human colon cancer cell line SW480 carrying multiple oncogenic mutations such as activated Ras (Fujita *et al.*, 1988), amplified c-Myc (Cherif *et al.*, 1988), a mutated APC allele (Munemitsu *et al.*, 1995) and a p53 mutation (Abarzua *et al.*, 1995) is effectively killed by anti-sense integrin alpha6 and laminin gamma2 RNAs as well as dominant-negative beta4 integrin (Fig. 4D). Similarly, integrin alpha6 ablation even leads to apoptosis of Ras/APCmin cells in the presence of active SV40 large T (not shown). Thus the survival of different types of highly transformed cells depends on alpha6 integrin expression, beta4 integrin expression and laminin5 expression irrespective of the status of major tumor suppressor genes, such as arf, p53 or rb, and for at least sw480 cells, murine colon epithelial cells, and the ras/APCmin cells, alpha6, beta4, and laminin5/gamma2 are required. The sensitivity of transformed cells to ablation of integrin signaling, for example, A6B4 integrin receptor signaling, is thus quite remarkable in its apparent generality.

Oncogenic mutations co-operate to engage autocrine integrin signaling. Importantly, this signaling mechanism, involving alpha6 integrin, beta4 integrin and the laminin gamma2 chain, becomes an essential component of the survival mechanism in transformed colonic epithelial cells. In addition, fibroblasts and human colon cancer cells also rely on integrin alpha6 for survival. In contrast, normal and partially transformed cells that express alpha6 integrin at low levels do not require this polypeptide for survival. Thus, integrin signaling inhibition can lead to selective killing of cancer cells.

The laminin-integrin receptor signaling loop is also relevant to the survival of cells transformed by other combinations of oncogenic lesions. Introduction of activated Ras together with dominant-negative p53 (Lloyd et al., 1997) into murine colonic epithelial cells (D'Abaco *et al.*, 1996; see also above) via retroviral infection supports this. Four distinct polyclonal pools of infected cells were derived by drug selection: 1) Control (beo/neo) cells, infected with two retroviruses carrying neomycin (neo) or bleomycin (bleo) drug resistance markers, respectively; 2) Ras cells, infected with a Ras/neo virus and a virus with the bleo marker; 3) DNp53 cells, infected with a DNp53/bleo virus and a virus with the neo marker; and 4) Ras/DNp53 cells, infected with a Ras/neo virus and a DNp53/bleo virus.

10 As the colon epithelial cells contain temperature-sensitive SV40 large T under control of the gamma interferon promoter, all cell populations were drug-selected at the permissive temperature (33°C) in the presence of gamma interferon. All further experiments were carried out at the non-permissive temperature for SV40 large T in the absence of gamma interferon, as described above for Ras+APCmin cells.

15 Similar to Ras+APCmin cells, only Ras/DNp53 cells but neither bleo/neo, Ras/bleo or DNp53/neo cells were able to grow in the absence of ECM contact in soft agar (not shown). Moreover, Ras and DNp53 cooperate in the suppression of caspase 3 activity in suspension (Fig. 2B), and in the induction of alpha6 integrin expression (Fig. 4A). In Ras/DNp53 cells passaged through a single round of soft agar growth, alpha6 integrin is expressed at even higher levels, demonstrating a correlation between the ability of the cells to survive in the absence of ECM contact and alpha6 integrin expression. In Ras/DNp53 cells beta4 integrin expression levels are also increased, when compared to controls (Fig. 4A). As expected expression of the laminin gamma2 chain is induced in Ras/bleo and Ras/DNp53 cells (Fig. 4B).

25 Anti-sense RNAs specific for alpha6 integrin and gamma2 laminin, as well as dominant-negative beta4 integrin were expressed in Ras/DNp53, Ras/bleo, DNp53/neo and neo/bleo cells. All three constructs efficiently inhibit the growth of Ras/DNp53 cells when attached to plastic. In contrast, the proliferation of neo/bleo, Ras/bleo and DNp53/neo cells is not affected by this treatment (Fig. 5A3). Anti-sense alpha6 integrin or dominant-negative beta4 integrin also inhibit the growth of Ras/DNp53 cells in soft agar (Fig. 5A4).

30 Integrin alpha6 expression can also be induced by activated Ras and DNp53 in primary murine colon crypt epithelial cells (not shown). Furthermore introduction of Ras and Myc oncoproteins into our control colon epithelial cells also leads to an induction of alpha6 expression (not shown), suggesting that induction of alpha6 integrin expression may be an integral component of distinct oncogene cooperation paradigms

a) Cell types to be tested

As described herein, there are a variety of cancer and transformed cell types that express alpha6 integrin and laminins at high levels (Dedhar *et al.*, 1993; Koshikawa *et al.*, 1999; Lohi *et al.*, 2000; Van Waes and Carey, 1992). As disclosed herein the following cell lines other than the
 5 fibroblasts require alpha6 and beta4 integrin expression, as well as laminin gamma2 chain expression: (1) the human colon carcinoma cell line SW480 (data not shown), (2) Ras+APCmin-transformed murine colon epithelial cells (see Fig. 3A) Murine fibroblasts transformed by activated Ras and Myc in conjunction with homozygous Arf null mutation require alpha6 expression for their survival. These cells do not express integrin beta4, but express beta1 integrin,
 10 indicating the importance of alpha6/beta1 receptors in the transformed fibroblasts.

b) xxxInducible expression of inhibitors

To interrupt alpha6 integrin and laminin gamma2 chain-dependent signaling in tumors regulatable alpha6 integrin and laminin gamma2 antisense mRNA expression as well as regulatable expression of the beta4 integrin the dominant-negative polypeptide described in
 15 Section C were used. Constitutive expression of these inhibitors leads to rapid cell death in tissue culture. In contrast, the establishment of clonal cell lines with inducible expression of anti-sense mRNAs or dominant-negative beta4 integrin minimize such limitations.

The doxycycline (dox)-inducible reverse tetracycline transactivator (rtTA) is frequently used to overexpress transgenes in a temporally regulated fashion in vitro and in vivo (Efrat *et al.*,
 20 1995; Gossen *et al.*, 1995; Ray *et al.*, 1997). These systems are, however, often compromised by the levels of gene expression in the absence of dox administration. The tetracycline controlled transcriptional silencer (tTS), a fusion protein containing the tet repressor and the KRAB-AB domain of the kid-1 transcriptional repressor, is inhibited by doxycycline. As shown in tissue culture (Freundlieb *et al.*, 1999) and in transgenic mice (Zhu *et al.*, 2001), tTS tightens the control
 25 of transgene expression in rtTA-based systems, i.e. tTS effectively eliminates leaky baseline expression without altering the inducibility of rtTA-regulated genes. Thus optimal "off/on" regulation of gene expression can be accomplished with the combined use of tTS and rtTA. The complete expression system is commercially available from CLONTECH. This system can be used for the preparation of all inducible cell lines.

30 Another regulatable system comprising the estrogen-dependent transactivator GalER-VP16 and a promoter under the control of Gal4 DNA binding sites (Brasemann *et al.*, 1993) can be used. (Perez-Roger *et al.*, 1997). This particular experimental set up, was used herein to show that the induction of the beta4 integrin dominant-negative mutant in SW480 colon cancer cells induces apoptosis in vitro, as measured by caspase 3 activation (Fig. 2B). For in vivo use,
 35 however, a point mutation has to be introduced into the GalER-VP16 transactivator that eliminates

its sensitivity to estrogen while retaining its response to the anti-estrogen 4OH-tamoxifen (Littlewood *et al.*, 1995). 4OH-tamoxifen has been demonstrated to reversibly regulate in vivo the activity of another regulatable transactivator, the MycER chimera (Pelengaris *et al.*, 1999).

Typically, inducible cell lines are first stably transfected with the anti-sense or dominant-negative constructs coupled to the regulatable promoters into the four test cell lines. Subsequently, the activator is introduced and the repressor, such as rtTA and tTS (see above) via infection using recombinant retroviruses with different selectable markers

D. References

- 10 Abarzua, P., LoSardo, J.E., Gubler, M.L. and Neri, A. (1995) Microinjection of monoclonal antibody PAB421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. *Cancer Res*, **55**, 3490-4.
- Akiyama, S.K., Nagata, K. and Yamada, K.M. (1990) Cell surface receptors for extracellular matrix components. *Biochim Biophys Acta*, **1031**, 91-110.
- 15 Braselmann, S., Graninger, P. and Busslinger, M. (1993) A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. *Proc Natl Acad Sci U S A*, **90**, 1657-61.
- Cherif, D., Le Coniat, M., Suarez, H.G., Bernheim, A. and Berger, R. (1988) Chromosomal localization of amplified c-myc in a human colon adenocarcinoma cell line with a biotinylated probe. *Cancer Genet Cytogenet*, **33**, 245-9.
- 20 Clark, E.A. and Brugge, J.S. (1995) Integrins and signal transduction pathways: the road taken. *Science*, **268**, 233-9.
- D'Abaco, G.M., Whitehead, R.H. and Burgess, A.W. (1996) Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas. *Mol Cell Biol*, **16**, 884-91.
- 25 Dedhar, S., Saulnier, R., Nagle, R. and Overall, C.M. (1993) Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. *Clin Exp Metastasis*, **11**, 391-400.
- Efrat, S., Fusco-DeMane, D., Lemberg, H., al Emran, O. and Wang, X. (1995) Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. *Proc Natl Acad Sci U S A*, **92**, 3576-80.
- 30 Freundlieb, S., Schirra-Muller, C. and Bujard, H. (1999) A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. *J Gene Med*, **1**, 4-12.
- 35 Fujita, J., Yoshida, O., Ebi, Y., Nakayama, H., Onoue, H., Rhim, J.S. and Kitamura, Y. (1988) Detection of ras oncogenes by analysis of p21 proteins in human tumor cell lines. *Urol Res*, **16**, 415-8.
- Giancotti, F.G. and Mainiero, F. (1994) Integrin-mediated adhesion and signaling in tumorigenesis. *Biochim Biophys Acta*, **1198**, 47-64.
- Giancotti, F.G. and Ruoslahti, E. (1999) Integrin signaling. *Science*, **285**, 1028-32.
- 40 Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W. and Bujard, H. (1995) Transcriptional activation by tetracyclines in mammalian cells. *Science*, **268**, 1766-9.
- He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T., Morin, P.J., Vogelstein, B. and Kinzler, K.W. (1998) Identification of c-MYC as a target of the APC pathway. *Science*, **281**, 1509-12.
- 45 Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. *Cell*, **69**, 11-25.
- Jat, P.S., Noble, M.D., Ataliotis, P., Tanaka, Y., Yannoutsos, N., Larsen, L. and Kioussis, D. (1991) Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. *Proc Natl Acad Sci U S A*, **88**, 5096-100.
- 50 Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing, J.R., Ashmun, R.A., Grosveld, G. and Sherr, C.J. (1997) Tumor suppression at the mouse INK4a locus mediated by the

- alternative reading frame product p19ARF. *Cell*, **91**, 649-59.
- Kauffmann-Zeh, A., Rodriguez-Viciana, P., Ulrich, E., Gilbert, C., Coffey, P., Downward, J. and Evan, G. (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. *Nature*, **385**, 544-8.
- 5 Kennel, S.J., Foote, L.J., Falcioni, R., Sonnenberg, A., Stringer, C.D., Crouse, C. and Hemler, M.E. (1989) Analysis of the tumor-associated antigen TSP-180. Identity with alpha 6-beta 4 in the integrin superfamily. *J Biol Chem*, **264**, 15515-21.
- Khawaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P.H. and Downward, J. (1997) Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and
- 10 protein kinase B/Akt cellular survival pathway. *Embo J*, **16**, 2783-93.
- Kikkawa, Y., Sanzen, N., Fujiwara, H., Sonnenberg, A. and Sekiguchi, K. (2000) Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. *J Cell Sci*, **113**, 869-76.
- Koshikawa, N., Moriyama, K., Takamura, H., Mizushima, H., Nagashima, Y., Yanoma, S. and
- 15 Miyazaki, K. (1999) Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. *Cancer Res*, **59**, 5596-601.
- Land, H., Parada, L.F. and Weinberg, R.A. (1983) Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature*, **304**, 596-602.
- Lee, J.W. and Juliano, R.L. (2000) alpha5beta1 integrin protects intestinal epithelial cells from
- 20 apoptosis through a phosphatidylinositol 3-kinase and protein kinase B- dependent pathway. *Mol Biol Cell*, **11**, 1973-87.
- Lin, C.Q. and Bissell, M.J. (1993) Multi-faceted regulation of cell differentiation by extracellular matrix. *Faseb J*, **7**, 737-43.
- Littlewood, T.D., Hancock, D.C., Danielian, P.S., Parker, M.G. and Evan, G.I. (1995) A modified
- 25 oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. *Nucleic Acids Res*, **23**, 1686-90.
- Lloyd, A.C., Obermuller, F., Staddon, S., Barth, C.F., McMahon, M. and Land, H. (1997) Cooperating oncogenes converge to regulate cyclin/cdk complexes. *Genes Dev*, **11**, 663-77.
- 30 Lohi, J., Oivula, J., Kivilaakso, E., Kiviluoto, T., Frojman, K., Yamada, Y., Burgeson, R.E., Leivo, I. and Virtanen, I. (2000) Basement membrane laminin-5 is deposited in colorectal adenomas and carcinomas and serves as a ligand for alpha3beta1 integrin. *Apmis*, **108**, 161-72.
- Mainiero, F., Murgia, C., Wary, K.K., Curatola, A.M., Pepe, A., Blumberg, M., Westwick, J.K.,
- 35 Der, C.J. and Giancotti, F.G. (1997) The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. *Embo J*, **16**, 2365-75.
- Mainiero, F., Pepe, A., Wary, K.K., Spinardi, L., Mohammadi, M., Schlessinger, J. and Giancotti, F.G. (1995) Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites
- 40 mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. *Embo J*, **14**, 4470-81.
- Malinda, K.M. and Kleinman, H.K. (1996) The laminins. *Int J Biochem Cell Biol*, **28**, 957-9.
- Marshall, M.S. (1995) Ras target proteins in eukaryotic cells. *Faseb J*, **9**, 1311-8.
- Morgenstern, J.P. and Land, H. (1990) Advanced mammalian gene transfer: high titre retroviral
- 45 vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res*, **18**, 3587-96.
- Mukhopadhyay, R., Theriault, R.L. and Price, J.E. (1999) Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. *Clin Exp Metastasis*, **17**, 325-32.
- 50 Munemitsu, S., Albert, I., Souza, B., Rubinfeld, B. and Polakis, P. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. *Proc Natl Acad Sci U S A*, **92**, 3046-50.
- Nejjari, M., Hafdi, Z., Dumortier, J., Bringuier, A.F., Feldmann, G. and Scoazec, J.Y. (1999) alpha6beta1 integrin expression in hepatocarcinoma cells: regulation and role in cell
- 55 adhesion and migration. *Int J Cancer*, **83**, 518-25.
- Niessen, C.M., Hogervorst, F., Jaspars, L.H., de Melker, A.A., Delwel, G.O., Hulsman, E.H., Kuikman, I. and Sonnenberg, A. (1994) The alpha 6 beta 4 integrin is a receptor for both

- laminin and kalinin. *Exp Cell Res*, **211**, 360-7.
- Parise, L.V., Lee, J. and Juliano, R.L. (2000) New aspects of integrin signaling in cancer. *Semin Cancer Biol*, **10**, 407-14.
- Pawson, T. and Scott, J.D. (1997) Signaling through scaffold, anchoring, and adaptor proteins. *Science*, **278**, 2075-80.
- 5 Pelengaris, S., Littlewood, T., Khan, M., Elia, G. and Evan, G. (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. *Mol Cell*, **3**, 565-77.
- Perez-Roger, I., Kim, S.H., Griffiths, B., Sewing, A. and Land, H. (1999) Cyclins D1 and D2
10 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). *Embo J*, **18**, 5310-20.
- Perez-Roger, I., Solomon, D.L., Sewing, A. and Land, H. (1997) Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. *Oncogene*, **14**, 2373-81.
- 15 Ray, P., Tang, W., Wang, P., Homer, R., Kuhn, C., 3rd, Flavell, R.A. and Elias, J.A. (1997) Regulated overexpression of interleukin 11 in the lung. Use to dissociate development-dependent and -independent phenotypes. *J Clin Invest*, **100**, 2501-11.
- Rcsnicoff, M., Valentinis, B., Herbert, D., Abraham, D., Friesen, P.D., Alnemri, E.S. and Baserga, R. (1998) The baculovirus anti-apoptotic p35 protein promotes transformation of mouse
20 embryo fibroblasts. *J Biol Chem*, **273**, 10376-80.
- Roper, E., Weinberg, W., Watt, F.M. and Land, H. (2001) p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes. *EMBO Rep*, **2**, 145-50.
- Ruley, H.E. (1983) Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. *Nature*, **304**, 602-6.
- 25 Sewing, A., Wiseman, B., Lloyd, A.C. and Land, H. (1997) High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. *Mol Cell Biol*, **17**, 5588-97.
- Shaw, L.M., Rabinovitz, I., Wang, H.H., Toker, A. and Mercurio, A.M. (1997) Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. *Cell*, **91**, 949-60.
- 30 Sonnenberg, A., Linders, C.J., Daams, J.H. and Kennel, S.J. (1990) The alpha 6 beta 1 (VLA-6) and alpha 6 beta 4 protein complexes: tissue distribution and biochemical properties. *J Cell Sci*, **96**, 207-17.
- Spinardi, L., Ren, Y.L., Sanders, R. and Giancotti, F.G. (1993) The beta 4 subunit cytoplasmic domain mediates the interaction of alpha 6 beta 4 integrin with the cytoskeleton of
35 hemidesmosomes. *Mol Biol Cell*, **4**, 871-84.
- Thompson, T.C., Southgate, J., Kitchener, G. and Land, H. (1989) Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. *Cell*, **56**, 917-30.
- Treisman, R. (1996) Regulation of transcription by MAP kinase cascades. *Curr Opin Cell Biol*, **8**, 205-15.
- 40 Van Waes, C. and Carey, T.E. (1992) Overexpression of the A9 antigen/alpha 6 beta 4 integrin in head and neck cancer. *Otolaryngol Clin North Am*, **25**, 1117-39.
- Wary, K.K., Mainiero, F., Isakoff, S.J., Marcantonio, E.E. and Giancotti, F.G. (1996) The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. *Cell*, **87**, 733-43.
- 45 Zhu, Z., Ma, B., Homer, R.J., Zheng, T. and Elias, J.A. (2001) Use of the tetracycline controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice. *J Biol Chem*, **30**, 30.

E. Sequences

1. SEQ ID NO:1 Human alpha6 integrin cds (acc# 4557674)

50 atggccgcccgcgggcagctgtgtctgtctctacctgtcggcggggctcctgtcccggctcggcgcagccttcaacttggac
actcgggaggagacaacgtgatccggaaatatggagaccgccgggagcctcttcggcttctcgtcggccatgcactggcaactg
cagcccaggagacaagcggctgtgtcgtcgtggggcccccgcgcgggagaaagcgttccactgcagagagccaacagaaacggga
gggctgtacagctcgcagatcaccgcccggggccatgcacgcggatcgagtttgataacgatgctgacccccagctcagaa
agcaaggaaagatcagtggtgggggtcaccgtccagagccaagggtccagggggcaagggtcgtgacatgtgtcaccgatat
55 gaaaaaaggcagcatgttaatacgaagcaggaatcccagagacatcttggcggtgttatgtcctgagtcagaatctcagg

attgaagacgatatggatgggggagattggagcttttgtgatgggcgattgagagccatgagaaatttggctcttggcag
 caagggtgtagcagctacttttactaaagactttcattacattgtatttggagccccgggtacttataactggaagggtatt
 gttcgtgtagagcaaaagaataaacacttttttgacatgaacatcttgaagatgggccttatgaagttggtggagagact
 gagcatgatgaaagtctcggttctgttccctgctaaccagttaacttaggttttcttggactcagggaagggtattgtttct
 5 aaagatgagatcacttttgtatctggtgctcccagagccaatcacagtggagccgtggttttgcgtaagagagacatgaag
 tctgcacatctctctccctgagcacatattcgatggagaagggtctggcctcttcatattggctaagtgtggcgggtggtggac
 ctcaacaaggatgggtggcaagatatagttattggagccccacagtatttggatagagatggagaagttggaggtgagtg
 batgtctacatgaaccagcaaggcagatggaataatgtgaagccaattcgctcttaattggaaccaaagattctatgtttggc
 attgcagtaaaaaatttggagatatataatcaagatgggtaccagatattgcagttggagctccgtatgatgacttggga
 10 aagggttttctctatcatggatctgcaaatggaataaaataccaaaccaacacaggttctcaagggtatatcaccttatttt
 ggatattcaattgctggaacatggaccttgatcgaaattcctaccctgatgtgctgttgggttccctctcagattcagta
 actattttcagatcccgccctgtgatttaatttcagaaaaacatcacagtaactcctaacagaattgacctccgcagaaa
 acagcgtgtggggcgccctagtgggatagctccaggttaaatcctgttttgaataactgctaaccctcggttataat
 ccttcaatatcaattgtggggcacacttgaagctgaaaaagaaagaaatctgggctatcctcaagagttcagtttcga
 15 aaccaagggttctgagcccaataatactcaagaactaactctgaagaggcagaaacagaaagtgtgcatggaggaaacctg
 tgggtacaggataatatcagagataaactcgctcccatccataaactcgctcagtgagatccaagagccaagctcctcg
 aggcagtgtaattcactccagaagttcttccaattctgaattcagatgaaccaagacagctcatattgatgttctacttc
 ttaaaaggggatgtggagacgacaatgtatgttaacagcaaccttaactagaaataaaatttgcaccgcagagaaggaaat
 caagacaaattttcttatttaccattcaaaaagggtgtaccagaactagttctaaaagatcagaaggatattgctttagaa
 20 ataacagtgcacaaacagcccttccaaccaaggaaatcccacaaaagatggcgatgacgccccatgaggctaaactgattgca
 acgtttccagacactttaacctattctgcataatagagaactgagggtcttccctgagaacacagtgtgattgtgtgccaac
 cagaatgggtcgcaagctgactgtgagctcggaatccttttaaagaaattcaaatgtcacttttatttgggttttaagt
 acaactgaagtcacctttgacaccccatatctggatatttaactctgaagttagaacaacaagcaatcaagataatttggct
 ccaattacagctaaagcaaaagtgggtattgaaactgcttttctcggtctcgggagttgctaaaccttccaggtgtatttt
 25 ggaggtacagttgttggcgagcaagctatgaaatctgaagatgaagtggaagtttaatatagagtatgaattcagggttaata
 aacttaggtaaaccttctacaaacctcggcacagcaaccttgaacattcagtgggccaaaagaaattagcaattgggaaatgg
 ttgctttatttgggtgaaagtagaatccaaaggattggaaaaggtaacttgtgagccacaaaaggagataaactccttgac
 ctaacggagctctcaactcaagaaagaaacgggaaatttactgaaaaacagatagatgataacagaaaaatttctttattt
 gctgaaagaaaaataaccagactcttaactgtagcgtgaactgtgaactgtgtgaacatcagatgcccgctcggggggctggac
 30 agcaaggcgtctcttattttgctcgtcgaggttatggaacagcacatctttagaggaatattccaaactgaactacttggac
 attctcatgagcagccttcatgtatgtgactgctgctgccgaaaatatcaggtcgccaaatgcaggcactcaggttcgagtg
 actgtgtttccctcaaagactgtagctcagttatcgggagtagcttgggtggatcatcctagtggtctattctcgctgggac
 ttgatgttgcctttattagtggtttatactatggaagtggtgttcttcaagagaaataagaaagatcattatgatgccaca
 tatcacaaggctgagatccatgctcagccatctgataaagagaggcttacttctgatgcatag

35 **2. SEQ ID NO:2 Human integrin alpha6 protein sequence (acc#
 NP_000201):**

1 maaagqlcll ylsagllsrl gaafnldtre dnvirkygdp gslfgfslam hwqlqpedkr
 61 lllvgaprg alplqranrt gglyscdita rgpctriefd ndadptsesk edqwmgvvtvq
 121 sqgpggkvvt cahryekrqh vntkqesrdi fgrcyvlsgn lrieddmdgg dwsfcdgrlr
 40 181 ghekfgscqq gvaatftkdf hyivfagpgt ynwkgivrve qknnftfdmn ifedgpyevg
 241 getehdeslv pvpansylgf sldegkgivs kdeitfvsga pranhsgavv llkrmdksah
 301 llpehifdge glassfydv avdlnkdgw qdivigapqy fdrdgevssa vyvymnqggr
 361 mwnvpirln gtkdsmfgia vknigdingd gypdiavgap yddlgkvfiy hgsangintk
 421 ptqvlkgisp yfgysiagnm dldrnsypdv avgsldsdt ifrsrpvini qktitvtpr
 45 481 idlrqktacg apsgiclvk scfeytanpa gynpsisivg tleakerrk sglssrvqfr
 541 nqgsepkytq eltlkrqkqk vcmeetlwlq dnirdklrpi pitasveige pssrrrvnsl
 601 pevlpilnsd epktahidvh flkegcgddn vcnslkley kfctregnd kfsylpiqkg
 661 vpevlvkdqk dialeltvtn spsnprnptk dgddaheakl iatfpdtlty sayreirafp
 721 ekqlscvanq ngsqadcelg npfkrnsnvt fylvlsttev tfdtpyldin lklettsnqd
 50 781 nlapitakak vvielllsvs gvakpsqvyf ggtvvgeqam ksedevegeli eyefrvnlng
 841 kpltnlgtat lniqwpkeis ngkwillylvk veskglekvt cepqkeinsl nlteshnsrk
 901 kreitekqid dnrkfslfae rkyqtlncsv nvnvcnirp lrgldskasl ilrsrlwnst
 961 fleeysklly ldilmrafid vtaaaenirl pnagtqvrvt vfpsktvaqy sgvpwwiilv
 1021 ailagilmla llvfllwkcg ffrknkdhdy datyhkaeh aqpsdkerlt sda

55 **3. SEQ ID NO:3 Mus musculus alpha6 integrin cds (acc# 7110658):**

atggccgctcgcgggccagttgtgctgctctacctgtccgcggggcttctagcccggctgggtacagccttcaacctggac
 accgcgaggaacaacgtgatccggaatccggggatcccgaggcctcttgcgcttctcgctcgccatgcactggcagttg
 cagccggaggacaagcggtgtgtgtgtgtggggacactcgggcagaagcactcccgcgtcagaggggcagacagagggg
 ggctgtacagctgtgacatcacctcccaggagccttgatcacggattgaatttgataatgacgctgtacctatgtcagaa
 60 agcaaggaaagaccagtggtatgggagtcactgtccagagccaaggtccagggggcacaagtggtgacgtgtgcacatcgata
 gaaaacggcagacgtcaacacgaagcaggagtcgcgggatatcttggaaagatgttatgtcctgagtcagaatctcaga
 attgaagatgatatggacggaggagactggagtttctcgatggccggttgagaggccatgaaaagtttggctcctgtcag
 caaggagtagcggtactttcactaaggactttcattacattgttttggagccccaggagacttacaactggaaaggatc
 gtccgtgtagaacaaaagaataaacacttttttgacatgaacatcttgaagatgggcctatgaagttgggtggagagaca
 65 gatcatgatgaaagtctcggtgccgttccctgctaacagttacctaaggcttttgcgtggactcagggaagggtattgtttct

aaagatgacatcacttttgggtgctccaagagccaatcacagtggggctgtagtggtgctaaaaagagacatgaag
 tccgcacatctgctccctgagtatatatttgacggagaaaggcctggcttcctcggttggtgatgagtgaggagtggtggaac
 ctcaatgcagatgggtggcagacatcgttatcgaggctccacagatatttgtagggatggtagagtcgggggtgcagtt
 tacgtctacatcaaccagcaaggcaaatggagtaattggaagccgattcgctcaaatgggacaaagactcgatgttggga
 5 atctctgtgaaaaatataggatgataaaccagatggctatccagatattgctgtggagctccctatgatgatctgggg
 aagggtttttatctatcatggatcccgactggcataattaccaagccaacacaggttctcgaggggacatcgcttacttc
 ggctattcaatcgctgggaatatggacctggatcggaattcctaccccgaccttgctgtgggctccctctcagactcggtc
 actattttcagatcccgccagtgatttaacattctaaaaacacacagtgactcctaacaagaattgacctccgcagaag
 tccatgtgtggctcacctagcgggatatgcctcaagggttaaagcctgttttgaaataactgcgaaaccttccgggtataaac
 10 cctccaatatcaatttttgggtattcttgaaagctgaaaaagaaagaaagaaatcaggggttgctatcgagagtgacgttccga
 aaccaagggttccgagccaaagtataactcaggagctgacctgaatcggcagaagcagcgggctgcatggaggagacctc
 tggctcaggagaacatcagagacaagctgcgtccatccccacacggttctgtggagatccaggagccacacgtctcgc
 cggcggttgaaactcactccccgaagttcttcccatcctgaattcaaatgaagccaaacgggtccagacagatgtccacttc
 ttaaaggaaggatgtggagacgacaatgtctgttaacagacaaccttaagctagagatataaatttggtaccgcagaaggaaat
 15 caagacaatttctcttaccttccaattcaaaaaggcatcccgaaattagtcctaaaaagatcagaaagatatagctctggaa
 ccaattacagcgaaggcaaaagtggttattgaattgcttcttccatcccgagtgctaaagccttcgcagagcctacgc
 acgttccagacactctgacatattccgcttacagagaactgagggttctccctgagaagcagctgagctgtgtggccaac
 cagaatggctcccaagccgactgtgagctcggaatccttcaagagaaattccagtggtactttctatctgattttaagt
 acaaccgagggtcacctttgacaccacagatctggatattaatctgaagttggaaacaacaagcaatcaggataaattgggt
 20 ccaattacagcgaaggcaaaagtggttattgaattgcttcttccatcccgagtgctaaagccttcgcagagcctacgc
 ggaggtacagttgtgtggtagcaagctatgaaatctgaagtagaagtaggaagtttaataagatgataaatttaggtgatt
 aacttaggcaagcctcttaaaaacctcgcacagcaaccttgaaatatacagtgggccaaggagattagcaatggcaaatgg
 ttgctttatttgatgaagttgaatccaaagggttggagcagatgtttgtgagccacacaatgaaataaactacctgaag
 25 ctgaagcgtctcacaactcaagaagaagaaacgggaacttctgaaaaacagatagatgacagcaggaatatttcttattt
 cctgaaagaaaaataccagactctcaactgcagcgtcaacgtcagggtgtgtgaacatcagggtgcccactgcgagggctggac
 acgaaggcctctctcggttctgtgttccaggttgggaacagcacatttctagaggaatattccaaactgaactacttggac
 attctcgtgagggttccatagatgtcacgcgtgctgctcagaatatacagctccctcacgcgggactcagggttcagtg
 acgggtgttccctcaagactgtagctcagattcaggagtagcttggtggatcatcctcctggctgttcttgcgggatt
 30 ctgatgctggctctattagtggttttactgtggaagtgtggcttcttcaagagaaataagaagatcattacgatgccacc
 tatcacaaggctgagatccataactcagcgtctgataaagagaggcttacttccgatgcatag

**4. SEQ ID NO:4 Mus musculus alpha6 integrin protein sequence (acc#
 NP_032423)**

1 mavagqlcll ylsagllarl gtafnldtre dnvirksgdp gelfgfslam hwqlqpedkr
 61 lllvgaprae alplqranrt gglyscdits rpgctriefd ndadpmsesk edqwmvgvtvq
 35 121 sqgpggkvvt cahryekrqh vntkqesrdi fgrcyvlsgn lrieddmdgg dwsfcdgrlr
 181 ghekfgscqg gvaatftkdf hyivfgapgt ynwkgivrve qknntffdmn ifedgpyevg
 241 getdhdeslv pvpansylgf sldsgkgivs kdditfvsga pranhsgavv l1krdmkeah
 301 llpeyifdfe glassfydyd avvdlnadgw qdivigapqy fdrdgevsga vyvyingggk
 361 wsnvkiprln gtdsmfgis vknigdingd gypdiavgap yddlgkvfly hgsptgiitk
 40 421 ptqvlegtsf yfgysiaqnm dldrnsypdl avgsldsvt ifrsrprvini lktitvtpnr
 481 idlrqkmcg spsgiclkvk acfeytakps gynppisilg ileaekerrk eglsservqfr
 541 nggsepktyt eltlnrqkqr acmeetlwlq enirdklrpi pitasveiqe pterrrvns1
 601 pevlpilnsn eaktvqtdvh flkegcgddn vcnsnlkley kfgtregnd kfssylpiqkg
 661 ipelvlkdqk dialeltvtn spsdprnprk dgddaheakl iatfpdtlty sayrelrafp
 45 721 ekqlscvanq ngsqadcelg npfkrnsst fylilsttev tfddttdldin lklettsnq
 781 klapitakak vviel11sls gvakpsqvyf ggtvvgqam ksedevgsli eyefrvnlg
 841 kplknlgtat lniqwpkeis ngkwilylmk veskgleqiv cephneinyl klkeshnsrk
 901 krelpekqid dskfelfpe rkyqtlncsv nvrvcnirp lrgldtkasl vlcsrlwnst
 961 fleeysklly ldilvrasi dtaaaqnikl phagtqrvrt vfpsktvaqy sgvaawill
 50 1021 avlagilmla llvflwkcg ffrknkdhv datyhkaeh tqpsdkerlt sda

5. SEQ ID NO:5 Human integrin beta4 subunit cds (acc# 6453379):

atggcagggccacgccccagcccatgggcccaggctgctcctggcagccttgatcagcgtcagcctctctgggaccttgaac
 cgctgcaagaaggccccagtgaaagagctgcacggagtggtgctcggttggtataaggactgcgcctactgcacagacgagatg
 55 ttcagggagccggcgtgcaacacccaggcggagctgctggcgcgggctgccagcgggagagcatcggtgcatggagagc
 agcttccaaatcacagaggagaccagattgacaccacctgcggcgcagccagatgtcccccaaggcctgcgggtccgt
 ctgcccggctgaggagcggcattttgagctggaggtgtttgagccactggagagccccgtggacctgtacatcctcatg
 gacttctccaaatccatgtccgatgatctggacaacctcaagaagatggggcagaacctggctcgggtcctgagccagctc
 accagcgactacactattggatttggcaagtttgggacaaagtcagcgtcccgagcagcagacatgaggcctgagaagctg
 aaggagccttggcccaacagtgaaccccccttctccttcaagaacgtcatcagcctgacagaagatgtggatgagttccgg
 60 aataaactgcaggagagcggatctcaggcaacctggatgctcctgagggcggtctcgatgccatcctgcagacagctgtg
 tgcacaggggacattggctggcgcccgagcagcaccacctgtggttcttccaccaggtcagccttccactatgaggct
 gatggcgccaacgtgctggtcggcatcatgagccgcaacagatgaacggtgccacctggacaccacgggacacctacacccag
 tacaggacacagactacccgtcggtgccacacctggtgcgctgctgcgcaagcacaacatcatccccatcttctgtgtc
 accaactactcctatagctactacgagaagcttcaacactatttccctgtctcctcactgggggtgctgagaggagctcg
 65 tccaacatcgtggagctgctggaggaggccttcaatcggatccgctcaacctggacatccgggacctagacagccccga

[illegible]

6. SEQ ID NO:6 Human beta4 integrin protein sequence (acc# CAB61345):

1 magprp spwa rlllaalisv slsgtl nrck kapvksc tec vrvdkdcayc tdmfrdrcc
61 ntgaellaag cqresivvme ssfqiteetq idttlrrsqm spgglrvrlr pgeerhfele
60 121 vfeplespvd lyilmdfns msddldnlkk mggnlarvls qltsdytfg gkfvdmvsvp
181 qtdmrpekll epwpsndppf sfknvisl te dvdefrnklq klerisgnlda peggfdailg
241 tavctrdigw rpdsthllvf stesafhyea dganavlagim srnderchld ttgtytgqyr
301 qdypsvptlv rllakhniip ifavtnsys yyeklhtyfir vsslgvlged ssnivellee
361 afnrirsnlc iraldsprgl rtevtskmfg ktrtgsfhir rgevlgvygq lralshvdgt
65 421 hvcqlpedqcn gnihlkpsfs dgtkmdagii cdvctcelq evrsarcsfn gdfvcgcqvc
481 segwsqgtcn cstgslsdiq pclregedkp csgrgecqcg hcvcygegry eggfceydnf

541 qcprtagflic ndrgrcsmgg cvcepgwtgp scdcpplsna cidenggienn grghcecgrc
 601 hchqqslytd ticeinysas trasartyap acsarrgapa rrrgarvrna tsrsrwtsl
 661 rearrrwcaa psgrtmrtap tatpkwkvtap lgptalswct rrrdcpssgf wwliplllll
 721 lplllalllll cwkycaccka clallpcnr ghmvgfkedh ymlrenlmas dhldtpmlrs
 5 781 gnlkgrdvvr wkvtnnmqrp gfathaasin ptelvpypgl lrlarlcten llkpdrtrea
 841 qlrqveenl nevyrqisgv hklqqtktfrq qpnaqkkqdh tivdtvmap rsakpalkl
 901 tekqvegraf hdlkvapgyy tltadgdarg mvefgegvel vdvrvplfir pedddekqll
 961 veaidvpagt atlgrrlvni tiikegardv vsfeqpefsv srgdqvarip virrvldggk
 1021 sqvsyrtqdg taggnrdyip vegellfpgg eawkelqvkl lelqevdall rgrqvrifhv
 10 1081 qlsnpkfgha lgqphsttii irdpdeldrs ftsqmlssqp pphgdlgapq nbnakaagrs
 1141 kihfnwlpss gkpmgyrvky wiqgdsesaa hlldskvpsv eltnlypycd yemkvcaayga
 1201 qgegpysslv scrthqevps epgrlafnv sstvtqlswa epaetngeit ayevcyglvn
 1261 ddnrpidgm kvlvdpknr mllienlres qpyrytvkar ngagwgpere ainlatqpk
 1321 rpsmsiipd ipivdaqsge dydsflmysd dvlrpsgsq rpsvsddtgc gwkfepllge
 15 1381 eldlrrvtwr lppeliprls aassgrssdae aphgppddgg agkggslpr satpgppgeh
 1441 lvngrmdfai pgstnsihxm tttssaaagt hlsphvphrv ltsstltdr ynsltrsehs
 1501 hsttlprdys tltssvshgl ppiwehgrsr lplswalgr sraqmkgfpp srgprdsiil
 1561 agrpaapswg pdsrltagvp dtprlvfsva lgptslrvsw qeprcerplq gysveyqlln
 1621 ggelhrlnip npaqtssvve dlplnhsyvf rvraqsqegw greregvti esqvhpgespl
 20 1741 afrrvdgspe srltvpplse nvykfkvga rtteggfgr egiitiesqd ggpfpqlgsr
 1801 aglfghplqs eyssistttht satpflvvp tlgaghleag gsltrhvtqe fvsrtlttsg
 1861 tltshmdqf fqt

7. SEQ ID NO:7 Mouse integrin beta4 subunit mRNA (not only cds) (acc#

L04678):

25 ggaccgtcgaggcagcgaggactgacccagctgggctcactgtattaagaagcggacccgcgacccggagcgcccggggacc
 cgatctgggagcctggagcgggtgacgcgcaggaatgcagctccgctgactcaccagcgctcctcctcactctgcgcgcgc
 ccgtccataaagcgtgctgctccgcccgcgcgcgcgcgcctgctgtccgcgcgggctcgccgcgcgcgtcagctcgacc
 caacgcagcccaagtccgaggtagtctcactaaggaggaggagatggcagggccctgttcagcccatgggtgaagctgc
 30 tgctgctggcagcaatgctgagtgccagcctcctggagacctggccaaccgctgcaagaaggctcaggtgaagagctgta
 ccgagtgcatccgggtggacaagagctgtgctcactgcacagcagagctgttcaaggagagggcgctgcaacacccaggcgg
 acgttctggtgtaggctgcaggggagagagcactcctggtcatggagagcagccttgaaatcacagagaacacccagatcg
 tcaccagcctgcaccgcagccaggtatctcccaaggcctgcaagtccggctgcggcggggtgaggagcgacgtttgtgt
 tccaggtctttgagccccctggagagccccctggatctgtatctcctcatggacttctccaactcctatgtctgacgatctgg
 35 acaactcaagcagatggggcagaacctggccaagatcctgcgcagcagctcaccagcgactacacccattggtattggaaagt
 ttgtggacaaagttagcgtctccacagacagacatgagggcccgagaaactgaaggagccctggccaacagtgatccccgt
 tctccttcaagaacgttatcagcttaacggagaatgtggaagaattctggaacaaactgcaaggagaacgcatctcaggca
 acctggagcgtcctgaaggggctttgatgccatctgcagacagctgtgtgcacaagggacattggctggagggctgaca
 40 gcacccactgctgggtgttctccacagctgtgctcactgcacagcagctgtggtgccaacgttctggcggcatcatga
 accgcaatgatgagaaatgccacctggacgcctcgggcgctacacccaatacaagacacaggactacccatcagtgccca
 cgctggttcgctgcttgcgaagcataacatcatcccatcttctgtgtcaccactactcttacagctactatgagaagc
 tccataagatttccccgctcctcctcctggcgctcctgcaggaggtatcctcaacatcgtggagctgctggaggaggcct
 45 tctatcgaaatcgtctcaacctggacatccggcctcggacagccccagaggcctgagaacagaggtcactccgatctc
 tccagaagacggagactgggtcctttcacatcaagcgggggaagtgggcacatacaatgtgcatctccgggcagtgaggg
 acatagatgggacacatgtgtgcccagctggctaaagaagaccaagggggaacatccacctgaaacccctcctctctgatg
 50 gcctccggatggacgcgagtgatctgtgacgtgtgcccctgtgagctgcaaaaggaagtgcgactgcgtcgtcact
 tcagaggagacttcatgtgtggacactgtgtgtgcaatgagggtggagtgggcaaaacctgcaactgctccacggctctc
 tgagtgcacacagccctgctgctgaggtgaggacaaacctgctcgggccaacggcgagtgccagtgccgacgctgtg
 55 tgtgctatggtgaaggccgctacaggggtcacttctgcgagtatgacaacttccagtgctcccggaacctctggattcctgt
 gcaatgcacggggagcgtgttctatgggagagtggtgtgtgagcctggttggacaggccgaggtcactgtgagtggtggcgtgtgactgcaacc
 gcaatgccacctgcatcgatagcaacgggggcatctgcaacggccgaggtcactgtgagtggtggcgtgtgactgcaacc
 agcagtcgctctacacggacacccctgtgagatcaactactctgcgatactgggtctctgtgaggtatctccgctcctgcg
 60 tacagtgccaggcctggggcaccggggagaagaagggcgcgctgtgacgattgccccctttaaagtcaagatggttagacg
 agcttaagaagaagaggtggtggagtagtctcctccgggatgaggtgacgactgcacttacagctacaacgtggagg
 65 gcgacggcagccctggggcccaacagcagctcctggtccacaaaaaagaagactgcctcccggtcctcctcctggtggctca
 tccccctgctcactctcctcctgttgcctcctggcgttgcctcctgctcctgctggaaactactgtgctgctgcaagcct
 gcttggggcttctccttgcctgcaacagaggtcacatggtgggctttaaaggaagatcactatatgcttcgggagaacctga
 tggcctctgacccactggacacgcccactgtacgaagcgggaacctcaagggaacagacacagctccgctggaagatcacca
 acaatgtgacgcgcccctggcttggccacccatgcggccagcaccagccccacggagctcgtaacctacgggctgtccttgc
 60 gccttggcgcgctctgactgagaacctbatgaagccgggacccgagagtgtagccagctacgacaggaggtggagggaaa
 atctgaatgaggtgtatagacaggtcagcggcgacacaaagctccagcagacgaagtccgacagcagcccaacgcgggga
 aaaagcaagaccacacacatttgggacacagtggttgcggcgccccgctccgcaacgagatgctgctgaagctgacagaga
 agcaggtggagcaggggtccttccatgaactgaaggtggccccctggctactacactgtcacggcagagcaggtgccccggg
 65 gcatgggtggagttccaggagggcgtaggtggtgagtgtagtgcctcctcctacccgctgaggtgatgatgaga
 agcagctgctggtggaggccattgatgtccctgtgagcactgccaccttggtcgccgtctggttaacatcaccattatca
 aggaacaagctagtggggtagtgctcctcgagcagcctgaatactcggtagtgcgtggagaccaggtggccccgcatccctg

tcatccggcacatcctggacaatggcaagtcctcctatagcacacaggataatacagcacaggaacccgggatt
 atgttcccgtggaggagctgctgttccatcctgggaaacctggaaggagtgcagggtgaagctactggagctgcagg
 aggttgactccctcctgctggcggccagggtccgcgcttccaagtccaactcagcaaccccaagttcggagcccgcttg
 gccagcccgacacaccaccgttattctcgatgaaacggacaggagctcctataatcaaacacttccatgcctccggccac
 5 cccatggagacctggcgcccccacagaaccccaatgccaaggctgcccgatccaggaagatccatttcaactggctgcccc
 ctcttggaacccaatgggtacaggggtgaagtactggatccagggcgactctgaatctgaagccccacttctagatagca
 aggtgccccctcagtggaactcaccaacctgtatccctattgcgactacgaaatgaaggtgtgtgcctatggggccaaagggtg
 aggggccccctatagctcactgtgttctcgcgcacccaccaggaagtaccagtgagccaggagggtggcttcaatgtag
 tctcttctacgggtgactcagctgagctgggagagccagctgagaccaatggcgagatcacagcctacgaggtctgctatg
 10 gactgggtcaatgaggacaacagaccatggacctaagaagggtgctcgtggacaacccaagaacgggagctgctgctca
 ttgagaatctgcgagattcccagccataccgatacacgggttaaggcgcgcaatggggcaggatggggaccggagagagag
 ctatcatcaacctggctacacagcccagcgccccatgtccatccctatcatccagacatccccatagtggaagcggccagg
 gtggagaagactacgaaaacttccctatgtacagtgatgagctcctgcgggtccccagccagcagcagcagggcggctgt
 ctgatgacactgagcacctgggtgaatggcggtggaacttgcctatccaggcagcgccaaactccctgcacagaatgactg
 15 cagccaatgtggcctatggcagcactctgagccacacactgtccaccagtgctgagcacgtcctccacccttaccggg
 actaccactctctgacagcagcagagcactccactcaggcacacttccagggactactccaccctcacttcccttctct
 cccaagcctccctcctatctgggaagatgggaggagcaggcttccgctgtcctggactcttgggtccttgagccgggctca
 catgaagggtgtgcccgcacccaggggttccaccagactctataatcctggccgggagctcagcagcacccctcctggggtac
 aggtattcccgtggggtgtgggtgtgctgacacaccactcgggtgtgttctctgcccggcgacgtcttgaagg
 20 tgagctggcaggagccacagtgatcggaagctgctgggtacagtggtgaataccagctactaacgtgcgtcgagatgc
 atcgggtcaacatccctaaccctggccaaacctcgggtgtggttagaggatctcctgctaactactctcatgtgtccggg
 tacgggacagagccagggggtggggtcgagagcgaggggtgtcatcaccatcgagtcccagggtgcaccgcagagcc
 ctctctgccccctgcccaggtcagccttctcctgagcaccgccagcgccccagggaccactggtgttctcactgcccctagcc
 cagactcccccgagctcagctgggagcgccgaggagccgcaatggagatacttggctacctgggtgacctgtgagatgg
 25 cccaaggaggagcaccagccagacacttccgggtggcaggagacaacccctgagagccggtgactgtacctggcctcagtg
 agaacgttcccttacaagttcaaggttcaggccaggacgacggggcttggggcagagcggtgagggatcatcaccatcg
 agtctcaggttggaggcccccttcccacagctgggcagcaatctgggctcttccagaacccagtgcaaaagcgagttcagca
 gctgacccagcagcagcagcaccagctgagcccttctcctatggatgggtctaacctggggaccagcgcttggaaagcag
 gaggctccctcaccggcatgtgacccaggaatctgtagcccgacctaaccggccagtggtgtctctcagcactcataatgg
 30 accaacagttcttccaaacctgaacctccccgcgccccagccacctggggccccctccttgcctcctctcctagcgcttct
 tccctctgctgctctacccacagagcttctgacacagagccagccccctgtagttagagagcaggggtagggtgctgtccagg
 aaccataaagtggttagaggtgatacaaggtcttctgactgcataccaccctgggtccaatccacatgtaacc

8. SEQ ID NO:8 Murine integrin beta4 protein sequence:

MAGPCCSPWV KLLLLARMLS ASLPGDLANR CKKAQVKSCT ECIRVDKSCA YCTDELFKERRCNTQADVLA
 35 AGCRGESILV MESSLEITEN TQIVTSLHRS QVSPQLQVR LRRGEERTFVQVFEPLESP VDLIYLMDFS
 NSMSDDLNL KQMGNLAKI LRQLTSDYTI GFGKFVDKVSVPQDMRPEK LKEPWPNSDP PFSFKNVISL
 TENVEEFWNK LQGERISGNL DAPEGGFDAILQTAVCTRDI GWRADSTHLL VFSTESAFHY EADGANVLG
 IMNRNDEKCH LDASGAYTQY
 KTQDYPSPVT LVRLLAKHNI IPIFAVTNYS YSYEKLHKY FVSSSLGLVQ EDSSNIVELLEAFYRIRSN
 40 LDIRALDSFR GLRTEVTSdT LQKTETGSFH IKRGEVGTYN VHLRAVEDIDGTHVCQLAKE DQGGNIHLKP
 SFSGLRMDA SVICDVCPCE LQKEVRSARC HFRGDFMCGHCVCNEGWSGK TCNCSTGSL S DTQPCLEGE
 DKPCSGHGEC QCGRCVCYGE GRYEGHFCEYDNFQCPRTSG FLCNDRGRCS MGEVCPEPGW TGRSCDCPLS
 NATCIDSNGG ICNCRGYCEC
 GRCHCNQQLS YDITTCIINY SAILGLCEDL RSCVQCQAWG TGEKKGRACD DCPFKVKMVDLKKKEVEVEY
 45 CSFRDEDDDC TSYNVEGDG SPGPNSTVLV HKKKDCLPAP SWWLIPLLIFLLELLALLLL LCWKYCACCK
 ACLGLLPCCN RGHMVGFED HYMLRENMA SDHLDTPMLRSGNLKGRDTV RWKITNNVQR PGFATHAAT
 SPTLVVPYGL SLRLGRLCTE NLMKPGTRECDQLRQVEEN LNEVYRQVSG AHKLQQTFR QQPNAKKKQD
 HTIVDTVLLA PRSAQMLLK
 LTKQVEQGS FHELKVAPGY YTVTAEQDAR GMVEFQEGVE LVDVRVPLFI RPEDDDEKQLLVEAIDVPVS
 50 TATLGRRLVN ITIIKEQASG VVSFEQPEYS VSRGDQVARI PVIRHLDNGKSQVSYSTQD NTAHGRDYV
 PVEGELLFHP GETWKELQVK LLELQEVDSL LRGRQVRRFQVQLSNPKFGA RLQGPSTTTV ILDETDRSLI
 NQTLSSPPPP HGDLAGPQNP NAKAAGSRKIHFNLPPPGK PMGYRVKYWI QGDSESEAH L LDSKVPSVEL
 TNLVPCYDYE MKVCAYGAKG
 EGPYSSLVSC RTHQEVSEP GRLLAFNVSS TVTQLSNAEP AETNGEITAY EVCYGLVNDNRPIGPMKKV
 55 LVDNPKNRML LIENLRDSQP YRYTVKARNG AGWGPEREAI INLATQPKRPMISIPIDIP IVDAQGGEDY
 ENFLMYSDDV LRSPASSQR SVSDTEHLV NGRMDFAYPGSANSLSHRMTA ANVAYGTHLS PHLSHRVLS
 SSTLTRDYHS LTRTEHSHSG TLPDRYSTLSLSQASLS GKMGGAGFRC PGLLGP

9. SEQ ID NO:9 Mouse beta4 dominant negative cds:

atggcaggggccctgttgagcccatgggtgaagctgctgctgctggcagcaatgctgagtgccagcctccctggagacctg
 60 gccaaccgctgcaagaaggctcaggtgaagagctgtaccgagtgcatccgggtggacaagagctgtgctactgcacagac
 gagctgttcaaggagaggcgctgcaacaccaggcgagcttctggctcagggctgcaggggagagagcatcctgggtcatg
 gagagcagccttgaatacacagagaaacccagatcgtaaccagcctgcaccgcagccaggtatctcccaaggcctgcaa
 gtccggctgcccgggggtgaggagcgacgttctgtgtccaggtcttggagccctggagagccccgtggatctgtatatc
 ctcatggacttctccaaactccatgtctgacgatctgggacaacctcaagcagatggggcagaacctggccaagatcctgcgc
 65 cagctcaccagcgactacacattggatttggaaagtctgtggacaaagtcagcgtccacacagacagacatgaggcccgag

aaactgaaggagccctggcccaacagtgatcccccggttctcttcaagaacgttatcagcttaacggagaatgtggaagaa
 ttcttggaacaaactgcaaggagaacgcattctcaggcaacctggacgctcctgaagggggcttgatgccatcctgcagaca
 gctgtgtgcacaaggagacattggctggagggtgacagacccacctgctgggtgttctccaccgagctgcttccactac
 gaggctgatggtgccaacgttctggccggcatcatgaaccgcaatgatgagaatgccacctggacgctcgggcgcttac
 5 acccaatacaagacacaggactaccatcagtgcccacgctggttcgctgcttgccaagcataacatcatccccatctt
 gctgtcaccactactcttacagctactatgagaagctccataagatttccccgctcctctctgggctcctgcaggag
 gattcatccaacatcgtggagctgctggaggagccttctatcgaattcgctccaacctggacatccgggctcgtggacagc
 cccagaggcctgagaacagagggtcacctccgatactctccagaagacggagactgggtccttccacatcaagcgggggaa
 gtggggcacatacaatgtgcatctccgggcagtgaggacatagatgggacacatgtgtgacagctggctaagaagaccaa
 10 gggggcaacatccacctgaaacctccttctctgagtgccctccggatggacgcgagtgatctgtgagctgtgcccctgt
 gagctgcaaaaaggagttcgatcagctcgtgtcacttcagaggagacttcatgtgtggacactgtgtgtgcaatgagggc
 tggagtggcaaacctgcaactgctccaccggctctctgagtgcacacagccctgctgctgagggtgaggacaaaccg
 tctcggggccacggcgagtgccagtgccgacgctgtgtgtgctatggtgaaggccgctacgagggtcacttctgcgagt
 gacaacttccagtgctccccgacctctggattcctgtgcaatgaccggggacgctgttctatgggagagctgtgtgtgag
 15 cctgggtggacaggccgagctgcgactgtccctcagcaatgccacctgcacatagcaacgggggcatctgcaacggc
 cgaggctactgtgagtggtggcgtgtgctgcaaccagcagtcgctctacacggacaccacctgtgagatcaactactct
 gctgatactgggtctctgtgaggatctccgctcctgcgtacagtgccaggcctggggcaccggggagaagaagggcgcg
 tbtgaacttccagtgctccctttaaagtcgaagtggtagacgagcttaagaaagaagggtggtgagctactgctcctccggat
 gaggatgacgactgcacttacagctacaacgtggaggcgacggcagccctggggcccaacagcacagctcctgggtccacaaa
 20 aagaaagactgcctcccgctccttctggtggtcctatccccctgctcatcttctcctgtgtgctcctggcggtgcttctg
 ctgctctgctggaaatga

10. SEQ ID NO:10 Mouse beta4 dominant negative protein sequence:

MAGPCCSPWV KLLLLARMLS ASLPGDLNR CKKAQVKSCT ECIRVDKSCA YCTDELFKERRCNTQADVLA
 AGCRGESILV MESSLEBITEN TQIVTSLHRS QVSPQLQVR LRRGEERTFVFQVFEPLSP VDLIILMDFS
 25 NSMSDDLNL KQMGQNLAKI LRQLTSDYTI GFGKFVDKVSVPQTDMRPEK LKEPWPNSDP PFSFKNVISL
 TENVEEFWNK LQGERISGNL DAPEGGFDAILQTAVCTRDI GWRADSTHLL VFSTESAFHY EADGANVLG
 IMNRNDEKCH LDASGAYTQY
 KTQDYPSPVT LVRLAKHNI IPIFAVTNYS YSYEKLHKY FVSSLGVLQ EDSSNIVELLBEEFYRIRSN
 LDIRALDSPR GLRTEVTSdT LQKTETGSFH IKRGEVGTYN VHLRAVEDIDGTHVCQLAKE DQGGNIHLKP
 30 SPSDGLRMDA SVICDVCPCE LQKEVRSARC HFRGDFMCGHCVCNEGWSGK TCNCSTGSL S DTQPCLEGE
 DKPCS GHGEC QCGRCVCYGE GRYEGHFCEYDNFQCPRTSG FLCNDRGRCS MGECVCEPGW TGRSCDCPLS
 NATCIDSNGG ICNCRGYCEC
 GRCHCNQQLS YDTTTCIN Y SAILGLCEDL RSCVQCQAWG TGEKKGRACD DCPFKVMVDELKKEEVVEY
 CSFRDEDDDC TSYNVEGDG SPGENSTVLV HKKDCCLPAP SWWLIPLLI FILLLLALLLLLCWK

11. SEQ ID NO:11 Murine laminin gamma2 chain complete cds (acc#

U43327):

atgcctgcgctcttggtcagctgctgcctcggtgtcgcgctcctgctgcccgcagccaggccacctccagga
 gggaggtctgtgattgcaatgggaagtcaggcaatgtgtctttgatcaggagctccatcgacaagcaggcag
 cgggttccgttgctcaactgcaatgacaatacagcgggggttactgcgagcggtcgaggagggttttac
 40 cagcatcagagcaagagccgctgcctaccctgcactgccactcctcctcagtgctggatgtgaca
 actctggacaatgcaggtgtaagccaggtgtgacaggacaaagatgtgaccagtgctcagccaggcttccat
 gctcaccgatgtggatgcacccgagaccaggggcaactagattccaagtgtgactgtgacccagctggcatc
 tctggaccctgtgattctggcgatgtgtctgcaaacagccgctcactggagagcgctgtgtaggtgccgac
 cagtgactatcatctggaccgggcaaacctgagggctgtaccagtggttctgctatgggcatcagccag
 45 ctgccacgcctctgcgacttcagtgctccacaaaactcactcacttccagtcaggatgtggtggaag
 gcggttcagagaaacggggccactgcaaaaactccactggtcacagcgccatcgggacgtgtttagttctgcc
 gaagatcagaccccgctctatttctggggccctgccaaattcctcggtaccagcaagtgaagtacgggcagag
 cctgtcttttgactaccgcgtggacagaggaggtagacagccgctctgcctacgatgtgatcctggaaggtgct
 ggtctacagatcagagctcctctgatggctccaggcaagacacttccctgtgggatcacaagacttacat
 50 tcagactgaatgaacatccaagcagtcactggagtcctccagctgagttatttcgaatatcgaaggttactgcg
 gaacctcacagccctcctgatgatccgagctacgtacggagaatatagtagagggtacattgataacgtgacc
 ctgggttcagcccgccctgtccttggagccccagcccttgggttgaacgttgtgtatgctgctggggtaca
 agggacaattctgccaggaatgtgcttctggttacaaaagagattcggcaagattgggcgcttttgccgctg
 tgttccctgtaactgccaaggggaggggctgtgatccagacacgggagattgctactcgggggacgagaat
 55 cctgacattgagtggtgctgactgtcccatcggtttctacaatgacccacatgacccccgagctgcaagccat
 gtcctgtgcacaatgggttcagctgttcagtgatgcttgagacagaggaggtggtgtgtaacaaactgtcccc
 tggggtcacaggtgcccgtgtgagctctgtgctgagcttcttggggtaccccttggggaacatggccca
 gtgaggccttgtcaacgtgccaatgcaacaacacgtggaccccaatgcctctgggaactgtgaccagttga
 caggcagatgcttgaaatgtatctacaacacggcggtgtctactgtgaccagtgcaagcaggttactttgg
 60 agacccattggctcccaaccagcagacaagtgtcgagcttgcaactgcagccccatgggtgaggagcctgga
 gagtgtcgagggtgatggcagctgtgttgaagccaggtttggcgccctcaactgtgatcacgcagccctaa
 ccagttgtcctgctgtacaatcaagtgaagattcagatggaccaggtttaccagcagctccagagcctgga

ggccctgggtttcaaaggctcaggggtgggtgggtgggtacagtcacagtcagctggaaggcaggatcgag
caggctgagcagggcccttcaggacattctgggagaagctcagatttcagaaggggcaatgagagccgttgctg
tccggctggccaaaggcaaggagccaagagaacgactacaagaccgcttgatgacctcaagatgactgcaga
aaggatccgggcccctgggcagtcagcatcagaacagagttcaggatacagagcagactcatctctcagatgcgc
5 ctgagctcggcaggaagcgaagctctcttggaaaacactaataatccattctcttgagcactacgtggggccga
atgattttaaaagtctggctcaggaggctacaagaaggcagacagccagctgagtcagctaacgcaatgaa
gcaactagcaagggaactgaggactactccaaacaagcactttcattggcccgcaagctcttgagtggagga
ggcgaagtggctcttgggacagctccgtgggtacaaggctcttatgggaaaattagagaaaaccaagtccctga
ggcagcagctgtcatggaggccaccaagccgacattgaagctgataggtcgatcagcacagctctccgct
10 cctggattctgcctctcagcttcaggagtcagtgatctgtcctttcagggtggaagcaaaggagatcagacaa
aaggctgattctctctcaaacctggtgaccagacaaacggatgcattcacgcgtgtgcgaaaacaatctgggga
actgggaaaaaagaacacggcagcttttacagactggaaaggataggagacagacttcagatcagctgctttc
ccgtgccaaccttgctaaaaacagagcccaagaagcgctaaagtatgggcaatgccactttttatgaagttgag
aacatcctgaagaacctccgagagtttgatctgcaggttgaagacagaaaagcagaggctgaagaggccatga
15 agagactctcctctattagccagaaggttgccgatgccagtgacaagaccagcaagcagaaacggccctggg
gagcgccactgccgacaccccaacgggcaagaacgcagctaggaggccctggagatcagcagcgagatagag
ctggagataggaggtctgaacttgaagctaatgtgacagcagatggggccttggccatggagaaaaggactg
ccactctgaagagcgagatgagagagatgattgagctggccagaaaggagctggagttgacacggataagga
cacggtgcagctgggtgattactgaagcccagcaagctgatgccagagccacagagtgccggagttaccatccaa
20 gacacrtcaacacattggacggcatcctacacctcatagaccagcctggcagtggtgagtaagaagggatga
tgctattagaacaagggttttccaagccaagaccagatcaacagtcgacttcggcccttgatgtctgacct
ggaggagaggggtgcgtcggcagaggaaccacctccatctgctggagactagcatagatggaattcttgcgtgat
gtgaagaacctggagaacattcgagacaacctgccccaggctgctacaatacccaagctcttgagcaacagt
ga

25 **12. SEQ ID NO:12 Murine laminin gamma2 chain protein sequence (acc#
AAA85256)**

1 mpalwlsccl gvaillpasq atsrrevcdc ngksrqcvfd qelhrqagsg frclnndnt
61 agvhcersre gfyqhskser clpcnchskg slsagcdnsq qcrckpgvtg qrcdqcpqgf
121 hmltdagctr dggqldskcd cdpagisgpc dsgrcvckpa vtgercdrcr prdyhldran
181 pegctqcfcy ghsaschasa dfsvhkitst fsqdvdgwka vxngapakl hwsqrhrdvf
241 ssarrsdpyv fvapakflgn qqvsyqgsls fdyrvdrgr qpsaydvile gaglqirapl
301 mapgktilpcg itktytfrln ehpsshwsq lsyfeyrll rnl tallmir atygeystgy
361 idnvtlvsar pvlgapapwv ercvcllyk gqfcqecass ykrdsarlga fgacvpcncq
421 gegacdptdg dcysgdenpd iecadcpigf yndphdprsc kpcpchngfs csvmpeteev
481 vcnnpcpgvt garcelcadg ffgdpfgeh pvrpcgrqc nnnvdpnasg ncdqitgrcl
35 541 kciyntagvy cdqckagyfg dplapnpadk cracncspmg aepgecrdg scvckpgfga
601 fncdhaalts cpacynqvki qmdqftqqlq slealvskaq ggggggtpvp qlegrieqae
661 qalqdilgea qisegamrav avrlakarsq endyktrldd lkmtaerira lgsqhqnrvq
721 dtsrlisqmr lslagseall entnihssseh yvgpndfksl aqeatrkads haesanamkq
40 781 laretedysk qalslarkll sgggsgswd ssvvgglmkg lektkslsq lsegtqadi
841 eadrsyqhs lrlldasqlq gvsdlfsqve akirrkads lsnlvtrqtd aftrvrnrlg
901 nweketrqll qtgkdrqts dqlsranla knragealsm gnatfyeven ilknlfrefl
961 qvedrkaeae eamkrless qkvadaedkt qqaetalgsa tadtqrakna arealeisse
1021 ieleigslnl eanvtadgal amekgtatl semremiela rkelefddk dtvqlvitea
45 1081 qgadaratsa gvtiqdtlnt ldgilhlidq pgsvdeegmm lleggllfqak tqinsrlrpl
1141 msdleervrr qrnhlhllet sidgiladvk nlenirdnlp pgcyntqale qq

**13. SEQ ID NO:13 Human laminin gamma2 chain complete cds (acc#
AH006634)**

atgcctgcgctctggctgggctgctgcctctgcttctcgctcctcctgccgcagccgggcccacctccaggagggaagtc
50 tgtgattgcaatgggaagtcaggcagtgatcttggatcggaacttcacagacaaactggtaatggattccgctgcctc
aactgcaatgacaacactgatggcattcactgcgagaagtgcaagaatggctttaccggcagagaaagggaccgctgt
ttgccttgaattgtaactccaaaggctctcttagtgcctgatgtgacaactctggacgggtgacgtgtaaacagggtgtg
acaggagccagatgcgaccgatgtctgcccaggcttcacatgctcacggatgcgggggtgcaccaagaccagagactgcta
gactccaagtgtgactgtgaccagctggcatcgaggccctgtgacggggccgctgtgtctgcaagccagctgttact
55 ggagaaacgtgtgataggtgtcgatcaggttactataatctggatggggggaaacctgagggtgtaccagtggttctgc
tatgggcattcagccagctgcgcagctctgcagaatacagtggtccataagatcacctctaccttcaatcaagatgttgat
ggctgggaaggctgtccaaagaaatgggtctctgcaaagctccaatgggtcacagcgccatcaagatgbgtttagctcagcc
caacgactagacctgtctattttgtggctcctgcgaattcttgggaatcaacagggtgagctatgggcaaaagctgtcc
tttgactaccgtgtggacagaggaggcagacacccatctgccatgatgtgatcttggaaaggtgtggtctacggatcaca
60 gctcccttgatgccacttgccaagacactgccttgggtccaccaagacttacacattcaggttaaatgagcatccaagc
aataattggagccccagctgagtbactttgagtatcgaagggtactgcggaatctcacagccctccgcatccgagctaca
tatggagaatacagtaactgggtacattgacaatgtgacctgatttcagcccgccctgtctctggagccccagcacctgg

gttgaacagtgtatatgtcctgttgggtacaaggggaatttbtgccaggattgtgcttctggctacaagagagattcagcg
 agactggggccttttggcacctgtattccttgaactgtcaagggggaggggcctgtgatccagacacaggagattgttat
 tcaggggatgagaatcctgacattgagtgctgactgcccatttgggttttacaacgatccgcagcagcccccgagctgc
 aagccatgtcctctgcataacgggttcagctgctcagtgatgccggagacggaggagggtgtgtgcaataactgccctccc
 5 ggggtcaccggtgcccgtgtgagctctgtgctgatggctacttttgggaccccttgggtgaacatggcccagtgaggcct
 tgtcagccctgtcaatgcaacaacatgtggaccccagtgcccttgggaattgtgaccggctgacaggcaggtgttgaag
 tgtatccacaacacagccggcatctactgcgaccagtgcaagcaggctacttcggggaccattggctcccaaccagca
 gacaagtgtcgagcttgcaactgttaaccccatgggctcagagcctgtaggatgtcgaagtgtggcacctgtgttgaag
 ccaggatttgggtggcccaactgtgagcatggagcattcagctgtccagctgtctataatcaagtgaaagtatcagatggat
 10 cagtttatgagcagccttcagagaatggaggccctgatttcaaaggctcagggtgtgtgatggagtagtacctgatcacag
 ctggaaggcaggatgcagcaggctgagcaggcccttcaggacattctgagagatgcccagatttcagaaggtgtcagaga
 tcccttgggtctccagttggccaaggtgaggagccaagacagctaccagagccgctggatgacctcaagatgactgtg
 gaaagagttcgggctctgggaagttagtaccagaaccgagttcgggatactcacaggctcatcactcagatgcagctgagc
 ctggcagaaagtgaagcttcccttgggaacactaacattctcgtcctcagaccactcgtggggccaaatggctttaaagt
 15 ctggctcaggaggccacaagattagcagaaagccacgttgagtcagccagtaacatggagcaactgagcaaggaaactgag
 gactatttccaaagccctctcactggtgcgcaaggccctgcataaggagtcggaagcgggaagcggtagcccgacggg
 gctgtggtgcaagggccttgggaaaaattgggaaaaaccaagtccttggccagcagttgacaagggaggccactcaagcg
 gaaattgaagcagataggtcttatcagcacagctctccgctcctggattcagtgctcggctcagggagtcagtgatcag
 tcttctcaggtggaagaagcaagaggtatcaaacaaaagcgagttcactctcaacgctggttaaccagcagcatatggatgag
 20 tccaagctacacaaaagaattcgggaaactggaaagaagacacagcagctcttacagaatggaaaaatgggagagag
 aatcagatcagctgcttcccggtgccaatcttgcataaagcagagcacaagaagcactgagtagtgggcaatgccactttt
 tatgaagttgagagcatctttaaaccctcagagagtttgacctgcagggtggacaacagaaaagcagaagctgaagaagcc
 atgaagagagctctcctacatcagccagaaggttccagatgccaagacccagcaagcagaagccctggggagc
 gctgctgctgctgcacagaggcacaagaatggggccggggaggccctggaaatctccagtgagattgaacaggagattggg
 25 agtctgaacttggaagccaatgtgacagcagatggagccttggccatggaaaagggactggcctctctgaagagttagatg
 agggagtggaaggagagctggaaaggaaggagctggagttgacacgaatatggatgcagtacagatggtgattacagaa
 gcccagaaggttgataccagagccaagaacgctggggttacaatccaagacacactcaacacattagacggcctcctgcat
 ctgatggaccagcctctcagtgtagatgaagaggggctggtcttactggagcagaagcttcccgagccaagaccagatc
 aacagccaactgcggcccatgtagtgcagagctggaagagagggcacgtcagcagagggggccacctccatttgcaggagaca
 30 agcatagatgggattctgctgtagtggaagaacttggaagaacattagggaacacctgccccaggctgctacaataccag
 gctcttgagcaacagtga

14. SEQ ID NO:14 Human laminin gamma2 chain protein sequence (acc# AAC50457) Alternative splice form

1 mpalwlgccl cfslllpaar atsrrvecdc ngksrqcifd relhrqtgng frclncndnt
 35 61 dgihececkn gfyhrerdr clpcncnsg slsarcnsg rcsckpgvtg arcdrcclpgf
 121 hmltdagctq dqrllldskcd cdpagiagpc dagrcvckpa vtgercdrcr sgyynldggn
 181 pegctqcfcy ghsascrssa eysvkhkitst fhqdvdgwka vqngspakl qwsqrhgdvf
 241 ssaqrldpvy fvapakflgn qvsvyqsls fdyrvdrgr hpsahdvile gaglrirtapl
 301 mplgkltlpcg ltktytfrln ehpsnnwspq lsfeyrrll rnlalrira tygeystgyi
 40 361 dnvttlisarp vsgapapwve qcicpvgykg qfcqdcasgy krdsarlpgf gtcipncnqg
 421 ggacdpdtdg cysgdenpdi ecadcpigfy ndphdprsc pcpchngfsc svmpeteevv
 481 cncpppgvtg arcelcadgy fgdpfgehgp vrpcqpcqcn nnvdpsasgn cdrltgrcllk
 541 cihntagiyc dqckagyfgd plapnpadkc racncnmpgs epvgcrsdgt cvckpgfggp
 601 ncehgafscp acynqvkiqm dqfmqqlqrm ealiskaagg dgvpvptele grmqqaegal
 45 661 qdlirdaqis egasrslglq lakvrsqens yqsrlddlkm tvervralgs qyqnrvrtdh
 721 rlitmqqlsl aeseaslgnt nipasdhvvg pngfkslage atrlaeshve sasnmqltr
 781 etedyskqal slvrkalheg vsgsgspdg avvgglvekl ektkslaqql treatgaeie
 841 adrsyghslr lldsvsrlqg vsdqsfqvee akrikqkads lstlvtrhmd efkrtqknlg
 901 nwkeeaqqll qngksgreks qdlisranla ksraqealsm gnatfyeyes ilknrlrefdl
 50 961 qvdnrkaeae eamkrlysis qkvsdasdkt qqaeralgsa aadaqrakng agealeisse
 1021 iegeigslnl eanvtadgal amekglaslk semrevegele erkelefdtn mdavqmvite
 1081 aqkvdrakn agvtiqdtln tldgllhlmd qplsvdeegl vllegqlsra ktqinsqlrp
 1141 mmseleerar qqrghlhile tsidgiladv knlenirdnl ppgcyntgal eqq

15. SEQ ID NO:15 Human laminin gamma2 chain protein sequence (acc# AAC50456) Alternative splice form

1 mpalwlgccl cfslllpaar aterrevcdc ngksrqcifd relhrqtgng frclncndnt
 61 dgihececkn gfyhrerdr clpcncnsg slsarcnsg rcsckpgvtg arcdrcclpgf
 121 hmltdagctq dqrllldskcd cdpagiagpc dagrcvckpa vtgercdrcr sgyynldggn
 181 pegctqcfcy ghsascrssa eysvkhkitst fhqdvdgwka vqngspakl qwsqrhgdvf
 60 241 ssaqrldpvy fvapakflgn qvsvyqsls fdyrvdrgr hpsahdvile gaglrirtapl
 301 mplgkltlpcg ltktytfrln ehpsnnwspq lsfeyrrll rnlalrira tygeystgyi
 361 dnvttlisarp vsgapapwve qcicpvgykg qfcqdcasgy krdsarlpgf gtcipncnqg
 421 ggacdpdtdg cysgdenpdi ecadcpigfy ndphdprsc pcpchngfsc svmpeteevv
 481 cncpppgvtg arcelcadgy fgdpfgehgp vrpcqpcqcn nnvdpsasgn cdrltgrcllk
 65 541 cihntagiyc dqckagyfgd plapnpadkc racncnmpgs epvgcrsdgt cvckpgfggp

5 601 ncehgafscp acynqvkiqm dqfmqqlgrm ealiskaggg dgvpdtele grmqaeqal
661 qdildraqis egasrslglq lakvrsqens ygsrlddtkm tvervralgs qygnrvrdth
721 rlitcmqlsl aeesealngt nipasdhvpg pngfkslage atrlaeshve sasnmegltr
781 etedysqkal slvrkalheg vsgsgspdyg avvgqlvekl ektkslaqql treatgaeie
841 adrsyqshlr lldsvsrlyg vsdgsfgvee akrikqkads lstlvtrhmd efkrtqknlg
901 nwkeeaqql qngksgreks dqllsranla ksraqealsm gnatfyeves ilknlrefdl
961 qvdnrkaeee eamkrlysis qkvsdasdtk qgaeralgsa aadaqrakng agealeisse
1021 ieqeigslnl eanvtadgal amekglaslk semrevegel erkelefdtn mdavqmvite
1081 aqkvldtrank avnqtqdtln tldgllhlmg m

10 16. Degenerate Human integrin beta4 subunit cds

atg gca gCg cca cgc ccc agc cca tgg gcc agg ctg ctg ctg gca gcc ttg atc agc gtc
agc ctg tct ggg acc ttg aac cgc tgc aag aag gcc cca gtg aag agc tgc acg gag tgt
gtc cgt gtg gat aag gac tgc gcc tac tgc aca gac gag atg ttc agg
gaccggcgctgcaaacaccaggcgaggctgctggccggcgggctgcccagcgaggagagatcgttggtcatggagagcagcttc
15 caaatcacagagagagaccagagctgagaccacctgcggcgagccagatgttcccccaaggccctcggggtccgtctgcgg
cccggtgaggagcgccattttgagctggaggtgtttgagccaactggagagaccccgctggagctgtacatcctcatggacttc
tccaactccatgtccgatgactgtgacacactcaagaagatggggcagcaacctggctcggtctgagccagctcaccagc
gactacactatggatttgcaagatttbtggacaagctcagcgtcccgagacggagcataggcctgagaagctgaaggag
ccttggccccaacagtgaccccccttctcttcaagaagcgtcatcagcctgacagaagatgtggatgagttccggaaataaa
20 ctgcaggggagagcggtatctcaggcaacctggatcctctctgaggcgggcttcgatgccactcctgacagacagctgtgtgcac
agggacatggctggcgcccgagcagccacctgtggcttcttccaccgtagccttccactatgaggtctgagtgaggg
gccaacgtgtcggttggtcatgtagcgcaacgataacgggtgccactggagcaccagggcactacaccagtaagg
acacaggaatacccgctgggtgcccacctgggtgcgctgctgcgaagcacaacatccccatcttgcgtgtcacaacac
tactcctatagctactacgagaagcttcaacacctatttccccgtctcctcactgggggtgctgcaggaggactcgtccaac
25 atcgtggagctgctggaggagggcttcaatcggtatcgctccaacctggacatcgccctcagacagccccaggcctt
cgagacagaggtcaacctcaagatgttccagaagcaggaggtatgggtcctttccatccggcggggggaagtgggtatatac
cagggtgcagctgcgggccccttgagcagctggatgggacgcacgtgtgccagctgcgggagggacagaagggaacatccat
ctgaaccttctctcgcagcggtcctcaagatggagcgcgggacatcatctgtgatagtgtgacctgcgagctgcaaaaagag
30 gtgcgggtcagctcgctgcagcttcaacggagacttctgtgcggacagtgatgtgtgcagcgagggttgagttggccagacc
tgcaactctcaccggctctctgagtgcacattcagccctgctgcgggagggcgaggacaagccgtgctccggcgctggg
gagtgccagtgccgggactgtgtgtgctacggcgaaggcgctacgagggtcagttctgtcgagatgaacaacctccaggt
ccccgcacttccgggttctcttgcaatgaccaggagcgtgctccatggcgagctgtgtgtgtgagctgtgttggaaggc
35 ccaagctgtgactgttccctcagcaattgccctgcactgcacgacaaatgggggacatctgtaattggacgtggccactgtgag
tgtgtgcgctgccaactgccaccagcagctcgctctacacggacacacatctgcggagatcaactactcggcgctccaccggggc
tctgcgaggacctacgtctcttgcgtgcagtgccaggcgtggggcaccggcgagaaagagggggcgacgtgtgaggaaatgca
40 acttcaaggtcaagatgggtggacgagcttaagagagggcaggaagtggtgtgctgcttctcctcgggagggatgagc
actgcacctacagctacacattggaaggtgacggcgccctggggccaacagcactgtcttggtgcacaagaagaagggaac
tgccctccgggctccttctgtgtggtctatccccctgctctctcctcctcctcggcgctcctggccctgtactgtgtgtatg
tggaaagtactgtgcctgctgcagagggctctgggtgcaacttctccccgtgtgcaaccgaggtcacatggtgggtcttaaggaa
45 gaccactacatgtgtcgggagaaactgtatggctcttgacacttggaacggcccatgtgcgcagcggggaacctcaagggc
cgtgacgtggttcgctgtggaaggtcaccaacaacatgcagcgccctggcttctggcaactcatgcccgcagcatcaacccaca
gagctggtgtccctacgggctgtccttgcgctgtggccgcttcttgacagagaacctgtgaagctgacactcgggagtg
gcccagctgcgcaggagcgtggaggagaaactgaaacgaggtctacaggagatctccggtgtgacaaagctcagacagac
aagtctccggcagcagccaattgcggggaaaaagcaagacacacacattgtggacacagtgctgatggcgcccgcctcgcc
50 aagccggccctgctgaagcttacagagaagcaggtggaacagagggcttccacagcaactcaaggtggcccccggtctacac
acctcactgcagacagcagcgcccggggactggtggagttccaggagggcgaggtggagtgagtgaggagtgccctc
tttatccggctgaggatgacgacgagaagcagctgctggttggagggcactgcagctgcggcagcagctgcacacctcggc
cgcgctcgtgtgaacatcaccatcacaagagcaagcagagacgtggtgtcctttagcagcctgagttctcggtcagc
cgcggggaccagggtggcccgcatccctgtcatccgggctgtccttggaaggcggaaggtccagggtctcctacgcgacag
55 gatggcacccgcgagggcaaccgggactacatccctgctggagggtgagctgtgttccagctggggaggcctggaagag
ctcaggttgaagctcctggagctgcaagaagtccaactcctcttgcggggcgccagggtccgcgttccacgtccagctc
acgaacccctaagtbtggggcccacctggggcagccccactccaccacacatcatcatcagggaaccagatgaaactggaccgg
agcttcaacgactgagatgtgtcatcacagccacccccacggcgacctggggcgcccgagaaaccccaatgctaaaggc
gctgggtccaggaatgaatccattcaactggtgccccccttctggcaaggcaatgggggtacaggttaaggtactggattcag
60 ggtgactcgaattcgaagaccacactctgcagacgaaggtgacctcagttggagctcaccaacctgtaccgctattgcgac
tatgagatgaaggtgtgcgctacggggctcaggcgaggggacctacagctcctgggtgtcctgcgcgacccacaggaa
gtgcccagcgagcaggcgctcggccttcaatgtcgtctcctccacgggtgacccagctgagctgggtgtagcggtgag
accaacggtgagatcacagctcagaggttctgtattggctggttaacgatagacaaccgacctattgggcccattgaagaaa
gtgctggttgaacaaccttaagaaccggatgtgtcttattgagaaccttcgggaggtcccagccctaccgctacacggtgaag
65 ggcgcaaccggggcggtcggggcctgagcgggaggccatcatcaactcgccacccagcccaaggcccaatgctccatc
cccatcatccttgacatcctcatctgtggaacgcccagcagcgggaggaggtcggggcggaaggcgagctgcccctgagtcgaca
ctacgctctccatcgggacgagagggccagcgtctcagatgacatggctcggtcggttggaggttcggagccctgtctggg
gaggagctggacctgcggcggtcagctggcggttcccccgagctcatccgcgcgctgtgcggcagcagcgggcgctcc
tccgacgcgagggcgccccacgggcccccgagcagcggcgggcgggcggaaggcgagctgcccctgagctgcgaca
65 cccgggcccccgagagcactggtgtaattggccgtaggaacttgcttccccggcagcacaacctcctgcagcaggtatg
accaacgaggtgctgtcctctgtgtgacccactgagccccacagtgccccaccggctgctaagcacatcctccacctc

acacgggactacaactcactgaccgctcagaacactcacactcgaccacactgcccaggagactactccacctcacctcc
 gtctcctcccacggcctccctcccatctgggaacacgggagagcaggcttccgctgtcttgggcccctggggtcccggagt
 cgggctcagatgaagggttcccccttccaggggcccacgagactctataatcctggctgggaggccagcagcgcctcc
 tggggcccagactctcgctgactgctggtgtgcccagacgcccacccgctggtgttctctgcccctggggcccacatct
 5 ctacagtgagctggcaggagccggtgagcggcgctgagggctacagtgaggagtagcagctgtaacggcggt
 gagctgcatcggtcaacatccccaaacctgcccagacctcggtggtggaagacctctgcccacccactcctacgtg
 ttccgctgctggggcccagagccaggaaggctggggcggagagcgtgaggggtgcatcaccattgaatcccagggtgacccg
 cagagcccactgtgtccctgcccaggtccgcttcttctgagcactccagtgcccaggcccgtggtgttactgccc
 ctgagcccagactcgctgagctgagctgggagcggccacggaggcccaatggggatctcgctcgctacctggtgacctgt
 10 gagatggcccaaggaggaggtccagccaccgcatctccgggtggatggagacagccccgagagccgggtgacgtgcccggc
 ctacagcagaacgtgcccataagttcaaggtgacggccaggaccactgagggcttcgggcccagagcgcgagggtcatc
 accatagagtcccaggatggaggtcccttcccgagctgggcagccgtgcccgggtcttccagcaccgctgcaaagcgag
 tacagcagcatctccaccaccacacagcgcaccgagcccttcttagtggtgcccagccctgggggcccagcactggag
 gcaggcggtccctcaccggcatgtgaccaggagttgtgagccggacactgaccaccagcggaaccttagcaccac
 15 atggaccaacagttcttccaaactga

17. SEQ ID NO:17 Human beta4 integrin protein sequence Variant V at 34 to I:

1 magprpspa rlllaaliev slsgtlnrck kapIksctec vrvdkdcayc tdemfrdrrc
 61 ntgaellaag cqresivme ssfqiteetq idtllrrsqm spqglrvrlr pgeerhfele
 120 121 vfeplepvd lyilmfdfs msddldnlkk mgnlarvlsl qltsdytigf gkfvdksvvp
 181 qtdmrpekkl epwpsndppf sfknvisite dvdefrnklq gerisgnlda peggfdaillq
 241 tavctrdigw rpdsthlilvf stesafhyea dganvlagim srnderchld ttgtytgxt
 301 qdypsvptlv rllaknhiip ifavtnsys yyeklhtyfp vselglvqed ssnivellee
 361 afnrirsnd iraldsprgl rtevtskmfq ktrtgsfhir rgevgyqvq lralehvdgt
 421 hvqqlpedgk gnihlkpsfs dglkmdagii cdvctcelqk evrsarcsfn gdfvcgqvc
 481 segwsgqtcn cstgsladiq pclregedkp csgrgecgcg hvcvgyegry eggfceydnf
 541 qcprtsgflc ndrgrcsmgq cvcepwtgtp scdclpsnat cidsgngicn grghcegcrc
 601 hchqqslytd ticeinysas trasartyap acsarrgapa rrrgarvrna tsrszwtsl
 661 rearrrwcaa psgrmttap tatpwkvtap lgptalswct rrrdcppgsf wwliplllll
 721 lpllllllll cwkyaccka clallpccnr ghmvfgedh ymlrenlmas dhldtpmlrs
 781 gnlkgrdvrr wkvtnnmqrp gfathaasin ptelvpysls lrlaricten llkpdtrca
 841 qlrqeveenl nevyrqisgv hklgqtkfrq qpnagkkqdh tivdtvmap rsakpallkl
 901 tekqveqraf hdlkvapgyy tltadqdarg mvefgeqvel vdvrvplfir pedddekqll
 961 veaidvpagt atlgrrlvni tiikeqardv vsfeqpefsv srgdqvarip virrvldggk
 1021 sqvsvyrtqdg taggnrdyip vegellfqpq eawkelqvkl lelqevdsl rgrqvrrfhv
 1081 qlsnpkfgah lggphsttii irdpdelers ftsqmlssqp pphgdldgapq npnakaagsr
 1141 kihfnwlpss gkpmgyrvky wiqgdsesea hllskvpsv eltnlypycd yemkvcaiga
 1201 qgegpysslv scrthqevps epgrlafnvv sstvtqlswa epaetngeit ayevcyglnv
 1261 ddnrpiqpmk kvldvnpknr millienlres qpyrytvkar ngagwgpere aiinlatgpk
 1321 rpsmsipiipd ipivdaqsge dydsflmysd dvlrspgsq rpsvsddtgc gwkfepllge
 1381 eldlrrvtwr lppeliprls assgrssdae aphgppddgg aggkqgslpr satpgppgeh
 1441 lvngrrmdaf pgstnslhrm tttssaaaygt hlsphvphrv ltsstltd ynsltrsehs
 1501 hsttlprdis tltsvsshgl ppiwehgrsr lplswalgsr sraqmkgfpp srgprdsiil
 1561 agrpaapswg pdsrltagvp dtptrlvfa lgptslrvsw qeprcerplq gysveyqlin
 1621 ggelhrlnip npagtsvvve dilpnhsyvf rvraqsgew greregvti esqvhpgspl
 1681 cplpgsaftl stpsappplv ftalspdselg lswerprprn gdivgylvtc emaggggpat
 1741 afrvdgspe srltvpglse nvpykfkvga rttegfger egiitiesqd ggpfpqlgsr
 1801 aglfqhplqs eyssistht satepflvqp tlgaghleag gsltrhvtqe fvsrtlttsg
 1861 tltshmdqqf fqt

18. SEQ ID NO:18 Human integrin beta4 subunit cds Variant at 34 V to I:

atg gca ggg cca cgc ccc agc cca tgg gcc agg ctg ctc ctg gca gcc ttg atc agc gtc
 agc ctc tct ggg acc ttg aac cgc tgc aag aag gcc cca AtA aag agc tgc acg gag tgt
 gtc cgt gtg gat aag gac tgc gcc tac tgc aca gac gag atg ttc agg
 gaccggcgctgcaacacccaggcggagctgctggccgagggtgccagcgggagagcatcggtgcatggagagcagcttc
 55 caaatcacagaggagacccagattgacaccacctgcccgcagccagatgtcccccaaggcctgcgggtccgtctgcgg
 cccggtgaggagcggcattttgagctggaggtgtttgagccactggagagccccgtggacctgtacatcctcatggacttc
 tccaaactccatgtccgatgatctggacaacctcaagaagatggggcagaacctgggtcgggtcctgagcagctcaccagc
 gactacactattggatttggcaagtttgtggacaaagttagcgtcccgcagacggacatgaggcctgagaagctgaaggag
 ccttggcccaacagtgaccccccttctcttcaagaacgtcatcagcctgacagaagatgtggatgagttccggaataaa
 60 ctgcaggagagcggatctcaggcaacctggatgctctgagggcggtctcgatgccatcctgcagacagctgtgtgcacg
 agggacattggctggcgccggacagcaccctgctggtcttctccaccgagtcagccttccactatgaggtgatggc
 gccacgtgctgctggcatcatgagccgcaacgatgaacggtgccacctggacaccagggcacctacacccagtagcagg
 acacaggactaccgtcggtgcccacctggtgctgctgcccagcacaacatcatccccatcttctgtgtaccaaac
 tactctatagctactacgagaagcttcaacatttccctgtctctcactgggggtgctgcaggaggactcgccaac
 65 atcgtaggagctgctggaggagccttcaatcggatccgctccaacctggacatccgggcccctagacagccccaggcctt

cggacagaggtcacctccaagatgttccagaagacgaggactgggtcctttcacatccggcggggggaagtgggtatatac
 caggtgcagctgcccccttgagcacgtggaaggacgcagctgtgcccagctgcccaggaccagaaggccaacatccat
 ctgaaaccttcttctccgacggtcctcaagatggacgccccatcatctgtgatgtgtgcacctgagagctgcaaaaagag
 5 tggcgggtcagctcgctgcagcttcaacggagacttcgtgtgcccagagctgtgtgtgacgagggctggagtggccagacc
 tgcaactgctccaccggtctctgagtgacattcagccctgctcgggagggcgaggacaagccgtgctccggcggtggg
 gagtggcagtgccggcactgtgtgtgtacccggaaggccgtacgagggctcagttctgagagtatgacaacttccagtg
 ccccgacttccgggttctctctgcaatgaccgaggacgctgctccatgggcccagtggtgtgtgtgagcctgggtggacaggc
 ccaagctgtgactgtccccctcagcaatgcccactgcatcgacagcaatgggggcatctgtaatggagctggccactgtgag
 10 tgtggccgctgcccactgcccaggcagctcgctctacacggacacatctgcgagatcaactactcggcgctccaccggggcc
 tctgagaggacctacgctcctgctgagtgccaggcggtggggccacggcgagagaagaaggggcgacagctgtgaggaaatgca
 acttcaaggtcaagatgggtggacgagcttaagagaggcgaggaggtgggtgggtgcgctgctccttccgggacgaggatgacg
 actgacacctacagctacacatggaaggtgacggcgccctgggcccacagcactgtcctgggtgcaagaagaaggagac
 tgccctccgggctccttctgtgtggtctacccccctgctcctcctcctcctcctgcccgtcctggccctgctactgctgctatgc
 15 tgaagtactgtgctgctgcaaggcctgctggcacttctcccgctgctgcaaccgaggtcacatgggtgggctttaaaggaa
 gaccactacatgctgcccggagaacctgatggcctctgaccacttggacacgccccatgctgcccagcgggaacctcaaggcc
 cgtgacgtgggtccgctggaaggtcaccaacaatgacggcgccctggccttggccactcatgcccgcagcatcaacccacaca
 gactgggtgcccctacgggtgctccttgcgcttggcccgcttgcacccgagaacctgctgaagcctgacactcgggagtgcc
 gcccagctgcccagggaggtggaggagaacctgaacgaggtctacaggcagatctccgggtgacacaaagctccagcagacc
 aagttccggcagcagcccaatgcccgggaaaaagcaagaccacacatgtggacacagtgctgagtgcccggcctcggcc
 20 aagccggcctgctgaagcttacagagaagcaggtggaaacagagggccttccacgacctcaaggtggccccggctactac
 accctcactgacagaccaggacgcccggggcatgtgtgaggttccaggagggcggtgagctgggtggaagctacgggtgccccctc
 tttatccggcctgaggatgacgacgagaagcagctgctgggtggagggcctcagcgtgcccgcaggcactgccacccctcggc
 cgccgcttggtaaacatcacatcatcaaggagcaagccagagacgtgggtgctccttggacagcctgagttctcggtaagc
 cgccgggacaggtggcccgcatccctgtcatccggcggtgctcctggacggcggggaagtcacaggttctcctaccgcacacag
 25 gatggcacccgacagggcaacccgggactacatccccgtggaggggtgagctgctgttccagcctggggagggcctggaaagag
 ctgaggtgaagctcctggagctgcaagaagttgactccctcctgcccggcgccaggtccggcgttccacgtccagctc
 agcaaccttaagtttggggcccacctggggccagccccactccaccacatcatcatcagggacccagatgaactggaccgg
 agcttcacagctcagatgttgcctcatcacagccacccctcagcggcgacctggggcggccgcagaaaccccaatgctaaaggcc
 gctgggtccaggagaagatccatttcaactggctgcccccttctggcaagccaatggggtacagggtaagtaactggattcag
 30 ggtgactccgaatccgaagccacctgctcgacagcaaggtgcccctcagtgaggtcaccacacctgtatcccgatgtgcag
 tatgagatgaaggtgtgcccctacggggctcaggggcgagggacccctacagctcctcgtgtcctgcccgaacccacaggaa
 gtgccacgagccagggcggtcctggccttcaatgtcgtcctcctccaggtgacccagctgagctgggtgagccggctgag
 accaacgggtgagatcacagcctacgaggtctgctatggcctggtcaacgatgacaaccgacctattggggccatgaagaaa
 35 gtgctgggtgacaacccataagaacccggatgctgcttattgagaaccttcgggagtcaccagccctaccgctacacgggtgaag
 cgcgcgaacggggccggctgggggctgagcgggagggcccatcatcaacctggccacccagcccaagggcccatgtccatc
 cccatccctgacatccctatcgtggagcccgagcggggaggactacgacagcttccctatgtacagcgatgacgtt
 ctacgcttccctcgggcagccagagggccagcgtctccgatgacactggctgcccgtggaaagtctgagccctgctgggg
 gaggagctggacctgcccgcgctcagctggcggtgcccccgagctcatcccgcgctgtcggccagcagcggcgctcc
 40 tccgacgcgcagggcgccccacgggcccccgacgacgagggcgccggcggggaaggcgccagcctgcccccgagtgcgaca
 cccgggcccccgagagacacctgggtgaatggccggatggacttggccttccggggcagcaccacacctcctgcacaggatg
 accacgaccagtgctgctgctatggcacccacctgagccacacgctgccccaccgctgctaaagcacatcctccacccctc
 acacgggactacaactcactgacccgctcagaacactcacactcgaccacactgcccagggactactccacctcactcc
 gctcctccacggcctcctccatctgggaacacgggagggagcaggttccgctgtcctgggcccctgggggtcccgaggt
 45 cgggctcagatgaagggttcccccttccagggggccacgagactctataatcctgggtgggagggccagcagcgcctcc
 tggggcccgagactctgcctgactgctgggtgtgcccgcacgcccacccgctgggtgttctctgcccctggggccacatct
 ctgaggtgagctggcaggagcccggtgagcagcggcgctgacgggtacagtggtgaggtaccagctgctgaacggcggt
 gagctgcatcggtcaacatccccacccctgcccagacctcgggtgggtgggaagacctcctgcccacacactcctacgtg
 50 tccgctgctggggcccgagccaggaagggtggggccgagagcgtgaggggtgtcatccatgaatccaggtgacccg
 cagagccactgtgtccctgcccaggtccgcttcaacttggagactccagtgcccagggcccgctgggtgtcactgccc
 ctgagcccagactcgtgagctgagctgggagcggccacggaggcccaatggggatatcgtcggtacctgtgactgtg
 gaggatggcccaaggaggaggtccagccacccgatttccgggtggatggagacagccccagagccgggtgacccgtgcccggc
 ctcagcgagaacgtgccctacaaggttcaaggtgacggccaggacactgagggcttccgggcccagagcggcagggcatcatc
 accatagagtcacaggtggaggtcccttcccgagctgggagcggctgcccgggctcttccagcaccggctgcaagcgag
 55 tacagcagcatctccaccacccacacagcggccacggagcccttctagtggggtccgacccctggggggccagcactggag
 gcagcggtcctccacccggcatgtgacccaggagttgtgagcggacactgaccaccagcgggaacctttagcaccac
 atggaccaacagttcttccaaacttga

19. SEQ ID NO:19 Degenerate Human integrin beta4 subunit cds variant at
34 Vto I:

atg gca ggg cca cgg ccc agc cca tgg gcc agg ctg ctg ctg gca gcc ttg atc agc gtc
 60 agc ctg tct ggg acc ttg aac cgc tgc aag aag gcc cca AtA aag agc tgc acg gag tgt
 gtc cgt gtg gat aag gac tgc gcc tac tgc aca gac gag atg ttc agg
 gaccggcgctgcaacacccaggcgagctgtgtggccggggctgcccagcgggagagcatcgtgggtcatggagagcagcttc
 caaatcacagaggagaccagattgacacacccctgcccgcagccagatgtcccccaaggcctcggggtccggtctgcgg
 cccgggtgaggagcggcatttttagctggaggtgtttaggacactggagagccccgtggacctgtacatcctcatggacttc
 65 tccaactccatgtccgatgctggacaacctcaagaagatggggcagaacctggctcgggtcctgagccagctcaccagc
 gactacactattggatttggcaagtttgtggacaaagtgcagctcccgcagacggacatgaggcctgagaagctgaaggag

ccttggecccaacagtgaccccccttctccttcaagaacgtcatcagcctgacagaagatgtggatgagttccggaataaa
 ctgcaggagagacggatctcaggcaacctggatgctcctgagggcggttcgatgccatcctgcagacagctgtgtgcacg
 agggacatgtgctggcgccggacagcaccacctgtggtcttctccaccgagtcagccttccactatgaggctgatggc
 gccaacgtgctggctggcatcatgagcgcgaacgatgaacggtgccacctggacaccacgggcacctacaccagtcacagg
 5 acacaggactaccgctcggtgcccacccctgggtgcgctgctgcgaagcacaacatcatccccatcttgtgtgccaac
 tactcctatagctactacgagaagcttcacacctatttccctgtctcctcactgggggtgctgcaggaggactcgtccaac
 atcgtggagctgctggaggaggccttcaatcggatccgctccaacctggacatccgggcccctagacagccccgaggcctt
 cggacagagggtcacctccaagatgttccagaagacgaggactgggtcctttcacatccggcgggggaagtgggtatatac
 cagggtgcagctggggcccttgagcacgtggatgggacgcagctgtgccagctgccggaggaccagaagggcaacatccat
 10 ctgaaaccttcttctccgacggcctcaagaaggacggcgatcatctgtgatgtgtgcacctgagctgcaaaaagag
 gtgagggtcagctcgtgcagcttcaacggagacttcgtgtgaggacagtggtgtgtgcagcagagggtggagtggccagacc
 tggcaactgctccaccggctcctgtgagtgacattcagccctgctcctgcgggagggcgaggacaagcgtcctccggcgtgg
 gagtggcagtgccgggactgtgtgtgtgctacggcgaaaggcgcgtacgagggtcagttctgcgagtatgacaacttccagtgt
 ccccgacttccgggttctcctgcaatgacggaggacgctgctccatggggcagtggtgtgtgagcctggttggacaggc
 15 ccaagctgtgactgtccccctcagcaatgccacctgcacagcaatgggggcatctgttaaggacgtggccactgtgag
 tggctgtgctccaccggctcctgtgagtgacattcagccctgctcctgcgggagggcgaggacaagcgtcctccggcgtgg
 tctgagggagcctacgctcctgctgagtgacggcggtggggcaccggcgagaagaagggcgacgtgtgaggaaatgca
 acttcaaggtcaagatggtggacgagcttaagagaggcgaggaggtggtggtgctgctccttccgggacgaggatgacg
 actgcacctacagctacacatggaaggtgacggcgccctggggcccaacagcactgtcctgggtgcaagaagaaggagac
 20 gagctgtgctccctacgggctgcttctgggtgctcctccctgctcctcctgctcctgctcctgctcctgctcctgctcctg
 tggagtaactgtgctgctgcaaggcctgctggaacttctcccgctgctgcaaccgaggtcacatggtgggtttaaaggaa
 gaccatcacatgctgcgggagaacctgatggcctctgaccacttggacacgcccattgctgcgcagcgggaacctcaagggc
 cgtgacgtggttccgctggaagggtcaccaacaacatgcagcggcctgggttggccactcatgcccgcagcatcaacccccaca
 25 agcttccggcagcagcccaatgcccgggaaaaagcaagaccacacatttgggacacagtgctgatggcgcccgcgtcgcc
 aagccggccctgctgaagcttacagagaagcaggtggaacagaggccttccacgacctcaaggtggcccccggtactac
 accctcactgcagaccaggacgcccgggcatggtggagttccaggaggcggtgagctggtgagcgtacgggtgcccctc
 ttatccggcctgaggatgacgacgagaagcagctgctggtggaggccatcgacgtgcccgcaggcactgccacctcggc
 30 cgccgctggttaacatcacatcatcaaggagcaagccagagacgtggtgtcctttgagcagcctgagttctcggtcagc
 cgccgggaccaggtggcccgcatcctgtcatccggcggtgctcctggacggcggaagtcccaggctcctctaccgcacacag
 gatggcaccgcgcagggcaaccgggactacatccccgtggagggtgagctgctgttccagcctggggagggcgtggaaagag
 ctgcaggtgaagctcctggagctgcaagaagttagctcctcctgcggggcccaggtccgcggttccacgtccagctc
 agcaacctaaagtgggggcccacctggggccagccccactccaccacatcatcatagggaccagatgaactggaccgg
 35 agcttccagagtcagatgtgtcatcacagccacccccctcagcgagcctggcgcccgcagaaacccaatgctaaaggcc
 gctgggtccaggaagatccatttcaactgggtgcccccttctgggcaagccaatgggggtacagggttaagtaactggatccag
 ggtgactccgaatccgaagccacctgctcgacagcaaggtgcccctcagtgaggctcaccacactgtaccggtattgcgac
 tatgagatgaagggtgctgcccctacgggggtcaggggcgaggaccctacagctcctggtgtcctgcccgcacccaccaggaa
 40 gtgcccagcgagccaggcgctgctggccttcaatgtcgtcctcctccaggtgacccagctgagctgggctgagcggcctgag
 accaacgggtgagatcacagcctacgaggtctgcttatggcctggtcaacgatgacaaccgacctattggggcccatgaagaaa
 gtgctggttgacaacctaaagaaccggatgctgcttattgaaaccttccggagtcaccagcctaccgctacacggtgaag
 cgcgcaaccggggccggctgggggctgagcgggaggccatcatcaacctggccaccagcccaagaggcccatgtccatc
 45 cccatcatccttgacatccctatcgtgacgcccagagcggggaggactacgacagcttctttagtacagcgatgacgtt
 ctacgctctccatccggcagccagaggccagcgtctccgatgacactggctgcggtggaagttcgagccctgctgggg
 gaggagctggacctgcggcgctcagtgggcggtgcccccgagctcatcccgcgctgctggccagcagcgggctcc
 tccgacgcggaggcgccccacgggcccccgagcagcggcgggcgggcggaagggcgagcctgccccgagtgccgacg
 cccgggccccccggagagcacttggtgaatggccggatggacttgccttccgggagcagcaacactcctgacagggatg
 50 accacgaccagtgctgctgcttatggcaccacctgagccacacgtgccccaccgctgctaaagcacatcctccacctc
 acacgggactacaactcactgaccgctcagaacactcacactcgaccacactgcccagggaactactccacctcactcc
 gtctcctcccacggcctcctcccctctgggaacacgggaggagcaggttccgctgtcctgggcccctggggteccggagt
 cgggctcagatgaaagggttcccccttccaggggccacagagactataatcctggctgggaggccagcagcgccctcc
 55 tggggcccagactctcgctgactgctggtgtgcccgcacgcccacccgctggtgttctcgtccctggggcccacatct
 ctgagagtgagctggcaggagccggtgagcggcgctgagggctacagtggtgagtagaccagctgctgaacggcggt
 gagctgcatcggtcaacatcccccaacctgcccagacctgggtggtggtggaagacctcctgcccacacctcctacgtg
 ttcccggtgcccggccagagccaggaaaggtggggccgagagcgtgagggtgtcatcaccattgaatcccaggtgacccg
 60 cagagcccactgtgtccctgccaggtctccgcttcaacttgagcactccagtgcccagggcccgctggtgttcaactgcc
 ctgagcccagactcgctgagctgagctgggagcggccagggcccaatggggatatcgtcggtacctggtgacctgt
 gagatggcccgaaggagggtccagccaccgcatccgggtggtgagagacggccgagagccggctgacggtgcccggg
 ctgagcgaagcgtgcccataaggttcaaggttcaggccaggaacactgagggttccgggcccagagggggtatc
 accatagagttccaggatggaggtcccttcccgagctgggagcggctgcccgggtccttccagcaccgctgcaaacgag
 tacagcagctctccaccaccacacagcgccaccgagcccttctagtggttccgacctgggggcccagcactggag
 gcaggcggtcctccacccggcatgtgaccaggagttgtgagccggacactgaccaccagcggaaccttagcaccac
 atggaccaacagttcttccaaactga

What is claimed is:

1. A method of reducing the proliferation of a cancer cell which comprises inhibiting ligand binding to an integrin receptor on the cancer cell, wherein the integrin receptor comprises an integrin.
2. The method of claim 1, wherein the integrin receptor comprises integrin B4.
3. The method of claim 1, wherein the integrin receptor comprises integrin A6.
4. The method of claim 1, wherein the ligand that binds to the integrin receptor is laminin5.
5. The method of claim 1, wherein the integrin receptor is A6B4.
6. The method of claim 1, wherein the ligand comprises laminin5.
7. The method of claim 1, wherein the ligand comprises the gamma-2 subunit of laminin5.
8. The method of claim 1, wherein inhibiting ligand binding to an integrin receptor comprises contacting a A6 integrin with a composition that inhibits ligand binding.
9. The method of claim 1, wherein inhibiting ligand binding to an integrin receptor comprises contacting a B4 integrin with a composition that inhibits ligand binding.
10. The method of claim 1, wherein inhibiting ligand binding to an integrin receptor comprises contacting a laminin5 with a composition that inhibits ligand binding.
11. The method of claim 1, wherein inhibiting ligand binding to an integrin receptor comprises contacting a gamma-2 subunit with a composition that inhibits ligand binding.
12. A method of reducing the proliferation of a cancer cell which comprises reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction.
13. The method of claim 12, wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a A6 integrin with a composition that inhibits an interaction between the B4 integrin and another integrin or protein molecule.
14. The method of claim 12, wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a B4 integrin with a composition that inhibits the interaction between the B4 integrin and another integrin or protein molecule..
15. The method of claim 12, wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a

laminin5 with a composition that inhibits ligand binding.

16. The method of claim 12, wherein reducing integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction comprises contacting a gamma2 subunit with a composition that inhibits ligand binding.

17. The method of claim 12, wherein the non-integrin protein comprises a growth factor receptor.

18. The method of claim 12, wherein the non-integrin protein comprises a hemidesmosome junction.

19. The method of claim 12, wherein the non-integrin protein comprises a SH2 domain.

20. The method of claim 19, wherein the non-integrin protein comprises a Shc protein.

21. The method of claim 12, wherein the non-integrin protein comprises a IRS-1 protein.

22. The method of claim 12, wherein the non-integrin protein comprises a IRS-2 protein.

23. A method of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin by the cancer cell.

24. The method of claim 23, wherein the production of an integrin is reduced by inhibiting signaling leading to induction of expression of an integrin.

25. The method of claim 23, wherein reducing the production of an integrin comprises inhibiting alpha6 production.

26. The method of claim 25, wherein inhibiting alpha6 production further comprises using antisense molecules to alpha6 mRNA.

27. The method of claim 23, wherein reducing the production of an integrin comprises inhibiting beta4 production.

28. The method of claim 27, wherein inhibiting beta4 production further comprises using antisense molecules to beta4 mRNA.

29. A method of reducing the proliferation of a cancer cell which comprises reducing the production of an integrin receptor ligand by the cancer cell.

30. The method of claim 29, wherein reducing the production of an integrin receptor ligand comprises inhibiting gamma2 production.

31. The method of claim 29, wherein reducing the production of an integrin receptor ligand comprises inhibiting laminin production.

32. The method of claim 29, wherein reducing the production of an integrin receptor

ligand comprises inhibiting laminin5 production.

33. A method of reducing the proliferation of a cancer cell which comprises interfering with an integrin signaling pathway.

34. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting an A6 integrin in the cell with a composition that inhibits ligand binding.

35. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting a B4 integrin with a composition that inhibits ligand binding.

36. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting a laminin5 with a composition that inhibits ligand binding.

37. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting a gamma2 subunit with a composition that inhibits ligand binding.

38. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting the cancer cell with a molecule that interferes with at least one of talin, paxillin, vinculin, a CAS family protein, CRX, NCK, FAK, ILK, Src, Fyn, Shc, Grb-2, Guanine nucleotide exchange factors, SOS, DOCK 180, Vav, Syk, P-1-3 kinase, AKT, Bad, Bid, Caspase 9, Cdc42, PAK, Rac, Rho, Rho kinase, Ras, Caveolin, Tetraspan, Receptor-type protein tyrosine phosphatase, SHP-2, Alpha-actinin, Filamin, Cytohesin, Beta3-endonexin, ICAP-1, RACK-1, CIB, actin, receptor tyrosine kinase, IRS-1 or IRS-2.

39. The method of claim 33, wherein interfering with an integrin signaling pathway comprises contacting the cancer cell with an agent that interferes with post-translational modification of integrins.

40. The method of claim 39, wherein the post translational modification is glycosylation or phosphorylation.

41. The method of claims 1, 12, 23, 29, 33, wherein the integrin comprises an A6 integrin.

42. The method of claims 1, 12, 23, 29, 33, wherein the integrin comprises a B4 integrin.

43. The method of claims 1, 12, 23, 29, 33, further comprising reducing a laminin5-integrin interaction.

44. The method of claims 1, 12, 23, 29, 33, further comprising reducing a laminin5 gamma2 integrin interaction.

45. The method of claims 1, 12, 23, 29, 33, wherein reducing the proliferation of the cancer cells is selective.

46. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell is not an MDA-MB-

435 cell.

47. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell is not an HMT-3522 cell.

48. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell is not an RKO colon carcinoma line.

49. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell does not express exogenous B4 integrin.

50. The method of claims 1, 12, 23, 29, 33, further comprising contacting the cancer cells with a small molecule, peptide, peptide mimetic, or oligonucleotide or synthetic analog thereof.

51. The method of claim 50, wherein the cancer cells are contacted with dominant-negative beta 4 integrin.

52. The method of claim 50, wherein the cancer cell is contacted with an antisense molecule.

53. The method of claim 52, wherein the antisense molecule is linked to a leader sequence which enables translocation across a cell membrane.

54. The method of claim 53, wherein the leader sequence binds to a cell surface protein which facilitates internalization.

55. The method of claim 54, wherein the leader sequence is TAT or antennapedia, or fragment thereof.

56. The method of claim 52, wherein the antisense molecule is an alpha6 RNA antisense molecule.

57. The method of claim 47, wherein the small molecule peptide, peptide mimetic, or oligonucleotide or synthetic analog thereof is linked to a carrier.

58. The method of claim 57, wherein the carrier is at least one of a lipidic carrier, charged carrier, retroviral carrier, TAT or fragment thereof, antennapedia or fragment thereof, or polyethylene glycol.

59. The method of any one of claims 1, 12, 23, 29, 33, further comprising contacting the cancer cell with another agent which modulates cell signaling, a chemotherapeutic drug, or treated with radiation or angiogenesis inhibitor.

60. The method of any of claims 1, 12, 23, 29, 33, wherein reducing the proliferation of cancer cell is *in vitro*.

61. The method of any of claims 1, 12, 23, 29, 33, wherein reducing the proliferation

of the cancer cell is *in vivo*.

62. The method of any of claims 1, 12, 23, 29, 33, wherein the cancer cell is selected from the group consisting of melanoma, adenoma, lymphoma, myeloma, carcinoma, plasmocytoma, sarcoma, glioma, thymoma, leukemia, skin cancer, retinal cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, stomach cancer, pancreas cancer, brain tumors, lung cancer, ovarian cancer, cervical cancer, hepatic cancer, gastrointestinal cancer, and head and neck cancer cells.

63. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell is killed.

64. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated Ras.

65. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated Ras and a mutated p53.

66. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated Ras and activates the AKT/PKB protein.

67. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated Ras, a mutated p53, and activates the AKT/PKB protein.

68. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated APC.

69. The method of claims 1, 12, 23, 29, 33, wherein the cancer cell expresses a mutated Ras and mutated APC.

70. A method of isolating molecules that bind with a target molecule selected from the group consisting of B4 integrin, alpha6 integrin, and the gamma2 subunit of laminin5 comprising 1) contacting a library of molecules with the target molecule and 2) collecting molecules that bind the target molecule producing an enriched population of molecules.

71. The method of claim 70, further comprising the step of repeating steps 1 and 2 with the enriched population of molecules.

72. The method of claim 70, wherein the library comprises a small molecule, peptide, peptide mimetic, or oligonucleotide.

73. A method of assessing a subject's risk of developing cancer comprising determining the amount of A6 present in a target cell obtained from the subject, wherein a determination of increased levels of A6 correlates with an increased risk of cancer.

74. The method of claim 73, further comprising comparing the amount A6 present to the

amount in a control cell.

75. The method of claim 73, wherein determining the amount of A6 present in the target cell comprises assaying the amount of A6 mRNA in the cell.

76. The method of claim 75, wherein the assaying the amount of mRNA in the cell comprises hybridizing a A6 probe to a sample of the subject's mRNA.

77. The method claim 75, wherein the assaying the amount of mRNA in the cell comprises hybridizing a A6 primer to a sample of the subject's mRNA.

78. The method claim 77, wherein the assaying the amount of mRNA further comprises performing an nucleic acid amplification reaction involving the primer.

79. The method of claim 78, wherein the nucleic acid amplification reaction comprises reverse transcription, producing a cDNA.

80. The method of claim 79, wherein the nucleic acid amplification reaction further comprises performing a polymerase chain reaction on the cDNA.

81. The method of claim 73, wherein determining the amount of A6 present in the target cell comprises assaying the amount of A6 protein in the cell.

82. A method of assessing a subject's risk of acquiring cancer comprising determining the amount of B4 present in a target cell obtained from the subject, wherein a determination of increased levels of B4 correlates with an increased risk of cancer.

83. The method of claim 82, further comprising comparing the amount B4 present to the amount in a control cell.

84. A method of assessing a subject's risk of acquiring cancer comprising determining the amount of laminin5 present in a target cell obtained from the subject, wherein a determination of increased levels of laminin5 correlates with an increased risk of cancer.

85. The method of claim 84, further comprising comparing the amount laminin5 present to the amount in a control cell.

86. A method of assessing a subject's risk of acquiring cancer comprising determining the amount of gamma2 subunit present in a target cell obtained from the subject, wherein a determination of increased levels of gamma2 subunit correlates with an increased risk of cancer.

87. The method of claim 86, further comprising comparing the amount gamma2 subunit present to the amount in a control cell.

88. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which inhibits ligand binding to an integrin receptor on

the cancer cell, wherein the integrin receptor comprises an integrin.

89. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces integrin-integrin interaction, integrin receptor clustering interaction, or integrin-non-integrin protein interaction.

90. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which reduces the production of an integrin or laminin by the cancer cell.

91. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to the patient a composition which interferes with an integrin signaling pathway.

92. The methods of claims 88-91, wherein the reduction in cancer cell proliferation is selective.

93. The method of any of claims 88-91, wherein the administering is local or systemic.

94. The method of any of claims 88-91, wherein the patient is additionally administered an agent which modulates cell signaling, a chemotherapeutic drug, or treated with radiation or angiogenesis inhibitor.

95. The method of claim 94, wherein the additional agent is administered serially or in combination.

96. The method of claim 93, wherein the local administering is direct application to cancer cells.

97. The method of claim 96, wherein the direct application to cancer cells is performed during surgery.

98. The method of claim 97, wherein the direct application to cancer cells is performed topically to cancerous tissue.

99. The method of claim 94, wherein the systemic administration is by subcutaneous, intraperitoneal, intra-arterial, intravenous, or bolus administration, or by application through a catheter or similar apparatus.

100. The method of claim 94, wherein the systemic administration comprises a long-term release formulation.

101. The method of claim 94, wherein the systemic administration is by oral administration.

102. The method of claim 101 wherein the oral administration comprises administering a pill, capsule, tablet, liquid or suspension.

103. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which inhibits ligand binding to integrin receptors on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

104. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents integrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins on cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

105. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which prevents integrin receptor subunits from interacting with one another, prevents integrin receptor clustering interaction, or prevents integrin receptor subunits from interacting with other proteins in cancer cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

106. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with integrin subunit or laminin production wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

107. A method of reducing the proliferation of a cancer cell in a patient which comprises administering to a patient a vector comprising coding sequence for a protein or peptide which interferes with an integrin signaling pathway of cells wherein the coding sequence is under the control of a promoter which functions in mammalian cells.

108. The methods of claims 103-107, wherein the reduction in cancer cell proliferation is selective.

109. The method of claims 103-107 wherein the vector is administered directly to a cancer cell.

110. The method of claims 103-107, wherein the vector is administered directly to a normal cell.


111. The method of claims 103-107, wherein the vector is packaged in a viral vector or liposome.

112. The method of claim 88 wherein the vector is a retroviral vector.

113. The method of any one of claims 103-107, wherein the vector is administered systemically.
114. The method of claim 109, wherein the direct administration is by topical application.
115. The method of claim 111, wherein the direct administration is by topical application.
116. The method of claim 114, wherein the direct administration is performed during surgery.
117. The method of claim 115, wherein the direct administration is performed during surgery.
118. The method of any of claims 103-107, wherein the patient is an animal.
119. The method of claim 118 wherein the animal is a mammal.
120. The method of claim 119, wherein the mammal is human.
121. The method of claims 103-107, wherein the cancer cells are selected from the group consisting of melanoma, adenoma, lymphoma, myeloma, carcinoma, plasmocytoma, sarcoma, glioma, thymoma, leukemia, skin cancer, retinal cancer, breast cancer, prostate cancer, colon cancer, esophageal cancer, stomach cancer, pancreas cancer, brain tumors, lung cancer, ovarian cancer, cervical cancer, hepatic cancer, gastrointestinal cancer, and head and neck cancer cells.
122. The method of any of claims 103-107 wherein the patient is additionally administered at least one of another agent which modulates cell signaling, a chemotherapeutic drug, an angiogenesis inhibitor or treated with radiation.
123. The method of claim 120 wherein the other agent which modifies cell signaling, chemotherapeutic drug, angiogenesis inhibitor or radiation treatment is administered serially or in combination.

1/8
FIG. 1A

Normal cells require integrin-matrix interactions for survival



**Cells transformed by co-operating oncogenic mutations
survive without contact to extra-cellular matrix**




FIG. 1B

No contact with
Extra-cellular matrix

Panel 2

Oncogenes co-operate to induce cancer cell survival via engagement of autocrine integrin signaling




FIG. 1C

Panel 3

Inhibition of oncogene-induced autocrine integrin signaling loop causes cancer cell death




FIG. 1D

Panel 4

5/8

FIG. 2




FIG. 3




FIG. 4





FIG. 5



SEQUENCE LISTING

<110> University of Rochester Medical Center

Deleu, Laurent
Land, Hartmut<120> COMPOSITIONS THAT INHIBIT PROLIFERATION
OF CANCER CELLS

<130> 21108.0005P1

<150> 60/239,705

<151> 2000-10-12

<150> 60/242,812

<151> 2000-10-24

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3222

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 1

atggcgcgcg	ccgggcagct	gtgcttgctc	tacctgtcgg	cggggctcct	gtcccggctc	60
ggcgcagcct	tcaacttggg	cactcgggag	gacaacgtga	tccggaaata	tggagacccc	120
gggagcctct	tccgcttctc	gctggccatg	cactggcaac	tgcagcccga	ggacaagcgg	180
ctgttgctcg	tgggggcccc	gcgcggagaa	gcgcttccac	tgcagagagc	caacagaacg	240
ggagggtgtg	acagctgcga	catcaccgcc	cgggggccat	gcacgcggat	cgagtttgat	300
aacgatgctg	acccacgctc	agaaagcaag	gaagatcagt	ggatgggggt	caccgtccag	360
agccaaggtc	cagggggcaa	ggtcgtgaca	tgtgctcacc	gatatgaaaa	aaggcagcat	420
gttaatacga	agcaggaatc	cogagacatc	tttgggcggg	gttatgtcct	gagtcagaat	480
ctcaggattg	aagacgatat	ggatggggga	gattggagct	tttgtgatgg	gcgattgaga	540
ggccatgaga	aatttggctc	ttgccagcaa	ggtgtagcag	ctacttttac	taaagacttt	600
cattacattg	tatttggagc	cccggtact	tataactgga	aagggtattg	tcgtgtagag	660
caaaagaata	acactttttt	tgacatgaac	atctttgaag	atgggcctta	tgaagttggg	720
ggagagactg	agcatgatga	aagtctcgtt	cctgttctct	ctaacagtta	cttaggtttt	780
tctttggact	cagggaaagg	tattgtttct	aaagatgaga	tcacttttgt	atctggtgct	840
cccagagcca	atcacagtgg	agccgtgggt	ttgctgaaga	gagacatgaa	gtctgcacat	900
ctcctccctg	agcacatatt	cgatggagaa	ggtctggcct	cttcatttgg	ctatgatgtg	960
gcggtggtgg	acctcaacaa	ggatgggtgg	caagatatag	ttattggagc	cccacagtat	1020
tttgatagag	atggagaagt	tggagggtga	gtgtatgtct	acatgaacca	gcaaggcaga	1080
tggaaataatg	tgaagccaat	tcgtcttaat	ggaaccaaag	attctatgtt	tggcatttga	1140
gtaaaaaata	ttggagatat	taatcaagat	ggctacccag	atattgcagt	tggagctccg	1200
tatgatgact	tgggaaagg	ttttatctat	catggatctg	caaattggaat	aaataccaaa	1260
ccaacacagg	ttctcaagg	tatatcacct	tattttggat	attcaattgc	tggaaacatg	1320
gaccttgatc	gaaattccta	ccctgatgtt	gctgttgggt	ccctctcaga	ttcagtaact	1380
attttcagat	cccggcctgt	gattaatatt	cagaaaacca	tcacagtaac	tcctaacaga	1440
attgacctcc	gccagaaaaac	agcgtgtggg	gcgcctagtg	ggatatgcct	ccaggttaaa	1500
tcctgttttg	aatatactgc	taaccccgct	ggttataatc	cttcaatatc	aattgtgggc	1560
acacttgaag	ctgaaaaaga	aagaagaaaa	tctgggctat	cctcaagagt	tcagtttcga	1620
aaccaaggtt	ctgagcccaa	atatactcaa	gaactaactc	tgaagaggca	gaaacagaaa	1680
gtgtgcatgg	aggaaaccct	gtggctacag	gataatatca	gagataaact	gcgtcccat	1740

```

ccccataactg cctcagtgga gatccaagag ccaagctctc gtaggcgagt gaattcactt 1800
ccagaagttc ttccaattct gaattcagat gaacccaaga cagctcatat tgatgttcac 1860
ttcttaaaaag agggatgtgg agacgacaat gtatgtaaca gcaaccttaa actagaatat 1920
aaattttgca cccgagaagg aaatcaagac aaattttctt atttaccat tcaaaaagg 1980
gtaccagaac tagttctaaa agatcagaag gatattgctt tagaaataac agtgacaaac 2040
agcccttcca acccaaggaa tcccacaaaa gatggcgatg acgcccata ggctaaaactg 2100
attgcaacgt ttccagacac tttaacctat tctgcatata gagaactgag ggctttccct 2160
gagaaacagt tgagttgtgt tgccaaccag aatggctcgc aagctgactg tgagctcgga 2220
aatcctttta aaagaaattc aaatgtcact ttttatttgg tttaagtac aactgaagtc 2280
acctttgaca ccccatatct ggatattaat ctgaagttag aaacaacaag caatcaagat 2340
aatttggctc caattacagc taaagcaaaa gtggttattg aactgctttt atcgggtctcg 2400
ggagttgcta aaccttccca ggtgtatttt ggaggtacag ttgttggcga gcaagctatg 2460
aaatctgaag atgaagtggg aagtttaata gagtatgaat tcagggtaat aaacttaggt 2520
aaacctctta caaacctcgg cacagcaacc ttgaacattc agtggccaaa agaaattagc 2580
aatgggaaat gggtgcttta ttgggtgaaa gtagaatcca aaggattgga aaaggtaact 2640
tgtgagccac aaaaggagat aaactccctg aacctaacgg agtctcacia ctcaagaaag 2700
aaacgggaaa ttactgaaaa acagatagat gataacagaa aattttcttt atttgctgaa 2760
agaaaatacc agactcttaa ctgtagcgtg aacgtgaact gtgtgaacat cagatgcccg 2820
ctgcgggggc tggcagacaa ggcgtctctt attttgcgct cgaggttatg gaacagcaca 2880
tttctagagg aatattccaa actgaactac ttggacattc tcatgcgagc cttcattgat 2940
gtgactgctg ctgccgaaaa tatcaggctg ccaaatgcag gcactcaggt tcgagtgact 3000
gtgtttccct caaagactgt agctcagtat tcgggagtag cttgggtggat catcctagt 3060
gctattctcg ctgggactct gatgcttgct ttattagtgt ttatactatg gaagtgtgg 3120
ttcttcaaga gaaataagaa agatcattat gatgccacat atcacaaggc tgagatccat 3180
gctcagccat ctgataaaga gaggcttact tctgatgcat ag 3222

```

<210> 2

<211> 1072

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 2

```

Met Ala Ala Ala Gly Gln Leu Cys Leu Leu Tyr Leu Ser Ala Gly Leu
1      5      10      15
Leu Ser Arg Leu Gly Ala Ala Phe Asn Leu Asp Thr Arg Glu Asp Asn
20     25     30
Val Ile Arg Lys Tyr Gly Asp Pro Gly Ser Leu Phe Gly Phe Ser Leu
35     40     45
Ala Met His Trp Gln Leu Gln Pro Glu Asp Lys Arg Leu Leu Val Gly
50     55     60
Ala Pro Arg Gly Glu Ala Leu Pro Leu Gln Arg Ala Asn Arg Thr Gly
65     70     75     80
Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly Pro Cys Thr Arg Ile
85     90     95
Glu Phe Asp Asn Asp Ala Asp Pro Thr Ser Glu Ser Lys Glu Asp Gln
100    105    110
Trp Met Gly Val Thr Val Gln Ser Gln Gly Pro Gly Gly Lys Val Val
115    120    125
Thr Cys Ala His Arg Tyr Glu Lys Arg Gln His Val Asn Thr Lys Gln
130    135    140
Glu Ser Arg Asp Ile Phe Gly Arg Cys Tyr Val Leu Ser Gln Asn Leu
145    150    155    160
Arg Ile Glu Asp Asp Met Asp Gly Gly Asp Trp Ser Phe Cys Asp Gly
165    170    175
Arg Leu Arg Gly His Glu Lys Phe Gly Ser Cys Gln Gln Gly Val Ala
180    185    190
Ala Thr Phe Thr Lys Asp Phe His Tyr Ile Val Phe Gly Ala Pro Gly
195    200    205

```

Thr	Tyr	Asn	Trp	Lys	Gly	Ile	Val	Arg	Val	Glu	Gln	Lys	Asn	Asn	Thr
210						215					220				
Phe	Phe	Asp	Met	Asn	Ile	Phe	Glu	Asp	Gly	Pro	Tyr	Glu	Val	Gly	Gly
225					230					235					240
Glu	Thr	Glu	His	Asp	Glu	Ser	Leu	Val	Pro	Val	Pro	Ala	Asn	Ser	Tyr
				245						250				255	
Leu	Gly	Phe	Ser	Leu	Asp	Ser	Gly	Lys	Gly	Ile	Val	Ser	Lys	Asp	Glu
				260				265					270		
Ile	Thr	Phe	Val	Ser	Gly	Ala	Pro	Arg	Ala	Asn	His	Ser	Gly	Ala	Val
		275					280					285			
Val	Leu	Leu	Lys	Arg	Asp	Met	Lys	Ser	Ala	His	Leu	Leu	Pro	Glu	His
	290					295					300				
Ile	Phe	Asp	Gly	Glu	Gly	Leu	Ala	Ser	Ser	Phe	Gly	Tyr	Asp	Val	Ala
305					310					315					320
Val	Val	Asp	Leu	Asn	Lys	Asp	Gly	Trp	Gln	Asp	Ile	Val	Ile	Gly	Ala
				325					330					335	
Pro	Gln	Tyr	Phe	Asp	Arg	Asp	Gly	Glu	Val	Gly	Gly	Ala	Val	Tyr	Val
				340				345					350		
Tyr	Met	Asn	Gln	Gln	Gly	Arg	Trp	Asn	Asn	Val	Lys	Pro	Ile	Arg	Leu
		355					360					365			
Asn	Gly	Thr	Lys	Asp	Ser	Met	Phe	Gly	Ile	Ala	Val	Lys	Asn	Ile	Gly
	370					375					380				
Asp	Ile	Asn	Gln	Asp	Gly	Tyr	Pro	Asp	Ile	Ala	Val	Gly	Ala	Pro	Tyr
385					390					395					400
Asp	Asp	Leu	Gly	Lys	Val	Phe	Ile	Tyr	His	Gly	Ser	Ala	Asn	Gly	Ile
				405					410					415	
Asn	Thr	Lys	Pro	Thr	Gln	Val	Leu	Lys	Gly	Ile	Ser	Pro	Tyr	Phe	Gly
			420					425					430		
Tyr	Ser	Ile	Ala	Gly	Asn	Met	Asp	Leu	Asp	Arg	Asn	Ser	Tyr	Pro	Asp
		435					440					445			
Val	Ala	Val	Gly	Ser	Leu	Ser	Asp	Ser	Val	Thr	Ile	Phe	Arg	Ser	Arg
	450					455					460				
Pro	Val	Ile	Asn	Ile	Gln	Lys	Thr	Ile	Thr	Val	Thr	Pro	Asn	Arg	Ile
465					470					475					480
Asp	Leu	Arg	Gln	Lys	Thr	Ala	Cys	Gly	Ala	Pro	Ser	Gly	Ile	Cys	Leu
				485					490					495	
Gln	Val	Lys	Ser	Cys	Phe	Glu	Tyr	Thr	Ala	Asn	Pro	Ala	Gly	Tyr	Asn
				500				505					510		
Pro	Ser	Ile	Ser	Ile	Val	Gly	Thr	Leu	Glu	Ala	Glu	Lys	Glu	Arg	Arg
		515					520					525			
Lys	Ser	Gly	Leu	Ser	Ser	Arg	Val	Gln	Phe	Arg	Asn	Gln	Gly	Ser	Glu
	530					535					540				
Pro	Lys	Tyr	Thr	Gln	Glu	Leu	Thr	Leu	Lys	Arg	Gln	Lys	Gln	Lys	Val
545					550					555					560
Cys	Met	Glu	Glu	Thr	Leu	Trp	Leu	Gln	Asp	Asn	Ile	Arg	Asp	Lys	Leu
				565					570					575	
Arg	Pro	Ile	Pro	Ile	Thr	Ala	Ser	Val	Glu	Ile	Gln	Glu	Pro	Ser	Ser
				580				585					590		
Arg	Arg	Arg	Val	Asn	Ser	Leu	Pro	Glu	Val	Leu	Pro	Ile	Leu	Asn	Ser
		595					600					605			
Asp	Glu	Pro	Lys	Thr	Ala	His	Ile	Asp	Val	His	Phe	Leu	Lys	Glu	Gly
	610					615					620				
Cys	Gly	Asp	Asp	Asn	Val	Cys	Asn	Ser	Asn	Leu	Lys	Leu	Glu	Tyr	Lys
625					630					635					640
Phe	Cys	Thr	Arg	Glu	Gly	Asn	Gln	Asp	Lys	Phe	Ser	Tyr	Leu	Pro	Ile
				645					650					655	
Gln	Lys	Gly	Val	Pro	Glu	Leu	Val	Leu	Lys	Asp	Gln	Lys	Asp	Ile	Ala
			660					665					670		
Leu	Glu	Ile	Thr	Val	Thr	Asn	Ser	Pro	Ser	Asn	Pro	Arg	Asn	Pro	Thr
		675					680					685			
Lys	Asp	Gly	Asp	Asp	Ala	His	Glu	Ala	Lys	Leu	Ile	Ala	Thr	Phe	Pro
	690					695					700				

Asp Thr Leu Thr Tyr Ser Ala Tyr Arg Glu Leu Arg Ala Phe Pro Glu
 705. 710 715 720
 Lys Gln Leu Ser Cys Val Ala Asn Gln Asn Gly Ser Gln Ala Asp Cys
 725 730 735
 Glu Leu Gly Asn Pro Phe Lys Arg Asn Ser Asn Val Thr Phe Tyr Leu
 740 745 750
 Val Leu Ser Thr Thr Glu Val Thr Phe Asp Thr Pro Tyr Leu Asp Ile
 755 760 765
 Asn Leu Lys Leu Glu Thr Thr Ser Asn Gln Asp Asn Leu Ala Pro Ile
 770 775 780
 Thr Ala Lys Ala Lys Val Val Ile Glu Leu Leu Ser Val Ser Gly
 785 790 795 800
 Val Ala Lys Pro Ser Gln Val Tyr Phe Gly Gly Thr Val Val Gly Glu
 805 810 815
 Gln Ala Met Lys Ser Glu Asp Glu Val Gly Ser Leu Ile Glu Tyr Glu
 820 825 830
 Phe Arg Val Ile Asn Leu Gly Lys Pro Leu Thr Asn Leu Gly Thr Ala
 835 840 845
 Thr Leu Asn Ile Gln Trp Pro Lys Glu Ile Ser Asn Gly Lys Trp Leu
 850 855 860
 Leu Tyr Leu Val Lys Val Glu Ser Lys Gly Leu Glu Lys Val Thr Cys
 865 870 875 880
 Glu Pro Gln Lys Glu Ile Asn Ser Leu Asn Leu Thr Glu Ser His Asn
 885 890 895
 Ser Arg Lys Lys Arg Glu Ile Thr Glu Lys Gln Ile Asp Asp Asn Arg
 900 905 910
 Lys Phe Ser Leu Phe Ala Glu Arg Lys Tyr Gln Thr Leu Asn Cys Ser
 915 920 925
 Val Asn Val Asn Cys Val Asn Ile Arg Cys Pro Leu Arg Gly Leu Asp
 930 935 940
 Ser Lys Ala Ser Leu Ile Leu Arg Ser Arg Leu Trp Asn Ser Thr Phe
 945 950 955 960
 Leu Glu Glu Tyr Ser Lys Leu Asn Tyr Leu Asp Ile Leu Met Arg Ala
 965 970 975
 Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg Leu Pro Asn Ala
 980 985 990
 Gly Thr Gln Val Arg Val Thr Val Phe Pro Ser Lys Thr Val Ala Gln
 995 1000 1005
 Tyr Ser Gly Val Pro Trp Trp Ile Ile Leu Val Ala Ile Leu Ala Gly
 1010 1015 1020
 Ile Leu Met Leu Ala Leu Leu Val Phe Ile Leu Trp Lys Cys Gly Phe
 1025 1030 1035 1040
 Phe Lys Arg Asn Lys Lys Asp His Tyr Asp Ala Thr Tyr His Lys Ala
 1045 1050 1055
 Glu Ile His Ala Gln Pro Ser Asp Lys Glu Arg Leu Thr Ser Asp Ala
 1060 1065 1070

<210> 3

<211> 3222

<212> DNA

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence; Note =
 synthetic construct

<400> 3

atggcgcgtcg	cgggccagtt	gtgcctgctc	tacctgtccg	cggggcttct	agcccggtcg	60
ggtacagcct	tcaacctgga	caccgcgag	gacaacgtga	tccggaaatc	gggggatccc	120
gggagcctct	tcggcttctc	gctcgccatg	cactggcagt	tcagccgga	ggacaagcgg	180
ctgttgcttg	tgggggcacc	tcgggcagaa	gcactccgcg	tcagagggc	gaacagaaca	240
gggggcctgt	acagctgtga	catcacctcc	cgaggacctt	gtacacggat	tgaatttgat	300

```

aatgacgctg atcctatgtc agaaagcaag gaagaccagt ggatgggagt cactgtccag 360
agccaagggtc cagggggcaa agtgggtgacg tgtgcacatc gatatgagaa acggcagcac 420
gtcaacacga agcaggagtc gcgggataatc tttggaagat gttatgtcct gagtcagaat 480
ctcagaattg aagatgatat ggacggagga gactggagti tctgcgatgg ccggttgaga 540
ggccatgaaa agtttggctc ctgtcagcaa ggagtagcgg ctactttcac taaggacttt 600
cattacattg tttttggagc cccagggact tacaactgga aagggatcgt ccgtgtagaa 660
caaaaagaata acactttttt tgacatgaac atctttgaag atggggcccta tgaagtgggt 720
ggagagacag atcatgatga aagtctctgtg cccgttcctg ctaacagtta cctaggcttt 780
tcgctggact cagggaagggt tattgtttct aaagatgaca tcacttttgt gtctggtgct 840
ccaagagcca atcacagtgg ggctgtagtg ttgctaaaaa gagacatgaa gtccgcacat 900
ctgtccctg agtatataat tgacggagaa ggcctggctt cctcgtttgg ctatgatgtg 960
gcagtgggtg acctcaatgc agatgggtgg caagacatcg ttatcggagc tccacagtat 1020
tttgatagggt atggtgaagt cgggggtgca gtttacgtct acattaacca gcaaggcaaa 1080
tggagtaatg tgaagccgat tcgtctaaat gggaccaaaag actcgatgtt tggaaatctct 1140
gtgaaaaata taggtgatat taaccaagat ggctatccag atattgtctg tggagctccc 1200
tatgatgacg tgggaagggt ttttatctat catggatccc cgactggcat aattaccaag 1260
ccaacacagg ttctcgagggt gacatcgctt tacttcggct attcaatcgc tgggaatatg 1320
gacctggatc ggaattccta ccccgacctt gctgtgggct cctctcaga ctcggtcact 1380
attttcagat cccggccagt gattaacatt ctaaaaacca tcacagtgc tcctaacaga 1440
attgacctcc gccagaagtc catgtgtggc tcacctagcg ggatatgcct caaggttaaa 1500
gcctgttttg aatatactgc gaaaccttcc ggttataacc ctccaatata aattttgggt 1560
attcttgaag ctgaaaaaga aagaagaaaa tcagggttgt catcgagagt tcagtttcga 1620
aaccaagggt ccgagccaaa gtatactcag gagctgaccc tgaatcggca gaagcagcgg 1680
gcgtgcatgg aggagacct ctggctgcag gagaacatca gagacaagct gcgtcccatc 1740
cccatcacgg cttctgtgga gatccaggag cccacgtctc gccggcgggt gaactcactc 1800
cccgaagttc ttcccatcct gaattcaaat gaagccaaaa cgggtccagac agatgtccac 1860
ttcttaaagg aaggatgtgg agacgacaat gtctgtaaca gcaaccttaa gctagagtat 1920
aaatttggta cccgagaagg aaatcaagac aaattctctt acctccaat tcaaaaaggc 1980
atcccagaat tagtcctaaa agatcagaaa gatatagctc tggaaaataac ggtgaccaac 2040
agcccttcgg atccaaggaa tccccgaaa gatggcgacg atgccatga agccaaactc 2100
atcgccacgt ttccagacac tctgacatat tccgcttaca gagaactgag ggctttccct 2160
gagaagcagc tgagctgtgt ggccaaccag aatggctccc aagccgactg tgagctcgga 2220
aatcctttca agagaaattc cagtgttact ttctatctga ttttaagtac aaccgagggtc 2280
acctttgaca ccacagatct ggatattaat ctgaagttgg aaacaacaag caatcaggat 2340
aaattggctc caattacagc gaaggcaaaa gtggttattg aattgctttt atccctctcc 2400
ggagtcgcta agccttcgca ggtgtatttt ggaggtacag ttgttgggtg gcaagctatg 2460
aaatctgaag atgaagtagg aagtttaata gagtatgaat ttagggtgat taacttaggc 2520
aagcctctta aaaacctcgg cacagcaacc ttgaatatac agtggcccaa ggagattagc 2580
aatggcaaat ggttgcttta tttgatgaaa gttgaatcca aaggtttgga gcagattgtt 2640
tgtgagccac acaatgaaat aaactacctg aagctgaagg agtctcaca ctcaagaaag 2700
aaacgggaac ttcctgaaaa acagatagat gacagcagga aattttcttt atttctgaa 2760
agaaaatacc agactctcaa ctgcagcgtc aacgtcaggt gtgtgaacat caggtgccca 2820
ctgcgagggc tggacagaa ggccctctctc gttctgtgtt ccaggttggt gaacagcaca 2880
tttctagagg aatattccaa actgaactac ttggacattc tcgtgagggc ttccatagat 2940
gtcacccgtg ctgctcagaa tatcaagctc cctcacgcgg gcactcaggt tcgagtgacg 3000
gtgtttccct caaagactgt agctcagtat tcaggagtag cttggtggat catcctcctg 3060
gctgttcttg ccgggattct gatgctggct ctattagtgt ttttactgtg gaagtgtggc 3120
ttcttcaaga gaaataagaa agatcattac gatgccacct atcacaaggc tgagatccat 3180
actcagccgt ctgataaaga gaggcttact tccgatgcat ag 3222

```

<210> 4

<211> 1073

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 4

Met Ala Val Ala Gly Gln Leu Cys Leu Leu Tyr Leu Ser Ala Gly Leu

1

5

10

15

Leu Ala Arg Leu Gly Thr Ala Phe Asn Leu Asp Thr Arg Glu Asp Asn
 20 25 30
 Val Ile Arg Lys Ser Gly Asp Pro Gly Ser Leu Phe Gly Phe Ser Leu
 35 40 45
 Ala Met His Trp Gln Leu Gln Pro Glu Asp Lys Arg Leu Leu Leu Val
 50 55 60
 Gly Ala Pro Arg Ala Glu Ala Leu Pro Leu Gln Arg Ala Asn Arg Thr
 65 70 75 80
 Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ser Arg Gly Pro Cys Thr Arg
 85 90 95
 Ile Glu Phe Asp Asn Asp Ala Asp Pro Met Ser Glu Ser Lys Glu Asp
 100 105 110
 Gln Trp Met Gly Val Thr Val Gln Ser Gln Gly Pro Gly Gly Lys Val
 115 120 125
 Val Thr Cys Ala His Arg Tyr Glu Lys Arg Gln His Val Asn Thr Lys
 130 135 140
 Gln Glu Ser Arg Asp Ile Phe Gly Arg Cys Tyr Val Leu Ser Gln Asn
 145 150 155 160
 Leu Arg Ile Glu Asp Asp Met Asp Gly Gly Asp Trp Ser Phe Cys Asp
 165 170 175
 Gly Arg Leu Arg Gly His Glu Lys Phe Gly Ser Cys Gln Gln Gly Val
 180 185 190
 Ala Ala Thr Phe Thr Lys Asp Phe His Tyr Ile Val Phe Gly Ala Pro
 195 200 205
 Gly Thr Tyr Asn Trp Lys Gly Ile Val Arg Val Glu Gln Lys Asn Asn
 210 215 220
 Thr Phe Phe Asp Met Asn Ile Phe Glu Asp Gly Pro Tyr Glu Val Gly
 225 230 235 240
 Gly Glu Thr Asp His Asp Glu Ser Leu Val Pro Val Pro Ala Asn Ser
 245 250 255
 Tyr Leu Gly Phe Ser Leu Asp Ser Gly Lys Gly Ile Val Ser Lys Asp
 260 265 270
 Asp Ile Thr Phe Val Ser Gly Ala Pro Arg Ala Asn His Ser Gly Ala
 275 280 285
 Val Val Leu Leu Lys Arg Asp Met Lys Ser Ala His Leu Leu Pro Glu
 290 295 300
 Tyr Ile Phe Asp Gly Glu Gly Leu Ala Ser Ser Phe Gly Tyr Asp Val
 305 310 315 320
 Ala Val Val Asp Leu Asn Ala Asp Gly Trp Gln Asp Ile Val Ile Gly
 325 330 335
 Ala Pro Gln Tyr Phe Asp Arg Asp Gly Glu Val Gly Gly Ala Val Tyr
 340 345 350
 Val Tyr Ile Asn Gln Gln Gly Lys Trp Ser Asn Val Lys Pro Ile Arg
 355 360 365
 Leu Asn Gly Thr Lys Asp Ser Met Phe Gly Ile Ser Val Lys Asn Ile
 370 375 380
 Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly Ala Pro
 385 390 395 400
 Tyr Asp Asp Leu Gly Lys Val Phe Ile Tyr His Gly Ser Pro Thr Gly
 405 410 415
 Ile Ile Thr Lys Pro Thr Gln Val Leu Glu Gly Thr Ser Pro Tyr Phe
 420 425 430
 Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu Asp Arg Asn Ser Tyr Pro
 435 440 445
 Asp Leu Ala Val Gly Ser Leu Ser Asp Ser Val Thr Ile Phe Arg Ser
 450 455 460
 Arg Pro Val Ile Asn Ile Leu Lys Thr Ile Thr Val Thr Pro Asn Arg
 465 470 475 480
 Ile Asp Leu Arg Gln Lys Ser Met Cys Gly Ser Pro Ser Gly Ile Cys
 485 490 495
 Leu Lys Val Lys Ala Cys Phe Glu Tyr Thr Ala Lys Pro Ser Gly Tyr
 500 505 510

Asn	Pro	Pro	Ile	Ser	Ile	Leu	Gly	Ile	Leu	Glu	Ala	Glu	Lys	Glu	Arg
	515						520					525			
Arg	Lys	Ser	Gly	Leu	Ser	Ser	Arg	Val	Gln	Phe	Arg	Asn	Gln	Gly	Ser
	530					535					540				
Glu	Pro	Lys	Tyr	Thr	Gln	Glu	Leu	Thr	Leu	Asn	Arg	Gln	Lys	Gln	Arg
	545				550					555					560
Ala	Cys	Met	Glu	Glu	Thr	Leu	Trp	Leu	Gln	Glu	Asn	Ile	Arg	Asp	Lys
			565						570					575	
Leu	Arg	Pro	Ile	Pro	Ile	Thr	Ala	Ser	Val	Glu	Ile	Gln	Glu	Pro	Thr
		580						585					590		
Ser	Arg	Arg	Arg	Val	Asn	Ser	Leu	Pro	Glu	Val	Leu	Pro	Ile	Leu	Asn
		595					600					605			
Ser	Asn	Glu	Ala	Lys	Thr	Val	Gln	Thr	Asp	Val	His	Phe	Leu	Lys	Glu
	610					615					620				
Gly	Cys	Gly	Asp	Asp	Asn	Val	Cys	Asn	Ser	Asn	Leu	Lys	Leu	Glu	Tyr
	625				630					635					640
Lys	Phe	Gly	Thr	Arg	Glu	Gly	Asn	Gln	Asp	Lys	Phe	Ser	Tyr	Leu	Pro
			645						650					655	
Ile	Gln	Lys	Gly	Ile	Pro	Glu	Leu	Val	Leu	Lys	Asp	Gln	Lys	Asp	Ile
			660					665					670		
Ala	Leu	Glu	Ile	Thr	Val	Thr	Asn	Ser	Pro	Ser	Asp	Pro	Arg	Asn	Pro
	675						680					685			
Arg	Lys	Asp	Gly	Asp	Asp	Ala	His	Glu	Ala	Lys	Leu	Ile	Ala	Thr	Phe
	690					695					700				
Pro	Asp	Thr	Leu	Thr	Tyr	Ser	Ala	Tyr	Arg	Glu	Leu	Arg	Ala	Phe	Pro
	705				710					715					720
Glu	Lys	Gln	Leu	Ser	Cys	Val	Ala	Asn	Gln	Asn	Gly	Ser	Gln	Ala	Asp
			725					730						735	
Cys	Glu	Leu	Gly	Asn	Pro	Phe	Lys	Arg	Asn	Ser	Ser	Val	Thr	Phe	Tyr
		740						745					750		
Leu	Ile	Leu	Ser	Thr	Thr	Glu	Val	Thr	Phe	Asp	Thr	Thr	Asp	Leu	Asp
	755					760						765			
Ile	Asn	Leu	Lys	Leu	Glu	Thr	Thr	Ser	Asn	Gln	Asp	Lys	Leu	Ala	Pro
	770					775					780				
Ile	Thr	Ala	Lys	Ala	Lys	Val	Val	Ile	Glu	Leu	Leu	Leu	Ser	Leu	Ser
	785				790					795					800
Gly	Val	Ala	Lys	Pro	Ser	Gln	Val	Tyr	Phe	Gly	Gly	Thr	Val	Val	Gly
			805					810						815	
Glu	Gln	Ala	Met	Lys	Ser	Glu	Asp	Glu	Val	Gly	Ser	Leu	Ile	Glu	Tyr
		820						825					830		
Glu	Phe	Arg	Val	Ile	Asn	Leu	Gly	Lys	Pro	Leu	Lys	Asn	Leu	Gly	Thr
	835					840					845				
Ala	Thr	Leu	Asn	Ile	Gln	Trp	Pro	Lys	Glu	Ile	Ser	Asn	Gly	Lys	Trp
	850				855						860				
Leu	Leu	Tyr	Leu	Met	Lys	Val	Glu	Ser	Lys	Gly	Leu	Glu	Gln	Ile	Val
	865			870						875					880
Cys	Glu	Pro	His	Asn	Glu	Ile	Asn	Tyr	Leu	Lys	Leu	Lys	Glu	Ser	His
			885					890						895	
Asn	Ser	Arg	Lys	Lys	Arg	Glu	Leu	Pro	Glu	Lys	Gln	Ile	Asp	Asp	Ser
		900						905					910		
Arg	Lys	Phe	Ser	Leu	Phe	Pro	Glu	Arg	Lys	Tyr	Gln	Thr	Leu	Asn	Cys
	915					920						925			
Ser	Val	Asn	Val	Arg	Cys	Val	Asn	Ile	Arg	Cys	Pro	Leu	Arg	Gly	Leu
	930				935						940				
Asp	Thr	Lys	Ala	Ser	Leu	Val	Leu	Cys	Ser	Arg	Leu	Trp	Asn	Ser	Thr
	945				950					955					960
Phe	Leu	Glu	Glu	Tyr	Ser	Lys	Leu	Asn	Tyr	Leu	Asp	Ile	Leu	Val	Arg
			965					970						975	
Ala	Ser	Ile	Asp	Val	Thr	Ala	Ala	Ala	Gln	Asn	Ile	Lys	Leu	Pro	His
		980						985					990		
Ala	Gly	Thr	Gln	Val	Arg	Val	Thr	Val	Phe	Pro	Ser	Lys	Thr	Val	Ala
	995						1000						1005		

Gln Tyr Ser Gly Val Ala Trp Trp Ile Ile Leu Leu Ala Val Leu Ala
 1010 1015 1020
 Gly Ile Leu Met Leu Ala Leu Leu Val Phe Leu Leu Trp Lys Cys Gly
 1025 1030 1035 1040
 Phe Phe Lys Arg Asn Lys Lys Asp His Tyr Asp Ala Thr Tyr His Lys
 1045 1050 1055
 Ala Glu Ile His Thr Gln Pro Ser Asp Lys Glu Arg Leu Thr Ser Asp
 1060 1065 1070
 Ala

<210> 5
 <211> 5622
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence; Note =
 synthetic construct

<400> 5
 atggcagggc cacgccccag cccatggggc aggetgctcc tggcagcctt gatcagcgtc 60
 agcctctctg ggaccttgaa ccgctgcaag aaggccccag tgaagagctg cacggagtgt 120
 gtccgtgttg ataaggactg cgctactgac acagacgaga tggtcaggga ccggcgctgc 180
 aacacccagg cggagctgct ggccgcgggc tgccagcggg agagcatcgt ggtcatggag 240
 agcagcttcc aaatcacaga ggagaccagc attgacacca ccctgcggcg cagccagatg 300
 tcccccaag gcctgcgggt ccgtctgcgg ccgggtgagg agcggcattt tgagctggag 360
 gtgtttgagc cactggagag ccccggtggc ctgtacatcc tcatggactt ctccaactcc 420
 atgtccgatg atctggacaa cctcaagaag atggggcaga acctggctcg ggtcctgagc 480
 cagctcacca gcgactacac taattggattt ggcaagtgtt tggacaaagt cagcgtcccg 540
 cagacggaca tgaggcctga gaagctgaag gagccttggc ccaacagtga ccccccttc 600
 tccttcaaga acgtcatcag cctgacagaa gatgtggatg agttccggaa taaactgcag 660
 ggagagcggg tctcaggcaa cctggatgct cctgagggcg gcttcgatgc catcctgcag 720
 acagctgtgt gcacgagggg cattggctgg cgcccggaac gcaccacct gctggtcttc 780
 tccaccgagt cagccttcca ctatgaggct gatggcgcca acgtgctggc tggcatcatg 840
 agccgcaacg atgaacggtg ccacctggac accacgggca cctacacca gtacaggaca 900
 caggactacc cgtcgttgcc caccctggtg cgctgctcg ccaagcaca catcatcccc 960
 atctttgctg tcaccaacta ctctatagc tactacgaga agcttcacac ctatttccct 1020
 gtctcctcac tgggggtgct gcaggaggac tcgtccaaca tctgtgagct gctggaggag 1080
 gccttcaatc ggatccgctc caacctggac atccggggcc tagacagccc ccgaggcctt 1140
 cggacagagg tcacctcaa gatgttccag aagacgagga ctgggtcctt tcacatccgg 1200
 cggggggaag tgggtatata ccagggtcag ctgcggggcc ttgagcacgt ggtgggacg 1260
 cacgtgtgcc agctgccgga ggaccagaag ggcaacatcc atctgaaacc ttcttcttcc 1320
 gacggcctca agatggacgc gggcatcatc tgtatgtgt gcacctgcga gctgcaaaaa 1380
 gaggtgcggt cagctcgtcg cagcttcaac ggagacttcg tgtgcggaca gtgtgtgtgc 1440
 agcgagggct ggagtggcca gacctgcaac tgcctccacc gctctctgag tgacattcag 1500
 ccctgcctgc gggagggcga ggacaagccg tgctccggcc gtggggagtg ccagtgcggg 1560
 cactgtgtgt gctacggcga aggcgctac gagggtcagt tctgcgagta tgacaacttc 1620
 cagtgtcccc gcacttccgg gttcctctgc aatgaccgag gacgctgctc catgggcccag 1680
 tgtgtgtgtg agcctgggtg gacaggccca agctgtgact gtccctcag caatgccacc 1740
 tgcactgaca gcaatggggg catctgtaat ggacgtggcc actgtgagtg tggccgctgc 1800
 cactgccacc agcagtcgct ctacacggac accatctcg agatcaacta ctcgcgctcc 1860
 acccgggcct ctgcgaggac ctacgctcct gcgtgcagtg ccaggcgtgg ggcaaccggc 1920
 agaagaaggg gcgcacgtgt gaggaatgca acttcaaggc caagatggtg gacgagctta 1980
 agagaggcga ggaggtggtg gtgcgctgct ccttccggga cgaggatgac gactgcacct 2040
 acagctacac catggaaggc gacggcgccc ctggggccaa cagcactgtc ctggtgcaca 2100
 agaagaaggg actgccctcc gggctccttc tgggtggctc tccccctgct cctcctcttc 2160
 ctgccgctcc tggcctgct actgctgcta tgctggaagt actgtgctg ctgcaaggcc 2220
 tgcctggcac ttctcccggt ctgcaaccga ggtcacatgg tgggctttaa ggaagaccac 2280
 tacatctgca gggagaacct gatggcctct gaccacttgg acacgccat gctgcgcagc 2340
 gggaacctca agggccgtga cgtggtccgc tgggaaggta ccaacaacat gcagcggcct 2400
 ggcttttgcca ctcatgccgc cagcatcaac cccacagagc tgggtgccta cgggctgtcc 2460

ttgcgcctgg	cccgccctttg	caccgagaac	ctgctgaagc	ctgacactcg	ggagtgcgcc	2520
cagctgcgcc	aggaggtgga	ggagaacctg	aacgaggtct	acaggcagat	ctccggtgta	2580
cacaagctcc	agcagaccaa	gttccgcgag	cagcccaatg	ccgggaaaaa	gcaagaccac	2640
accattgtgg	acacagtgtc	gatggcgccc	cgctcggcca	agccggccct	gctgaagctt	2700
acagagaagc	aggtggaaca	gagggccttc	cacgacctca	aggtggcccc	cggctactac	2760
acctcactg	cagaccagga	cgcccggggc	atgggtgagt	tccaggaggg	cgtaggctg	2820
gtggacgtac	gggtgcccc	ctttatccgg	cctgaggatg	acgacgagaa	gcagctgctg	2880
gtggaggcca	tcgacgtgcc	cgcaggcact	gccacctcgc	gccgcccgc	ggtaaaccatc	2940
accatcatca	aggagcaagc	cagagacgtg	gtgtcctttg	agcagcctga	gttctcgggtc	3000
agccgcgggg	accaggtggc	ccgcacccct	gtcatccggc	gtgtcctgga	cggcggggaag	3060
tccagggtct	cctaccgcac	acaggatggc	accgcgcagg	gcaaccggga	ctacatcccc	3120
gtggagggtg	agctgctgtt	ccagcctggg	gaggcctgga	aagagctgca	ggtgaagctc	3180
ctggagctgc	aagaagttga	ctccctcctg	cggggccggc	aggtccgccc	tttccacgtc	3240
cagctcagca	acctaaagtt	tggggcccac	ctggggccagc	cccactccac	caccatcatc	3300
atcaggggacc	cagatgaact	ggaccgggagc	ttcacgagtc	agatgttgtc	atcacagcca	3360
ccccctcacg	gcgacctggg	cgccccgcag	aaccccaatg	ctaaggccgc	tgggtccagg	3420
aagatccatt	tcaactggct	gcccccttct	ggcaagccaa	tggggtagacg	ggtaaagtac	3480
tggattcagg	gtgactccga	atccgaagcc	cacctgctcg	acagcaaggt	gccctcagtg	3540
gagctcacca	acctgtaccc	gtattgcgac	tatgagatga	aggtgtgcgc	ctacggggct	3600
cagggcgagg	gacctacag	ctccctgggtg	tcctgcgcga	cccaccagga	agtgccacgc	3660
gagccagggc	gtctggcctt	caatgtcgtc	tcctccacgg	tgacctagct	gagctgggct	3720
gagccggctg	agaccaacgg	tgagatcaca	gcctacgagg	tctgtatgg	cctggccaac	3780
gatgacaacc	gacctattgg	gcccataag	aaagtctgg	ttgacaaccc	taagaaccgg	3840
atgctgctta	ttgagaacct	tcgggagtc	cagccctacc	gctacacggt	gaaggcgccg	3900
aacggggccg	gctggggggc	tgagcgggag	gccatcatca	acctggccac	ccagcccag	3960
aggcccatgt	ccatccccc	catccctgac	atccctatcg	tggacgccc	gagcggggag	4020
gactacgaca	gcttccttat	gtacagcgat	gacgttctac	gctctccatc	gggcagccag	4080
aggccacg	tctccgatga	cactggctgc	ggctggaagt	tcgagccct	gctgggggag	4140
gagctggacc	tgcggcgcgt	cacgtggcgg	ctgcccccg	agctcatccc	gcgcctgtcg	4200
gccagcagcg	ggcgctcctc	cgacgcccag	gcgcccacg	ggcccccgga	cgacggcggc	4260
gcgggcccga	agggcggcag	cctgccccgc	agtgcgacac	ccggggcccc	cggagagcac	4320
ctgggtgaatg	gcgggatgga	ctttgccttc	ccgggcagca	ccaactccct	gcacaggatg	4380
accacgacca	gtgctgctgc	ctatggcacc	cacctgagcc	cacacgtgcc	ccaccgcgtg	4440
ctaagcacat	cctccaccct	cacacgggac	tacaactcac	tgacctgctc	agaacactca	4500
cactcgacca	cactgcccag	ggactactcc	acctcacct	ccgtctcctc	ccacggcctc	4560
cctcccattct	gggaacacgg	gaggagcagg	cttccgctgt	cctgggccc	ggggtcccgg	4620
agtggggctc	agatgaaagg	gttccccct	tccaggggcc	cacgagactc	tataatcctg	4680
gctggggaggc	cagcagcgcc	ctcctggggc	ccagactctc	gcctgactgc	tgggtgtgcc	4740
gacacgccc	cccgccctgt	gttctctgcc	ctggggccc	catctctcag	agtgagctgg	4800
caggagccgc	ggtgcgagcg	gccgctgcag	ggctacagt	tggagtacca	gctgctgaac	4860
ggcggtgagc	tgcatcggtc	caacatcccc	aacctgccc	agacctcggt	ggtggtggaa	4920
gacctcctgc	ccaaccactc	ctacgtgttc	cgctgcccgg	cccagagcca	ggaaggctgg	4980
ggccgagagc	gtgagggtgt	catcaccatt	gaatcccagg	tgaccccga	gagcccactg	5040
tgtccccctgc	caggctccgc	cttcactttg	agcactccca	gtgccccagg	cccgtgggtg	5100
ttcactgccc	tgagcccaga	ctcgctgcag	ctgagctggg	agcgcccacg	gaggcccaat	5160
ggggatatcg	tcggctacct	ggtgacctgt	gagatggccc	aaggaggagg	tccagccacc	5220
gcattccggg	tggatggaga	cagccccgag	agccggctga	ccgtgcccgg	cctcagcgag	5280
aacgtgccct	acaagttaa	ggtgcaggcc	aggaccactg	agggcttcgg	gccagagcgc	5340
gagggcatca	tcacataga	gtcccaggat	ggaggctccc	tcccgcagct	gggcagccgt	5400
gccgggctct	tccagcacc	gctgcaaagc	gagtacagca	gcattctccac	caccacacac	5460
agcgccaccg	agcccttcc	agtgggtccg	acctggggg	cccagcacc	ggaggcaggc	5520
ggctccctca	cccggcatgt	gacccaggag	tttgtgagcc	ggacactgac	caccagcgga	5580
accttagca	cccacatgga	ccaacagttc	ttccaaactt	ga		5622

<210> 6

<211> 1873

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 6

```

Met Ala Gly Pro Arg Pro Ser Pro Trp Ala Arg Leu Leu Leu Ala Ala
 1           5           10           15
Leu Ile Ser Val Ser Leu Ser Gly Thr Leu Asn Arg Cys Lys Lys Ala
      20           25           30
Pro Val Lys Ser Cys Thr Glu Cys Val Arg Val Asp Lys Asp Cys Ala
      35           40           45
Tyr Cys Thr Asp Glu Met Phe Arg Asp Arg Arg Cys Asn Thr Gln Ala
      50           55           60
Glu Leu Leu Ala Ala Gly Cys Gln Arg Glu Ser Ile Val Val Met Glu
65           70           75           80
Ser Ser Phe Gln Ile Thr Glu Glu Thr Gln Ile Asp Thr Thr Leu Arg
      85           90           95
Arg Ser Gln Met Ser Pro Gln Gly Leu Arg Val Arg Leu Arg Pro Gly
      100          105          110
Glu Glu Arg His Phe Glu Leu Glu Val Phe Glu Pro Leu Glu Ser Pro
      115          120          125
Val Asp Leu Tyr Ile Leu Met Asp Phe Ser Asn Ser Met Ser Asp Asp
      130          135          140
Leu Asp Asn Leu Lys Lys Met Gly Gln Asn Leu Ala Arg Val Leu Ser
145          150          155          160
Gln Leu Thr Ser Asp Tyr Thr Ile Gly Phe Gly Lys Phe Val Asp Lys
      165          170          175
Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys Leu Lys Glu Pro
      180          185          190
Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys Asn Val Ile Ser Leu
      195          200          205
Thr Glu Asp Val Asp Glu Phe Arg Asn Lys Leu Gln Gly Glu Arg Ile
      210          215          220
Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Leu Gln
225          230          235          240
Thr Ala Val Cys Thr Arg Asp Ile Gly Trp Arg Pro Asp Ser Thr His
      245          250          255
Leu Leu Val Phe Ser Thr Glu Ser Ala Phe His Tyr Glu Ala Asp Gly
      260          265          270
Ala Asn Val Leu Ala Gly Ile Met Ser Arg Asn Asp Glu Arg Cys His
      275          280          285
Leu Asp Thr Thr Gly Thr Tyr Thr Gln Tyr Arg Thr Gln Asp Tyr Pro
      290          295          300
Ser Val Pro Thr Leu Val Arg Leu Leu Ala Lys His Asn Ile Ile Pro
305          310          315          320
Ile Phe Ala Val Thr Asn Tyr Ser Tyr Ser Tyr Tyr Glu Lys Leu His
      325          330          335
Thr Tyr Phe Pro Val Ser Ser Leu Gly Val Leu Gln Glu Asp Ser Ser
      340          345          350
Asn Ile Val Glu Leu Leu Glu Glu Ala Phe Asn Arg Ile Arg Ser Asn
      355          360          365
Leu Asp Ile Arg Ala Leu Asp Ser Pro Arg Gly Leu Arg Thr Glu Val
      370          375          380
Thr Ser Lys Met Phe Gln Lys Thr Arg Thr Gly Ser Phe His Ile Arg
385          390          395          400
Arg Gly Glu Val Gly Ile Tyr Gln Val Gln Leu Arg Ala Leu Glu His
      405          410          415
Val Asp Gly Thr His Val Cys Gln Leu Pro Glu Asp Gln Lys Gly Asn
      420          425          430
Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys Met Asp Ala Gly
      435          440          445
Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys Glu Val Arg Ser
450          455          460

```

Ala Arg Cys Ser Phe Asn Gly Asp Phe Val Cys Gly Gln Cys Val Cys
 465 470 475 480
 Ser Glu Gly Trp Ser Gly Gln Thr Cys Asn Cys Ser Thr Gly Ser Leu
 485 490 495
 Ser Asp Ile Gln Pro Cys Leu Arg Glu Gly Glu Asp Lys Pro Cys Ser
 500 505 510
 Gly Arg Gly Glu Cys Gln Cys Gly His Cys Val Cys Tyr Gly Glu Gly
 515 520 525
 Arg Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro Arg
 530 535 540
 Thr Ser Gly Phe Leu Cys Asn Asp Arg Gly Arg Cys Ser Met Gly Gln
 545 550 555 560
 Cys Val Cys Glu Pro Gly Trp Thr Gly Pro Ser Cys Asp Cys Pro Leu
 565 570 575
 Ser Asn Ala Thr Cys Ile Asp Ser Asn Gly Gly Ile Cys Asn Gly Arg
 580 585 590
 Gly His Cys Glu Cys Gly Arg Cys His Cys His Gln Gln Ser Leu Tyr
 595 600 605
 Thr Asp Thr Ile Cys Glu Ile Asn Tyr Ser Ala Ser Thr Arg Ala Ser
 610 615 620
 Ala Arg Thr Tyr Ala Pro Ala Cys Ser Ala Arg Gly Ala Pro Ala
 625 630 635 640
 Arg Arg Arg Gly Ala Arg Val Arg Asn Ala Thr Ser Arg Ser Arg Trp
 645 650 655
 Trp Thr Ser Leu Arg Glu Ala Arg Arg Trp Trp Cys Ala Ala Pro Ser
 660 665 670
 Gly Thr Arg Met Thr Thr Ala Pro Thr Ala Thr Pro Trp Lys Val Thr
 675 680 685
 Ala Pro Leu Gly Pro Thr Ala Leu Ser Trp Cys Thr Arg Arg Arg Asp
 690 695 700
 Cys Pro Pro Gly Ser Phe Trp Trp Leu Ile Pro Leu Leu Leu Leu
 705 710 715 720
 Leu Pro Leu Leu Ala Leu Leu Leu Leu Cys Trp Lys Tyr Cys Ala
 725 730 735
 Cys Cys Lys Ala Cys Leu Ala Leu Leu Pro Cys Cys Asn Arg Gly His
 740 745 750
 Met Val Gly Phe Lys Glu Asp His Tyr Met Leu Arg Glu Asn Leu Met
 755 760 765
 Ala Ser Asp His Leu Asp Thr Pro Met Leu Arg Ser Gly Asn Leu Lys
 770 775 780
 Gly Arg Asp Val Val Arg Trp Lys Val Thr Asn Met Gln Arg Pro
 785 790 795 800
 Gly Phe Ala Thr His Ala Ala Ser Ile Asn Pro Thr Glu Leu Val Pro
 805 810 815
 Tyr Gly Leu Ser Leu Arg Leu Ala Arg Leu Cys Thr Glu Asn Leu Leu
 820 825 830
 Lys Pro Asp Thr Arg Glu Cys Ala Gln Leu Arg Gln Glu Val Glu Glu
 835 840 845
 Asn Leu Asn Glu Val Tyr Arg Gln Ile Ser Gly Val His Lys Leu Gln
 850 855 860
 Gln Thr Lys Phe Arg Gln Gln Pro Asn Ala Gly Lys Lys Gln Asp His
 865 870 875 880
 Thr Ile Val Asp Thr Val Leu Met Ala Pro Arg Ser Ala Lys Pro Ala
 885 890 895
 Leu Leu Lys Leu Thr Glu Lys Gln Val Glu Gln Arg Ala Phe His Asp
 900 905 910
 Leu Lys Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp Ala
 915 920 925
 Arg Gly Met Val Glu Phe Gln Glu Gly Val Glu Leu Val Asp Val Arg
 930 935 940
 Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys Gln Leu Leu
 945 950 955 960

Val Glu Ala Ile Asp Val Pro Ala Gly Thr Ala Thr Leu Gly Arg Arg
 965 970 975
 Leu Val Asn Ile Thr Ile Ile Lys Glu Gln Ala Arg Asp Val Val Ser
 980 985 990
 Phe Glu Gln Pro Glu Phe Ser Val Ser Arg Gly Asp Gln Val Ala Arg
 995 1000 1005
 Ile Pro Val Ile Arg Arg Val Leu Asp Gly Gly Lys Ser Gln Val Ser
 1010 1015 1020
 Tyr Arg Thr Gln Asp Gly Thr Ala Gln Gly Asn Arg Asp Tyr Ile Pro
 1025 1030 1035 1040
 Val Glu Gly Glu Leu Leu Phe Gln Pro Gly Glu Ala Trp Lys Glu Leu
 1045 1050 1055
 Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg Gly
 1060 1065 1070
 Arg Gln Val Arg Arg Phe His Val Gln Leu Ser Asn Pro Lys Phe Gly
 1075 1080 1085
 Ala His Leu Gly Gln Pro His Ser Thr Thr Ile Ile Ile Arg Asp Pro
 1090 1095 1100
 Asp Glu Leu Asp Arg Ser Phe Thr Ser Gln Met Leu Ser Ser Gln Pro
 1105 1110 1115 1120
 Pro Pro His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys Ala
 1125 1130 1135
 Ala Gly Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Ser Gly Lys
 1140 1145 1150
 Pro Met Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu Ser
 1155 1160 1165
 Glu Ala His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr Asn
 1170 1175 1180
 Leu Tyr Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly Ala
 1185 1190 1195 1200
 Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Thr His Gln
 1205 1210 1215
 Glu Val Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser Ser
 1220 1225 1230
 Thr Val Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly Glu
 1235 1240 1245
 Ile Thr Ala Tyr Glu Val Cys Tyr Gly Leu Val Asn Asp Asp Asn Arg
 1250 1255 1260
 Pro Ile Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn Arg
 1265 1270 1275 1280
 Met Leu Leu Ile Glu Asn Leu Arg Glu Ser Gln Pro Tyr Arg Tyr Thr
 1285 1290 1295
 Val Lys Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala Ile
 1300 1305 1310
 Ile Asn Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile Ile
 1315 1320 1325
 Pro Asp Ile Pro Ile Val Asp Ala Gln Ser Gly Glu Asp Tyr Asp Ser
 1330 1335 1340
 Phe Leu Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ser Gly Ser Gln
 1345 1350 1355 1360
 Arg Pro Ser Val Ser Asp Asp Thr Gly Cys Gly Trp Lys Phe Glu Pro
 1365 1370 1375
 Leu Leu Gly Glu Glu Leu Asp Leu Arg Arg Val Thr Trp Arg Leu Pro
 1380 1385 1390
 Pro Glu Leu Ile Pro Arg Leu Ser Ala Ser Ser Gly Arg Ser Ser Asp
 1395 1400 1405
 Ala Glu Ala Pro His Gly Pro Pro Asp Asp Gly Gly Ala Gly Gly Lys
 1410 1415 1420
 Gly Gly Ser Leu Pro Arg Ser Ala Thr Pro Gly Pro Pro Gly Glu His
 1425 1430 1435 1440
 Leu Val Asn Gly Arg Met Asp Phe Ala Phe Pro Gly Ser Thr Asn Ser
 1445 1450 1455

13

Leu His Arg Met Thr Thr Thr Ser Ala Ala Ala Tyr Gly Thr His Leu
 1460 1465 1470
 Ser Pro His Val Pro His Arg Val Leu Ser Thr Ser Ser Thr Leu Thr
 1475 1480 1485
 Arg Asp Tyr Asn Ser Leu Thr Arg Ser Glu His Ser His Ser Thr Thr
 1490 1495 1500
 Leu Pro Arg Asp Tyr Ser Thr Leu Thr Ser Val Ser Ser His Gly Leu
 1505 1510 1515 1520
 Pro Pro Ile Trp Glu His Gly Arg Ser Arg Leu Pro Leu Ser Trp Ala
 1525 1530 1535
 Leu Gly Ser Arg Ser Arg Ala Gln Met Lys Gly Phe Pro Pro Ser Arg
 1540 1545 1550
 Gly Pro Arg Asp Ser Ile Ile Leu Ala Gly Arg Pro Ala Ala Pro Ser
 1555 1560 1565
 Trp Gly Pro Asp Ser Arg Leu Thr Ala Gly Val Pro Asp Thr Pro Thr
 1570 1575 1580
 Arg Leu Val Phe Ser Ala Leu Gly Pro Thr Ser Leu Arg Val Ser Trp
 1585 1590 1595 1600
 Gln Glu Pro Arg Cys Glu Arg Pro Leu Gln Gly Tyr Ser Val Glu Tyr
 1605 1610 1615
 Gln Leu Leu Asn Gly Gly Glu Leu His Arg Leu Asn Ile Pro Asn Pro
 1620 1625 1630
 Ala Gln Thr Ser Val Val Val Glu Asp Leu Leu Pro Asn His Ser Tyr
 1635 1640 1645
 Val Phe Arg Val Arg Ala Gln Ser Gln Glu Gly Trp Gly Arg Glu Arg
 1650 1655 1660
 Glu Gly Val Ile Thr Ile Glu Ser Gln Val His Pro Gln Ser Pro Leu
 1665 1670 1675 1680
 Cys Pro Leu Pro Gly Ser Ala Phe Thr Leu Ser Thr Pro Ser Ala Pro
 1685 1690 1695
 Gly Pro Leu Val Phe Thr Ala Leu Ser Pro Asp Ser Leu Gln Leu Ser
 1700 1705 1710
 Trp Glu Arg Pro Arg Arg Pro Asn Gly Asp Ile Val Gly Tyr Leu Val
 1715 1720 1725
 Thr Cys Glu Met Ala Gln Gly Gly Gly Pro Ala Thr Ala Phe Arg Val
 1730 1735 1740
 Asp Gly Asp Ser Pro Glu Ser Arg Leu Thr Val Pro Gly Leu Ser Glu
 1745 1750 1755 1760
 Asn Val Pro Tyr Lys Phe Lys Val Gln Ala Arg Thr Thr Glu Gly Phe
 1765 1770 1775
 Gly Pro Glu Arg Glu Gly Ile Ile Thr Ile Glu Ser Gln Asp Gly Gly
 1780 1785 1790
 Pro Phe Pro Gln Leu Gly Ser Arg Ala Gly Leu Phe Gln His Pro Leu
 1795 1800 1805
 Gln Ser Glu Tyr Ser Ser Ile Ser Thr Thr His Thr Ser Ala Thr Glu
 1810 1815 1820
 Pro Phe Leu Val Gly Pro Thr Leu Gly Ala Gln His Leu Glu Ala Gly
 1825 1830 1835 1840
 Gly Ser Leu Thr Arg His Val Thr Gln Glu Phe Val Ser Arg Thr Leu
 1845 1850 1855
 Thr Thr Ser Gly Thr Leu Ser Thr His Met Asp Gln Gln Phe Phe Gln
 1860 1865 1870
 Thr

<210> 7

<211> 5907

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =

synthetic construct

<400> 7
 ggaccgtcga ggcagcgga ctgaccagc tgggctcact gtattaagaa gcggaccgcg 60
 gaccgagc gcccgggac ccgatctggg agcctggacg ggtgcagcgc gcaggaatgc 120
 agtccgcctg actcaccagc gccctcttcc tacctgcgcg gcccgctccat aaagcgctgc 180
 tcgtcccgcg cgcgcgcgc gccctgctgt cccgcgggc tcgcccgcgc gctcagctcg 240
 acccaacgca gcccagtc gaggtagtct cactaaggag gaggaggatg gcagggccct 300
 gttgcagccc atgggtgaag ctgctgctgc tggcacgaat gctgagtgcc agcctccctg 360
 gagacctggc caaccgctgc aagaaggctc aggtgaagag ctgtaccgag tgcacccggg 420
 tggacaagag ctgtgcctac tgcacagacg agctgttcaa ggagaggcgc tgcaacacc 480
 aggcggacgt tctggctgca ggctgcaggg gagagagcat cctggctcatg gagagcagcc 540
 ttgaaatcac agagaacacc cagatcgtca ccagcctgca ccgcagccag gtatctcccc 600
 aaggcctgca agtccggctg cggcggggtg aggagcgac gtttgtgtc caggtctttg 660
 agcccctgga gagcccctg gatctgtata tctcatgga ctctccaac tccatgtctg 720
 acgatctgga caacctcaag cagatggggc agaacctggc caagatcctg cgcagctca 780
 ccagcgacta caccattgga ttggaaagt ttgtggacaa agtcagcgtc ccacagacag 840
 acatgaggcc cgagaaactg aaggagccct ggcccacag tgatccccg ttctcttca 900
 agaacgttat cagcttaacg gagaatgtgg aagaattctg gaacaaactg caaggagaac 960
 gcatctcagg caacctggac gctcctgaag ggggctttga tgccatcctg cagacagctg 1020
 tgtgcacaag ggacattggc tggagggtg acagcaccga cctgctgggt ttctccaccg 1080
 agtctgcctt ccactacgag gctgatgggt ccaacgttct gcgcctacac ccaatacaag acacaggact 1200
 atgatgagaa atgccacctg gacgcctcgg ttgccaagca taacatcatc cccatctttg 1260
 acccatcagt gccacgctg gttcgcctgc agaagctcca taagtatttc cccgtctcct 1320
 ctgtcaccaa ctactcttac agctactatg acatcgtgga gctgctggag gaggccttct 1380
 ctctggcggt cctgcaggag gattcatcca cctcggacag ctctgggac cccagaggc ctgagaacag 1440
 atcgaaattc ctccaacctg gacatccggg agactgggtc ctttcacatc aagcgggggg 1500
 aggtcacctc cgatactctc cagaagacgg catctccggg cagtggagga catagatggg acacatgtgt 1560
 aagtggcac atacaatgtg caagggggca acatccacct gaaacctcc ttctctgatg 1620
 gccagctggc taaagaagac gtgatctgtg acgtgtgccc ctgtgagctg caaaaggaag 1680
 gcctccgat ggacgcgagt gtgatctgtg acttcatgtg tggacactgt gtgtgcaatg 1740
 ttcgatcagc tcgctgtcac ttcagaggag ccaccggctc tctgagtgac acacagccct 1800
 agggctggag tggcaaaacc tgcaactgct cgggccacgg cgagtgcag tgcggacgct 1860
 gcctgcgtga gggtaggac aaacctgtct gaggctactg cgagtatgac aacttccagt 1920
 gtgtgtgcta tggtagaggc cgctacgagg gtcactctg cagtagtgac ctgttctatg ggagagtgtg 1980
 gtccccggac ctctggattc ctgtgcaatg accggggacg cgcactgtcc cctcagcaat gccacctgca 2040
 tgtgtgagcc tgggtggaca ggccgcagct gggcctactg tgagtgtggc cgttgtcact 2100
 tcgatagcaa cgggggcatc tgcaacggcc gaggctactg caactactct gcgatactgg 2160
 gcaaccagca gtgcctctac acggacacca cctgtgagat ctggggcacc ggggagaaga 2220
 gtctctgtga ggtctccgc tectgcgtac agtgccaggc ctggggcacc ggttagacgag cttaaagaaag 2280
 aagggcgcg cgtgtgacgat tgccttccgg atgaggatga cgactgcact tacagctaca 2340
 aagaggtggt ggagtactgc tccttccggg acagcacagt cctgggtccac aaaaagaaag 2400
 acgtggaggg cgacggcagc cctgggcccc tgggtggctc tccctctgct catcttctc ctgttgctcc 2460
 actgcctccc ggctccttcc tggctggctc tgcctgggaa actgtgcctg ctgcaaaagg tgcctggggc 2520
 tggcgttgct tctgctgctc tgcctgggaa tgggctttaa ggaagatcac tatatgcttc 2580
 ttcttctctg ctgcaaccga ggtcacatgg gaccacctgg acacgcccac gctacgaagc gggaaacctca 2640
 gggagaacct gatggcctct tggaaagatca ccaacaatgt tcgtacccta cgggtgttcc ctgctgctt 2700
 agggacgaga cacagtccgc cagcaccagc cccacggagc cgggcacccg agagtgtgac cagctacgcc 2760
 cccatgccc cagcaccagc cttatgaagc atagacaggt cagcggcgca cacaagctcc 2820
 gccgcctctg cactgagaac aatgaggtgt ccgggaaaaa gcaagaccac accattgttg 2880
 aggaggtgga gtaacgacag cagcccaacg cgtccgcga agcagatgct gctgaagctg acagagaagc 2940
 acacagtgtt gctggcgccc cgtccgcga aggtggcccc tggctactac actgtcacgg 3000
 aggtggagca ggggtccttc catgaactga aggtggcccc cgtggagctg gtggatgtgc 3060
 cagagcagga tgcgcggggc atggtggagt tccaggaggg cgtggagctg gtggaggcca 3120
 gagtgcctt ctcatccgg cctgaggatg atgatgagaa gcagctgctg gtggaggcca 3180
 ttgatgtccc tgtgagcact gccaccttg gtcgcccgtc ggtaaacatc accattatca 3240
 aggaacaagc tagtggggtg gtgtccttcg acagcctga atactcggtg agtcgtggag 3300
 accaggtggc ccgcatccct gtcatccggc acatcctgga caatggcaag tcccaggctt 3360
 cctatagcac acaggataat acagcacacg gacaccggga ttatgttccc gtggaggag 3420
 agctgctgtt ccatcctggg gaaacctgga aggagttgca ggtgaagcta ctggagctgc 3480
 aggaggttga ctccctcctg cgtggccgcg aggtccgcgc cttccaagtc caactcagca 3540

```

accccaagtt cggagcccgc ctggggccagc ccagcacaa caccgttatt ctcgatgaaa 3600
cggacaggag tctcataaat caaacacttt catcgctcc gccaccccat ggagacctgg 3660
gcgccccaca gaacccaat gccaaaggctg ccgatccag gaagatccat ttcaactggc 3720
tgccccctcc tggcaagcca atgggggtaca ggtgaagta ctgatccag ggcgactctg 3780
aatctgaagc ccaccttcta gatagcaagg tgcctcagt ggaactcacc aacctgtatc 3840
cctattgcga ctacgaaatg aagggtgtgt cctatggggc caagggtgag gggccctata 3900
gctcactggg gtcttgccgc acccaccagg aagtaccag tgagccaggg aggtggcctt 3960
tcaatgtagt ctcttctacg gtgactcagc tgagctgggc agagccagct gagaccaatg 4020
gcgagatcac agcctacgag gtctgtatg gactggtcaa tgaggacaac agaccattg 4080
gacctatgaa gaagggtgctc gtggacaacc ccaagaaccg gatgctgctc attgagaatc 4140
tgcgagattc ccagccatac cgatacacgg ttaaggcgcg caatggggca ggtggggac 4200
ccgagagaga ggctatcatc aacctggcta cacagcccaa gcggcccatg tccatcccta 4260
tcatcccaga catcccata gtggacgccc aggggtggaga agactacgaa aacttcctta 4320
tgtacagtga tgacgtcctg cgggtccccag ccagcagcca gaggccagc gtttctgatg 4380
acactgagca cctgggtgaat ggccggatgg actttgcta tccaggcagc gccaaactccc 4440
tgcacagaat gactgcagcc aatgtggcct atggcagca tctgagccca cacctgtccc 4500
accgagtgtc gagcacgtcc tccaccctta cccgggacta ccactctctg acacgcacag 4560
agcactccca ctccaggcaca cttcccaggg actactccac cctcacttcc ctttctctcc 4620
aagcctccct cctatctggg aagatgggag gagcaggctt ccgtgtcct ggactcttgg 4680
gtccttgagc cgggctcaca tgaagggtgt gccgcaccc aggggttcac cagactctat 4740
aatcctggcc gggcagtcag cagcaccctc ctgggggtaca ggattcccgt ggggctgtgg 4800
gtgtgcctga cacaccact cggtgtgtgt tctctgccct ggggcgcacg tctttgaagg 4860
tgagctggca ggagccacag tgtgatcgga cgctgctggg ctacagtgtg gaataccagc 4920
tactaacgtg cgtcgagatg catcggtcga acatccctaa ccctggccaa acctcgggtg 4980
tggtagagga tctcctgcct aactactctc atgtgttccg ggtacgggca cagagccagg 5040
agggctgggg tcgagagcga gaggggtgtca tcaccatcga gtcccagggtg caccgcgaga 5100
gccctctctg cccctgccca ggctcagcct tcactctgag cacccccagc gcccaggac 5160
cactgggtgt cactgcccta agccagact cccgcagct cagctgggag cggccgagga 5220
gccgcaatgg agatatactt ggctaccttg tgacctgtga gatggcccaa ggaggagcac 5280
cagccaggac cttccgggtg gacggagaca accctgagag ccggttgact gtacctggcc 5340
tcagttagaa cgcttcttac aagttcaagg ttcaggccag gacgaccgag ggctttgggc 5400
cagagcgtga gggatatcat accatcgagt ctcaggttg agggcccttc ccacagctgg 5460
gcagcaattc tgggctcttc cagaaccag tgcaaagcga gttcagcagc gtgaccagca 5520
cgcacagcac cagactgag ccttctctca tggatggtct aaccctgggg acccagcgcc 5580
tggaagcagg aggtccctc acccggcatg tgaccagga attcgtgacc cggaccttaa 5640
cggccagtgg ctctctcagc actcatatgg accaacagtt cttccaaacc tgaacctccc 5700
ccgcgccccca gccacctggg cccctccttg cctctctctc tagcgccttc ttcctctgct 5760
gctctaccca cgagcttgct gaccacagag ccagcccttg tagtcagaga gcagggttag 5820
gtgctgtcca ggaaccataa agtgggtaga ggtgatacaa ggtctttctg actgcacccc 5880
accctgggtc caatcccaca tgtaacc

```

<210> 8

<211> 1466

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 8

```

Met Ala Gly Pro Cys Cys Ser Pro Trp Val Lys Leu Leu Leu Leu Ala
 1             5             10             15
Arg Met Leu Ser Ala Ser Leu Pro Gly Asp Leu Ala Asn Arg Cys Lys
          20          25          30
Lys Ala Gln Val Lys Ser Cys Thr Glu Cys Ile Arg Val Asp Lys Ser
          35          40          45
Cys Ala Tyr Cys Thr Asp Glu Leu Phe Lys Glu Arg Arg Cys Asn Thr
          50          55          60

```

Gln	Ala	Asp	Val	Leu	Ala	Ala	Gly	Cys	Arg	Gly	Glu	Ser	Ile	Leu	Val	65	70	75	80
Met	Glu	Ser	Ser	Leu	Glu	Ile	Thr	Glu	Asn	Thr	Gln	Ile	Val	Thr	Ser	85	90	95	
Leu	His	Arg	Ser	Gln	Val	Ser	Pro	Gln	Gly	Leu	Gln	Val	Arg	Leu	Arg	100	105	110	
Arg	Gly	Glu	Glu	Arg	Thr	Phe	Val	Phe	Gln	Val	Phe	Glu	Pro	Leu	Glu	115	120	125	
Ser	Pro	Val	Asp	Leu	Tyr	Ile	Leu	Met	Asp	Phe	Ser	Asn	Ser	Met	Ser	130	135	140	
Asp	Asp	Leu	Asp	Asn	Leu	Lys	Gln	Met	Gly	Gln	Asn	Leu	Ala	Lys	Ile	145	150	155	160
Leu	Arg	Gln	Leu	Thr	Ser	Asp	Tyr	Thr	Ile	Gly	Phe	Gly	Lys	Phe	Val	165	170	175	
Asp	Lys	Val	Ser	Val	Pro	Gln	Thr	Asp	Met	Arg	Pro	Glu	Lys	Leu	Lys	180	185	190	
Glu	Pro	Trp	Pro	Asn	Ser	Asp	Pro	Pro	Phe	Ser	Phe	Lys	Asn	Val	Ile	195	200	205	
Ser	Leu	Thr	Glu	Asn	Val	Glu	Glu	Phe	Trp	Asn	Lys	Leu	Gln	Gly	Glu	210	215	220	
Arg	Ile	Ser	Gly	Asn	Leu	Asp	Ala	Pro	Glu	Gly	Gly	Phe	Asp	Ala	Ile	225	230	235	240
Leu	Gln	Thr	Ala	Val	Cys	Thr	Arg	Asp	Ile	Gly	Trp	Arg	Ala	Asp	Ser	245	250	255	
Thr	His	Leu	Leu	Val	Phe	Ser	Thr	Glu	Ser	Ala	Phe	His	Tyr	Glu	Ala	260	265	270	
Asp	Gly	Ala	Asn	Val	Leu	Ala	Gly	Ile	Met	Asn	Arg	Asn	Asp	Glu	Lys	275	280	285	
Cys	His	Leu	Asp	Ala	Ser	Gly	Ala	Tyr	Thr	Gln	Tyr	Lys	Thr	Gln	Asp	290	295	300	
Tyr	Pro	Ser	Val	Pro	Thr	Leu	Val	Arg	Leu	Leu	Ala	Lys	His	Asn	Ile	305	310	315	320
Ile	Pro	Ile	Phe	Ala	Val	Thr	Asn	Tyr	Ser	Tyr	Ser	Tyr	Tyr	Glu	Lys	325	330	335	
Leu	His	Lys	Tyr	Phe	Pro	Val	Ser	Ser	Leu	Gly	Val	Leu	Gln	Glu	Asp	340	345	350	
Ser	Ser	Asn	Ile	Val	Glu	Leu	Leu	Glu	Glu	Ala	Phe	Tyr	Arg	Ile	Arg	355	360	365	
Ser	Asn	Leu	Asp	Ile	Arg	Ala	Leu	Asp	Ser	Pro	Arg	Gly	Leu	Arg	Thr	370	375	380	
Glu	Val	Thr	Ser	Asp	Thr	Leu	Gln	Lys	Thr	Glu	Thr	Gly	Ser	Phe	His	385	390	395	400
Ile	Lys	Arg	Gly	Glu	Val	Gly	Thr	Tyr	Asn	Val	His	Leu	Arg	Ala	Val	405	410	415	
Glu	Asp	Ile	Asp	Gly	Thr	His	Val	Cys	Gln	Leu	Ala	Lys	Glu	Asp	Gln	420	425	430	
Gly	Gly	Asn	Ile	His	Leu	Lys	Pro	Ser	Phe	Ser	Asp	Gly	Leu	Arg	Met	435	440	445	
Asp	Ala	Ser	Val	Ile	Cys	Asp	Val	Cys	Pro	Cys	Glu	Leu	Gln	Lys	Glu	450	455	460	
Val	Arg	Ser	Ala	Arg	Cys	His	Phe	Arg	Gly	Asp	Phe	Met	Cys	Gly	His	465	470	475	480
Cys	Val	Cys	Asn	Glu	Gly	Trp	Ser	Gly	Lys	Thr	Cys	Asn	Cys	Ser	Thr	485	490	495	
Gly	Ser	Leu	Ser	Asp	Thr	Gln	Pro	Cys	Leu	Arg	Glu	Gly	Glu	Asp	Lys	500	505	510	
Pro	Cys	Ser	Gly	His	Gly	Glu	Cys	Gln	Cys	Gly	Arg	Cys	Val	Cys	Tyr	515	520	525	
Gly	Glu	Gly	Arg	Tyr	Glu	Gly	His	Phe	Cys	Glu	Tyr	Asp	Asn	Phe	Gln	530	535	540	
Cys	Pro	Arg	Thr	Ser	Gly	Phe	Leu	Cys	Asn	Asp	Arg	Gly	Arg	Cys	Ser	545	550	555	560

Met	Gly	Glu	Cys	Val	Cys	Glu	Pro	Gly	Trp	Thr	Gly	Arg	Ser	Cys	Asp		
				565					570					575			
Cys	Pro	Leu	Ser	Asn	Ala	Thr	Cys	Ile	Asp	Ser	Asn	Gly	Gly	Ile	Cys		
			580					585					590				
Asn	Gly	Arg	Gly	Tyr	Cys	Glu	Cys	Gly	Arg	Cys	His	Cys	Asn	Gln	Gln		
		595						600				605					
Ser	Leu	Tyr	Thr	Asp	Thr	Thr	Cys	Glu	Ile	Asn	Tyr	Ser	Ala	Ile	Leu		
	610					615					620						
Gly	Leu	Cys	Glu	Asp	Leu	Arg	Ser	Cys	Val	Gln	Cys	Gln	Ala	Trp	Gly		
625					630					635					640		
Thr	Gly	Glu	Lys	Lys	Gly	Arg	Ala	Cys	Asp	Asp	Cys	Pro	Phe	Lys	Val		
			645						650					655			
Lys	Met	Val	Asp	Glu	Leu	Lys	Lys	Glu	Glu	Val	Val	Glu	Tyr	Cys	Ser		
			660					665					670				
Phe	Arg	Asp	Glu	Asp	Asp	Asp	Cys	Thr	Tyr	Ser	Tyr	Asn	Val	Glu	Gly		
	675						680					685					
Asp	Gly	Ser	Pro	Gly	Pro	Asn	Ser	Thr	Val	Leu	Val	His	Lys	Lys	Lys		
	690					695					700						
Asp	Cys	Leu	Pro	Ala	Pro	Ser	Trp	Trp	Leu	Ile	Pro	Leu	Leu	Ile	Phe		
705					710					715					720		
Leu	Leu	Leu	Leu	Leu	Ala	Leu	Leu	Leu	Leu	Cys	Trp	Lys	Tyr	Cys			
			725						730					735			
Ala	Cys	Cys	Lys	Ala	Cys	Leu	Gly	Leu	Leu	Pro	Cys	Cys	Asn	Arg	Gly		
			740				745						750				
His	Met	Val	Gly	Phe	Lys	Glu	Asp	His	Tyr	Met	Leu	Arg	Glu	Asn	Leu		
	755						760					765					
Met	Ala	Ser	Asp	His	Leu	Asp	Thr	Pro	Met	Leu	Arg	Ser	Gly	Asn	Leu		
	770					775					780						
Lys	Gly	Arg	Asp	Thr	Val	Arg	Trp	Lys	Ile	Thr	Asn	Asn	Val	Gln	Arg		
785					790					795					800		
Pro	Gly	Phe	Ala	Thr	His	Ala	Ala	Ser	Thr	Ser	Pro	Thr	Glu	Leu	Val		
			805						810						815		
Pro	Tyr	Gly	Leu	Ser	Leu	Arg	Leu	Gly	Arg	Leu	Cys	Thr	Glu	Asn	Leu		
		820						825					830				
Met	Lys	Pro	Gly	Thr	Arg	Glu	Cys	Asp	Gln	Leu	Arg	Gln	Glu	Val	Glu		
	835						840					845					
Glu	Asn	Leu	Asn	Glu	Val	Tyr	Arg	Gln	Val	Ser	Gly	Ala	His	Lys	Leu		
	850					855					860						
Gln	Gln	Thr	Lys	Phe	Arg	Gln	Gln	Pro	Asn	Ala	Gly	Lys	Lys	Gln	Asp		
865					870					875					880		
His	Thr	Ile	Val	Asp	Thr	Val	Leu	Leu	Ala	Pro	Arg	Ser	Ala	Lys	Gln		
			885						890					895			
Met	Leu	Leu	Lys	Leu	Thr	Glu	Lys	Gln	Val	Glu	Gln	Gly	Ser	Phe	His		
		900						905					910				
Glu	Leu	Lys	Val	Ala	Pro	Gly	Tyr	Tyr	Thr	Val	Thr	Ala	Glu	Gln	Asp		
	915						920					925					
Ala	Arg	Gly	Met	Val	Glu	Phe	Gln	Glu	Gly	Val	Glu	Leu	Val	Asp	Val		
	930					935					940						
Arg	Val	Pro	Leu	Phe	Ile	Arg	Pro	Glu	Asp	Asp	Asp	Glu	Lys	Gln	Leu		
945					950					955					960		
Leu	Val	Glu	Ala	Ile	Asp	Val	Pro	Val	Ser	Thr	Ala	Thr	Leu	Gly	Arg		
			965						970					975			
Arg	Leu	Val	Asn	Ile	Thr	Ile	Ile	Lys	Glu	Gln	Ala	Ser	Gly	Val	Val		
		980						985					990				
Ser	Phe	Glu	Gln	Pro	Glu	Tyr	Ser	Val	Ser	Arg	Gly	Asp	Gln	Val	Ala		
	995						1000					1005					
Arg	Ile	Pro	Val	Ile	Arg	His	Ile	Leu	Asp	Asn	Gly	Lys	Ser	Gln	Val		
	1010					1015					1020						
Ser	Tyr	Ser	Thr	Gln	Asp	Asn	Thr	Ala	His	Gly	His	Arg	Asp	Tyr	Val		
1025				1030						1035					1040		
Pro	Val	Glu	Gly	Glu	Leu	Leu	Phe	His	Pro	Gly	Glu	Thr	Trp	Lys	Glu		
			1045						1050						1055		

Leu Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg
 1060 1065 1070
 Gly Arg Gln Val Arg Arg Phe Gln Val Gln Leu Ser Asn Pro Lys Phe
 1075 1080 1085
 Gly Ala Arg Leu Gly Gln Pro Ser Thr Thr Thr Val Ile Leu Asp Glu
 1090 1095 1100
 Thr Asp Arg Ser Leu Ile Asn Gln Thr Leu Ser Ser Pro Pro Pro Pro
 1105 1110 1115 1120
 His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys Ala Ala Gly
 1125 1130 1135
 Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Pro Gly Lys Pro Met
 1140 1145 1150
 Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu Ser Glu Ala
 1155 1160 1165
 His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr Asn Leu Tyr
 1170 1175 1180
 Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly Ala Lys Gly
 1185 1190 1195 1200
 Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Thr His Gln Glu Val
 1205 1210 1215
 Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser Ser Thr Val
 1220 1225 1230
 Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly Glu Ile Thr
 1235 1240 1245
 Ala Tyr Glu Val Cys Tyr Gly Leu Val Asn Glu Asp Asn Arg Pro Ile
 1250 1255 1260
 Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn Arg Met Leu
 1265 1270 1275 1280
 Leu Ile Glu Asn Leu Arg Asp Ser Gln Pro Tyr Arg Tyr Thr Val Lys
 1285 1290 1295
 Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala Ile Ile Asn
 1300 1305 1310
 Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile Ile Pro Asp
 1315 1320 1325
 Ile Pro Ile Val Asp Ala Gln Gly Gly Glu Asp Tyr Glu Asn Phe Leu
 1330 1335 1340
 Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ala Ser Ser Gln Arg Pro
 1345 1350 1355 1360
 Ser Val Ser Asp Asp Thr Glu His Leu Val Asn Gly Arg Met Asp Phe
 1365 1370 1375
 Ala Tyr Pro Gly Ser Ala Asn Ser Leu His Arg Met Thr Ala Ala Asn
 1380 1385 1390
 Val Ala Tyr Gly Thr His Leu Ser Pro His Leu Ser His Arg Val Leu
 1395 1400 1405
 Ser Thr Ser Ser Thr Leu Thr Arg Asp Tyr His Ser Leu Thr Arg Thr
 1410 1415 1420
 Glu His Ser His Ser Gly Thr Leu Pro Arg Asp Tyr Ser Thr Leu Thr
 1425 1430 1435 1440
 Ser Leu Ser Ser Gln Ala Ser Leu Leu Ser Gly Lys Met Gly Gly Ala
 1445 1450 1455
 Gly Phe Arg Cys Pro Gly Leu Leu Gly Pro
 1460 1465

<210> 9

<211> 2205

<212> DNA

<213> Artificial Sequence

<220>

 <223> Description of Artificial Sequence; Note =
 synthetic construct

```

<400> 9
atggcagggc cctgttgacg cccatgggtg aagctgctgc tgctggcacg aatgctgagt      60
gccagcctcc ctggagacct ggccaaccgc tgcaagaagg ctcagggtgaa gagctgtacc      120
gagtgcatcc ggggtggacaa gagctgtgcc tactgcacag acgagctgtt caaggagagg      180
cgctgcaaca cccaggcgga cgttctggct gcaggctgca ggggagagag catcctggtc      240
atggagagca gccttgaaat cacagagaac acccagatcg tcaccagcct gcaccgcagc      300
caggatcttc ccgaaggcct gcaagtccgg ctgaggcgagg gtgaggagcg cacgtttgtg      360
ttccagggtct ttgagcccct ggagagcccc gtggatctgt atatcctcat ggacttctcc      420
aactccatgt ctgacgatct ggacaacctc aagcagatgg ggcagaacct ggccaagatc      480
ctgcgccagc tcaccagcga ctacaccatt ggatttgga agtttgtgga caaagtacgc      540
gtcccacaga cagacatgag gcccagaaaa ctgaaggagc cctggcccaa cagtgatccc      600
ccgttctcct tcaagaacgt tatcagctta acggagaatg tggaagaatt ctggaacaaa      660
ctgcaaggag aacgcattctc aggcacacctg gacgctcctg aagggggcctt tgatgccatc      720
ctgcagacag ctgtgtgcac aagggacatt ggctggaggg ctgacagcac ccacctgtg      780
gtgttctcca ccgagtctgc cttccactac gaggctgatg gtgccaacgt tctggccggc      840
atcatgaacc gcaatgatga gaaatgccac ctggacgcct cgggccccta caccataac      900
aagacacagg actaccatc agtgcccacg ctggttcgcc tgcttgccaa gcataaacatc      960
atccccatct ttgtgtcac caactactct tacagctact atgagaagct ccataagtat      1020
ttccccgtct cctctctggg cgtcctgcag gaggattcat ccaacatcgt ggagctgtg      1080
gaggaggcct tctatcgaat tcgctccaac ctggacatcc gggctctgga cagccccaga      1140
ggcctgagaa cagaggtcac ctccgatact ctccagaaga cggagactgg gtcctttcac      1200
atcaagcggg gggaagtggg cacatacaat gtgcatctcc gggcagtggg ggacatagat      1260
gggacacatg tgtgccagct ggctaaagaa gaccaagggg gcaacatcca cctgaaaccc      1320
tccttctctg atggcctccg gatggacgag agtgtgatct gtgacgtgtg cccctgtgag      1380
ctgcaaaaagg aagtctgatc agctcgtctg cacttcagag gagacttcat gtgtggacac      1440
tgtgtgtgca atgagggctg gagggtgaaa acctgcaact gctccaccgg ctctctgagt      1500
gacacacagc cctgcctgag tgagggtagg gacaaaccgt gctcgggcca cggcgagtgc      1560
cagtgcggag ctgtgtgtg ctatggtgaa ggccgctacg agggtcactt ctgagagtat      1620
gacaacttcc agtgtccccg gacctctgga ttctgtgca atgaccgggg acgctgttct      1680
atgggagagt gtgtgtgtga gcctggttgg acaggcgca gctgcgactg tcccctcagc      1740
aatgccacct gcacgatag caacgggggc atctgcaacg gccgaggcta ctgtgagtgt      1800
ggcgttgttc actgcaacca gcagtcgctc tacacggaca ccacctgtga gatcaactac      1860
ctgcgataac tgggtctctg tgaggatctc cgctcctgag tacagtcca ggcctggggc      1920
accggggaga agaaagggcg cgcgtgtgac gattccccct ttaaagtcaa gatggtagac      1980
gagcttaaga aagaagaggt ggtggagtac tgctccttcc gggatgagga tgacgactgc      2040
acttacagct acaacgtgga gggcgacggc agccctgggc ccaacagcac agtccctggc      2100
cacaaaaaga aagactgcct cccggctcct tctgtgtggc tcatccccct gctcatcttc      2160
ctcctgttgc tctgtgcgtt gcttctgctg ctctgctgga aatga      2205

```

<210> 10

<211> 734

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 10

```

Met Ala Gly Pro Cys Cys Ser Pro Trp Val Lys Leu Leu Leu Leu Ala
 1             5             10             15
Arg Met Leu Ser Ala Ser Leu Pro Gly Asp Leu Ala Asn Arg Cys Lys
      20             25             30
Lys Ala Gln Val Lys Ser Cys Thr Glu Cys Ile Arg Val Asp Lys Ser
      35             40             45
Cys Ala Tyr Cys Thr Asp Glu Leu Phe Lys Glu Arg Arg Cys Asn Thr
      50             55             60
Gln Ala Asp Val Leu Ala Ala Gly Cys Arg Gly Glu Ser Ile Leu Val
      65             70             75             80
Met Glu Ser Ser Leu Glu Ile Thr Glu Asn Thr Gln Ile Val Thr Ser
      85             90             95

```

Leu	His	Arg	Ser	Gln	Val	Ser	Pro	Gln	Gly	Leu	Gln	Val	Arg	Leu	Arg
Arg	Gly	Glu	Glu	Arg	Thr	Phe	Val	Phe	Gln	Val	Phe	Glu	Pro	Leu	Glu
Ser	Pro	Val	Asp	Leu	Tyr	Ile	Leu	Met	Asp	Phe	Ser	Asn	Ser	Met	Ser
Asp	Asp	Leu	Asp	Asn	Leu	Lys	Gln	Met	Gly	Gln	Asn	Leu	Ala	Lys	Ile
Leu	Arg	Gln	Leu	Thr	Ser	Asp	Tyr	Thr	Ile	Gly	Phe	Gly	Lys	Phe	Val
Asp	Lys	Val	Ser	Val	Pro	Gln	Thr	Asp	Met	Arg	Pro	Glu	Lys	Leu	Lys
Glu	Pro	Trp	Pro	Asn	Ser	Asp	Pro	Pro	Phe	Ser	Phe	Lys	Asn	Val	Ile
Ser	Leu	Thr	Glu	Asn	Val	Glu	Glu	Phe	Trp	Asn	Lys	Leu	Gln	Gly	Glu
Arg	Ile	Ser	Gly	Asn	Leu	Asp	Ala	Pro	Glu	Gly	Gly	Phe	Asp	Ala	Ile
Leu	Gln	Thr	Ala	Val	Cys	Thr	Arg	Asp	Ile	Gly	Trp	Arg	Ala	Asp	Ser
Thr	His	Leu	Leu	Val	Phe	Ser	Thr	Glu	Ser	Ala	Phe	His	Tyr	Glu	Ala
Asp	Gly	Ala	Asn	Val	Leu	Ala	Gly	Ile	Met	Asn	Arg	Asn	Asp	Glu	Lys
Cys	His	Leu	Asp	Ala	Ser	Gly	Ala	Tyr	Thr	Gln	Tyr	Lys	Thr	Gln	Asp
Tyr	Pro	Ser	Val	Pro	Thr	Leu	Val	Arg	Leu	Leu	Ala	Lys	His	Asn	Ile
Ile	Pro	Ile	Phe	Ala	Val	Thr	Asn	Tyr	Ser	Tyr	Ser	Tyr	Tyr	Glu	Lys
Leu	His	Lys	Tyr	Phe	Pro	Val	Ser	Ser	Leu	Gly	Val	Leu	Gln	Glu	Asp
Ser	Ser	Asn	Ile	Val	Glu	Leu	Leu	Glu	Glu	Ala	Phe	Tyr	Arg	Ile	Arg
Ser	Asn	Leu	Asp	Ile	Arg	Ala	Leu	Asp	Ser	Pro	Arg	Gly	Leu	Arg	Thr
Glu	Val	Thr	Ser	Asp	Thr	Leu	Gln	Lys	Thr	Glu	Thr	Gly	Ser	Phe	His
Ile	Lys	Arg	Gly	Glu	Val	Gly	Thr	Tyr	Asn	Val	His	Leu	Arg	Ala	Val
Glu	Asp	Ile	Asp	Gly	Thr	His	Val	Cys	Gln	Leu	Ala	Lys	Glu	Asp	Gln
Gly	Gly	Asn	Ile	His	Leu	Lys	Pro	Ser	Phe	Ser	Asp	Gly	Leu	Arg	Met
Asp	Ala	Ser	Val	Ile	Cys	Asp	Val	Cys	Pro	Cys	Glu	Leu	Gln	Lys	Glu
Val	Arg	Ser	Ala	Arg	Cys	His	Phe	Arg	Gly	Asp	Phe	Met	Cys	Gly	His
Cys	Val	Cys	Asn	Glu	Gly	Trp	Ser	Gly	Lys	Thr	Cys	Asn	Cys	Ser	Thr
Gly	Ser	Leu	Ser	Asp	Thr	Gln	Pro	Cys	Leu	Arg	Glu	Gly	Glu	Asp	Lys
Pro	Cys	Ser	Gly	His	Gly	Glu	Cys	Gln	Cys	Gly	Arg	Cys	Val	Cys	Tyr
Gly	Glu	Gly	Arg	Tyr	Glu	Gly	His	Phe	Cys	Glu	Tyr	Asp	Asn	Phe	Gln
Cys	Pro	Arg	Thr	Ser	Gly	Phe	Leu	Cys	Asn	Asp	Arg	Gly	Arg	Cys	Ser
Met	Gly	Glu	Cys	Val	Cys	Glu	Pro	Gly	Trp	Thr	Gly	Arg	Ser	Cys	Asp
Cys	Pro	Leu	Ser	Asn	Ala	Thr	Cys	Ile	Asp	Ser	Asn	Gly	Gly	Ile	Cys

Asn Gly Arg Gly Tyr Cys Glu Cys Gly Arg Cys His Cys Asn Gln Gln
 595 600 605
 Ser Leu Tyr Thr Asp Thr Thr Cys Glu Ile Asn Tyr Ser Ala Ile Leu
 610 615 620
 Gly Leu Cys Glu Asp Leu Arg Ser Cys Val Gln Cys Gln Ala Trp Gly
 625 630 635 640
 Thr Gly Glu Lys Lys Gly Arg Ala Cys Asp Asp Cys Pro Phe Lys Val
 645 650 655
 Lys Met Val Asp Glu Leu Lys Lys Glu Glu Val Val Glu Tyr Cys Ser
 660 665 670
 Phe Arg Asp Glu Asp Asp Asp Cys Thr Tyr Ser Tyr Asn Val Glu Gly
 675 680 685
 Asp Gly Ser Pro Gly Pro Asn Ser Thr Val Leu Val His Lys Lys Lys
 690 695 700
 Asp Cys Leu Pro Ala Pro Ser Trp Trp Leu Ile Pro Leu Leu Ile Phe
 705 710 715 720
 Leu Leu Leu Leu Leu Ala Leu Leu Leu Leu Cys Trp Lys
 725 730

<210> 11

<211> 3579

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
 synthetic construct

<400> 11

atgcctgcgc	tctggctcag	ctgctgcctc	ggtgtcgcgc	tctgtctgcc	cgccagccag	60
gccacctcca	ggagggaagt	ctgtgattgc	aatgggaagt	ccaggcaatg	tgtctttgat	120
caggagctcc	atcgacaagc	aggcagcggg	ttccgttgcc	tcaactgcaa	tgacaataca	180
gcgggggttc	actgcgagcg	gtcgagggag	gggttttacc	agcatcagag	caagagccgc	240
tgctaccctt	gcaactgcc	ctcaaaggg	tccctcagtg	ctggatgtga	caactctgga	300
caatgcaggt	gtaagccagg	tgtgacagga	caaagatgtg	accagtgtca	gccaggcttc	360
catatgtctc	ccgatgtctg	atgcacccga	gaccaggggc	aactagattc	caagtgtgac	420
tgtgaccag	ctggcatctc	tggacctgt	gattctggcc	gatgtgtctg	caaaccagcc	480
gtcactggag	agcgtgtgta	taggtgccga	ccacgtgact	atcatctgga	ccgggcaaac	540
cctgagggct	gtacccagtg	tttctgctat	gggcattcag	ccagctgcca	cgctctgcc	600
gacttcagtg	tccacaaaat	cacttcaact	ttcagtcagg	atgtggatgg	ttggaaggcg	660
gttcagagaa	acggggcacc	tgcaaaactc	cactggtcac	agcggcatcg	ggacgtgttt	720
agttctgccc	gaagatcaga	ccccgtctat	ttcgtggccc	ctgccaaatt	cctcggtaac	780
cagcaagtga	gttacgggca	gagcctgtct	tttgactacc	gcgtggacag	aggaggtaga	840
cagcgtctct	cctacgatgt	gatcctggaa	ggtgtcggtc	tacagatcag	agctcctctg	900
atggctccag	gcaagacact	tccttgtggg	atcacaaaga	cttacacatt	cagactgaat	960
gaacatccaa	gcagtcactg	gagtcaccag	ctgagttatt	tcgaatatcg	aaggttactg	1020
cggaacctca	cagccctcct	gatgatccga	gctacgtacg	gagaatatag	tacagggtac	1080
attgataacg	tgacctgggt	ttcagcccg	cctgtccttg	gagccccagc	cccttgggtt	1140
gaacgttgtg	tatgcctgct	gggttacaag	ggacaattct	gccaggaatg	tgcttctggg	1200
tacaaaagag	attcggcaag	attgggcgct	tttggcgctt	gtgttccctg	taactgccaa	1260
ggggaggggg	cctgtgatcc	agacacggga	gattgctact	cgggggacga	gaatcctgac	1320
attgagtggt	ctgactgtcc	catcggtttc	tacaatgacc	cacatgaccc	ccgcagctgc	1380
agggcattgc	cctgtcacaa	tgggttcagc	tgttcagtga	tgctgagac	agaggaggtg	1440
gtgtgttaaca	actgtccccc	tggggtcaca	ggtgcccgtg	gtgagctctg	tgctgatggc	1500
ttctttgggg	atcccttttg	ggaacatggc	ccagtgaggg	cttgtcaacg	ctgccaatgc	1560
aacaacaacg	tggaccccaa	tgctctctgg	aactgtgacc	agttgacagg	cagatgcttg	1620
aaatgtatct	acaacacggc	cgtgtgtctac	tgtgaccagt	gcaaaagcagg	ttactttgga	1680
gacccatttg	ctcccaaccc	agcagacaag	tgtcagcttt	gcaactgcag	ccccatgggt	1740
gcggagcctg	gagagtgtcg	aggtgatggc	agctgtgttt	gcaagccagg	ctttggcgcc	1800
ttcaactgtg	atcacgcagc	cctaaccagt	tgtcctgctt	gctacaatca	agtgaagatt	1860
cagatggacc	agttttaccca	gcagctccag	agcctggagg	ccctgggttc	aaaggctcag	1920
ggtggtggtg	gtgggtggtac	agtccagtg	cagctggaag	gcaggatcga	gcaggctgag	1980

```

caggcccttc aggacattct gggagaagct cagatttcag aaggggcaat gagagccgtt 2040
gctgtccggc tggccaaggc aaggagccaa gagaacgact acaagaccg cctggatgac 2100
ctcaagatga ctgcagaaag gatccgggcc ctgggcagtc agcatcagaa cagagttcag 2160
gatacgaagc gactcatctc tcagatgcgc ctgagtcagg caggaagcga agctctcttg 2220
gaaaacacta atatccattc ttctgagcac tacgtggggc cgaatgattt taaaagtcctg 2280
gctcaggagg ctacaagaaa ggcagacagc cagctgagtc cagctaacgc aatgaagcaa 2340
ctagcaaggg aaactgagga ctactccaaa caagcacttt cattggcccg caagctcttg 2400
agtggaggag gcggaagtgg ctcttgggac agctccgtgg tacaaggctt tatgggaaaa 2460
ttagagaaaa ccaagtccct gagccagcag ctgtcattgg agggcaccca agccgacatt 2520
gaagctgata ggtcgtatca gcacagtctc cgctctctgg attctgcctc tcagcttcag 2580
ggagtcagtg atctgtcctt tcaggtggaa gcaaagagga tcagacaaaa ggctgattct 2640
ctctcaaaccc tggtgaccag acaaacggat gcattcacgc gtgtgcgaaa caatctgggg 2700
aactgggaaa aagaaacacg gcagcttcta cagactggaa aggataggag acagacttca 2760
gatcagctgc ttcccggtgc caaccttgct aaaaacagag cccaagaagc gctaagtatg 2820
ggcaatgcca ctttttatga agttgagaac atcctgaaga acctccgaga gtttgatctg 2880
caggttgaag acagaaaagc agaggctgaa gaggccatga agagactctc ctctattagc 2940
cagaaggttg cggatgccag tgacaagacc cagcaagcag aaacggccct ggggagcgcc 3000
actgccgaca cccaacgggc aaagaacgca gctagggagg ccctggagat cagcagcgag 3060
atagagctgg agataggag tctgaacttg gaagctaattg tgacagcaga tggggccttg 3120
gccatggaga aagggactgc cactctgaag agcgagatga gagagatgat tgagctggcc 3180
agaaaggagc tggagtttga cacggataag gacacggtgc agctgggtgat tactgaagcc 3240
cagcaagctg atgccagagc cagcagtgcc ggagttacca tccaagacac rctcaacaca 3300
ttggacggca tcctacacct catagaccag cctggcagtg tggatgaaga agggatgatg 3360
ctattagaac aagggctttt ccaagccaag acccagatca acagtcgact tcggcccttg 3420
atgtctgacc tggaggagag ggtgcgtcgg cagaggaacc acctccatct gctggagact 3480
agcatagatg gaattcttgc tgatgtgaag aacctggaga acattcgaga caacctgccc 3540
ccaggctgct acaataccca agctcttgag caacagtga 3579

```

<210> 12

<211> 1192

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 12

```

Met Pro Ala Leu Trp Leu Ser Cys Cys Leu Gly Val Ala Leu Leu Leu
1      5      10      15
Pro Ala Ser Gln Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly
20     25     30
Lys Ser Arg Gln Cys Val Phe Asp Gln Glu Leu His Arg Gln Ala Gly
35     40     45
Ser Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Ala Gly Val His
50     55     60
Cys Glu Arg Ser Arg Glu Gly Phe Tyr Gln His Gln Ser Lys Ser Arg
65     70     75     80
Cys Leu Pro Cys Asn Cys His Ser Lys Gly Ser Leu Ser Ala Gly Cys
85     90     95
Asp Asn Ser Gly Gln Cys Arg Cys Lys Pro Gly Val Thr Gly Gln Arg
100    105    110
Cys Asp Gln Cys Gln Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys
115    120    125
Thr Arg Asp Gln Gly Gln Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala
130    135    140
Gly Ile Ser Gly Pro Cys Asp Ser Gly Arg Cys Val Cys Lys Pro Ala
145    150    155    160
Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Pro Arg Asp Tyr His Leu
165    170    175
Asp Arg Ala Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His
180    185    190

```

Ser Ala Ser Cys His Ala Ser Ala Asp Phe Ser Val His Lys Ile Thr
 195 200 205
 Ser Thr Phe Ser Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn
 210 215 220
 Gly Ala Pro Ala Lys Leu His Trp Ser Gln Arg His Arg Asp Val Phe
 225 230 235 240
 Ser Ser Ala Arg Arg Ser Asp Pro Val Tyr Phe Val Ala Pro Ala Lys
 245 250 255
 Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp
 260 265 270
 Tyr Arg Val Asp Arg Gly Gly Arg Gln Pro Ser Ala Tyr Asp Val Ile
 275 280 285
 Leu Glu Gly Ala Gly Leu Gln Ile Arg Ala Pro Leu Met Ala Pro Gly
 290 295 300
 Lys Thr Leu Pro Cys Gly Ile Thr Lys Thr Tyr Thr Phe Arg Leu Asn
 305 310 315 320
 Glu His Pro Ser Ser His Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr
 325 330 335
 Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Leu Met Ile Arg Ala Thr
 340 345 350
 Tyr Gly Glu Tyr Ser Thr Gly Tyr Ile Asp Asn Val Thr Leu Val Ser
 355 360 365
 Ala Arg Pro Val Leu Gly Ala Pro Ala Pro Trp Val Glu Arg Cys Val
 370 375 380
 Cys Leu Leu Gly Tyr Lys Gly Gln Phe Cys Gln Glu Cys Ala Ser Gly
 385 390 395 400
 Tyr Lys Arg Asp Ser Ala Arg Leu Gly Ala Phe Gly Ala Cys Val Pro
 405 410 415
 Cys Asn Cys Gln Gly Glu Gly Ala Cys Asp Pro Asp Thr Gly Asp Cys
 420 425 430
 Tyr Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile
 435 440 445
 Gly Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro Cys Pro
 450 455 460
 Cys His Asn Gly Phe Ser Cys Ser Val Met Pro Glu Thr Glu Glu Val
 465 470 475 480
 Val Cys Asn Asn Cys Pro Pro Gly Val Thr Gly Ala Arg Cys Glu Leu
 485 490 495
 Cys Ala Asp Gly Phe Phe Gly Asp Pro Phe Gly Glu His Gly Pro Val
 500 505 510
 Arg Pro Cys Gln Arg Cys Gln Cys Asn Asn Asn Val Asp Pro Asn Ala
 515 520 525
 Ser Gly Asn Cys Asp Gln Leu Thr Gly Arg Cys Leu Lys Cys Ile Tyr
 530 535 540
 Asn Thr Ala Gly Val Tyr Cys Asp Gln Cys Lys Ala Gly Tyr Phe Gly
 545 550 555 560
 Asp Pro Leu Ala Pro Asn Pro Ala Asp Lys Cys Arg Ala Cys Asn Cys
 565 570 575
 Ser Pro Met Gly Ala Glu Pro Gly Glu Cys Arg Gly Asp Gly Ser Cys
 580 585 590
 Val Cys Lys Pro Gly Phe Gly Ala Phe Asn Cys Asp His Ala Ala Leu
 595 600 605
 Thr Ser Cys Pro Ala Cys Tyr Asn Gln Val Lys Ile Gln Met Asp Gln
 610 615 620
 Phe Thr Gln Gln Leu Gln Ser Leu Glu Ala Leu Val Ser Lys Ala Gln
 625 630 635 640
 Gly Gly Gly Gly Gly Thr Val Pro Val Gln Leu Glu Gly Arg Ile
 645 650 655
 Glu Gln Ala Glu Gln Ala Leu Gln Asp Ile Leu Gly Glu Ala Gln Ile
 660 665 670
 Ser Glu Gly Ala Met Arg Ala Val Ala Val Arg Leu Ala Lys Ala Arg
 675 680 685

Ser Gln Glu Asn Asp Tyr Lys Thr Arg Leu Asp Asp Leu Lys Met Thr
 690 695 700
 Ala Glu Arg Ile Arg Ala Leu Gly Ser Gln His Gln Asn Arg Val Gln
 705 710 715 720
 Asp Thr Ser Arg Leu Ile Ser Gln Met Arg Leu Ser Leu Ala Gly Ser
 725 730 735
 Glu Ala Leu Leu Glu Asn Thr Asn Ile His Ser Ser Glu His Tyr Val
 740 745 750
 Gly Pro Asn Asp Phe Lys Ser Leu Ala Gln Glu Ala Thr Arg Lys Ala
 755 760 765
 Asp Ser His Ala Glu Ser Ala Asn Ala Met Lys Gln Leu Ala Arg Glu
 770 775 780
 Thr Glu Asp Tyr Ser Lys Gln Ala Leu Ser Leu Ala Arg Lys Leu Leu
 785 790 795 800
 Ser Gly Gly Gly Gly Ser Gly Ser Trp Asp Ser Ser Val Val Gln Gly
 805 810 815
 Leu Met Gly Lys Leu Glu Lys Thr Lys Ser Leu Ser Gln Gln Leu Ser
 820 825 830
 Leu Glu Gly Thr Gln Ala Asp Ile Glu Ala Asp Arg Ser Tyr Gln His
 835 840 845
 Ser Leu Arg Leu Leu Asp Ser Ala Ser Gln Leu Gln Gly Val Ser Asp
 850 855 860
 Leu Ser Phe Gln Val Glu Ala Lys Arg Ile Arg Gln Lys Ala Asp Ser
 865 870 875 880
 Leu Ser Asn Leu Val Thr Arg Gln Thr Asp Ala Phe Thr Arg Val Arg
 885 890 895
 Asn Asn Leu Gly Asn Trp Glu Lys Glu Thr Arg Gln Leu Leu Gln Thr
 900 905 910
 Gly Lys Asp Arg Arg Gln Thr Ser Asp Gln Leu Leu Ser Arg Ala Asn
 915 920 925
 Leu Ala Lys Asn Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr
 930 935 940
 Phe Tyr Glu Val Glu Asn Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu
 945 950 955 960
 Gln Val Glu Asp Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu
 965 970 975
 Ser Ser Ile Ser Gln Lys Val Ala Asp Ala Ser Asp Lys Thr Gln Gln
 980 985 990
 Ala Glu Thr Ala Leu Gly Ser Ala Thr Ala Asp Thr Gln Arg Ala Lys
 995 1000 1005
 Asn Ala Ala Arg Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Leu Glu
 1010 1015 1020
 Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly Ala Leu
 1025 1030 1035 1040
 Ala Met Glu Lys Gly Thr Ala Thr Leu Lys Ser Glu Met Arg Glu Met
 1045 1050 1055
 Ile Glu Leu Ala Arg Lys Glu Leu Glu Phe Asp Thr Asp Lys Asp Thr
 1060 1065 1070
 Val Gln Leu Val Ile Thr Glu Ala Gln Gln Ala Asp Ala Arg Ala Thr
 1075 1080 1085
 Ser Ala Gly Val Thr Ile Gln Asp Thr Leu Asn Thr Leu Asp Gly Ile
 1090 1095 1100
 Leu His Leu Ile Asp Gln Pro Gly Ser Val Asp Glu Glu Gly Met Met
 1105 1110 1115 1120
 Leu Leu Glu Gln Gly Leu Phe Gln Ala Lys Thr Gln Ile Asn Ser Arg
 1125 1130 1135
 Leu Arg Pro Leu Met Ser Asp Leu Glu Glu Arg Val Arg Arg Gln Arg
 1140 1145 1150
 Asn His Leu His Leu Leu Glu Thr Ser Ile Asp Gly Ile Leu Ala Asp
 1155 1160 1165
 Val Lys Asn Leu Glu Asn Ile Arg Asp Asn Leu Pro Pro Gly Cys Tyr
 1170 1175 1180

Asn Thr Gln Ala Leu Glu Gln Gln
1185 1190

<210> 13
<211> 3582
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence; Note =
synthetic construct

```

<400> 13
atgcctgcgc tctggctggg ctgctgcctc tgcttctcgc tcctcctgcc cgcagcccgg      60
gccacctcca ggagggaagt ctgtgattgc aatgggaagt ccaggcagtg tatctttgat      120
cgggaacttc acagacaaac tggtaatgga ttccgctgcc tcaactgcaa tgacaacact      180
gatggcattc actcgcagaa gtgcaagaat ggcttttacc ggcacagaga aaggggaccgc      240
tgtttgcctt gcaattgtaa ctccaaaggc tctcttagtg ctgatgtga caactctgga      300
cgggtgcagct gtaaacaggg tgtgacagga gccagatgag accgatgtct gccaggcttc      360
cacatgctca cggatgcggg gtgcacccaa gaccagagac tgctagactc caagtgtgac      420
tgtgacccag ctggcatcgc agggccctgt gacgcgggac gctgtgtctg caagccagct      480
gttactggag aacgctgtga taggtgtcga tcaggttact ataactctgga tggggggaac      540
cctgagggct gtacccagtg tttctgctat gggcattcag ccagctgccg cagctctgca      600
gaatacagtg tccataagat cacctctacc tttcatcaag atgttgatgg ctggaaggct      660
gtccaacgaa atgggtctcc tgcaaaagtc caatggtcac agcgccatca agatgtgttt      720
agctcagccc aacgactaga ccctgtctat tttgtggctc ctgccaaatt tcttgggaat      780
caacagggtga gctatgggca aagcctgtcc tttgactacc gtgtggacag aggaggcaga      840
caccatctcg cccatgatgt gattctggaa ggtgctggtc tacggatcac agctcccttg      900
atgccacttg gcaagacact gccttggtgg ctaccaaga cttaacacatt cagggttaaat      960
gagcatccaa gcaataattg gagccccag ctgagttact ttgagtatcg aaggttactg     1020
cggaaatctca cagccctccg catccgagct acatatggag aatacagtac tgggtacatt     1080
gacaatgtga cctgatttc agcccgccct gtctctggag cccagcacc ctgggtgaa     1140
cagtgatatat gtctgttggt gtacaagggt caattctgcc aggatgtgac tctctgttac     1200
aagagagatt cagcgagact ggggcctttt ggcacctgta ttccttgtaa ctgtcaaggg     1260
ggaggggcct gtgatccaga cacaggagat tgtatttcag gggatgagaa tcctgacatt     1320
gagtggtgctg actgcccatt tggtttctac aacgatccgc acgacccccg cagctgcaag     1380
ccatgtccct gtcataacgg gttcagctgc tcagtgtatg cggagacgga ggaggtggtg     1440
tgcaataact gcccctcccg ggtcacccgt gcccgctgtg agctctgtgc tgatggctac     1500
tttggggacc cctttggtga acatggccca gtgaggcctt gtcagccctg tcaatgcaac     1560
aacaatgttg accccagtgct ctctgggaat tgtgaccggc tgacaggcag gtgtttgaag     1620
tgtatccaca acacagcccg catctactgc gaccagtgca aagcaggcta cttcggggac     1680
ccattggctc ccaaccagc agacaagtgt cgagcttgca actgtaaccc catgggctca     1740
gagcctgtag gatgtcgaag tgatggcacc tbtgtttgca agccaggatt tgggtgcccc     1800
aactgtgagc atggagcatt cagctgtcca gcttgcata atcaagtga gattcagatg     1860
gatcagttta tgcagcagct tcagagaatg gaggccctga tttcaaaggc tcagggtggt     1920
gatggagtag tacctgatac agagctggaa ggcaggatgc agcaggctga gcaggccctt     1980
caggacattc tgagagatgc ccagatttca gaaggtgcta gcagatccct tggctccag     2040
ttggccaagg tgaggagcca agagaacagc taccagagcc gctggatga cctcaagatg     2100
actgtgaaaa gagttcgggc tctgggaagt cagtaccaga accgagttcg ggatactcac     2160
aggctcatca ctcatatgca gctgagcctg gcagaaagtg aagcttccctt gggaaacact     2220
aacattccctg cctcagacca ctacgtgggg ccaaattggct ttaaaagtct ggctcaggag     2280
gccacaagat tagcagaaaag ccacgittgag tcagccagta acatggagca actgacaagg     2340
gaaactgagg actattccaa acaagccctc tcaactggtgc gcaaggccct gcatgaagga     2400
gtcggaaagcg gaagcggtag ccgggacggt gctgtggtgc aagggcttgt ggaaaaattg     2460
gagaaaacca agtccctggc ccagcagttg acaaggaggg ccactcaagc ggaaattgaa     2520
gcagataggt cttatcagca cagtctccgc ctctggatt cagtgtctcg gcttcaggga     2580
gtcagtgatc agtcccttca ggtggaagaa gcaaagagga tcaaaacaaa agcggattca     2640
ctctcaacgc tggtaaccag gcatatggat gaggttcaag gtacacaaaa gaatctggga     2700
aactggaagc aagaagcaca gcagctctta cagaattgaa aaagtgggag agagaaatca     2760
gatcagctgc tttcccgctg caatcttgct aaaagcagag cacaagaagc actgagtatg     2820
ggcaatgcc a ttttttatga agttgagagc atcttataaa acctcagaga gtttgacctg     2880
caggtggaca acagaaaagc agaagctgaa gaagccatga agagactctc ctacatcagc     2940

```

```

cagaaggttt cagatgccag tgacaagacc cagcaagcag aaagagccct ggggagcgct 3000
gctgctgatg cacagagggc aaagaatggg gccggggagg ccctggaaat ctccagtggag 3060
attgaacagg agattgggag tctgaacttg gaagccaatg tgacagcaga tggagccttg 3120
gccatggaaa agggactggc ctctctgaag agtgagatga ggggaagtga aggagagctg 3180
gaaaggaagg agctggagtt tgacacgaat atggatgcag tacagatggg gattacagaa 3240
gcccagaagg ttgataccag agccaagaac gctgggggta caatccaaga cacactcaac 3300
acattagacg gcctcctgca tctgatggac cagcctctca gtgtagatga agaggggctg 3360
gtcttactgg agcagaagct ttcccagacc aagaccaga tcaacagcca actgcggccc 3420
atgatgtcag agctggaaga gagggcacgt cagcagaggg gccacctcca tttgctggag 3480
acaagcatag atgggattct ggctgatgtg aagaacttg agaacattag ggacaacctg 3540
ccccaggct gctacaatac ccaggctctt gagcaacagt ga 3582

```

<210> 14

<211> 1193

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 14

```

Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu
1          5          10          15
Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly
20          25          30
Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly
35          40          45
Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His
50          55          60
Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg
65          70          75          80
Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys
85          90          95
Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg
100         105         110
Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys
115         120         125
Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala
130         135         140
Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala
145         150         155         160
Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu
165         170         175
Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His
180         185         190
Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr
195         200         205
Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn
210         215         220
Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe
225         230         235         240
Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys
245         250         255
Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp
260         265         270
Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile
275         280         285
Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly
290         295         300
Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn
305         310         315         320

```



```

Val Glu Lys Leu Glu Lys Thr Lys Ser Leu Ala Gln Gln Leu Thr Arg
      820      825      830
Glu Ala Thr Gln Ala Glu Ile Glu Ala Asp Arg Ser Tyr Gln His Ser
      835      840      845
Leu Arg Leu Leu Asp Ser Val Ser Arg Leu Gln Gly Val Ser Asp Gln
      850      855      860
Ser Phe Gln Val Glu Glu Ala Lys Arg Ile Lys Gln Lys Ala Asp Ser
      865      870      875      880
Leu Ser Thr Leu Val Thr Arg His Met Asp Glu Phe Lys Arg Thr Gln
      885      890      895
Lys Asn Leu Gly Asn Trp Lys Glu Glu Ala Gln Gln Leu Leu Gln Asn
      900      905      910
Gly Lys Ser Gly Arg Glu Lys Ser Asp Gln Leu Leu Ser Arg Ala Asn
      915      920      925
Leu Ala Lys Ser Arg Ala Gln Glu Ala Leu Ser Met Gly Asn Ala Thr
      930      935      940
Phe Tyr Glu Val Glu Ser Ile Leu Lys Asn Leu Arg Glu Phe Asp Leu
      945      950      955      960
Gln Val Asp Asn Arg Lys Ala Glu Ala Glu Glu Ala Met Lys Arg Leu
      965      970      975
Ser Tyr Ile Ser Gln Lys Val Ser Asp Ala Ser Asp Lys Thr Gln Gln
      980      985      990
Ala Glu Arg Ala Leu Gly Ser Ala Ala Ala Asp Ala Gln Arg Ala Lys
      995      1000      1005
Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln Glu
      1010      1015      1020
Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly Ala Leu
      1025      1030      1035      1040
Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met Arg Glu Val
      1045      1050      1055
Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp Thr Asn Met Asp
      1060      1065      1070
Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys Val Asp Thr Arg Ala
      1075      1080      1085
Lys Asn Ala Gly Val Thr Ile Gln Asp Thr Leu Asn Thr Leu Asp Gly
      1090      1095      1100
Leu Leu His Leu Met Asp Gln Pro Leu Ser Val Asp Glu Glu Gly Leu
      1105      1110      1115      1120
Val Leu Leu Glu Gln Lys Leu Ser Arg Ala Lys Thr Gln Ile Asn Ser
      1125      1130      1135
Gln Leu Arg Pro Met Met Ser Glu Leu Glu Glu Arg Ala Arg Gln Gln
      1140      1145      1150
Arg Gly His Leu His Leu Leu Glu Thr Ser Ile Asp Gly Ile Leu Ala
      1155      1160      1165
Asp Val Lys Asn Leu Glu Asn Ile Arg Asp Asn Leu Pro Pro Gly Cys
      1170      1175      1180
Tyr Asn Thr Gln Ala Leu Glu Gln Gln
      1185      1190

```

<210> 15

<211> 1111

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 15

```

Met Pro Ala Leu Trp Leu Gly Cys Cys Leu Cys Phe Ser Leu Leu Leu
  1           5           10           15

```

Pro Ala Ala Arg Ala Thr Ser Arg Arg Glu Val Cys Asp Cys Asn Gly
 20 25 30
 Lys Ser Arg Gln Cys Ile Phe Asp Arg Glu Leu His Arg Gln Thr Gly
 35 40 45
 Asn Gly Phe Arg Cys Leu Asn Cys Asn Asp Asn Thr Asp Gly Ile His
 50 55 60
 Cys Glu Lys Cys Lys Asn Gly Phe Tyr Arg His Arg Glu Arg Asp Arg
 65 70 75 80
 Cys Leu Pro Cys Asn Cys Asn Ser Lys Gly Ser Leu Ser Ala Arg Cys
 85 90 95
 Asp Asn Ser Gly Arg Cys Ser Cys Lys Pro Gly Val Thr Gly Ala Arg
 100 105 110
 Cys Asp Arg Cys Leu Pro Gly Phe His Met Leu Thr Asp Ala Gly Cys
 115 120 125
 Thr Gln Asp Gln Arg Leu Leu Asp Ser Lys Cys Asp Cys Asp Pro Ala
 130 135 140
 Gly Ile Ala Gly Pro Cys Asp Ala Gly Arg Cys Val Cys Lys Pro Ala
 145 150 155 160
 Val Thr Gly Glu Arg Cys Asp Arg Cys Arg Ser Gly Tyr Tyr Asn Leu
 165 170 175
 Asp Gly Gly Asn Pro Glu Gly Cys Thr Gln Cys Phe Cys Tyr Gly His
 180 185 190
 Ser Ala Ser Cys Arg Ser Ser Ala Glu Tyr Ser Val His Lys Ile Thr
 195 200 205
 Ser Thr Phe His Gln Asp Val Asp Gly Trp Lys Ala Val Gln Arg Asn
 210 215 220
 Gly Ser Pro Ala Lys Leu Gln Trp Ser Gln Arg His Gln Asp Val Phe
 225 230 235 240
 Ser Ser Ala Gln Arg Leu Asp Pro Val Tyr Phe Val Ala Pro Ala Lys
 245 250 255
 Phe Leu Gly Asn Gln Gln Val Ser Tyr Gly Gln Ser Leu Ser Phe Asp
 260 265 270
 Tyr Arg Val Asp Arg Gly Gly Arg His Pro Ser Ala His Asp Val Ile
 275 280 285
 Leu Glu Gly Ala Gly Leu Arg Ile Thr Ala Pro Leu Met Pro Leu Gly
 290 295 300
 Lys Thr Leu Pro Cys Gly Leu Thr Lys Thr Tyr Thr Phe Arg Leu Asn
 305 310 315 320
 Glu His Pro Ser Asn Asn Trp Ser Pro Gln Leu Ser Tyr Phe Glu Tyr
 325 330 335
 Arg Arg Leu Leu Arg Asn Leu Thr Ala Leu Arg Ile Arg Ala Thr Tyr
 340 345 350
 Gly Glu Tyr Ser Thr Gly Tyr Ile Asp Asn Val Thr Leu Ile Ser Ala
 355 360 365
 Arg Pro Val Ser Gly Ala Pro Ala Pro Trp Val Glu Gln Cys Ile Cys
 370 375 380
 Pro Val Gly Tyr Lys Gly Gln Phe Cys Gln Asp Cys Ala Ser Gly Tyr
 385 390 395 400
 Lys Arg Asp Ser Ala Arg Leu Gly Pro Phe Gly Thr Cys Ile Pro Cys
 405 410 415
 Asn Cys Gln Gly Gly Gly Ala Cys Asp Pro Asp Thr Gly Asp Cys Tyr
 420 425 430
 Ser Gly Asp Glu Asn Pro Asp Ile Glu Cys Ala Asp Cys Pro Ile Gly
 435 440 445
 Phe Tyr Asn Asp Pro His Asp Pro Arg Ser Cys Lys Pro Cys Pro Cys
 450 455 460
 His Asn Gly Phe Ser Cys Ser Val Met Pro Glu Thr Glu Glu Val Val
 465 470 475 480
 Cys Asn Asn Cys Pro Gly Val Thr Gly Ala Arg Cys Glu Leu Cys
 485 490 495
 Ala Asp Gly Tyr Phe Gly Asp Pro Phe Gly Glu His Gly Pro Val Arg
 500 505 510

Pro	Cys	Gln	Pro	Cys	Gln	Cys	Asn	Asn	Asn	Val	Asp	Pro	Ser	Ala	Ser
		515					520					525			
Gly	Asn	Cys	Asp	Arg	Leu	Thr	Gly	Arg	Cys	Leu	Lys	Cys	Ile	His	Asn
		530					535				540				
Thr	Ala	Gly	Ile	Tyr	Cys	Asp	Gln	Cys	Lys	Ala	Gly	Tyr	Phe	Gly	Asp
					550					555					560
Pro	Leu	Ala	Pro	Asn	Pro	Ala	Asp	Lys	Cys	Arg	Ala	Cys	Asn	Cys	Asn
				565					570						575
Pro	Met	Gly	Ser	Glu	Pro	Val	Gly	Cys	Arg	Ser	Asp	Gly	Thr	Cys	Val
			580					585					590		
Cys	Lys	Pro	Gly	Phe	Gly	Gly	Pro	Asn	Cys	Glu	His	Gly	Ala	Phe	Ser
		595					600					605			
Cys	Pro	Ala	Cys	Tyr	Asn	Gln	Val	Lys	Ile	Gln	Met	Asp	Gln	Phe	Met
		610				615					620				
Gln	Gln	Leu	Gln	Arg	Met	Glu	Ala	Leu	Ile	Ser	Lys	Ala	Gln	Gly	Gly
					630					635					640
Asp	Gly	Val	Val	Pro	Asp	Thr	Glu	Leu	Glu	Gly	Arg	Met	Gln	Gln	Ala
				645						650					655
Glu	Gln	Ala	Leu	Gln	Asp	Ile	Leu	Arg	Asp	Ala	Gln	Ile	Ser	Glu	Gly
			660					665					670		
Ala	Ser	Arg	Ser	Leu	Gly	Leu	Gln	Leu	Ala	Lys	Val	Arg	Ser	Gln	Glu
		675					680						685		
Asn	Ser	Tyr	Gln	Ser	Arg	Leu	Asp	Asp	Leu	Lys	Met	Thr	Val	Glu	Arg
		690				695					700				
Val	Arg	Ala	Leu	Gly	Ser	Gln	Tyr	Gln	Asn	Arg	Val	Arg	Asp	Thr	His
				710						715					720
Arg	Leu	Ile	Thr	Gln	Met	Gln	Leu	Ser	Leu	Ala	Glu	Ser	Glu	Ala	Ser
				725						730					735
Leu	Gly	Asn	Thr	Asn	Ile	Pro	Ala	Ser	Asp	His	Tyr	Val	Gly	Pro	Asn
			740					745					750		
Gly	Phe	Lys	Ser	Leu	Ala	Gln	Glu	Ala	Thr	Arg	Leu	Ala	Glu	Ser	His
		755					760					765			
Val	Glu	Ser	Ala	Ser	Asn	Met	Glu	Gln	Leu	Thr	Arg	Glu	Thr	Glu	Asp
		770				775					780				
Tyr	Ser	Lys	Gln	Ala	Leu	Ser	Leu	Val	Arg	Lys	Ala	Leu	His	Glu	Gly
				790						795					800
Val	Gly	Ser	Gly	Ser	Gly	Ser	Pro	Asp	Gly	Ala	Val	Val	Gln	Gly	Leu
				805					810						815
Val	Glu	Lys	Leu	Glu	Lys	Thr	Lys	Ser	Leu	Ala	Gln	Gln	Leu	Thr	Arg
			820					825					830		
Glu	Ala	Thr	Gln	Ala	Glu	Ile	Glu	Ala	Asp	Arg	Ser	Tyr	Gln	His	Ser
							840					845			
Leu	Arg	Leu	Leu	Asp	Ser	Val	Ser	Arg	Leu	Gln	Gly	Val	Ser	Asp	Gln
						855					860				
Ser	Phe	Gln	Val	Glu	Glu	Ala	Lys	Arg	Ile	Lys	Gln	Lys	Ala	Asp	Ser
				870						875					880
Leu	Ser	Thr	Leu	Val	Thr	Arg	His	Met	Asp	Glu	Phe	Lys	Arg	Thr	Gln
				885					890						895
Lys	Asn	Leu	Gly	Asn	Trp	Lys	Glu	Glu	Ala	Gln	Gln	Leu	Leu	Gln	Asn
			900					905					910		
Gly	Lys	Ser	Gly	Arg	Glu	Lys	Ser	Asp	Gln	Leu	Leu	Ser	Arg	Ala	Asn
			915				920					925			
Leu	Ala	Lys	Ser	Arg	Ala	Gln	Glu	Ala	Leu	Ser	Met	Gly	Asn	Ala	Thr
						935					940				
Phe	Tyr	Glu	Val	Glu	Ser	Ile	Leu	Lys	Asn	Leu	Arg	Glu	Phe	Asp	Leu
					950					955					960
Gln	Val	Asp	Asn	Arg	Lys	Ala	Glu	Ala	Glu	Glu	Ala	Met	Lys	Arg	Leu
				965					970						975
Ser	Tyr	Ile	Ser	Gln	Lys	Val	Ser	Asp	Ala	Ser	Asp	Lys	Thr	Gln	Gln
				980				985					990		
Ala	Glu	Arg	Ala	Leu	Gly	Ser	Ala	Ala	Ala	Asp	Ala	Gln	Arg	Ala	Lys
				995				1000					1005		

Asn Gly Ala Gly Glu Ala Leu Glu Ile Ser Ser Glu Ile Glu Gln Glu
 1010 1015 1020
 Ile Gly Ser Leu Asn Leu Glu Ala Asn Val Thr Ala Asp Gly Ala Leu
 1025 1030 1035 1040
 Ala Met Glu Lys Gly Leu Ala Ser Leu Lys Ser Glu Met Arg Glu Val
 1045 1050 1055
 Glu Gly Glu Leu Glu Arg Lys Glu Leu Glu Phe Asp Thr Asn Met Asp
 1060 1065 1070
 Ala Val Gln Met Val Ile Thr Glu Ala Gln Lys Val Asp Thr Arg Ala
 1075 1080 1085
 Lys Asn Ala Gly Val Thr Ile Gln Asp Thr Leu Asn Thr Leu Asp Gly
 1090 1095 1100
 Leu Leu His Leu Met Gly Met
 1105 1110

<210> 16

<211> 5622

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
 synthetic construct

<400> 16

atggcagcgc	cacgccccag	cccatgggccc	aggctgctcc	tggcagcctt	gatcagcgtc	60
agcctctctg	ggaccttgaa	ccgctgcaag	aaggccccag	tgaagagctg	cacggagtgt	120
gtccgtgtgg	ataaggactg	cgccactatgc	acagacgaga	tggtcaggga	ccggcgctgc	180
aacacccagg	cggagctgct	ggccgcgggc	tgccagcggg	agagcatcgt	ggtcatggag	240
agcagcttcc	aaatcacaga	ggagaccacg	attgacacca	ccctgcggcg	cagccagatg	300
tcccccaag	gcctgcgggt	ccgtctgcgg	cccggtgagg	agcggcattt	tgagctggag	360
gtgtttgagc	cactggagag	ccccgtggac	ctgtacatcc	tcattggactt	ctccaactcc	420
atgtccgatg	atctggacaa	cctcaagaag	atggggcaga	acctggctcg	ggtcctgagc	480
cagctcacca	gcgactacac	tattggattt	ggcaagtttg	tggacaaagt	cagcgtcccc	540
cagacggaca	tgaggcctga	gaagctgaag	gagccttggc	ccaacagtga	cccccccttc	600
tccttcaaga	acgtcatcag	cctgacagaa	gatgtggatg	agttccggaa	taaaactgcag	660
ggagagcggg	tctcaggcaa	cctggatgct	cctgagggcg	gcttcgatgc	catcctgcag	720
acagctgtgt	gcacgaggga	cattggcttg	cgccccgaca	gcacccacct	gctggctctc	780
tccaccgagt	cagccttcca	ctatgaggct	gatggcgcca	acgtgctggc	tggcatcatg	840
agccgcaacg	atgaacgggtg	ccacctggac	accacgggca	cctacaccca	gtacaggaca	900
caggactacc	cgctcggtgcc	cacctgggtg	cgctgctcg	ccaagcaca	catcatcccc	960
atcttctgct	ctcacaacta	ctcctatagc	tactacagag	agcttcacac	ctatttccct	1020
gtctcctcac	tgggggtgct	gcaggaggac	tcgtccaaca	tcgtggagct	gctggaggag	1080
gccttcaatc	ggatccgctc	caacctggac	atccggggcc	tagacagccc	ccgaggcctt	1140
cggacagagg	tcacctccaa	gatgttccag	aagacgagga	ctgggtcctt	tcacatccgg	1200
cggggggaag	tgggtatata	ccaggtgcag	ctgcggggcc	ttgagcacgt	ggatgggacg	1260
cacgtgtgcc	agctgccgga	ggaccagaag	ggcaacatcc	atctgaaacc	ttccttctcc	1320
gacggcctca	agatggagcg	gggcatcatc	tgtgatgtgt	gcacctgcga	gctgcaaaaa	1380
gaggtgcggg	cagctcgctg	cagcttcaac	ggagacttcg	tgtgcggaca	gtgtgtgtgc	1440
agcaggggct	ggagtggcca	gacctgcaac	tgctccaccg	gctctctgag	tgacattcag	1500
ccctgcctgc	gggagggcga	ggacaagccg	tgctccggcc	gtggggagtg	ccagtgcggg	1560
cactgtgtgt	gctacggcga	aggccgctac	gagggtcagt	tctgcgagta	tgacaacttc	1620
cagtgctccc	gctactccgg	gttccctctg	aatgaccgag	gacgctgtct	catgggccag	1680
tgtgtgtgtg	agcctgggtg	gacaggccca	agctgtgact	gtccccctcag	caatgccacc	1740
tgcatcgaca	gcaatggggg	catctgtaat	ggacgtggcc	actgtgagtg	tggccgctgc	1800
cactgccacc	agcagtcgct	ctacacggac	accatctgcg	agatcaacta	ctcggcgctc	1860
acccgggcct	ctgcgaggac	ctacgctcct	gcgtgcagtg	ccaggcgtgg	ggcaccggcg	1920
agaagaaggg	gcgcacgtgt	gaggaatgca	acttcaaagg	caagatggtg	gacgagctta	1980
agagaggcga	ggaggtgggtg	gtgcgctgct	ccttccggga	cgaggatgac	gactgcacct	2040
acagctacac	catggaagggt	gacggcgccc	ctgggcccga	cagcactgtc	ctggtgcaca	2100
agaagaaggg	actgccctcc	gggctccttc	tggtggctca	tccccctgct	cctcctcctc	2160
ctgccgctcc	tggccctgct	actgctgcta	tgctggaagt	actgtgcctg	ctgcaaggcc	2220

tgcctggcac	ttctcccggtg	ctgcaaccga	ggtcacatgg	tgggctttaa	ggaagaccac	2280
tacatgctgc	gggagaacct	gatggcctct	gaccacttgg	acacgcccac	gctgcgcagc	2340
gggaacctca	agggccgtga	cgtgggtccgc	tggaaaggtca	ccaacaacat	gcagcggcct	2400
ggcttttgcca	ctcatgcccgc	cagcatcaac	cccacagagc	tgggtcccta	cgggctgtcc	2460
ttgcgcctgg	cccgcctttg	caccgagaac	ctgctgaagc	ctgacactcg	ggagtgcgcc	2520
cagctgcgcc	aggaggtgga	ggagaacctg	aacgaggtct	acaggcagat	ctccggtgta	2580
cacaagctcc	agcagaccaa	gttccggcag	cagcccaatg	ccgggaaaaa	gcaagaccac	2640
accattgtgg	acacagtgtc	gatggcgccc	cgctcgccca	agccggccct	gctgaagctt	2700
acagagaagc	aggtggaaca	gagggccttc	cacgacctca	aggtggcccc	cggctactac	2760
accctcactg	cagaccagga	cgcccggggc	atggtggagt	tccaggaggg	cgtggagctg	2820
gtggacgtac	gggtgccctt	ctttatccgg	cctgaggatg	acgacgagaa	gcagctgctg	2880
gtggaggcca	tcgacgtgcc	cgcaggcact	gccacctcgc	gccgccgccc	ggtaaaccatc	2940
accatcatca	aggagcaagc	cagagacgtg	gtgtcctttg	agcagcctga	gttctcggtc	3000
agccgcgggg	accaggtggc	ccgcatccct	gtcatccggc	gtgtcctgga	cggcggaag	3060
tcccaggctc	cctaccgcac	acaggatggc	accgcgcagg	gcaaccggga	ctacatcccc	3120
gtggagggtg	agctgctgtt	ccagcctggg	gaggcctgga	aagagctgca	ggtgaagctc	3180
ctggagctgc	aagaagtga	ctccctcctg	cggggccgcc	aggtccgccc	tttccacgtc	3240
cagctcagca	accctaagtt	tggggcccac	ctgggcccag	cccactccac	caccatcatc	3300
atcaggggacc	cagatgaact	ggaccggagc	ttcacgagtc	agatgttgtc	atcacagcca	3360
ccccctcacg	gcgacctggg	cgccccgcag	aaccccaatg	ctaaggccgc	tgggtccagg	3420
aagatccatt	tcaactggct	gcccccttct	ggcaagccaa	tggggtagac	ggtaaagtac	3480
tggattcagg	gtgactccga	atccgaagcc	cacctgctcg	acagcaaggt	gccctcagtg	3540
gagctcacca	acctgtacct	gtattgcgac	tatgagatga	aggtgtgcgc	ctacggggct	3600
caggggcagg	gaccctacag	ctccctgggtg	tcctgccgca	cccaccagga	agtgccccagc	3660
gagccagggc	gtctggcctt	caatgtcgtc	tcctccacgg	tgaccacagct	gagctgggct	3720
gagccggctg	agaccaacgg	tgagatcaca	gcctacgagg	tctgctatgg	cctggtcaac	3780
gatgacaacc	gacctattgg	gccccatgaag	aaagtgtcgg	ttgacaaccc	taagaaccgg	3840
atgctgctta	ttgagaacct	tcgggagttc	cagccctacc	gctacacggt	gaaggcgctc	3900
aacggggccg	gctggggggc	tgagcggggg	gccatcatca	acctggccac	ccagcccaag	3960
aggcccatgt	ccatccccat	catccctgac	atccctatcg	tggacgccc	gagcggggag	4020
gactacgaca	gcttccttat	gtacagcgat	gacgttctac	gctctccatc	gggcagccag	4080
aggcccagcg	tctccgatga	cactggctgc	ggctggaagt	tcgagccctc	gctgggggag	4140
gagctggacc	tgcggcgcgt	caagtggcgg	ctgccccggg	agctcatccc	gcgcctgtcg	4200
gccagcagcg	ggcgctcctc	cgacgcggag	gcgccccacg	ggcccccgga	cgacggcggc	4260
gcggggcgga	agggcggcag	cctgccccgc	agtgcgacac	ccgggcccc	cggagagcac	4320
ctggtgaatg	gccggatgga	ctttgccttc	ccgggcagca	ccaactccct	gcacaggatg	4380
accacgacca	gtgctgctgc	ctatggcacc	cacctgagcc	cacacgtgcc	ccaccgcgtg	4440
ctaagcacat	ccctcaccct	cacacgggac	tacaactcac	tgaccgcgtc	agaacactca	4500
cactcgacca	cactgccgag	ggactactcc	accctcacct	ccgtctcctc	ccacggcctc	4560
cctcccatct	gggaacacgg	gaggagcagg	cttccgctgt	cctgggccc	gggttcccgg	4620
agtcgggctc	agatgaaagg	gttccccctt	tccaggggcc	cacgagactc	tataatcctg	4680
gctgggaggc	cagcagcgcc	ctcctggggc	ccagactctc	gcctgactgc	tgggtgtgcc	4740
gacacgcccc	ccgcctgggt	gttctctgcc	ctggggccca	catctctcag	agtgagctgg	4800
caggagccgc	ggtgcgagcg	gccgctgcag	ggctacagtg	tggagtacca	gctgctgaac	4860
ggcgggtgagc	tgcatcggtc	caacatcccc	aaccctgccc	agacctcggt	ggtggtggaa	4920
gacctcctgc	ccaaccactc	ctacgtgttc	cgctgcggg	cccagagcca	ggaaggctgg	4980
ggccgagagc	gtgagggtgt	catcaccatt	gaatcccagg	tgaccccgca	gagcccactg	5040
tgtccccctgc	caggctccgc	cttcaactttg	agcaactccc	gtgccccagg	cccgctggtg	5100
ttcactgccc	tgagccacga	ctcgctgcag	ctgagctggg	agcggccacg	gaggcccaat	5160
ggggatatcg	tcggctacct	ggtgacctgt	gagatggccc	aaggaggagg	tccagccacc	5220
gcattccggg	tggatggaga	cagccccgag	agccggctga	ccgtgcgggg	cctcagcgag	5280
aacgtgccct	acaagttcaa	ggtgcaggcc	aggaccactg	agggcttcgg	gccagagcgc	5340
gagggcacat	tcaccataga	gtcccaggat	ggaggtccct	tcccgagct	gggcagccgt	5400
gccgggctct	tccagcacc	gctgcaaaagc	gagttacagca	gcattctccac	caccacacac	5460
agcgccaccg	agcccttcc	agtgggtccg	accctggggg	cccagcacct	ggaggcaggc	5520
ggctccctca	cccgcatgt	gaccaggag	tttgtgagcc	ggacactgac	caccagcgga	5580
acccttagca	cccatatgga	ccaacagttc	ttccaaactt	ga		5622

<210> 17

<211> 1873

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 17

Met	Ala	Gly	Pro	Arg	Pro	Ser	Pro	Trp	Ala	Arg	Leu	Leu	Leu	Ala	Ala	1	5	10	15
Leu	Ile	Ser	Val	Ser	Leu	Ser	Gly	Thr	Leu	Asn	Arg	Cys	Lys	Lys	Ala	20	25	30	35
Pro	Ile	Lys	Ser	Cys	Thr	Glu	Cys	Val	Arg	Val	Asp	Lys	Asp	Cys	Ala	40	45	50	55
Tyr	Cys	Thr	Asp	Glu	Met	Phe	Arg	Asp	Arg	Arg	Cys	Asn	Thr	Gln	Ala	60	65	70	75
Glu	Leu	Leu	Ala	Ala	Gly	Cys	Gln	Arg	Glu	Ser	Ile	Val	Val	Met	Glu	80	85	90	95
Ser	Ser	Phe	Gln	Ile	Thr	Glu	Glu	Thr	Gln	Ile	Asp	Thr	Thr	Leu	Arg	100	105	110	115
Arg	Ser	Gln	Met	Ser	Pro	Gln	Gly	Leu	Arg	Val	Arg	Leu	Arg	Pro	Gly	120	125	130	135
Glu	Glu	Arg	His	Phe	Glu	Leu	Glu	Val	Phe	Glu	Pro	Leu	Glu	Ser	Pro	140	145	150	155
Val	Asp	Leu	Tyr	Ile	Leu	Met	Asp	Phe	Ser	Asn	Ser	Met	Ser	Asp	Asp	160	165	170	175
Leu	Asp	Asn	Leu	Lys	Lys	Met	Gly	Gln	Asn	Leu	Ala	Arg	Val	Leu	Ser	180	185	190	195
Gln	Leu	Thr	Ser	Asp	Tyr	Thr	Ile	Gly	Phe	Gly	Lys	Phe	Val	Asp	Lys	200	205	210	215
Val	Ser	Val	Pro	Gln	Thr	Asp	Met	Arg	Pro	Glu	Lys	Leu	Lys	Glu	Pro	220	225	230	235
Trp	Pro	Asn	Ser	Asp	Pro	Pro	Phe	Ser	Phe	Lys	Asn	Val	Ile	Ser	Leu	240	245	250	255
Thr	Glu	Asp	Val	Asp	Glu	Phe	Arg	Asn	Lys	Leu	Gln	Gly	Glu	Arg	Ile	260	265	270	275
Ser	Gly	Asn	Leu	Asp	Ala	Pro	Glu	Gly	Gly	Phe	Asp	Ala	Ile	Leu	Gln	280	285	290	295
Thr	Ala	Val	Cys	Thr	Arg	Asp	Ile	Gly	Trp	Arg	Pro	Asp	Ser	Thr	His	300	305	310	315
Leu	Leu	Val	Phe	Ser	Thr	Glu	Ser	Ala	Phe	His	Tyr	Glu	Ala	Asp	Gly	320	325	330	335
Ala	Asn	Val	Leu	Ala	Gly	Ile	Met	Ser	Arg	Asn	Asp	Glu	Arg	Cys	His	340	345	350	355
Leu	Asp	Thr	Thr	Gly	Thr	Tyr	Thr	Gln	Tyr	Arg	Thr	Gln	Asp	Tyr	Pro	360	365	370	375
Ser	Val	Pro	Thr	Leu	Val	Arg	Leu	Leu	Ala	Lys	His	Asn	Ile	Ile	Pro	380	385	390	395
Ile	Phe	Ala	Val	Thr	Asn	Tyr	Ser	Tyr	Ser	Tyr	Tyr	Glu	Lys	Leu	His	400	405	410	415
Thr	Tyr	Phe	Pro	Val	Ser	Ser	Leu	Gly	Val	Leu	Gln	Glu	Asp	Ser	Ser	420	425	430	435
Asn	Ile	Val	Glu	Leu	Leu	Glu	Glu	Ala	Phe	Asn	Arg	Ile	Arg	Ser	Asn	440	445	450	455
Leu	Asp	Ile	Arg	Ala	Leu	Asp	Ser	Pro	Arg	Gly	Leu	Arg	Thr	Glu	Val	460	465	470	475
Thr	Ser	Lys	Met	Phe	Gln	Lys	Thr	Arg	Thr	Gly	Ser	Phe	His	Ile	Arg	480	485	490	495
Arg	Gly	Glu	Val	Gly	Ile	Tyr	Gln	Val	Gln	Leu	Arg	Ala	Leu	Glu	His	500	505	510	515
Val	Asp	Gly	Thr	His	Val	Cys	Gln	Leu	Pro	Glu	Asp	Gln	Lys	Gly	Asn	520	525	530	535

Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys Met Asp Ala Gly
 435 440 445
 Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys Glu Val Arg Ser
 450 455 460
 Ala Arg Cys Ser Phe Asn Gly Asp Phe Val Cys Gly Gln Cys Val Cys
 465 470 475 480
 Ser Glu Gly Trp Ser Gly Gln Thr Cys Asn Cys Ser Thr Gly Ser Leu
 485 490 495
 Ser Asp Ile Gln Pro Cys Leu Arg Glu Gly Glu Asp Lys Pro Cys Ser
 500 505 510
 Gly Arg Gly Glu Cys Gln Cys Gly His Cys Val Cys Tyr Gly Glu Gly
 515 520 525
 Arg Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro Arg
 530 535 540
 Thr Ser Gly Phe Leu Cys Asn Asp Arg Gly Arg Cys Ser Met Gly Gln
 545 550 555 560
 Cys Val Cys Glu Pro Gly Trp Thr Gly Pro Ser Cys Asp Cys Pro Leu
 565 570 575
 Ser Asn Ala Thr Cys Ile Asp Ser Asn Gly Gly Ile Cys Asn Gly Arg
 580 585 590
 Gly His Cys Glu Cys Gly Arg Cys His Cys His Gln Gln Ser Leu Tyr
 595 600 605
 Thr Asp Thr Ile Cys Glu Ile Asn Tyr Ser Ala Ser Thr Arg Ala Ser
 610 615 620
 Ala Arg Thr Tyr Ala Pro Ala Cys Ser Ala Arg Arg Gly Ala Pro Ala
 625 630 635 640
 Arg Arg Arg Gly Ala Arg Val Arg Asn Ala Thr Ser Arg Ser Arg Trp
 645 650 655
 Trp Thr Ser Leu Arg Glu Ala Arg Arg Trp Trp Cys Ala Ala Pro Ser
 660 665 670
 Gly Thr Arg Met Thr Thr Ala Pro Thr Ala Thr Pro Trp Lys Val Thr
 675 680 685
 Ala Pro Leu Gly Pro Thr Ala Leu Ser Trp Cys Thr Arg Arg Arg Asp
 690 695 700
 Cys Pro Pro Gly Ser Phe Trp Trp Leu Ile Pro Leu Leu Leu Leu Leu
 705 710 715 720
 Leu Pro Leu Leu Ala Leu Leu Leu Leu Leu Cys Trp Lys Tyr Cys Ala
 725 730 735
 Cys Cys Lys Ala Cys Leu Ala Leu Leu Pro Cys Cys Asn Arg Gly His
 740 745 750
 Met Val Gly Phe Lys Glu Asp His Tyr Met Leu Arg Glu Asn Leu Met
 755 760 765
 Ala Ser Asp His Leu Asp Thr Pro Met Leu Arg Ser Gly Asn Leu Lys
 770 775 780
 Gly Arg Asp Val Val Arg Trp Lys Val Thr Asn Asn Met Gln Arg Pro
 785 790 795 800
 Gly Phe Ala Thr His Ala Ala Ser Ile Asn Pro Thr Glu Leu Val Pro
 805 810 815
 Tyr Gly Leu Ser Leu Arg Leu Ala Arg Leu Cys Thr Glu Asn Leu Leu
 820 825 830
 Lys Pro Asp Thr Arg Glu Cys Ala Gln Leu Arg Gln Glu Val Glu Glu
 835 840 845
 Asn Leu Asn Glu Val Tyr Arg Gln Ile Ser Gly Val His Lys Leu Gln
 850 855 860
 Gln Thr Lys Phe Arg Gln Gln Pro Asn Ala Gly Lys Lys Gln Asp His
 865 870 875 880
 Thr Ile Val Asp Thr Val Leu Met Ala Pro Arg Ser Ala Lys Pro Ala
 885 890 895
 Leu Leu Lys Leu Thr Glu Lys Gln Val Glu Gln Arg Ala Phe His Asp
 900 905 910
 Leu Lys Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp Ala
 915 920 925

Arg Gly Met Val Glu Phe Gln Glu Gly Val Glu Leu Val Asp Val Arg
 930 935 940
 Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys Gln Leu Leu
 945 950 955 960
 Val Glu Ala Ile Asp Val Pro Ala Gly Thr Ala Thr Leu Gly Arg Arg
 965 970 975
 Leu Val Asn Ile Thr Ile Ile Lys Glu Gln Ala Arg Asp Val Val Ser
 980 985 990
 Phe Glu Gln Pro Glu Phe Ser Val Ser Arg Gly Asp Gln Val Ala Arg
 995 1000 1005
 Ile Pro Val Ile Arg Arg Val Leu Asp Gly Gly Lys Ser Gln Val Ser
 1010 1015 1020
 Tyr Arg Thr Gln Asp Gly Thr Ala Gln Gly Asn Arg Asp Tyr Ile Pro
 1025 1030 1035 1040
 Val Glu Gly Glu Leu Phe Gln Pro Gly Glu Ala Trp Lys Glu Leu
 1045 1050 1055
 Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg Gly
 1060 1065 1070
 Arg Gln Val Arg Arg Phe His Val Gln Leu Ser Asn Pro Lys Phe Gly
 1075 1080 1085
 Ala His Leu Gly Gln Pro His Ser Thr Thr Ile Ile Ile Arg Asp Pro
 1090 1095 1100
 Asp Glu Leu Asp Arg Ser Phe Thr Ser Gln Met Leu Ser Ser Gln Pro
 1105 1110 1115 1120
 Pro Pro His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys Ala
 1125 1130 1135
 Ala Gly Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Ser Gly Lys
 1140 1145 1150
 Pro Met Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu Ser
 1155 1160 1165
 Glu Ala His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr Asn
 1170 1175 1180
 Leu Tyr Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly Ala
 1185 1190 1195 1200
 Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Thr His Gln
 1205 1210 1215
 Glu Val Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser Ser
 1220 1225 1230
 Thr Val Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly Glu
 1235 1240 1245
 Ile Thr Ala Tyr Glu Val Cys Tyr Gly Leu Val Asn Asp Asp Asn Arg
 1250 1255 1260
 Pro Ile Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn Arg
 1265 1270 1275 1280
 Met Leu Leu Ile Glu Asn Leu Arg Glu Ser Gln Pro Tyr Arg Tyr Thr
 1285 1290 1295
 Val Lys Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala Ile
 1300 1305 1310
 Ile Asn Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile Ile
 1315 1320 1325
 Pro Asp Ile Pro Ile Val Asp Ala Gln Ser Gly Glu Asp Tyr Asp Ser
 1330 1335 1340
 Phe Leu Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ser Gly Ser Gln
 1345 1350 1355 1360
 Arg Pro Ser Val Ser Asp Asp Thr Gly Cys Gly Trp Lys Phe Glu Pro
 1365 1370 1375
 Leu Leu Gly Glu Glu Leu Asp Leu Arg Arg Val Thr Trp Arg Leu Pro
 1380 1385 1390
 Pro Glu Leu Ile Pro Arg Leu Ser Ala Ser Ser Gly Arg Ser Ser Asp
 1395 1400 1405
 Ala Glu Ala Pro His Gly Pro Pro Asp Asp Gly Gly Ala Gly Gly Lys
 1410 1415 1420

Gly Gly Ser Leu Pro Arg Ser Ala Thr Pro Gly Pro Pro Gly Glu His
 1425 1430 1435 1440
 Leu Val Asn Gly Arg Met Asp Phe Ala Phe Pro Gly Ser Thr Asn Ser
 1445 1450 1455
 Leu His Arg Met Thr Thr Thr Ser Ala Ala Tyr Gly Thr His Leu
 1460 1465 1470
 Ser Pro His Val Pro His Arg Val Leu Ser Thr Ser Thr Leu Thr
 1475 1480 1485
 Arg Asp Tyr Asn Ser Leu Thr Arg Ser Glu His Ser His Ser Thr Thr
 1490 1495 1500
 Leu Pro Arg Asp Tyr Ser Thr Leu Thr Ser Val Ser Ser His Gly Leu
 1505 1510 1515 1520
 Pro Pro Ile Trp Glu His Gly Arg Ser Arg Leu Pro Leu Ser Trp Ala
 1525 1530 1535
 Leu Gly Ser Arg Ser Arg Ala Gln Met Lys Gly Phe Pro Pro Ser Arg
 1540 1545 1550
 Gly Pro Arg Asp Ser Ile Ile Leu Ala Gly Arg Pro Ala Ala Pro Ser
 1555 1560 1565
 Trp Gly Pro Asp Ser Arg Leu Thr Ala Gly Val Pro Asp Thr Pro Thr
 1570 1575 1580
 Arg Leu Val Phe Ser Ala Leu Gly Pro Thr Ser Leu Arg Val Ser Trp
 1585 1590 1595 1600
 Gln Glu Pro Arg Cys Glu Arg Pro Leu Gln Gly Tyr Ser Val Glu Tyr
 1605 1610 1615
 Gln Leu Leu Asn Gly Gly Glu Leu His Arg Leu Asn Ile Pro Asn Pro
 1620 1625 1630
 Ala Gln Thr Ser Val Val Val Glu Asp Leu Leu Pro Asn His Ser Tyr
 1635 1640 1645
 Val Phe Arg Val Arg Ala Gln Ser Gln Glu Gly Trp Gly Arg Glu Arg
 1650 1655 1660
 Glu Gly Val Ile Thr Ile Glu Ser Gln Val His Pro Gln Ser Pro Leu
 1665 1670 1675 1680
 Cys Pro Leu Pro Gly Ser Ala Phe Thr Leu Ser Thr Pro Ser Ala Pro
 1685 1690 1695
 Gly Pro Leu Val Phe Thr Ala Leu Ser Pro Asp Ser Leu Gln Leu Ser
 1700 1705 1710
 Trp Glu Arg Pro Arg Arg Pro Asn Gly Asp Ile Val Gly Tyr Leu Val
 1715 1720 1725
 Thr Cys Glu Met Ala Gln Gly Gly Gly Pro Ala Thr Ala Phe Arg Val
 1730 1735 1740
 Asp Gly Asp Ser Pro Glu Ser Arg Leu Thr Val Pro Gly Leu Ser Glu
 1745 1750 1755 1760
 Asn Val Pro Tyr Lys Phe Lys Val Gln Ala Arg Thr Thr Glu Gly Phe
 1765 1770 1775
 Gly Pro Glu Arg Glu Gly Ile Ile Thr Ile Glu Ser Gln Asp Gly Gly
 1780 1785 1790
 Pro Phe Pro Gln Leu Gly Ser Arg Ala Gly Leu Phe Gln His Pro Leu
 1795 1800 1805
 Gln Ser Glu Tyr Ser Ser Ile Ser Thr Thr His Thr Ser Ala Thr Glu
 1810 1815 1820
 Pro Phe Leu Val Gly Pro Thr Leu Gly Ala Gln His Leu Glu Ala Gly
 1825 1830 1835 1840
 Gly Ser Leu Thr Arg His Val Thr Gln Glu Phe Val Ser Arg Thr Leu
 1845 1850 1855
 Thr Thr Ser Gly Thr Leu Ser Thr His Met Asp Gln Gln Phe Phe Gln
 1860 1865 1870
 Thr

<210> 18
 <211> 5622
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 18

atggcagggc	cacgccccag	cccatgggccc	aggctgctcc	tggcagcctt	gatcagcgctc	60
agcctctctg	ggaccttgaa	ccgctgcaag	aaggccccaa	taaagagctg	cacggagtgt	120
gtccgtgttg	ataaggactg	cgcctactgc	acagacgaga	tgttcaggga	ccggcgctgc	180
aacaccagg	cggagctgct	ggccgcgggc	tgccagcggg	agagcatcgt	ggctcatggag	240
agcagcttcc	aaatcacaga	ggagaccag	attgacacca	ccctgcggcg	cagccagatg	300
tccccccaag	gcctgcgggt	ccgtctgcgg	cccggtgagg	agcggcattt	tgagctggag	360
gtgtttgagc	cactggagag	ccccgtggac	ctgtacatcc	tcatggactt	ctccaactcc	420
atgtccgatg	atctggacaa	cctcaagaag	atggggcaga	acctggctcg	ggtcctgagc	480
cagctcacca	gcgactacac	tattggattt	ggcaagtgtg	tggacaaaagt	cagcgtccccg	540
cagacggaca	tgaggcctga	gaagctgaag	gagccttggc	ccaacagtga	cccccccttc	600
tccttcaaga	acgtcatcag	cctgacagaa	gatgtggatg	agttccggaa	taaactgcag	660
ggagagcggg	tctcaggcaa	cctggatgct	cctgagggcg	gcttcgatgc	catcctgcag	720
acagctgtgt	gcacgaggga	cattggctgg	cgccccgaca	gcaccacct	gctggtcttc	780
tccaccgagt	cagccttcca	ctatgaggct	gatggcgcca	acgtgctggc	tggcatcatg	840
agccgcaacg	atgaacggtg	ccacctggac	accacgggca	cctacaccca	gtacaggaca	900
caggactacc	cgctcggtgc	caccctgggt	cgcctgctcg	ccaagcacia	catcatcccc	960
atctttgctg	tcaccaacta	ctcctatagc	tactacgaga	agcttcacac	ctatttccct	1020
gtctcctcac	tgggggtgct	gcaggaggac	tcgtccaaca	tcgtggagct	gctggaggag	1080
gccttcaatc	ggatccgctc	caacctggac	atccgggcc	tagacagccc	ccgagccctt	1140
cggacagagg	tcacctccaa	gatgttccag	aagacgagga	ctgggtcctt	tcacatccgg	1200
cggggggaag	tgggtatata	ccagggtgcag	ctgcggggccc	ttgagcacgt	ggatgggacg	1260
cacgtgtgcc	agctgcggga	ggaccagaag	ggcaacatcc	atctgaaacc	ttccttctcc	1320
gacggcctca	agatggacgc	gggcatcatc	tgtgatgtgt	gcacctgcga	gctgcaaaaa	1380
gaggtgcggt	cagctcgctg	cagcttcaac	ggagacttcg	tgtgcggaca	gtgtgtgtgc	1440
agcgagggt	ggagtggcca	gacctgcaac	tgtccaccg	gctctctgag	tgacattcag	1500
ccctgcctgc	gggagggcga	ggacaagccg	tgtccggcc	gtggggagtg	ccagtgcggg	1560
cactgtgtgt	gctacggcga	aggccgctac	gagggtcagt	tctgcgagta	tgacaacttc	1620
cagtgtcccc	gcacttccgg	gttcctctgc	aatgaccgag	gacgtgctc	catgggccag	1680
tgtgtgtgtg	agcctgggtg	gacaggccca	agctgtgact	gtccccctag	caatgccacc	1740
tgcatcgaca	gcaatggggg	catctgtaat	ggacgtggcc	actgtgagt	tggccgctgc	1800
cactgccacc	agcagtcgct	ctacacggac	accatctcgc	agatcaacta	ctcggcgctc	1860
acccgggcct	ctgcgaggac	ctacgctcct	gcgtgcagtg	ccaggcgctg	ggcaccggcg	1920
agaagaagg	gcgcacgtgt	gaggaatgca	acttcaaggt	caagatgggt	gacgagctta	1980
agagaggcga	ggaggtgggt	gtgcgctgct	ccttccggga	cgaggatgac	gactgcacct	2040
acagctacac	catggaaggt	gacggcgccc	ctgggcccac	cagcactgtc	ctggtgcaca	2100
agaagaagg	actgccttcc	gggctccttc	tgggtgctca	tccccctgct	cctcctcctc	2160
ctgcccgtcc	tggccctgct	actgctgcta	tgttggaagt	actgtgcctg	ctgcaaggcc	2220
tgcctggcac	ttctcccggt	ctgcaaccga	ggtcacatgg	tgggctttaa	ggaagaccac	2280
tacatgctgc	gggagaacct	gatggcctct	gaccacttgg	acacgcccac	gctgcgcagc	2340
gggaacctca	agggccgtga	cgtggtccgc	tggaaagtca	ccaacaacat	gcagcgccct	2400
ggctttgcca	ctcatgccgc	cagcatcaac	cccacagagc	tggtgcccta	cgggctgtcc	2460
ttgcgcctgg	ccgcctttg	caccgagaac	ctgctgaagc	ctgacactcg	ggagtgcgcc	2520
cagctgcgcc	aggaggtgga	ggagaacctg	aacgaggtct	acaggcagat	ctccgggtgta	2580
cacaagctcc	agcagaccaa	gttcgggcag	cagcccaatg	ccgggaaaaa	gcaagaccac	2640
accattgtgg	acacagtgtc	gatggcgccc	cgtctggcca	agccggccct	gctgaagctt	2700
acagagaagc	aggtggaaca	gagggccttc	cacgacctca	aggtggcccc	cggctactac	2760
acctcactg	cagaccagga	cgcccggggc	atggtggagt	tccaggaggg	cgtggagctg	2820
gtggacgtac	gggtgcccct	ctttatccgg	cctgaggatg	acgacgagaa	gcagctgctg	2880
gtggaggcca	tcgacgtgcc	cgcaggcact	gccaccctcg	gccgccgctt	ggtaaacatc	2940
accatcatca	aggagcaagc	cagagacgtg	gtgtcctttg	agcagcctga	gttctcggtc	3000
agccgcgggg	accagtggtg	cgcctccctg	gtgtcctgga	cggcggggaa	cggcggggaa	3060
tcccaggctc	cctaccgcac	acaggatggc	accgcgcagg	gcaaccggga	ctacatcccc	3120
gtggaggggtg	agctgtgtgt	ccagcctggg	gagggcctgga	aagagctgca	ggtgaagctc	3180
ctggagctgc	aagaagttga	ctccctcctg	cggggccggc	aggtccggcg	tttccacgtc	3240
cagctcagca	accctaagtt	tggggccccc	ctggggccagc	cccactccac	caccatcatc	3300

atcagggacc	cagatgaact	ggaccggagc	ttcacgagtc	agatgttgtc	atcacagcca	3360
ccccctcacg	gcgacctggg	cgccccgcag	aaccccaatg	ctaaggccgc	tgggtccagg	3420
aagatccatt	tcaactggct	gcccccttct	ggcaagccaa	tgggttacag	ggtaaagtac	3480
tggattccagg	gtgactccga	atccgaagcc	cacctgctcg	acagcaaggc	gccctcagtg	3540
gagctcacca	acctgtaccc	gtattgcgac	tatgagatga	aggtgtgcgc	ctacggggct	3600
cagggcgagg	gaccctacag	ctccctggtg	tectgccgca	cccaccagga	agtgccagc	3660
gagccagggc	gtctggcctt	caatgtcgtc	tctccacgg	tgaccagct	gagctgggct	3720
gagccggctg	agaccaacgg	tgagatcaca	gcctacgagg	tctgctatgg	cctggtcaac	3780
gatgacaacc	gacctattgg	gcccataaag	aaagtgtctg	ttgacaacc	taagaaccgg	3840
atgctgctta	ttgagaacct	tcgggagtc	cagccctacc	gctacaagg	gaaggcgcgc	3900
aacggggccg	gctggggggc	tgagcgggag	gccatcatca	acctggccac	ccagcccaag	3960
aggcccatgt	ccatcccat	catccctgac	atccctatcg	tgagcgcga	gagcgggag	4020
gactacgaca	gcttccctat	gtacagcgat	gacgttctac	gctctccatc	gggcagccag	4080
aggcccagcg	tctccgatga	caactggctgc	ggctggaagt	tcgagccct	gctgggggag	4140
gagctggacc	tgccgcgcgt	cacgtggcgg	ctgcccccg	agctcatccc	gcgctgtcg	4200
gccagcagcg	ggcgtcctc	cgacgcgag	gcgccccacg	ggcccccgga	cgacggcggc	4260
gcggggcgga	aggcgggcag	cctgccccgc	agtgcgacac	ccgggcccc	cggagagcac	4320
ctggtgaatg	gccggatgga	ctttgccttc	ccgggcagca	ccaactccct	gcacaggatg	4380
accacgacca	gtgctgctgc	ctatggcacc	cacctgagcc	cacacgtgcc	ccaccgctg	4440
ctaagcacat	cctccaccct	cacacgggac	tacaactcac	tgaccgctc	agaacactca	4500
cactcgacca	cactgcogag	ggactactcc	accctcacct	ccgtctcctc	ccacggcctc	4560
cctcccatct	gggaacacgg	gaggagcagg	cttccgctgt	cctgggccc	ggggtcccgg	4620
agtcgggctc	agatgaaagg	gttccccct	tccaggggcc	cacgagactc	tataatcctg	4680
gctggggaggc	cagcagcgcc	ctcctggggc	ccagactctc	gcctgactgc	tgggtgtgcc	4740
gacacgcca	cccgcttgt	gttctctgcc	ctggggccca	catctctcag	agtgagctgg	4800
caggagccgc	ggtgcgagcg	gccgtgcag	ggctacagt	tggagtacca	gctgctgaac	4860
ggcgggtgagc	tgcatcggt	caacatcccc	aacctgccc	agacctcgg	ggtggtggaa	4920
gacctcctgc	ccaaccactc	ctacgtgttc	cgcgtgcgg	cccagagcca	ggaaggctgg	4980
ggccgagagc	gtgagggtgt	catcaccatt	gaatcccagg	tgaccccgca	gagccactg	5040
tgtccctctc	caggctccgc	cttcaacttt	agcactccca	gtgccccagg	cccgtgtgtg	5100
ttcactgccc	tgagcccaga	ctcgtgcag	ctgagctggg	agcggccaag	gaggcccaat	5160
ggggatatcg	tcggctacct	ggtgacctgt	gagatggccc	aaggaggagg	tccagccacc	5220
gcattccggg	tggatggaga	cagcccggag	agccggctga	ccgtgcggg	cctcagcgag	5280
aacgtgccct	acaagttcaa	ggtgcaggcc	aggaccactg	agggtctcgg	gccagagcgc	5340
gagggcacat	tcaccataga	gtcccaggat	ggaggtccct	tcccgagct	gggcagccgt	5400
gccgggctct	tccagcacc	gctgcaaagc	gagtacagca	gcattctccac	caccacacc	5460
agcgcacccg	agcccttct	agtgggtccg	accctggggg	cccagcacct	ggaggcaggc	5520
ggctccctca	cccgcatgt	gaccagggag	tttgtgagcc	ggacactgac	caccagcgga	5580
acccttagca	cccacatgga	ccaacagttc	ttccaaactt	ga		5622

<210> 19

<211> 5622

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =
synthetic construct

<400> 19

atggcagggc	cacggcccag	cccatgggcc	aggctgtctc	tggcagcctt	gatcagcgtc	60
agcctctctg	ggaccttgaa	ccgctgcaag	aaggcccaa	taaagagctg	cacggagtgt	120
gtccgtgtgg	ataaggactg	cgcctactgc	acagacgaga	tgttcaggga	ccggcgctgc	180
aacaccagg	cggagctgct	ggccgcgggc	tgccagcggg	agagcatcgt	ggtcatggag	240
agcagcttcc	aaatcacaga	ggagacccag	attgacacca	ccctgcggcg	cagccagatg	300
tccccccaag	gectgcgggt	ccgtctgcgg	cccggtgagg	agcggcattt	tgagctggag	360
gtgtttgagc	cactggagag	ccccgtggac	ctgtacatcc	tcattggactt	ctccaactcc	420
atgtccgatg	atctggacaa	cctcaagaag	atggggcaga	acctggctcg	ggtcctgagc	480
cagctcacca	gcgactacac	tattggattt	ggcaagtttg	tggacaaagt	cagcgtccc	540
cagacggaca	tgaggcctga	gaagctgaag	gagccttggc	ccaacagtga	cccccccttc	600

tccttcaaga	acgtcatcag	cctgacagaa	gatgtggatg	agttccggaa	taaactgcag	660
ggagagcggg	tctcaggcaa	cctggatgct	cctgagggcg	gcttcgatgc	catcctgcag	720
acagctgtgt	gcacgaggga	cattggcttg	cgcccggaca	gcacccacct	gctgggtctt	780
tccaccgagt	cagccttcca	ctatgaggct	gatggcgcca	acgtgctggc	tggcatcatg	840
agccgcaacg	atgaacgggtg	ccacctggac	accacgggca	cctacacca	gtacaggaca	900
caggactacc	cgtcgggtgc	cacctgggtg	cgctgctcg	ccaagcaca	catcatcccc	960
atctttgctg	tcaccaacta	ctcctatagc	tactacgaga	agcttcacac	ctatctccct	1020
gtctcctcac	tgggggtgct	gcaggaggac	tcgtccaaca	tcgtggagct	gctggaggag	1080
gccttcaatc	ggatccgctc	caacctggac	atccggggcc	tagacagccc	ccgaggcctt	1140
cggacagagg	tcacctccaa	gatgttccag	aagacagga	ctgggtcctt	tcacatccgg	1200
cggggggaag	tgggtatata	ccagggtcag	ctgcggggcc	ttgagcacgt	ggatgggacg	1260
caagtggtgc	agctgccgga	ggaccagaag	ggcaacatcc	atctgaaacc	ttccttctcc	1320
gacggcctca	agatggacgc	gggcatcatc	tgtgatgtgt	gcacctgcga	gctgcaaaaa	1380
gagggtcggt	cagctcgctg	cagcttcaac	ggagacttcg	tgtgaggaca	gtgtgtgtgc	1440
agcgagggtc	ggagtggcca	gacctgcaac	tgctccaccg	gctctctgag	tgacattcag	1500
ccctgcctgc	gggaggcgga	ggacaagccg	tgctccggcc	gtggggagtg	ccagtgcggg	1560
cactgtgtgt	gctacggcga	aggccgctac	gagggtcagt	tctgcgagta	tgacaacttc	1620
cagtgtcccc	gcacttccgg	gttcctctgc	aatgaccgag	gacgctgtct	catgggccag	1680
tgtgtgtgtg	agcctgggtg	gacaggccca	agctgtgact	gtccccctag	caatgccacc	1740
tgcatcgaca	gcaatggggg	catctgtaat	ggacgtggcc	actgtgagtg	tggccgctgc	1800
cactgccacc	agcagtcgct	ctacacggac	accatctgcg	agatcaacta	ctcggcgtcc	1860
accggggcct	ctgcgaggac	ctacgctcct	gcgtgcagtg	ccaggcgtgg	ggcaccggcg	1920
agaagaaggg	gcgcacgtgt	gaggaatgca	acttcaaggt	caagatgggt	gacgagctta	1980
agagaggcga	ggaggtgggtg	gtgcgctgct	ccttccggga	cgaggatgac	gactgcacct	2040
acagctacac	catggaaggt	gacggcgccc	ctgggcccga	cagcactgtc	ctgggtgcaca	2100
agaagaaggg	actgccctcc	gggtcccttc	tgggtgctca	tccccctgct	cctcctcttc	2160
ctgccgctcc	tggccctgct	actgtgcta	tgttggaagt	actgtgcctg	ctgcaaggcc	2220
tgctgtgcac	ttctcccgtg	ctgcaaccga	ggtcacatgg	tgggctttaa	ggaagaccac	2280
tacatgctgc	gggagaacct	gatggcctct	gaccacttgg	acacgcccac	gctgcgcagc	2340
gggaacctca	agggccgtga	cgtggtccgc	tggaaaggtc	ccaacaacat	gcagcggcct	2400
ggctttgcca	ctcatgcgcg	cagcatcaac	cccacagagc	tgggtgccta	cgggctgtcc	2460
ttgcgcctgg	cccgcctttg	caccgagaac	ctgctgaagc	ctgacactcg	ggagtgcgcc	2520
cagctgcgcc	aggaggtgga	ggagaacctg	aacgaggtct	acaggcagat	ctccggtgta	2580
cacaagctcc	agcagacca	gttccggcag	cagcccaatg	ccgggaaaaa	gcaagaccac	2640
accattgtgg	acacagtgtc	gatggcgccc	cgctcggcca	agccggccct	gctgaagctt	2700
acagagaagc	aggtggaaca	gagggccttc	cacgacctca	aggtggcccc	cggctactac	2760
acctcactg	cagaccagga	cgcccggggc	atggttgaag	tccaggaggg	cgtggagctg	2820
gtggacgtac	gggtgcccc	ctttatccgg	cctgaggatg	acgacgagaa	gcagctgtct	2880
gtggaggcca	tcgacgtgcc	cgcaggcact	gccacctcgc	gccgcccgtc	ggtaaacatc	2940
accatcatca	aggagcaagc	cagagacgtg	gtgtcctttg	agcagcctga	gttctcggtc	3000
agccgcgggg	accaggtggc	ccgcatccct	gtcatccggc	gtgtcctgga	cggcgggaag	3060
tcccagggtc	cctaccgcac	acaggatggc	accgcgcagg	gcaaccggga	ctacatcccc	3120
gtggagggtg	agctgctgtt	ccagcctggg	gaggcctgga	aagagctgca	ggtgaagctc	3180
ctggagctgc	aagaagtiga	ctccctcctg	cggggccggc	aggtccggcg	tttccacgtc	3240
cagctcagca	accctaagtt	tggggcccac	ctggggccagc	cccactccac	caccatcatc	3300
atcagggaac	cagatgaact	ggaccggagc	ttcacgagtc	agatgttgtc	atcacagcca	3360
ccccctcacg	gcgacctggg	cgccccgcag	aaccccaatg	ctaaggccgc	tgggtccagg	3420
aagatccatt	tcaactggct	gcccccttct	ggcaagccaa	tggggtagac	ggtaaaagta	3480
tggattcagg	gtgactccga	atccgaagcc	cacctgctcg	acagcaaggt	gccctcagtg	3540
gagctcacca	acctgtaccc	gtattgagac	tatgagatga	aggtgtgcgc	ctacggggct	3600
caggggcgagg	gacctacag	ctccctgggtg	tcctgcccga	cccaccagga	agtgccccagc	3660
gagccagggc	gtctggcctt	caatgtcgtc	tcctccacgg	tgacctagct	gagctgggct	3720
gagccggctg	tgaccaacgg	tgagatcaca	gcctacgagg	tctgctatgg	cctggtcaac	3780
gatgacaacc	gacctattgg	gcccataag	aaagtgtgtg	ttgacaaccc	taagaaccgg	3840
atgtgtctta	ttgagaacct	tcgggagtc	cagccctacc	gctacacggt	gaaggcgcgc	3900
aacggggccg	gctggggggc	tgagcgggag	gccatcatca	acctggccac	ccagcccagg	3960
aggccccatg	ccatccccat	catccctgac	atccctatcg	tggacgcccc	gagcggggag	4020
gactacgaca	gctcccttat	gtacagcgat	gacgttctac	gctctccatc	gggagccag	4080
aggccagcgc	tctccgatga	cactggctgc	ggcttgaagt	tcgagccctc	gctgggggag	4140
gagctggacc	tgcggcgcgt	cacgtggcgg	ctgcccccg	agctcatccc	gcgcctgtcg	4200
gccagcagcg	ggcgtccttc	cgacgcccag	gcgccccacg	ggccccggga	cgacggcggc	4260
gcggggcggg	agggcggcag	cctgccccgc	agtgcgacac	ccggggcccc	cggagagcac	4320

ctggtgaatg	gccggatgga	ctttgccttc	ccgggcagca	ccaactccct	gcacaggatg	4380
accacgacca	gtgctgctgc	ctatggcacc	cacctgagcc	cacacgtgcc	ccaccgcgtg	4440
ctaagcacat	cctccaccct	cacacgggac	tacaactcac	tgaccogctc	agaacactca	4500
cactcgacca	cactgccgag	ggactactcc	accctcacct	ccgtctcctc	ccacggcctc	4560
cctcccatct	gggaacacgg	gaggagcagg	cttccgctgt	cctgggccct	gggtcccgg	4620
agtcgggctc	agatgaaagg	gttccccct	tccaggggcc	cacgagactc	tataatcctg	4680
gctgggaggc	cagcagcgcc	ctcctggggc	ccagactctc	gcctgactgc	tggtgtgccc	4740
gacacgcccc	cccgcctggt	gttctctgcc	ctggggccca	catctctcag	agtgagctgg	4800
caggagccgc	ggtgcgagcg	gccgctgcag	ggctacagtg	tggagtacca	gctgctgaac	4860
ggcgggtgagc	tgcacgggct	caacatcccc	aaccctgccc	agacctcggg	ggtggtggaa	4920
gacctcctgc	ccaaccactc	ctacgtgttc	cgcgtgcggg	cccagagcca	ggaaggctgg	4980
ggccgagagc	gtgagggtgt	catcaccatt	gaatcccagg	tgaccccgca	gagcccactg	5040
tgtcccctgc	caggctccgc	cttcactttg	agcactccca	gtgcccagg	cccgtggtg	5100
ttcactgccc	tgagcccaga	ctcgtgcag	ctgagctggg	agcgccacg	gaggcccaat	5160
ggggatatcg	tcggctacct	ggtgacctgt	gagatggccc	aaggaggagg	tccagccacc	5220
gcattccggg	tggatggaga	cagccccgag	agccggctga	ccgtgccggg	cctcagcgag	5280
aacgtgccct	acaagttcaa	ggtgcaggcc	aggaccactg	agggtctcgg	gccagagcgc	5340
gagggcatca	tcacataga	gtcccaggat	ggaggtccct	tccgcagct	gggcagccgt	5400
gccgggctct	tccagcacc	gctgcaaagc	gagtacagca	gcatctccac	caccacacc	5460
agcgccaccg	agcccttct	agtgggtccg	accctggggg	cccagcacct	ggaggcaggc	5520
ggctccctca	cccgcatgt	gaccagggag	tttgtgagcc	ggacactgac	caccagcgga	5580
acccttagca	cccacatgga	ccaacagttc	ttccaaactt	ga		5622

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/030465 A3

(51) International Patent Classification⁷: **C07K 14/705**,
A61K 38/17, 31/7088, 38/39, G01N 33/566, 33/50, C12Q
1/68, A61P 35/00

(74) Agents: **SPRATT, Gwendolyn, D. et al.**; Needle &
Rosenberg, P.C., Suite 1200, The Candler Building, 127
Peachtree Street, N.E., Atlanta, GA 30303-1811 (US).

(21) International Application Number: **PCT/US01/32127**

(22) International Filing Date: 12 October 2001 (12.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/239,705 12 October 2000 (12.10.2000) US
60/242,812 24 October 2000 (24.10.2000) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF ROCHESTER** [US/US]; 601 Elmwood
Avenue, Box 706, Rochester, NY 14642 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAND, Hartmut**
[US/US]; 195 Hollywood Avenue, Rochester, NY 14618
(US). **DELEU, Laurent** [US/US]; 104 Westland Avenue,
Rochester, NY 14618 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:


— with international search report

(88) Date of publication of the international search report:
13 March 2003

[Continued on next page]

(54) Title: COMPOSITIONS THAT INHIBIT PROLIFERATION OF CANCER CELLS

Normal cells require integrin-matrix interactions for survival



Panel 1

(57) Abstract: Disclosed are compositions and methods for reducing the proliferation of cancer cells through targeted interactions with integrins.

WO 02/030465 A3

WO 02/030465 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Inte al Application No
PCT/US 01/32127

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/705 A61K38/17 A61K31/7088 A61K38/39 G01N33/566
G01N33/50 C12Q1/68 //A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TAGLIABUE E ET AL: "Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells."</p> <p>CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES FEB 1998, vol. 4, no. 2, February 1998 (1998-02), pages 407-410, XP001119072</p> <p>ISSN: 1078-0432</p> <p>abstract</p> <p>introduction</p> <p>page 407</p> <p>discussion</p> <p>page 409 -page 410</p> <p>---</p> <p>-/-</p>	1-128

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

25 November 2002

Date of mailing of the international search report

11/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dumont, E

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 01/32127

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 10646 A (PYKE CHARLES ;TRYGGVASON KARL (FI); KALLUNKI PEKKA (US)) 11 April 1996 (1996-04-11) abstract; claims 1-40	1,7,12, 13,17, 30-34, 40,47, 53,55, 63-65, 89,90
X	FIELDS ET AL: "Integrins: cell adhesion molecules in cancer" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 8, no. 6, August 1998 (1998-08), pages 633-644, XP002105988 ISSN: 1354-3776 abstract Introduction	1,13,24, 30,34
X	NICKOLS A ET AL: "ANTIANGIOGENIC AND ANTICANCER ACTIVITIES OF ANTAGONISTS OF INTEGRINALPHAVBETA3" PROCEEDINGS OF THE 88TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN DIEGO, APR. 12 - 16, 1997, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, AACR, US, vol. 38, 1 March 1997 (1997-03-01), page 206 XP002071773 the whole document	1,13,34
X	WO 98 46265 A (MEYER DEBRA M ;SEARLE & CO (US); NICKOLS G ALLEN (US); SMITH JEFFR) 22 October 1998 (1998-10-22) abstract; claims 1-17	34
A	BACHELDER ROBIN E ET AL: "p53 Inhibits alpha6beta4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB." JOURNAL OF CELL BIOLOGY, vol. 147, no. 5, 29 November 1999 (1999-11-29), pages 1063-1072, XP002222121 ISSN: 0021-9525 abstract page 1070, paragraph 2	1-128

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/32127

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RABINOVITZ ISAAC ET AL: "The integrin alpha-6-beta-4 and the biology of carcinoma." BIOCHEMISTRY AND CELL BIOLOGY, vol. 74, no. 6, 1996, pages 811-821, XP001120471 ISSN: 0829-8211 the whole document	1-128
T	MERCURIO ARTHUR M ET AL: "Towards a mechanistic understanding of tumor invasion: Lessons from the alpha6beta4 integrin." SEMINARS IN CANCER BIOLOGY, vol. 11, no. 2, April 2001 (2001-04), pages 129-141, XP002222122 ISSN: 1044-579X the whole document especially Table 1, Fig. 3 page 137, column 1, last paragraph -column 2, paragraph 1	1-128
A	D'ABACO GIOVANNA M ET AL: "Synergy between Apc-min and an activated ras mutation is sufficient to induce colon carcinomas." MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 3, 1996, pages 884-891, XP002222123 ISSN: 0270-7306 cited in the application the whole document	1-128
A	O'CONNOR KATHLEEN L ET AL: "Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells." JOURNAL OF CELL BIOLOGY, vol. 143, no. 6, 14 December 1998 (1998-12-14), pages 1749-1760, XP002919093 ISSN: 0021-9525 the whole document	49
A	CLARKE ASTRID S ET AL: "Activation of the p21 pathway of growth arrest and apoptosis by the beta-4 integrin cytoplasmic domain." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 39, 1995, pages 22673-22676, XP002222124 ISSN: 0021-9258 the whole document	51

INTERNATIONAL SEARCH REPORT

.....national application No.
PCT/US 01/32127

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: -
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-62, 65-72, as far as they are directed to in vivo methods, and claims 64, 76-128 are directed to a method of treatment of the human/animal body or to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

Continuation of Box I.1

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body
- Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Present claims 9-12, 14-17, 37-40 relate to a method involving a composition defined by reference to a desirable characteristic or property, namely inhibition of ligand binding to an integrin receptor. The claims cover methods involving all compositions having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a limited number of such compositions. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the composition by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to compositions including antibodies, antisense molecules, functional nucleic acids, primers and probes as defined in the description.

The above reasoning applies by analogy to claims 41, 42 and 62, which relate to methods involving a molecule or an agent defined by reference to a desirable characteristic, i.e. interference with at least one of the cellular proteins mentioned in claim 41, interference with post-translational modifications of integrins, or modulation of cell signaling. The application does not provide support within the meaning of Article 6 PCT and disclosure within the meaning Article 5 PCT for such a molecule or agent. Consequently, a search has not been carried out for those parts of claims 41, 42 and 62 relating to such a molecule or agent.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/32127

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9610646	A	11-04-1996	US 5660982 A	26-08-1997
			AT 182180 T	15-07-1999
			AU 699183 B2	26-11-1998
			AU 3745195 A	26-04-1996
			CA 2201865 A1	11-04-1996
			DE 69510810 D1	19-08-1999
			DE 69510810 T2	04-11-1999
			DK 784703 T3	29-11-1999
			WO 9610646 A1	11-04-1996
			EP 0784703 A1	23-07-1997
			ES 2133813 T3	16-09-1999
			GR 3031488 T3	31-01-2000
			US 2002052307 A1	02-05-2002
			US 6143505 A	07-11-2000
WO 9846265	A	22-10-1998	AU 6954498 A	11-11-1998
			US 6193968 B1	27-02-2001
			WO 9846265 A1	22-10-1998

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)